CA2537321A1 - Heterocyclic inhibitors of mek and methods of use thereof - Google Patents
Heterocyclic inhibitors of mek and methods of use thereof Download PDFInfo
- Publication number
- CA2537321A1 CA2537321A1 CA002537321A CA2537321A CA2537321A1 CA 2537321 A1 CA2537321 A1 CA 2537321A1 CA 002537321 A CA002537321 A CA 002537321A CA 2537321 A CA2537321 A CA 2537321A CA 2537321 A1 CA2537321 A1 CA 2537321A1
- Authority
- CA
- Canada
- Prior art keywords
- heteroaryl
- aryl
- heterocyclyl
- alkyl
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 103
- 125000000623 heterocyclic group Chemical group 0.000 title claims description 195
- 239000003112 inhibitor Substances 0.000 title description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 254
- 229940002612 prodrug Drugs 0.000 claims abstract description 76
- 239000000651 prodrug Substances 0.000 claims abstract description 76
- 150000003839 salts Chemical class 0.000 claims abstract description 53
- 241000124008 Mammalia Species 0.000 claims abstract description 52
- 238000011282 treatment Methods 0.000 claims abstract description 45
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 174
- 125000003118 aryl group Chemical group 0.000 claims description 163
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 122
- -1 phosphate ester Chemical class 0.000 claims description 109
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 102
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 102
- 125000000217 alkyl group Chemical group 0.000 claims description 85
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 76
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 76
- 229920006395 saturated elastomer Polymers 0.000 claims description 66
- 125000005843 halogen group Chemical group 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 61
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 59
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 59
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 59
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 59
- 125000003342 alkenyl group Chemical group 0.000 claims description 57
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 55
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 125000000304 alkynyl group Chemical group 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 35
- 229910020008 S(O) Inorganic materials 0.000 claims description 30
- 125000004043 oxo group Chemical group O=* 0.000 claims description 28
- 125000002837 carbocyclic group Chemical group 0.000 claims description 24
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 23
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims description 23
- 125000004429 atom Chemical group 0.000 claims description 23
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 21
- 125000000539 amino acid group Chemical group 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 18
- 229910019142 PO4 Inorganic materials 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 17
- 239000010452 phosphate Substances 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000005647 linker group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 39
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 22
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 19
- 150000002431 hydrogen Chemical class 0.000 claims 18
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 5
- 239000004474 valine Substances 0.000 claims 5
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 36
- 206010028980 Neoplasm Diseases 0.000 abstract description 23
- 201000010099 disease Diseases 0.000 abstract description 22
- 201000011510 cancer Diseases 0.000 abstract description 12
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract description 5
- 229910052727 yttrium Inorganic materials 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 220
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 183
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 164
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 143
- 239000000243 solution Substances 0.000 description 112
- 239000000047 product Substances 0.000 description 111
- 238000006243 chemical reaction Methods 0.000 description 97
- 238000002360 preparation method Methods 0.000 description 96
- 230000015572 biosynthetic process Effects 0.000 description 93
- 238000003786 synthesis reaction Methods 0.000 description 92
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 90
- 235000019439 ethyl acetate Nutrition 0.000 description 90
- 239000007787 solid Substances 0.000 description 85
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 82
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 82
- 239000011541 reaction mixture Substances 0.000 description 81
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 78
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 65
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 63
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 52
- 238000005481 NMR spectroscopy Methods 0.000 description 51
- 239000012267 brine Substances 0.000 description 50
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 50
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- 238000005160 1H NMR spectroscopy Methods 0.000 description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- 239000012044 organic layer Substances 0.000 description 39
- 238000003818 flash chromatography Methods 0.000 description 38
- 238000000746 purification Methods 0.000 description 35
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 32
- 239000000725 suspension Substances 0.000 description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 26
- 150000002148 esters Chemical class 0.000 description 25
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 24
- 239000002253 acid Substances 0.000 description 22
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 22
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 22
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 20
- 239000007788 liquid Substances 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 238000010992 reflux Methods 0.000 description 19
- 238000004293 19F NMR spectroscopy Methods 0.000 description 18
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 18
- 239000008194 pharmaceutical composition Substances 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 16
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 16
- 239000000284 extract Substances 0.000 description 16
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 15
- 230000008878 coupling Effects 0.000 description 15
- 238000010168 coupling process Methods 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 15
- YHNRUSMOYCDMJS-UHFFFAOYSA-N o-(cyclopropylmethyl)hydroxylamine Chemical compound NOCC1CC1 YHNRUSMOYCDMJS-UHFFFAOYSA-N 0.000 description 15
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 14
- HSFNEBWXUWQGNW-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-n-(2-hydroxyethoxy)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound OCCONC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl HSFNEBWXUWQGNW-UHFFFAOYSA-N 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 14
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 14
- 239000003960 organic solvent Substances 0.000 description 14
- 238000010561 standard procedure Methods 0.000 description 14
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- 238000007363 ring formation reaction Methods 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- 101150041968 CDC13 gene Proteins 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- 230000002159 abnormal effect Effects 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 230000010261 cell growth Effects 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 10
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 10
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- YLPFLKCGZGXPFI-UHFFFAOYSA-N methyl 6-amino-4-(4-bromo-2-chloroanilino)-5-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(N)C(Cl)=C1NC1=CC=C(Br)C=C1Cl YLPFLKCGZGXPFI-UHFFFAOYSA-N 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- RZRBEUMGDQTYNA-UHFFFAOYSA-N 4-(4-bromo-2-chloroanilino)-5,6-dichloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)C(Cl)=C1NC1=CC=C(Br)C=C1Cl RZRBEUMGDQTYNA-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 9
- 102000043136 MAP kinase family Human genes 0.000 description 9
- 108091054455 MAP kinase family Proteins 0.000 description 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 229910052763 palladium Inorganic materials 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 7
- JENGFSJGUVYCHQ-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-n-(cyclopropylmethoxy)-8-fluoroimidazo[1,2-a]pyridine-6-carboxamide Chemical compound C1CC1CONC(=O)C1=CN2C=CN=C2C(F)=C1NC1=CC=C(Br)C=C1Cl JENGFSJGUVYCHQ-UHFFFAOYSA-N 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000007859 condensation product Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- XZTSFVPMMQNIAJ-UHFFFAOYSA-N o-(2-ethenoxyethyl)hydroxylamine Chemical compound NOCCOC=C XZTSFVPMMQNIAJ-UHFFFAOYSA-N 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 7
- 238000010792 warming Methods 0.000 description 7
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 6
- ILMIEWNDXAKVNI-UHFFFAOYSA-N 4,6-dichloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)C=C1Cl ILMIEWNDXAKVNI-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 229910002666 PdCl2 Inorganic materials 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- PXAJQJMDEXJWFB-UHFFFAOYSA-N acetone oxime Chemical compound CC(C)=NO PXAJQJMDEXJWFB-UHFFFAOYSA-N 0.000 description 6
- 230000005595 deprotonation Effects 0.000 description 6
- 238000010537 deprotonation reaction Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 150000002443 hydroxylamines Chemical class 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- NHHCTYLYMAUZHD-UHFFFAOYSA-N methyl 5-bromo-2-(2-chloroanilino)-3,4-difluorobenzoate Chemical compound COC(=O)C1=CC(Br)=C(F)C(F)=C1NC1=CC=CC=C1Cl NHHCTYLYMAUZHD-UHFFFAOYSA-N 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- IYCZHTKLJQLKMW-UHFFFAOYSA-N tert-butyl 6-amino-4-(4-bromo-2-chloroanilino)pyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CN=C(N)C=C1NC1=CC=C(Br)C=C1Cl IYCZHTKLJQLKMW-UHFFFAOYSA-N 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 5
- WWWTWPXKLJTKPM-UHFFFAOYSA-N 2-aminooxyethanol Chemical compound NOCCO WWWTWPXKLJTKPM-UHFFFAOYSA-N 0.000 description 5
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 5
- ITYWODCTYSDDQT-UHFFFAOYSA-N 4-(4-bromo-2-chloroanilino)-6-chloropyridine-3-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CN=C(Cl)C=C1NC1=CC=C(Br)C=C1Cl ITYWODCTYSDDQT-UHFFFAOYSA-N 0.000 description 5
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 5
- QPUQVLGZNFJHCD-UHFFFAOYSA-N 6-(2-chloroanilino)-7-fluoro-3-methyl-2,1-benzoxazole-5-carboxylic acid Chemical compound OC(=O)C1=CC2=C(C)ON=C2C(F)=C1NC1=CC=CC=C1Cl QPUQVLGZNFJHCD-UHFFFAOYSA-N 0.000 description 5
- CXNKXAGWACKPKC-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-7-fluoro-3-methyl-1,2-benzoxazole-5-carboxylic acid Chemical compound OC(=O)C=1C=C2C(C)=NOC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CXNKXAGWACKPKC-UHFFFAOYSA-N 0.000 description 5
- DRRFUQMCLFJCDN-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl DRRFUQMCLFJCDN-UHFFFAOYSA-N 0.000 description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 5
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 5
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229940043279 diisopropylamine Drugs 0.000 description 5
- AAUBVINEXCCXOK-UHFFFAOYSA-N ethyl 4,6-dichloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)C=C1Cl AAUBVINEXCCXOK-UHFFFAOYSA-N 0.000 description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- OVHUPKYGIWERSV-UHFFFAOYSA-N methyl 4-(4-bromo-2-chloroanilino)-5,6-dichloropyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C(Cl)=C1NC1=CC=C(Br)C=C1Cl OVHUPKYGIWERSV-UHFFFAOYSA-N 0.000 description 5
- NEPVQFNYWYBUFR-UHFFFAOYSA-N methyl 4-(4-bromo-2-chloroanilino)-5-chloro-6-hydrazinylpyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(NN)C(Cl)=C1NC1=CC=C(Br)C=C1Cl NEPVQFNYWYBUFR-UHFFFAOYSA-N 0.000 description 5
- SUUIBASDMLZZPY-UHFFFAOYSA-N methyl 5-acetyl-2-(2-chloroanilino)-3,4-difluorobenzoate Chemical compound COC(=O)C1=CC(C(C)=O)=C(F)C(F)=C1NC1=CC=CC=C1Cl SUUIBASDMLZZPY-UHFFFAOYSA-N 0.000 description 5
- VHNBCNJMJRBOAN-UHFFFAOYSA-N methyl 7-(4-bromo-2-chloroanilino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylate Chemical compound COC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl VHNBCNJMJRBOAN-UHFFFAOYSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 238000007127 saponification reaction Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229940124530 sulfonamide Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 4
- YZGDBYYQGNHYAV-UHFFFAOYSA-N 3-amino-6-(4-bromo-2-chloroanilino)-7-fluoro-1,2-benzoxazole-5-carboxylic acid Chemical compound OC(=O)C=1C=C2C(N)=NOC2=C(F)C=1NC1=CC=C(Br)C=C1Cl YZGDBYYQGNHYAV-UHFFFAOYSA-N 0.000 description 4
- GONDNJRVKJZYEK-UHFFFAOYSA-N 3-benzyl-7-(4-bromo-2-chloroanilino)-8-chloro-n-(cyclopropylmethoxy)-[1,2,4]triazolo[4,3-a]pyridine-6-carboxamide Chemical compound ClC1=CC(Br)=CC=C1NC(C(=CN12)C(=O)NOCC3CC3)=C(Cl)C1=NN=C2CC1=CC=CC=C1 GONDNJRVKJZYEK-UHFFFAOYSA-N 0.000 description 4
- XQIATTAAVBLNAN-UHFFFAOYSA-N 5-bromo-2,3,4-trifluorobenzoic acid Chemical compound OC(=O)C1=CC(Br)=C(F)C(F)=C1F XQIATTAAVBLNAN-UHFFFAOYSA-N 0.000 description 4
- FVAGIKQSUOJNRT-UHFFFAOYSA-N 6-(2,4-dichloroanilino)-7-fluoro-3-methyl-1,2-benzoxazole-5-carboxylic acid Chemical compound OC(=O)C=1C=C2C(C)=NOC2=C(F)C=1NC1=CC=C(Cl)C=C1Cl FVAGIKQSUOJNRT-UHFFFAOYSA-N 0.000 description 4
- HDLYKTAZFYFKEW-UHFFFAOYSA-N 6-(2-chloroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3-methyl-2,1-benzoxazole-5-carboxamide Chemical compound OCCONC(=O)C1=CC2=C(C)ON=C2C(F)=C1NC1=CC=CC=C1Cl HDLYKTAZFYFKEW-UHFFFAOYSA-N 0.000 description 4
- ROIKTCFZWMIEEE-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C(C)=NN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl ROIKTCFZWMIEEE-UHFFFAOYSA-N 0.000 description 4
- MFPCSJJHFOEXPJ-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-n-(2-hydroxyethoxy)-3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxamide Chemical compound OCCONC(=O)C1=CN2C(C)=NN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl MFPCSJJHFOEXPJ-UHFFFAOYSA-N 0.000 description 4
- YXUXRISIJYTNCS-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-n-(cyclopropylmethoxy)-3-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound C1CN(C)CCN1C1=CN=C2N1C=C(C(=O)NOCC1CC1)C(NC=1C(=CC(Br)=CC=1)Cl)=C2Cl YXUXRISIJYTNCS-UHFFFAOYSA-N 0.000 description 4
- SPWOSOVUCYTNGI-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C(F)=C1NC1=CC=C(Br)C=C1Cl SPWOSOVUCYTNGI-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 229940124647 MEK inhibitor Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 150000003927 aminopyridines Chemical class 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 230000000340 anti-metabolite Effects 0.000 description 4
- 239000002256 antimetabolite Substances 0.000 description 4
- 229940100197 antimetabolite Drugs 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 229960004424 carbon dioxide Drugs 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- IADRZSLECZWZIT-UHFFFAOYSA-N ethyl 4-(4-bromo-2-chloroanilino)-5,6-dichloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)C(Cl)=C1NC1=CC=C(Br)C=C1Cl IADRZSLECZWZIT-UHFFFAOYSA-N 0.000 description 4
- QDHHLXABEXNRJX-UHFFFAOYSA-N ethyl 4-hydroxy-6-oxo-1h-pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CNC(O)=CC1=O QDHHLXABEXNRJX-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- RQTIBWYZCQZWOC-UHFFFAOYSA-N methyl 3-benzyl-7-(4-bromo-2-chloroanilino)-8-chloro-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylate Chemical compound N=1N=C2C(Cl)=C(NC=3C(=CC(Br)=CC=3)Cl)C(C(=O)OC)=CN2C=1CC1=CC=CC=C1 RQTIBWYZCQZWOC-UHFFFAOYSA-N 0.000 description 4
- LGIUQDSHXXLYCG-UHFFFAOYSA-N methyl 6-azido-4-(4-bromo-2-chloroanilino)-5-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(N=[N+]=[N-])C(Cl)=C1NC1=CC=C(Br)C=C1Cl LGIUQDSHXXLYCG-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000005897 peptide coupling reaction Methods 0.000 description 4
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- HZXJVDYQRYYYOR-UHFFFAOYSA-K scandium(iii) trifluoromethanesulfonate Chemical compound [Sc+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F HZXJVDYQRYYYOR-UHFFFAOYSA-K 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- CPBNOLFQEDHRCM-UHFFFAOYSA-N tert-butyl 4-(4-bromo-2-chloroanilino)-6-chloropyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CN=C(Cl)C=C1NC1=CC=C(Br)C=C1Cl CPBNOLFQEDHRCM-UHFFFAOYSA-N 0.000 description 4
- YAELKEVWDOOJJX-UHFFFAOYSA-N tert-butyl 6-amino-4-(4-bromo-2-chloroanilino)-5-fluoropyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CN=C(N)C(F)=C1NC1=CC=C(Br)C=C1Cl YAELKEVWDOOJJX-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 4
- 238000001665 trituration Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 3
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- MUUAQFJJUGVBGB-UHFFFAOYSA-N 1-bromo-2,3,4-trifluorobenzene Chemical compound FC1=CC=C(Br)C(F)=C1F MUUAQFJJUGVBGB-UHFFFAOYSA-N 0.000 description 3
- ZLTYCXCLNDFFKO-UHFFFAOYSA-N 5-[7-(4-bromo-2-fluoroanilino)-8-fluoroimidazo[1,2-a]pyridin-6-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound FC1=CC(Br)=CC=C1NC1=C(F)C2=NC=CN2C=C1C1=NNC(=O)O1 ZLTYCXCLNDFFKO-UHFFFAOYSA-N 0.000 description 3
- KWQACFCLUAMPDU-UHFFFAOYSA-N 6-(2-chloroanilino)-n-(cyclopropylmethoxy)-7-fluoro-3-methyl-2,1-benzoxazole-5-carboxamide Chemical compound C1CC1CONC(=O)C1=CC2=C(C)ON=C2C(F)=C1NC1=CC=CC=C1Cl KWQACFCLUAMPDU-UHFFFAOYSA-N 0.000 description 3
- MCAHUWAGPMQWRK-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3-methyl-1,2-benzoxazole-5-carboxamide Chemical compound OCCONC(=O)C=1C=C2C(C)=NOC2=C(F)C=1NC1=CC=C(Br)C=C1Cl MCAHUWAGPMQWRK-UHFFFAOYSA-N 0.000 description 3
- CGRHABYUCHONCD-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-n-(cyclopropylmethoxy)-7-fluoro-3-methyl-1,2-benzoxazole-5-carboxamide Chemical compound C1CC1CONC(=O)C=1C=C2C(C)=NOC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CGRHABYUCHONCD-UHFFFAOYSA-N 0.000 description 3
- JHYORGRGVTZEBK-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-n-(2-hydroxyethoxy)-3-(piperidin-1-ylmethyl)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound C=1N=C2C(Cl)=C(NC=3C(=CC(Br)=CC=3)Cl)C(C(=O)NOCCO)=CN2C=1CN1CCCCC1 JHYORGRGVTZEBK-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 3
- 229940127007 Compound 39 Drugs 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 3
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 3
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 230000002280 anti-androgenic effect Effects 0.000 description 3
- 230000003388 anti-hormonal effect Effects 0.000 description 3
- 239000000051 antiandrogen Substances 0.000 description 3
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000010936 aqueous wash Methods 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000012964 benzotriazole Substances 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- LKMWTAPKOUSWHM-UHFFFAOYSA-N ethyl 5-chloro-3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylate Chemical compound C(C)OC(=O)C=1C=CC=2N(C1Cl)C(=NN2)C LKMWTAPKOUSWHM-UHFFFAOYSA-N 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000026030 halogenation Effects 0.000 description 3
- 238000005658 halogenation reaction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- HMKNKWJIRCGBBP-UHFFFAOYSA-N imidazo[1,2-a]pyridin-3-ylmethanamine Chemical class C1=CC=CN2C(CN)=CN=C21 HMKNKWJIRCGBBP-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 239000012444 intercalating antibiotic Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- HHAMGFVBGIBWEJ-UHFFFAOYSA-N methyl 2-(2-chloroanilino)-3,4-difluoro-5-(2-trimethylsilylethynyl)benzoate Chemical compound COC(=O)C1=CC(C#C[Si](C)(C)C)=C(F)C(F)=C1NC1=CC=CC=C1Cl HHAMGFVBGIBWEJ-UHFFFAOYSA-N 0.000 description 3
- UPXZTUASRXFGEX-UHFFFAOYSA-N methyl 2-(2-chloroanilino)-5-cyano-3,4-difluorobenzoate Chemical compound COC(=O)C1=CC(C#N)=C(F)C(F)=C1NC1=CC=CC=C1Cl UPXZTUASRXFGEX-UHFFFAOYSA-N 0.000 description 3
- GCCZOHAHHWPFFU-UHFFFAOYSA-N methyl 6-(4-bromo-2-chloroanilino)-7-fluoro-3-methyl-1,2-benzoxazole-5-carboxylate Chemical compound COC(=O)C1=CC=2C(C)=NOC=2C(F)=C1NC1=CC=C(Br)C=C1Cl GCCZOHAHHWPFFU-UHFFFAOYSA-N 0.000 description 3
- AQMLRZVAIFMUFA-UHFFFAOYSA-N methyl 7-(4-bromo-2-chloroanilino)-8-chloro-3-(methylaminomethyl)imidazo[1,2-a]pyridine-6-carboxylate Chemical compound COC(=O)C1=CN2C(CNC)=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl AQMLRZVAIFMUFA-UHFFFAOYSA-N 0.000 description 3
- BOZRSKNAQWAPEB-UHFFFAOYSA-N methyl 7-(4-bromo-2-chloroanilino)-8-chloro-3-[[[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]methyl]imidazo[1,2-a]pyridine-6-carboxylate Chemical compound COC(=O)C1=CN2C(CNCC(=O)OC(C)(C)C)=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl BOZRSKNAQWAPEB-UHFFFAOYSA-N 0.000 description 3
- NETQKENPKCVDCZ-UHFFFAOYSA-N methyl 7-(4-bromo-2-chloroanilino)-8-chloro-3-formylimidazo[1,2-a]pyridine-6-carboxylate Chemical compound COC(=O)C1=CN2C(C=O)=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl NETQKENPKCVDCZ-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- NWELCUKYUCBVKK-UHFFFAOYSA-N pyridin-2-ylhydrazine Chemical compound NNC1=CC=CC=N1 NWELCUKYUCBVKK-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000002381 testicular Effects 0.000 description 3
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical group ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- NMPVEAUIHMEAQP-UHFFFAOYSA-N 2-Bromoacetaldehyde Chemical compound BrCC=O NMPVEAUIHMEAQP-UHFFFAOYSA-N 0.000 description 2
- QQDCXQURAAVVHQ-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl methanesulfonate Chemical compound CC(C)(C)OC(=O)NCCOS(C)(=O)=O QQDCXQURAAVVHQ-UHFFFAOYSA-N 0.000 description 2
- HKDXIDOASMRHRZ-UHFFFAOYSA-N 2-[[7-(4-bromo-2-chloroanilino)-8-chloroimidazo[1,2-a]pyridine-6-carbonyl]amino]oxyethyl dihydrogen phosphate Chemical compound OP(O)(=O)OCCONC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl HKDXIDOASMRHRZ-UHFFFAOYSA-N 0.000 description 2
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical class ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 2
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- VGOALPIDEXVYQI-UHFFFAOYSA-N 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-n-[3-imidazol-1-yl-5-(trifluoromethyl)phenyl]-4-methylbenzamide Chemical compound C1=C(C#CC=2N3N=CC=CC3=NC=2)C(C)=CC=C1C(=O)NC(C=C(C=1)C(F)(F)F)=CC=1N1C=CN=C1 VGOALPIDEXVYQI-UHFFFAOYSA-N 0.000 description 2
- NSQJHKHHSQKILC-UHFFFAOYSA-N 3-amino-6-(4-bromo-2-chloroanilino)-7-fluoro-n-(2-hydroxyethoxy)-1,2-benzoxazole-5-carboxamide Chemical compound OCCONC(=O)C=1C=C2C(N)=NOC2=C(F)C=1NC1=CC=C(Br)C=C1Cl NSQJHKHHSQKILC-UHFFFAOYSA-N 0.000 description 2
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 2
- GKHIYZYURHIGSB-UHFFFAOYSA-N 3-ethyl-8-fluoro-7-(2-fluoro-4-methylanilino)-n-(2-hydroxyethoxy)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound OCCONC(=O)C1=CN2C(CC)=CN=C2C(F)=C1NC1=CC=C(C)C=C1F GKHIYZYURHIGSB-UHFFFAOYSA-N 0.000 description 2
- GDRLWCPMLULBNF-UHFFFAOYSA-N 4,5,6-trichloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)C(Cl)=C1Cl GDRLWCPMLULBNF-UHFFFAOYSA-N 0.000 description 2
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 2
- INMZDDDQLHKGPF-UHFFFAOYSA-N 4-bromo-2-chloroaniline Chemical compound NC1=CC=C(Br)C=C1Cl INMZDDDQLHKGPF-UHFFFAOYSA-N 0.000 description 2
- KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 2
- LJWRKSPLQUIEAW-UHFFFAOYSA-N 5-bromo-2-(2-chloroanilino)-3,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC(Br)=C(F)C(F)=C1NC1=CC=CC=C1Cl LJWRKSPLQUIEAW-UHFFFAOYSA-N 0.000 description 2
- ODASLOWZKNNAKH-UHFFFAOYSA-N 6-(2,4-dichloroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3-methyl-1,2-benzoxazole-5-carboxamide Chemical compound OCCONC(=O)C=1C=C2C(C)=NOC2=C(F)C=1NC1=CC=C(Cl)C=C1Cl ODASLOWZKNNAKH-UHFFFAOYSA-N 0.000 description 2
- WPQHKPZQJXYOOG-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-3-methylimidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C(C)=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl WPQHKPZQJXYOOG-UHFFFAOYSA-N 0.000 description 2
- SXBDEFJKOQZBQW-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-n-(cyclopropylmethoxy)-3-(dimethylamino)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound C1CC1CONC(=O)C1=CN2C(N(C)C)=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl SXBDEFJKOQZBQW-UHFFFAOYSA-N 0.000 description 2
- WYOCLSQMNYYDAE-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-n-(cyclopropylmethoxy)-3-(morpholin-4-ylmethyl)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound ClC1=CC(Br)=CC=C1NC(C(=CN12)C(=O)NOCC3CC3)=C(Cl)C1=NC=C2CN1CCOCC1 WYOCLSQMNYYDAE-UHFFFAOYSA-N 0.000 description 2
- GTUZSSSUYQWPTP-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-n-(cyclopropylmethoxy)-3-[(dimethylamino)methyl]imidazo[1,2-a]pyridine-6-carboxamide Chemical compound C1CC1CONC(=O)C1=CN2C(CN(C)C)=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl GTUZSSSUYQWPTP-UHFFFAOYSA-N 0.000 description 2
- ZMDRKWQVFLNVQB-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-n-(cyclopropylmethoxy)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound ClC1=CC(Br)=CC=C1NC1=C(Cl)C2=NC=CN2C=C1C(=O)NOCC1CC1 ZMDRKWQVFLNVQB-UHFFFAOYSA-N 0.000 description 2
- GUGQNEMJUZJECR-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C(C)=C1NC1=CC=C(Br)C=C1Cl GUGQNEMJUZJECR-UHFFFAOYSA-N 0.000 description 2
- SBXOHQFXNRTVGM-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-8-chloro-n'-(2-chloroacetyl)imidazo[1,2-a]pyridine-6-carbohydrazide Chemical compound FC1=CC(Br)=CC=C1NC1=C(Cl)C2=NC=CN2C=C1C(=O)NNC(=O)CCl SBXOHQFXNRTVGM-UHFFFAOYSA-N 0.000 description 2
- YZQQNOIYCZLLID-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-8-chloroimidazo[1,2-a]pyridine-6-carbohydrazide Chemical compound NNC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1F YZQQNOIYCZLLID-UHFFFAOYSA-N 0.000 description 2
- UIEJDMATSWMGJD-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1F UIEJDMATSWMGJD-UHFFFAOYSA-N 0.000 description 2
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 238000006683 Mannich reaction Methods 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 229910017974 NH40H Inorganic materials 0.000 description 2
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- GOOHAUXETOMSMM-GSVOUGTGSA-N R-propylene oxide Chemical compound C[C@@H]1CO1 GOOHAUXETOMSMM-GSVOUGTGSA-N 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 238000012382 advanced drug delivery Methods 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 210000001109 blastomere Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000001723 carbon free-radicals Chemical class 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- XWJXULFLZWQHML-UHFFFAOYSA-N ethyl 4,5,6-trichloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)C(Cl)=C1Cl XWJXULFLZWQHML-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- RDAYEGAKDQBKJB-UHFFFAOYSA-N methyl 7-(4-ethenyl-2-fluoroanilino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylate Chemical compound COC(=O)C1=CN2C=CN=C2C(F)=C1NC1=CC=C(C=C)C=C1F RDAYEGAKDQBKJB-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- MNWYVVFHNHMOQJ-UHFFFAOYSA-N n-(cyclopropylmethyl)hydroxylamine Chemical compound ONCC1CC1 MNWYVVFHNHMOQJ-UHFFFAOYSA-N 0.000 description 2
- VMFMUJZRXZXYAH-UHFFFAOYSA-N n-[5-[[5-chloro-4-[2-[2-(dimethylamino)-2-oxoacetyl]anilino]pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound C=CC(=O)NC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)C(=O)C(=O)N(C)C)C(Cl)=CN=2)C(OC)=CC=1N1CCN(C)CC1 VMFMUJZRXZXYAH-UHFFFAOYSA-N 0.000 description 2
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- YWNYAUCCVBZMPH-VIFPVBQESA-N o-[(2s)-2-[tert-butyl(dimethyl)silyl]oxybutyl]hydroxylamine Chemical compound NOC[C@H](CC)O[Si](C)(C)C(C)(C)C YWNYAUCCVBZMPH-VIFPVBQESA-N 0.000 description 2
- AQFWNELGMODZGC-UHFFFAOYSA-N o-ethylhydroxylamine Chemical compound CCON AQFWNELGMODZGC-UHFFFAOYSA-N 0.000 description 2
- NUXCOKIYARRTDC-UHFFFAOYSA-N o-ethylhydroxylamine;hydron;chloride Chemical compound Cl.CCON NUXCOKIYARRTDC-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 150000002924 oxiranes Chemical group 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- GHTCDIMLJVTPEP-UHFFFAOYSA-N pyrazolo[1,5-a]pyridin-2-amine Chemical class C1=CC=CN2N=C(N)C=C21 GHTCDIMLJVTPEP-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 108010077182 raf Kinases Proteins 0.000 description 2
- 102000009929 raf Kinases Human genes 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- BHIGZYWRVWZUHG-UHFFFAOYSA-N tert-butyl n-(3-hydroxy-2,2-dimethylpropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC(C)(C)CO BHIGZYWRVWZUHG-UHFFFAOYSA-N 0.000 description 2
- LQGKMFUJQWMZNC-UHFFFAOYSA-N tert-butyl n-(4-aminooxybutan-2-yl)carbamate Chemical compound NOCCC(C)NC(=O)OC(C)(C)C LQGKMFUJQWMZNC-UHFFFAOYSA-N 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- PMHHCLXJMNLEIE-GSVOUGTGSA-N (2r)-1-iodopropan-2-ol Chemical compound C[C@@H](O)CI PMHHCLXJMNLEIE-GSVOUGTGSA-N 0.000 description 1
- RBACIKXCRWGCBB-SCSAIBSYSA-N (2r)-2-ethyloxirane Chemical compound CC[C@@H]1CO1 RBACIKXCRWGCBB-SCSAIBSYSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- RBACIKXCRWGCBB-UHFFFAOYSA-N 1,2-Epoxybutane Chemical compound CCC1CO1 RBACIKXCRWGCBB-UHFFFAOYSA-N 0.000 description 1
- NLMVYUBGWZWUGB-UHFFFAOYSA-N 1,2-benzoxazol-3-amine Chemical compound C1=CC=C2C(N)=NOC2=C1 NLMVYUBGWZWUGB-UHFFFAOYSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- AHFMSNDOYCFEPH-UHFFFAOYSA-N 1,2-difluoroethane Chemical compound FCCF AHFMSNDOYCFEPH-UHFFFAOYSA-N 0.000 description 1
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Substances C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- UMHYXHCNNYUYGK-UHFFFAOYSA-N 1-[7-(4-bromo-2-chloroanilino)-8-chloroimidazo[1,2-a]pyridin-6-yl]ethanone Chemical compound CC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl UMHYXHCNNYUYGK-UHFFFAOYSA-N 0.000 description 1
- ZRONMPPDQBXARP-UHFFFAOYSA-N 1-aminooxy-2-methylpropan-2-ol Chemical compound CC(C)(O)CON ZRONMPPDQBXARP-UHFFFAOYSA-N 0.000 description 1
- FSNWKKDILGLXFA-UHFFFAOYSA-N 1-aminooxy-3,3-dimethylbutan-2-ol Chemical compound CC(C)(C)C(O)CON FSNWKKDILGLXFA-UHFFFAOYSA-N 0.000 description 1
- PJOCRKSXKKGYCO-UHFFFAOYSA-N 1-aminooxy-3-methoxypropan-2-ol Chemical compound COCC(O)CON PJOCRKSXKKGYCO-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical class [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- FZKCAHQKNJXICB-UHFFFAOYSA-N 2,1-benzoxazole Chemical group C1=CC=CC2=CON=C21 FZKCAHQKNJXICB-UHFFFAOYSA-N 0.000 description 1
- KQFJLRSPVMTBLE-UHFFFAOYSA-N 2-(2-hydroxy-3,3-dimethylbutoxy)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(OCC(O)C(C)(C)C)C(=O)C2=C1 KQFJLRSPVMTBLE-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- GCUNXHWKISRLSW-GFCCVEGCSA-N 2-[(2r)-2-[tert-butyl(dimethyl)silyl]oxypropoxy]isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(OC[C@@H](C)O[Si](C)(C)C(C)(C)C)C(=O)C2=C1 GCUNXHWKISRLSW-GFCCVEGCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XNNKZHGWDYGGIP-UHFFFAOYSA-N 2-[[5-[7-(4-bromo-2-fluoroanilino)-8-fluoroimidazo[1,2-a]pyridin-6-yl]-1,3,4-oxadiazol-2-yl]amino]ethanol Chemical compound O1C(NCCO)=NN=C1C(C(=C1F)NC=2C(=CC(Br)=CC=2)F)=CN2C1=NC=C2 XNNKZHGWDYGGIP-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- UKQGSVWBONLFAR-UHFFFAOYSA-N 2-aminooxy-2-methylpropan-1-ol Chemical compound OCC(C)(C)ON UKQGSVWBONLFAR-UHFFFAOYSA-N 0.000 description 1
- XIHMVBYRFOJGLN-UHFFFAOYSA-N 2-aminooxyethylcarbamic acid Chemical compound NOCCNC(O)=O XIHMVBYRFOJGLN-UHFFFAOYSA-N 0.000 description 1
- SZVUPDRKOWDKAR-UHFFFAOYSA-N 2-aminooxypropan-1-ol Chemical compound OCC(C)ON SZVUPDRKOWDKAR-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- HWZUMEVIIGNXGM-UHFFFAOYSA-N 2-chloro-4-methyl-5-nitropyridine Chemical compound CC1=CC(Cl)=NC=C1[N+]([O-])=O HWZUMEVIIGNXGM-UHFFFAOYSA-N 0.000 description 1
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- KTRZQCIGJUWSGE-UHFFFAOYSA-N 2-chloropropanedial Chemical compound O=CC(Cl)C=O KTRZQCIGJUWSGE-UHFFFAOYSA-N 0.000 description 1
- MEQBJJUWDCYIAB-UHFFFAOYSA-N 2-chloropyridin-3-amine Chemical compound NC1=CC=CN=C1Cl MEQBJJUWDCYIAB-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical class CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- HEAYDCIZOFDHRM-UHFFFAOYSA-N 2-tert-butyloxirane Chemical compound CC(C)(C)C1CO1 HEAYDCIZOFDHRM-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
- AGMZSYQMSHMXLT-UHFFFAOYSA-N 3-aminobutan-1-ol Chemical compound CC(N)CCO AGMZSYQMSHMXLT-UHFFFAOYSA-N 0.000 description 1
- UNYHAFYVPBNWGT-UHFFFAOYSA-N 3-aminooxy-1,1,1-trifluoropropan-2-ol Chemical compound NOCC(O)C(F)(F)F UNYHAFYVPBNWGT-UHFFFAOYSA-N 0.000 description 1
- KAHKXUXOXXKPLO-UHFFFAOYSA-N 3-aminooxypropan-1-ol Chemical compound NOCCCO KAHKXUXOXXKPLO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SXAXZLYJPLISIP-UHFFFAOYSA-N 3-bromo-7-(4-bromo-2-chloroanilino)-8-chloro-n-(2-hydroxyethoxy)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound OCCONC(=O)C1=CN2C(Br)=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl SXAXZLYJPLISIP-UHFFFAOYSA-N 0.000 description 1
- IMZQLFVADHUXFO-UHFFFAOYSA-N 3-chloro-7-(2,4-dichloroanilino)-n-(2-ethenoxyethoxy)-8-fluoroimidazo[1,2-a]pyridine-6-carboxamide Chemical compound C=COCCONC(=O)C1=CN2C(Cl)=CN=C2C(F)=C1NC1=CC=C(Cl)C=C1Cl IMZQLFVADHUXFO-UHFFFAOYSA-N 0.000 description 1
- ZOQDGMRYMRFKRV-UHFFFAOYSA-N 3-methyl-2,1-benzoxazole Chemical class C1=CC=CC2=C(C)ON=C21 ZOQDGMRYMRFKRV-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- UYTWCEYZEQBILY-UHFFFAOYSA-N 4,6-dichloro-5-fluoropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)C(F)=C1Cl UYTWCEYZEQBILY-UHFFFAOYSA-N 0.000 description 1
- CBSZOUNRMFQJOB-UHFFFAOYSA-N 4,6-dichloro-5-methylpyridine-3-carboxylic acid Chemical compound CC1=C(Cl)N=CC(C(O)=O)=C1Cl CBSZOUNRMFQJOB-UHFFFAOYSA-N 0.000 description 1
- SNZTWTPHAOXTON-UHFFFAOYSA-N 4-(4-bromo-2-chloroanilino)-5-chloro-6-(2-hydroxypropylamino)pyridine-3-carboxylic acid Chemical compound BrC1=CC(=C(C=C1)NC1=C(C(=NC=C1C(=O)O)NCC(C)O)Cl)Cl SNZTWTPHAOXTON-UHFFFAOYSA-N 0.000 description 1
- ACKWHPURNTYNOA-UHFFFAOYSA-N 4-(4-bromo-2-chloroanilino)-6-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)C=C1NC1=CC=C(Br)C=C1Cl ACKWHPURNTYNOA-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- GZRMNMGWNKSANY-UHFFFAOYSA-N 4-bromo-2-fluoroaniline Chemical compound NC1=CC=C(Br)C=C1F GZRMNMGWNKSANY-UHFFFAOYSA-N 0.000 description 1
- YWDBFEUMTBHUQK-UHFFFAOYSA-N 5-[7-(4-bromo-2-fluoroanilino)-8-chloroimidazo[1,2-a]pyridin-6-yl]-1,3,4-oxadiazol-2-amine Chemical compound O1C(N)=NN=C1C(C(=C1Cl)NC=2C(=CC(Br)=CC=2)F)=CN2C1=NC=C2 YWDBFEUMTBHUQK-UHFFFAOYSA-N 0.000 description 1
- FAZBYWAFKABYKV-UHFFFAOYSA-N 5-[7-(4-bromo-2-fluoroanilino)-8-chloroimidazo[1,2-a]pyridin-6-yl]-3h-1,3,4-oxadiazole-2-thione Chemical compound FC1=CC(Br)=CC=C1NC1=C(Cl)C2=NC=CN2C=C1C1=NN=C(S)O1 FAZBYWAFKABYKV-UHFFFAOYSA-N 0.000 description 1
- ZSICWVCNHASNGV-UHFFFAOYSA-N 5-bromo-4-(4-bromo-2-chloroanilino)-6-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)C(Br)=C1NC1=CC=C(Br)C=C1Cl ZSICWVCNHASNGV-UHFFFAOYSA-N 0.000 description 1
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical group C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 1
- FICOZADEPHTOPW-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-7-fluoro-n-(2-hydroxyethoxy)pyrazolo[1,5-a]pyridine-5-carboxamide Chemical compound OCCONC(=O)C1=CC2=CC=NN2C(F)=C1NC1=CC=C(Br)C=C1Cl FICOZADEPHTOPW-UHFFFAOYSA-N 0.000 description 1
- LLXZNFYIVVPKQQ-UHFFFAOYSA-N 6-[5-(aminomethyl)-1,3,4-oxadiazol-2-yl]-n-(4-bromo-2-fluorophenyl)-8-chloroimidazo[1,2-a]pyridin-7-amine Chemical compound O1C(CN)=NN=C1C(C(=C1Cl)NC=2C(=CC(Br)=CC=2)F)=CN2C1=NC=C2 LLXZNFYIVVPKQQ-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- JWYWORXAAYOPGB-UHFFFAOYSA-N 7-(2,4-dichloroanilino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C(F)=C1NC1=CC=C(Cl)C=C1Cl JWYWORXAAYOPGB-UHFFFAOYSA-N 0.000 description 1
- PJJWOWSVCJNOGV-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-3-[[[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]methyl]imidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C(CNCC(=O)OC(C)(C)C)=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl PJJWOWSVCJNOGV-UHFFFAOYSA-N 0.000 description 1
- JKAKPGNWHYCSCW-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-n-(cyclopropylmethoxy)-3-(methylaminomethyl)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound C1CC1CONC(=O)C1=CN2C(CNC)=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl JKAKPGNWHYCSCW-UHFFFAOYSA-N 0.000 description 1
- FLJZZQWXKCDADK-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-chloro-n-(cyclopropylmethoxy)-3-methylimidazo[1,2-a]pyridine-6-carboxamide Chemical compound C1CC1CONC(=O)C1=CN2C(C)=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1Cl FLJZZQWXKCDADK-UHFFFAOYSA-N 0.000 description 1
- MFWFYLMFYYBAIX-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)-8-fluoro-n-(2-hydroxyethoxy)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound OCCONC(=O)C1=CN2C=CN=C2C(F)=C1NC1=CC=C(Br)C=C1Cl MFWFYLMFYYBAIX-UHFFFAOYSA-N 0.000 description 1
- MTTNNRMJDBVLIC-UHFFFAOYSA-N 7-(4-bromo-2-chloroanilino)imidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C=C1NC1=CC=C(Br)C=C1Cl MTTNNRMJDBVLIC-UHFFFAOYSA-N 0.000 description 1
- SAXCSWJOZMHOAA-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-8-chloro-n-(2-hydroxyethoxy)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound OCCONC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1F SAXCSWJOZMHOAA-UHFFFAOYSA-N 0.000 description 1
- YAVNKAKDSPKNQX-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-8-chloro-n-(cyclopropylmethoxy)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound FC1=CC(Br)=CC=C1NC1=C(Cl)C2=NC=CN2C=C1C(=O)NOCC1CC1 YAVNKAKDSPKNQX-UHFFFAOYSA-N 0.000 description 1
- LYQFMWLOPXCZMH-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-8-fluoroimidazo[1,2-a]pyridine-6-carbohydrazide Chemical compound NNC(=O)C1=CN2C=CN=C2C(F)=C1NC1=CC=C(Br)C=C1F LYQFMWLOPXCZMH-UHFFFAOYSA-N 0.000 description 1
- IGMGMXNHPLPUQX-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C(F)=C1NC1=CC=C(Br)C=C1F IGMGMXNHPLPUQX-UHFFFAOYSA-N 0.000 description 1
- CBLHDEVPXRZOHC-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C(C)=C1NC1=CC=C(Br)C=C1F CBLHDEVPXRZOHC-UHFFFAOYSA-N 0.000 description 1
- JLVYNMNYWOKTJK-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-n-(2-hydroxyethoxy)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound OCCONC(=O)C1=CN2C=CN=C2C=C1NC1=CC=C(Br)C=C1F JLVYNMNYWOKTJK-UHFFFAOYSA-N 0.000 description 1
- CMUMFLRFDQEYHF-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-n-(cyclopropylmethoxy)-8-fluoroimidazo[1,2-a]pyridine-6-carboxamide Chemical compound FC1=CC(Br)=CC=C1NC1=C(F)C2=NC=CN2C=C1C(=O)NOCC1CC1 CMUMFLRFDQEYHF-UHFFFAOYSA-N 0.000 description 1
- MFHQCHJYBVTHEB-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-n-ethoxy-8-fluoro-3-(morpholin-4-ylmethyl)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound C=1N=C2C(F)=C(NC=3C(=CC(Br)=CC=3)F)C(C(=O)NOCC)=CN2C=1CN1CCOCC1 MFHQCHJYBVTHEB-UHFFFAOYSA-N 0.000 description 1
- MUOSTNSOWIMQDO-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-n-ethoxy-8-fluoroimidazo[1,2-a]pyridine-6-carboxamide Chemical compound CCONC(=O)C1=CN2C=CN=C2C(F)=C1NC1=CC=C(Br)C=C1F MUOSTNSOWIMQDO-UHFFFAOYSA-N 0.000 description 1
- POQWRBZNQLHZFX-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)imidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C=C1NC1=CC=C(Br)C=C1F POQWRBZNQLHZFX-UHFFFAOYSA-N 0.000 description 1
- MTBJRAXTUBUCJA-UHFFFAOYSA-N 7-(4-bromo-2-methylanilino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound CC1=CC(Br)=CC=C1NC1=C(Cl)C2=NC=CN2C=C1C(O)=O MTBJRAXTUBUCJA-UHFFFAOYSA-N 0.000 description 1
- ZXQDMIUHFBAYSF-UHFFFAOYSA-N 7-(4-bromo-2-methylanilino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound CC1=CC(Br)=CC=C1NC1=C(F)C2=NC=CN2C=C1C(O)=O ZXQDMIUHFBAYSF-UHFFFAOYSA-N 0.000 description 1
- BRWCKXQUWVPMFP-UHFFFAOYSA-N 7-(4-chloro-2-fluoroanilino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C(F)=C1NC1=CC=C(Cl)C=C1F BRWCKXQUWVPMFP-UHFFFAOYSA-N 0.000 description 1
- CTPVXVGCUMKPSX-UHFFFAOYSA-N 8-chloro-7-(2,4-dichloroanilino)-n-(2-hydroxyethoxy)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound OCCONC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=C(Cl)C=C1Cl CTPVXVGCUMKPSX-UHFFFAOYSA-N 0.000 description 1
- NVBNSACTYLGCLA-UHFFFAOYSA-N 8-chloro-7-(2,4-dichloroanilino)imidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=C(Cl)C=C1Cl NVBNSACTYLGCLA-UHFFFAOYSA-N 0.000 description 1
- CFHJETVTEOGFGW-UHFFFAOYSA-N 8-chloro-7-(2,4-difluoroanilino)imidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=C(F)C=C1F CFHJETVTEOGFGW-UHFFFAOYSA-N 0.000 description 1
- CCEULDNBSVWLLU-UHFFFAOYSA-N 8-chloro-7-(2-fluoroanilino)-n-(2-hydroxyethoxy)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound OCCONC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=CC=C1F CCEULDNBSVWLLU-UHFFFAOYSA-N 0.000 description 1
- FHZKTWXNUOENJW-UHFFFAOYSA-N 8-chloro-7-(2-fluoroanilino)imidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=CC=C1F FHZKTWXNUOENJW-UHFFFAOYSA-N 0.000 description 1
- JQLDTKUUHGCPSZ-UHFFFAOYSA-N 8-chloro-n-(cyclopropylmethoxy)-7-(2-fluoroanilino)imidazo[1,2-a]pyridine-6-carboxamide Chemical compound FC1=CC=CC=C1NC1=C(Cl)C2=NC=CN2C=C1C(=O)NOCC1CC1 JQLDTKUUHGCPSZ-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 101100189356 Mus musculus Papolb gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical class CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- FTFRZXFNZVCRSK-UHFFFAOYSA-N N4-(3-chloro-4-fluorophenyl)-N6-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-4,6-diamine Chemical compound C1CN(C)CCC1NC1=NC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=N1 FTFRZXFNZVCRSK-UHFFFAOYSA-N 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical class COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical class CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 229910019891 RuCl3 Inorganic materials 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- XMACCNOGDFVTGY-UHFFFAOYSA-N [2-amino-1-[7-(4-bromo-2-chloroanilino)-8-chloro-6-(cyclopropylmethoxy)imidazo[1,2-a]pyridin-3-yl]-2-oxoethyl]-methylcarbamic acid Chemical compound BrC1=CC(=C(C=C1)NC1=C(C=2N(C=C1OCC1CC1)C(=CN2)C(C(N)=O)N(C(O)=O)C)Cl)Cl XMACCNOGDFVTGY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000000475 acetylene derivatives Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 238000009468 active modified atmosphere packaging Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-O bis(2-hydroxyethyl)azanium Chemical compound OCC[NH2+]CCO ZBCBWPMODOFKDW-UHFFFAOYSA-O 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 150000004768 bromobenzenes Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- JJNHBFYGCSOONU-UHFFFAOYSA-M carbanide;cyclopenta-1,3-diene;dimethylaluminum;titanium(4+);chloride Chemical compound [CH3-].[Ti+3]Cl.C[Al]C.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 JJNHBFYGCSOONU-UHFFFAOYSA-M 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 125000005534 decanoate group Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 229960003887 dichlorophen Drugs 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- ORVACBDINATSAR-UHFFFAOYSA-N dimethylaluminum Chemical compound C[Al]C ORVACBDINATSAR-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- IHESWEHYRFZRBN-UHFFFAOYSA-N ethyl 2-chloro-6-hydrazinylpyridine-3-carboxylate Chemical compound C(C)OC(C1=C(N=C(C=C1)NN)Cl)=O IHESWEHYRFZRBN-UHFFFAOYSA-N 0.000 description 1
- SEFFUTOCCLZPNV-UHFFFAOYSA-N ethyl 5-chloro-4-hydroxy-6-oxo-1h-pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CNC(O)=C(Cl)C1=O SEFFUTOCCLZPNV-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 208000028149 female reproductive system neoplasm Diseases 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical class OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- KIMZVDLDHKECSU-UHFFFAOYSA-N imidazo[1,2-a]pyridine-3-carbaldehyde Chemical compound C1=CC=CN2C(C=O)=CN=C21 KIMZVDLDHKECSU-UHFFFAOYSA-N 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000011967 lanthanide triflate Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910000372 mercury(II) sulfate Inorganic materials 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- SPJQBGGHUDNAIC-UHFFFAOYSA-N methyl 2,5-dichlorobenzoate Chemical compound COC(=O)C1=CC(Cl)=CC=C1Cl SPJQBGGHUDNAIC-UHFFFAOYSA-N 0.000 description 1
- CENMJRDHQVOPTJ-UHFFFAOYSA-N methyl 2-(propan-2-ylideneamino)oxybenzoate Chemical compound COC(=O)C1=CC=CC=C1ON=C(C)C CENMJRDHQVOPTJ-UHFFFAOYSA-N 0.000 description 1
- JMOYQSBCBHBDNO-UHFFFAOYSA-N methyl 3-chloro-7-(2,4-dichloroanilino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylate Chemical compound COC(=O)C1=CN2C(Cl)=CN=C2C(F)=C1NC1=CC=C(Cl)C=C1Cl JMOYQSBCBHBDNO-UHFFFAOYSA-N 0.000 description 1
- KWRYQZBIAVVSMG-UHFFFAOYSA-N methyl 3-ethyl-8-fluoro-7-(2-fluoro-4-methylanilino)imidazo[1,2-a]pyridine-6-carboxylate Chemical compound COC(=O)C1=CN2C(CC)=CN=C2C(F)=C1NC1=CC=C(C)C=C1F KWRYQZBIAVVSMG-UHFFFAOYSA-N 0.000 description 1
- GFVUYSLLYBAAFU-UHFFFAOYSA-N methyl 4-(4-bromo-2-chloroanilino)-6-chloro-5-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C(C)=C1NC1=CC=C(Br)C=C1Cl GFVUYSLLYBAAFU-UHFFFAOYSA-N 0.000 description 1
- IGLBCFCDAJIRMO-UHFFFAOYSA-N methyl 6-(2,4-dichloroanilino)-7-fluoro-3-methyl-1,2-benzoxazole-5-carboxylate Chemical compound COC(=O)C1=CC=2C(C)=NOC=2C(F)=C1NC1=CC=C(Cl)C=C1Cl IGLBCFCDAJIRMO-UHFFFAOYSA-N 0.000 description 1
- JYPKZSALXCEPNH-UHFFFAOYSA-N methyl 6-azido-4-(4-bromo-2-chloroanilino)-5-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(N=[N+]=[N-])C(C)=C1NC1=CC=C(Br)C=C1Cl JYPKZSALXCEPNH-UHFFFAOYSA-N 0.000 description 1
- PLMMRPBAGASMIR-UHFFFAOYSA-N methyl 7-(2,4-dichloroanilino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylate Chemical compound COC(=O)C1=CN2C=CN=C2C(F)=C1NC1=CC=C(Cl)C=C1Cl PLMMRPBAGASMIR-UHFFFAOYSA-N 0.000 description 1
- KXIQCNMUCPYEES-UHFFFAOYSA-N methyl 7-(4-bromo-2-fluoroanilino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylate Chemical compound COC(=O)C1=CN2C=CN=C2C(Cl)=C1NC1=CC=C(Br)C=C1F KXIQCNMUCPYEES-UHFFFAOYSA-N 0.000 description 1
- CGLVTUAXRMJQPW-UHFFFAOYSA-N methyl 7-(4-ethyl-2-fluoroanilino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylate Chemical compound FC1=CC(CC)=CC=C1NC1=C(F)C2=NC=CN2C=C1C(=O)OC CGLVTUAXRMJQPW-UHFFFAOYSA-N 0.000 description 1
- NXLWNBPGLNYHAX-UHFFFAOYSA-N methyl 8-fluoro-7-(2-fluoro-4-methylanilino)-3-(2-trimethylsilylethynyl)imidazo[1,2-a]pyridine-6-carboxylate Chemical compound COC(=O)C1=CN2C(C#C[Si](C)(C)C)=CN=C2C(F)=C1NC1=CC=C(C)C=C1F NXLWNBPGLNYHAX-UHFFFAOYSA-N 0.000 description 1
- NRPGLNJEHFQLHN-UHFFFAOYSA-N methyl 8-fluoro-7-(2-fluoro-4-methylanilino)-3-iodoimidazo[1,2-a]pyridine-6-carboxylate Chemical compound COC(=O)C1=CN2C(I)=CN=C2C(F)=C1NC1=CC=C(C)C=C1F NRPGLNJEHFQLHN-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- BTDBMFODXFTFIL-UHFFFAOYSA-N methyl imidazo[1,2-a]pyridine-6-carboxylate Chemical compound C1=C(C(=O)OC)C=CC2=NC=CN21 BTDBMFODXFTFIL-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- SXKLNBJCHYEPDL-UHFFFAOYSA-N n,n-difluorosulfamoyl fluoride Chemical compound FN(F)S(F)(=O)=O SXKLNBJCHYEPDL-UHFFFAOYSA-N 0.000 description 1
- ACXLZQQEGRXRJF-UHFFFAOYSA-N n-(4-bromo-2-fluorophenyl)-8-chloro-6-[5-(chloromethyl)-1,3,4-oxadiazol-2-yl]imidazo[1,2-a]pyridin-7-amine Chemical compound FC1=CC(Br)=CC=C1NC1=C(Cl)C2=NC=CN2C=C1C1=NN=C(CCl)O1 ACXLZQQEGRXRJF-UHFFFAOYSA-N 0.000 description 1
- YGFLCNPXEPDANQ-UHFFFAOYSA-N n-[bis[(2-methylpropan-2-yl)oxy]phosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(OC(C)(C)C)OC(C)(C)C YGFLCNPXEPDANQ-UHFFFAOYSA-N 0.000 description 1
- HSZCJVZRHXPCIA-UHFFFAOYSA-N n-benzyl-n-ethylaniline Chemical compound C=1C=CC=CC=1N(CC)CC1=CC=CC=C1 HSZCJVZRHXPCIA-UHFFFAOYSA-N 0.000 description 1
- PAVLETGHAKGMBG-UHFFFAOYSA-N n-ethoxy-7-(4-ethyl-2-fluoroanilino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxamide Chemical compound CCONC(=O)C1=CN2C=CN=C2C(F)=C1NC1=CC=C(CC)C=C1F PAVLETGHAKGMBG-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- IOXXVNYDGIXMIP-UHFFFAOYSA-N n-methylprop-2-en-1-amine Chemical compound CNCC=C IOXXVNYDGIXMIP-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- KVGGSRKAJYWCQS-UHFFFAOYSA-N o-(2-methoxyethyl)hydroxylamine Chemical compound COCCON KVGGSRKAJYWCQS-UHFFFAOYSA-N 0.000 description 1
- OOHKBWPOLBTKMR-UHFFFAOYSA-N o-(4-nitrophenyl)hydroxylamine Chemical compound NOC1=CC=C([N+]([O-])=O)C=C1 OOHKBWPOLBTKMR-UHFFFAOYSA-N 0.000 description 1
- YWNYAUCCVBZMPH-SECBINFHSA-N o-[(2r)-2-[tert-butyl(dimethyl)silyl]oxybutyl]hydroxylamine Chemical compound NOC[C@@H](CC)O[Si](C)(C)C(C)(C)C YWNYAUCCVBZMPH-SECBINFHSA-N 0.000 description 1
- MDNVANLCJLEKMY-MRVPVSSYSA-N o-[(2r)-2-[tert-butyl(dimethyl)silyl]oxypropyl]hydroxylamine Chemical compound NOC[C@@H](C)O[Si](C)(C)C(C)(C)C MDNVANLCJLEKMY-MRVPVSSYSA-N 0.000 description 1
- MDNVANLCJLEKMY-QMMMGPOBSA-N o-[(2s)-2-[tert-butyl(dimethyl)silyl]oxypropyl]hydroxylamine Chemical compound NOC[C@H](C)O[Si](C)(C)C(C)(C)C MDNVANLCJLEKMY-QMMMGPOBSA-N 0.000 description 1
- HLYVNXRHROOICH-UHFFFAOYSA-N o-propan-2-ylhydroxylamine Chemical compound CC(C)ON HLYVNXRHROOICH-UHFFFAOYSA-N 0.000 description 1
- PRAARDGLAWZXML-UHFFFAOYSA-N o-propylhydroxylamine Chemical compound CCCON PRAARDGLAWZXML-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N phenyl bromide Natural products BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 125000005541 phosphonamide group Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Chemical group 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical class OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- DVUBDHRTVYLIPA-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CC=C21 DVUBDHRTVYLIPA-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical class [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- YTNBLLVHFGPKPA-UHFFFAOYSA-N tert-butyl 4-(4-bromo-2-chloroanilino)-5,6-dichloropyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CN=C(Cl)C(Cl)=C1NC1=CC=C(Br)C=C1Cl YTNBLLVHFGPKPA-UHFFFAOYSA-N 0.000 description 1
- MLSOJKQSIYNNCH-UHFFFAOYSA-N tert-butyl 4-(4-bromo-2-chloroanilino)-5-chloro-6-(2-oxopropylamino)pyridine-3-carboxylate Chemical compound CC(=O)CNC1=NC=C(C(=O)OC(C)(C)C)C(NC=2C(=CC(Br)=CC=2)Cl)=C1Cl MLSOJKQSIYNNCH-UHFFFAOYSA-N 0.000 description 1
- XRFVAZGLTPAMKQ-UHFFFAOYSA-N tert-butyl 4-[[7-(4-bromo-2-chloroanilino)-8-chloro-6-(cyclopropylmethoxycarbamoyl)imidazo[1,2-a]pyridin-3-yl]methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CN=C2N1C=C(C(=O)NOCC1CC1)C(NC=1C(=CC(Br)=CC=1)Cl)=C2Cl XRFVAZGLTPAMKQ-UHFFFAOYSA-N 0.000 description 1
- OAKQKBRICFLEPS-UHFFFAOYSA-N tert-butyl 6-azido-4-(4-bromo-2-chloroanilino)pyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CN=C(N=[N+]=[N-])C=C1NC1=CC=C(Br)C=C1Cl OAKQKBRICFLEPS-UHFFFAOYSA-N 0.000 description 1
- FESDUDPSRMWIDL-UHFFFAOYSA-N tert-butyl n,n'-di(propan-2-yl)carbamimidate Chemical compound CC(C)NC(OC(C)(C)C)=NC(C)C FESDUDPSRMWIDL-UHFFFAOYSA-N 0.000 description 1
- SQGVTSILTDRAAI-UHFFFAOYSA-N tert-butyl n-(2-aminooxyethyl)-n-methylcarbamate Chemical compound NOCCN(C)C(=O)OC(C)(C)C SQGVTSILTDRAAI-UHFFFAOYSA-N 0.000 description 1
- JRLJOAREDJOYLW-UHFFFAOYSA-N tert-butyl n-(2-aminooxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCON JRLJOAREDJOYLW-UHFFFAOYSA-N 0.000 description 1
- GPTXCAZYUMDUMN-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCO GPTXCAZYUMDUMN-UHFFFAOYSA-N 0.000 description 1
- XQQUYJATURPPOH-UHFFFAOYSA-N tert-butyl n-(3-aminooxy-2,2-dimethylpropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC(C)(C)CON XQQUYJATURPPOH-UHFFFAOYSA-N 0.000 description 1
- QNYPOLKQWXCIGA-UHFFFAOYSA-N tert-butyl n-(3-aminooxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCON QNYPOLKQWXCIGA-UHFFFAOYSA-N 0.000 description 1
- XDJCYKMWJCYQJM-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCO XDJCYKMWJCYQJM-UHFFFAOYSA-N 0.000 description 1
- UDICTKJZWXXLJB-UHFFFAOYSA-N tert-butyl n-[2-(1,3-dioxoisoindol-2-yl)oxyethyl]carbamate Chemical compound C1=CC=C2C(=O)N(OCCNC(=O)OC(C)(C)C)C(=O)C2=C1 UDICTKJZWXXLJB-UHFFFAOYSA-N 0.000 description 1
- LZSWYRVYQPBKBJ-UHFFFAOYSA-N tert-butyl n-[3-(1,3-dioxoisoindol-2-yl)oxy-2,2-dimethylpropyl]carbamate Chemical compound C1=CC=C2C(=O)N(OCC(C)(CNC(=O)OC(C)(C)C)C)C(=O)C2=C1 LZSWYRVYQPBKBJ-UHFFFAOYSA-N 0.000 description 1
- JYEVUDXCQHLXNG-UHFFFAOYSA-N tert-butyl pyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=CN=C1 JYEVUDXCQHLXNG-UHFFFAOYSA-N 0.000 description 1
- YJKBMRIXPNAHBN-MRVPVSSYSA-N tert-butyl-[(2r)-1-iodopropan-2-yl]oxy-dimethylsilane Chemical compound IC[C@@H](C)O[Si](C)(C)C(C)(C)C YJKBMRIXPNAHBN-MRVPVSSYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000006173 tetrahydropyranylmethyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- GDJZZWYLFXAGFH-UHFFFAOYSA-M xylenesulfonate group Chemical group C1(C(C=CC=C1)C)(C)S(=O)(=O)[O-] GDJZZWYLFXAGFH-UHFFFAOYSA-M 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9 and R10, W and Y are defined in the specification. Such compounds are MEK inhibitors and useful in the treament of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative disease in mammals and pharmaceutical compositons conataining such compounds.
Description
HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF
BACKGROUND OF THE INVENTION
1. Field of the Invention This invention relates to a series of novel heterocyclic compounds that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
BACKGROUND OF THE INVENTION
1. Field of the Invention This invention relates to a series of novel heterocyclic compounds that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
2. Description of the state of the art to Cell signaling through growth factor receptors and protein kinases is an important regulator of cell growth, proliferation and differentiation. In normal cell growth, growth factors, through receptor activation (i.e. PDGF or EGF and others), activate MAP kinase pathways. One of the most important and most well understood MAP kinase pathways involved in normal and uncontrolled cell growth is the Ras/Raf kinase pathway. Active GTP-bound Ras results in the activation and indirect phosphorylation of Raf kinase. Raf then phosphorylates MEK1 and 2 on two serine residues (5218 and 5222 for MEK1 and S222and 5226 for MEK2) (Ahn et al., Methods in Enzymology, 2001, 332, 417-431). Activated MEK then phosphorylates its only known substrates, the MAP kinases, ERKl and 2. ERK phosphorylation by 2o MEK occurs on Y204 and T202 for ERK1 and Y185 and T183 for ERK2 (Ahn et al., Methods in Enzymology, 2001, 332, 417-431). Phosphorylated ERK dimerizes and then translocates to the nucleus where it accumulates (Khokhlatchev et al., Cell, 1998, 93, 605-615). In the nucleus, ERK is involved in several important cellular functions, including but not limited to nuclear transport, signal transduction, DNA
repair, nucleosome assembly and translocation, and mRNA processing and translation (Ahn et al., Molecular Cell, 2000, 6, 1343-1354). Overall, treatment of cells with growth factors leads to the activation of ERK1 and 2 which results in proliferation and, in some cases, differentiation (Lewis et al., Adv. Cancer Res., 1998, 74, 49-139).
In proliferative diseases, genetic mutations and/or overexpression of the 3o growth factor receptors, downstream signaling proteins, or protein kinases involved in the ERK kinase pathway lead to uncontrolled cell proliferation and, eventually, tumor formation. For example, some cancers contain mutations which result in the continuous activation of this pathway due to continuous production of growth factors.
Other mutations can lead to defects in the deactivation of the activated GTP-bound Ras complex, again resulting in activation of the MAP kinase pathway. Mutated, oncogenic forms of Ras are found in 50% of colon and >90% pancreatic cancers as well as many others types of cancers (Kohl et al., Science, 1993, 260, 1834-1837).
Recently, bRaf mutations have been identified in more than 60% of malignant melanoma (Davies, H. et al., Nature, 2002, 417, 949-954). These mutations in bRaf result in a constitutively active MAP kinase cascade. Studies of primary tumor 1o samples and cell lines have also shown constitutive or overactivation of the MAP
kinase pathway in cancers of pancreas, colon, lung, ovary and kidney (Hoshino, R. et al., Oncogene, 1999, 18, 813-822). Hence, there is a strong correlation between cancers and an overactive MAP kinase pathway resulting from genetic mutations.
As constitutive or overactivation of MAP kinase cascade plays a pivotal role in cell proliferation and differentiation, inhibition of this pathway is believed to be beneficial in hyperproliferative diseases. MEK is a key player in this pathway as it is downstream of Ras and Raf. Additionally, it is an attractive therapeutic target because the only known substrates for MEK phosphorylation are the MAP kinases, ERK1 and 2. Inhibition of MEK has been shown to have potential therapeutic benefit in several studies. For example, small molecule MEK inhibitors have been shown to inhibit human tumor growth in nude mouse xenografts, (Sebolt-Leopold et al., Nature-Medicine, 1999, S (7), 810-816; Trachet et al., AACR April 6-10, 2002, Poster #5426; Tecle, H., IBC 2"d International Conference of Protein Kinases, September 9-10, 2002), block static allodynia in animals (WO 01/05390 published January 25, 2001) and inhibit growth of acute myeloid leukemia cells (Milella et al., J.
Clin.
Invest., 2001, 108 (6), 851-859).
Small molecule inhibitors of MEK have been disclosed. At least thirteen patent applications have appeared in the last several years: US 5,525,625 filed January 24, 1995; WO 98/43960 published October 8, 1998; WO 99/01421 published January 14, 1999; WO 99/01426 published January 14, 1999; WO 00/41505 published July 20, 2000; WO 00/42002 published July 20, 2000; WO 00/42003 published July 20, 2000; WO 00/41994 published July 20, 2000; WO 00/42022 published July 20, 2000;
WO 00/42029 published July 20, 2000; WO 00/68201 published November 16, 2000;
WO 01/68619 published September 20, 2001; and WO 02/06213 published January 24, 2002.
SUMMARY OF THE INVENTION
This invention provides for novel heterocyclic compounds, and pharmaceutically acceptable salts and prodrugs thereof that are useful in the treatment of hyperproliferative diseases. Specifically, one aspect of the present invention relates to compounds of Formula I that act as MEK inhibitors. Also provided is a to method for treatment of cancer. Also provided are formulations containing compounds of Formula I and methods of using the compounds to treat a patient in need thereof. In addition, there are described processes for preparing the inhibitory compounds of Formula I.
Accordingly, the present invention provides compounds of the Formula I:
Rlp Y R
R~ \ R9 ~~Rs N-p R
I
and pharmaceutically accepted salts, prodrugs and solvates thereof, where:
2o Rl, R2, R7, R8, R9, and Rl° are independently hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -ORS, -C(O)R3, -C(O)ORS, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SOZNR3R4, -NR4C(O)R3, -C(O)NR3R4, -NRSC(O)NR3R°, -NRSC(NCN)NR3R4, -NR3R4, C1-C1°
alkyl, CZ-C10 alkenyl, CZ-C1° alkynyl, C3-C1° cycloalkyl, C3-C1°
cycloalkylalkyl, -S(O)~(C1-C6 alkyl), -S(O)~(CR4R5)m aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m aryl, -NR4(CR4R5)m aryl, -O(CR4R5)m heteroaryl, -NR4(CR4R5)m heteroaryl, -O(CR4R5)m heterocyclyl or -NR4(CR4R5)m heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, vitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SOZR6, -SOZNR3R4, -C(O)R3, -C(O)ORS, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NRSC(O)NR3R4, -NRSC(NCN)NR3R4, -ORS, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is hydrogen, trifluoromethyl, C~-Clo alkyl, C2-Clo alkenyl, CZ-Clo alkynyl, to C3-Coo cycloalkyl, C3-Coo cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate, or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, vitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOzR~~~, -SOZNRR~, -C(O)R, C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SR', -S(O)R"", -S 02R ~~~, -NR R ~, -NR C(O)NR"R ~~, -NR C(NCN)NR ~R ~~, -OR , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, heteroaryl or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, vitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOZR~~~, -SOZNRR~, -C(O)R, -C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SOzR~~~, -NRR~, -NR C(O)NR ~R ~~, -NR C(NCN)NR ~R ~~, -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R"' independently are hydrogen, lower alkyl, lower alkenyl, aryl and arylalkyl, and R"" is lower alkyl, lower alkenyl, aryl or arylalkyl, or any two of R', R", R"' or R"" together with the atom to which they are attached form a 4 to 10 3o membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl carbocyclic rings, heteroaryl rings or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, vitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and RS independently are hydrogen or CI-C6 alkyl, or R4 and RS together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein said alkyl or any of said carbocyclic, heteroaryl and heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, vitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOZR~~~, -SOZNRR~, -C(O)R~~~, to -C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SOZR~~~, -NRR~, -NR C(O)NR ~R ~~, -NR C(NCN)NR ~R ~~, -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R6 is trifluoromethyl, CI-C,o alkyl, C3-CIO cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, vitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOZR~~~, -SOZNRR~, -C(O)R, -C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SOZR~~~, -NRR, -NRC(O)NR~R~~, -NRC(NCN)NR~R~~, -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, heterocyclyl, -C(O)ORS, -C(O)NR3R4, -C(O)NR40R3, -C(O)R40R3, -C(O)(C3-C,o cycloalkyl), -C(O)(CI-CIO alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SOZ)CH3 or CR30R3, wherein any of said heteroaryl, heterocyclyl, -C(O)ORS, -C(O)NR3R4, -C(O)NR40R3, -C(O)R40R3, -C(O)(C3-C,0 cycloalkyl), -C(O)(CI-Coo alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SOZ)CH3 and CR30R3 are optionally substituted with one or more groups independently selected from -NR3R4, -ORS, -RZ, C~-C10 alkyl, CZ-CIO alkenyl, and CZ-Clo alkynyl, wherein any of said CI-CIO alkyl, CZ-CIO
alkenyl, 3o and CZ-CIO alkynyl are optionally substituted with 1 or more groups independently selected from -NR3R4 and -ORS;
mis0, 1,2,3,4or5;
j is 0, 1 or 2; and Y is a linker.
In another embodiment, this invention relates to compounds of the general Formula II:
W
io R~
R N I Y~/
R R9 /~Rs ~N R2 R' ~
II
1o where R', RZ, R3, R4, R5, R6, R7, R8, R9, R'°, R', R", R"', R"", W, Y, m and j are as defined above, and R" is hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -ORS, -C(O)R3, -C(O)ORS, NR4C(O)OR6, -OC(O)R3, -NR4SOZR6, -SOZNR3R4, -NR4C(O)R3, -C(O)NR3R4, -NRSC(O)NR3R4, -NRSC(NCl~NR3R4, -NR3R4, C1-C,° alkyl, Cz-Cio alkenyl, Cz-Clo alkynyl, C3-Clo cycloalkyl, C3-Clo cycloalkylalkyl, -S(O)~(Cl-C6 alkyl), -S(O)~(CR4R5)m aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR~RS)m aryl, -NRø(CR4R5)m aryl, -O(CR4R5)m heteroaryl, -NR4(CR4R5)m heteroaryl, -O(CR4R5)m heterocyclyl or -NR4(CR4R5)m heterocyclyl, wherein any of 2o said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SOZNR3Ra, -C(O)R3, -C(O)ORS, -OC(O)R3, -NR.~C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, 2s -NRSC(O)NR3R4, -NRSC(NCN)NR3R4, -ORS, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl.
repair, nucleosome assembly and translocation, and mRNA processing and translation (Ahn et al., Molecular Cell, 2000, 6, 1343-1354). Overall, treatment of cells with growth factors leads to the activation of ERK1 and 2 which results in proliferation and, in some cases, differentiation (Lewis et al., Adv. Cancer Res., 1998, 74, 49-139).
In proliferative diseases, genetic mutations and/or overexpression of the 3o growth factor receptors, downstream signaling proteins, or protein kinases involved in the ERK kinase pathway lead to uncontrolled cell proliferation and, eventually, tumor formation. For example, some cancers contain mutations which result in the continuous activation of this pathway due to continuous production of growth factors.
Other mutations can lead to defects in the deactivation of the activated GTP-bound Ras complex, again resulting in activation of the MAP kinase pathway. Mutated, oncogenic forms of Ras are found in 50% of colon and >90% pancreatic cancers as well as many others types of cancers (Kohl et al., Science, 1993, 260, 1834-1837).
Recently, bRaf mutations have been identified in more than 60% of malignant melanoma (Davies, H. et al., Nature, 2002, 417, 949-954). These mutations in bRaf result in a constitutively active MAP kinase cascade. Studies of primary tumor 1o samples and cell lines have also shown constitutive or overactivation of the MAP
kinase pathway in cancers of pancreas, colon, lung, ovary and kidney (Hoshino, R. et al., Oncogene, 1999, 18, 813-822). Hence, there is a strong correlation between cancers and an overactive MAP kinase pathway resulting from genetic mutations.
As constitutive or overactivation of MAP kinase cascade plays a pivotal role in cell proliferation and differentiation, inhibition of this pathway is believed to be beneficial in hyperproliferative diseases. MEK is a key player in this pathway as it is downstream of Ras and Raf. Additionally, it is an attractive therapeutic target because the only known substrates for MEK phosphorylation are the MAP kinases, ERK1 and 2. Inhibition of MEK has been shown to have potential therapeutic benefit in several studies. For example, small molecule MEK inhibitors have been shown to inhibit human tumor growth in nude mouse xenografts, (Sebolt-Leopold et al., Nature-Medicine, 1999, S (7), 810-816; Trachet et al., AACR April 6-10, 2002, Poster #5426; Tecle, H., IBC 2"d International Conference of Protein Kinases, September 9-10, 2002), block static allodynia in animals (WO 01/05390 published January 25, 2001) and inhibit growth of acute myeloid leukemia cells (Milella et al., J.
Clin.
Invest., 2001, 108 (6), 851-859).
Small molecule inhibitors of MEK have been disclosed. At least thirteen patent applications have appeared in the last several years: US 5,525,625 filed January 24, 1995; WO 98/43960 published October 8, 1998; WO 99/01421 published January 14, 1999; WO 99/01426 published January 14, 1999; WO 00/41505 published July 20, 2000; WO 00/42002 published July 20, 2000; WO 00/42003 published July 20, 2000; WO 00/41994 published July 20, 2000; WO 00/42022 published July 20, 2000;
WO 00/42029 published July 20, 2000; WO 00/68201 published November 16, 2000;
WO 01/68619 published September 20, 2001; and WO 02/06213 published January 24, 2002.
SUMMARY OF THE INVENTION
This invention provides for novel heterocyclic compounds, and pharmaceutically acceptable salts and prodrugs thereof that are useful in the treatment of hyperproliferative diseases. Specifically, one aspect of the present invention relates to compounds of Formula I that act as MEK inhibitors. Also provided is a to method for treatment of cancer. Also provided are formulations containing compounds of Formula I and methods of using the compounds to treat a patient in need thereof. In addition, there are described processes for preparing the inhibitory compounds of Formula I.
Accordingly, the present invention provides compounds of the Formula I:
Rlp Y R
R~ \ R9 ~~Rs N-p R
I
and pharmaceutically accepted salts, prodrugs and solvates thereof, where:
2o Rl, R2, R7, R8, R9, and Rl° are independently hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -ORS, -C(O)R3, -C(O)ORS, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SOZNR3R4, -NR4C(O)R3, -C(O)NR3R4, -NRSC(O)NR3R°, -NRSC(NCN)NR3R4, -NR3R4, C1-C1°
alkyl, CZ-C10 alkenyl, CZ-C1° alkynyl, C3-C1° cycloalkyl, C3-C1°
cycloalkylalkyl, -S(O)~(C1-C6 alkyl), -S(O)~(CR4R5)m aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m aryl, -NR4(CR4R5)m aryl, -O(CR4R5)m heteroaryl, -NR4(CR4R5)m heteroaryl, -O(CR4R5)m heterocyclyl or -NR4(CR4R5)m heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, vitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SOZR6, -SOZNR3R4, -C(O)R3, -C(O)ORS, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NRSC(O)NR3R4, -NRSC(NCN)NR3R4, -ORS, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is hydrogen, trifluoromethyl, C~-Clo alkyl, C2-Clo alkenyl, CZ-Clo alkynyl, to C3-Coo cycloalkyl, C3-Coo cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate, or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, vitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOzR~~~, -SOZNRR~, -C(O)R, C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SR', -S(O)R"", -S 02R ~~~, -NR R ~, -NR C(O)NR"R ~~, -NR C(NCN)NR ~R ~~, -OR , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, heteroaryl or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, vitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOZR~~~, -SOZNRR~, -C(O)R, -C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SOzR~~~, -NRR~, -NR C(O)NR ~R ~~, -NR C(NCN)NR ~R ~~, -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R"' independently are hydrogen, lower alkyl, lower alkenyl, aryl and arylalkyl, and R"" is lower alkyl, lower alkenyl, aryl or arylalkyl, or any two of R', R", R"' or R"" together with the atom to which they are attached form a 4 to 10 3o membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl carbocyclic rings, heteroaryl rings or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, vitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and RS independently are hydrogen or CI-C6 alkyl, or R4 and RS together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein said alkyl or any of said carbocyclic, heteroaryl and heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, vitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOZR~~~, -SOZNRR~, -C(O)R~~~, to -C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SOZR~~~, -NRR~, -NR C(O)NR ~R ~~, -NR C(NCN)NR ~R ~~, -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R6 is trifluoromethyl, CI-C,o alkyl, C3-CIO cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, vitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOZR~~~, -SOZNRR~, -C(O)R, -C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SOZR~~~, -NRR, -NRC(O)NR~R~~, -NRC(NCN)NR~R~~, -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, heterocyclyl, -C(O)ORS, -C(O)NR3R4, -C(O)NR40R3, -C(O)R40R3, -C(O)(C3-C,o cycloalkyl), -C(O)(CI-CIO alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SOZ)CH3 or CR30R3, wherein any of said heteroaryl, heterocyclyl, -C(O)ORS, -C(O)NR3R4, -C(O)NR40R3, -C(O)R40R3, -C(O)(C3-C,0 cycloalkyl), -C(O)(CI-Coo alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SOZ)CH3 and CR30R3 are optionally substituted with one or more groups independently selected from -NR3R4, -ORS, -RZ, C~-C10 alkyl, CZ-CIO alkenyl, and CZ-Clo alkynyl, wherein any of said CI-CIO alkyl, CZ-CIO
alkenyl, 3o and CZ-CIO alkynyl are optionally substituted with 1 or more groups independently selected from -NR3R4 and -ORS;
mis0, 1,2,3,4or5;
j is 0, 1 or 2; and Y is a linker.
In another embodiment, this invention relates to compounds of the general Formula II:
W
io R~
R N I Y~/
R R9 /~Rs ~N R2 R' ~
II
1o where R', RZ, R3, R4, R5, R6, R7, R8, R9, R'°, R', R", R"', R"", W, Y, m and j are as defined above, and R" is hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -ORS, -C(O)R3, -C(O)ORS, NR4C(O)OR6, -OC(O)R3, -NR4SOZR6, -SOZNR3R4, -NR4C(O)R3, -C(O)NR3R4, -NRSC(O)NR3R4, -NRSC(NCl~NR3R4, -NR3R4, C1-C,° alkyl, Cz-Cio alkenyl, Cz-Clo alkynyl, C3-Clo cycloalkyl, C3-Clo cycloalkylalkyl, -S(O)~(Cl-C6 alkyl), -S(O)~(CR4R5)m aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR~RS)m aryl, -NRø(CR4R5)m aryl, -O(CR4R5)m heteroaryl, -NR4(CR4R5)m heteroaryl, -O(CR4R5)m heterocyclyl or -NR4(CR4R5)m heterocyclyl, wherein any of 2o said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SOZNR3Ra, -C(O)R3, -C(O)ORS, -OC(O)R3, -NR.~C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, 2s -NRSC(O)NR3R4, -NRSC(NCN)NR3R4, -ORS, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl.
\\\DE - 80248/0026 - 214630 v1 In another embodiment, this invention relates to compounds of the general Formula III:
W R' Rio Y
W R' Rio Y
7 N ~~ s R~~N ~R Rz R
III
where RI, R2, R~, R4, R5, R6, R', R8, R9, Rio, R', R'., R"', R"", W, y, m and j are as defined above.
In another embodiment, this invention relates to compounds of the general Formula IV:
W Ri Rlo ~ I Y
s R \ ~ .R R2 R
O ~N
IV
where R', RZ, R3, R4, R5, R6, R', R8, R9, R'°, R', R", R"', R"", W, Y, m and j are as defined above.
In another embodiment, this invention relates to compounds of the general Formula V:
W
Rio Y ~Rt R' / N~R9 l~ R8 R~~
V
\NDE - 80248/0026- 214630 v1 where R', R2, R3, R4, R5, R6, R7, R8, R9, R'o, Ry R., R.., R"., R...., W, y, m and j are as defined above.
In a further aspect the present invention provides compositions that inhibit MEK comprising compounds of Formulas I-V.
The invention is also directed to pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of compounds of Formula I-V. Methods of making the compounds of Formula I-V are also described.
In a further aspect the present invention provides a method of using the l0 compounds of this invention to treat diseases or medical conditions mediated by MEK. For example, this invention provides a method for treatment of a hyperproliferative disorder in a mammal comprising administrating to said mammal one or more compounds of Formulas I-V or a pharmaceutically acceptable salt or prodrug thereof in an amount effective to treat said hyperproliferative disorder.
In a further aspect the present invention provides treating or preventing an MEK-mediated condition, comprising administering to a human or animal in need thereof a pharmaceutical composition comprising a compound of Formula I-V or a pharmaceutically-acceptable salt or in vivo cleavable prodrug thereof in an amount effective to treat or prevent said MEK-mediated condition.
2o The inventive compounds may further be used advantageously in combination with other known therapeutic agents.
The invention also relates to pharmaceutical compositions comprising an effective amount of an agent selected from compounds of Formulas I-V or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.
Additional advantages and novel features of this invention shall be set forth in part in the description that follows, and in part will become apparent to those skilled in the art upon examination of the following specification or may be learned by the practice of the invention. The advantages of the invention may be realized and attained by means of the instrumentalities, combinations, compositions, and methods particularly pointed out in the appended claims.
BRIEF DESCRIPTION OF THE FIGURES
The accompanying drawings, which are incorporated herein and form a part of the specification, illustrate non-limiting embodiments of the present invention, and together with the description, serve to explain the principles of the invention.
In the Figures:
Figure 1 shows a reaction scheme for the synthesis of compound 10a.
Figure 2 shows a reaction scheme for the synthesis of compound 12a.
1o Figure 3 shows a reaction scheme for the synthesis of compound 13a.
Figure 4 shows a reaction scheme for the synthesis of compound 12b.
Figure 5 shows a reaction scheme for the synthesis of compound 19.
Figure 6 shows a reaction scheme for the synthesis of compound 21.
Figure 7 shows a reaction scheme for the synthesis of compound 30.
Figure 8 shows a reaction scheme for the synthesis of compound 31.
Figure 9 shows a reaction scheme for the synthesis of compound 33a.
Figure 10 shows a reaction scheme for the synthesis of compounds-36-38.
Figure 11 shows a reaction scheme for the synthesis of compound 39.
Figure 12 shows a reaction scheme for the synthesis of compounds 44a and 2o 44b.
Figure 13 shows a reaction scheme for the synthesis of compounds 47a and 47b.
Figure 14 shows a reaction scheme for the synthesis of compounds 53a, 53b and 54a.
Figure 15 shows a reaction scheme for the synthesis of compounds 57a and 57b.
Figure 16 shows a reaction scheme for the synthesis of compound 63.
Figure 17 shows a reaction scheme for the synthesis of compounds 73a and 73b.
Figure 18 shows a reaction scheme for the synthesis of compound 74.
Figures 19A-19G illustrate specific compounds of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The inventive compounds of the Formulas I-V and the pharmaceutically acceptable salts and prodrugs thereof of this invention are useful in the treatment of hyperproliferative diseases. Specifically, one aspect the present invention relates to compounds of Formula I-V that act as MEK inhibitors. In general, one aspect of the invention relates to compounds having the general Formula I:
Ri° y R
R~ \ R9 ~~R8 N-p R
I
and pharmaceutically accepted salts, prodrugs and solvates thereof, where:
Rl, RZ, R7, R8, R9, and Rl° are independently hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -ORS, -C(O)R3, -C(O)ORS, NR4C(O)OR6, -OC(O)R3, -NR4SOzR6, -SOZNR3R4, -NR4C(O)R3, -C(O)NR3R4, -1VRSC(O)NR3R4, -NRSC(NCN)NR3R4, -NR3R4, C1-C1° alkyl, CZ-Clo alkenyl, CZ-C,° alkynyl, C3-C1° cycloalky~l, C3-C,°
cycloalkylalkyl, -S(O)~(C1-C6 alkyl), -S(O)~(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m aryl, -NR4(CR4R5)m aryl, -O(CR4R5)m heteroaryl, -NR4(CR4R5)m heteroaryl, -O(CR4R5)m heterocyclyl or -NR4(CR4R5)m heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SOzR6, -SO2NR3R4, -C(O)R3, -C(O)ORS, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NRSC(O)NR3R4, -NRSC(NCN)NR3R4, -ORS, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is hydrogen, trifluoromethyl, C1-Clo alkyl, CZ-Clo alkenyl, C2-Clo alkynyl, C3-C10 cycloalkyl, C3-C,o cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate, or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, to heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOZR~~~, -S02NRR~, -C(O)R, C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SR', -S(O)R"", -S OZR ~~~, -NR R ~, -NR C(O)NR"R ~~, -NR C(NCl~NR ~R ~~, -OR , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, heteroaryl or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRS02R~~~, -SOZNRR~, -C(O)R, -C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SOZR~~~, -NRR~, -NRC(O)NR~R~~, -NRC(NCI~NR~R~~, -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R"' independently are hydrogen, lower alkyl, lower alkenyl, aryl or arylalkyl, and R"" is lower alkyl, lower alkenyl, aryl or arylalkyl, or any two of R', R", R"' or R"" together with the atom to which they are attached form a 4 to membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl carbocyclic rings, heteroaryl rings or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
III
where RI, R2, R~, R4, R5, R6, R', R8, R9, Rio, R', R'., R"', R"", W, y, m and j are as defined above.
In another embodiment, this invention relates to compounds of the general Formula IV:
W Ri Rlo ~ I Y
s R \ ~ .R R2 R
O ~N
IV
where R', RZ, R3, R4, R5, R6, R', R8, R9, R'°, R', R", R"', R"", W, Y, m and j are as defined above.
In another embodiment, this invention relates to compounds of the general Formula V:
W
Rio Y ~Rt R' / N~R9 l~ R8 R~~
V
\NDE - 80248/0026- 214630 v1 where R', R2, R3, R4, R5, R6, R7, R8, R9, R'o, Ry R., R.., R"., R...., W, y, m and j are as defined above.
In a further aspect the present invention provides compositions that inhibit MEK comprising compounds of Formulas I-V.
The invention is also directed to pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of compounds of Formula I-V. Methods of making the compounds of Formula I-V are also described.
In a further aspect the present invention provides a method of using the l0 compounds of this invention to treat diseases or medical conditions mediated by MEK. For example, this invention provides a method for treatment of a hyperproliferative disorder in a mammal comprising administrating to said mammal one or more compounds of Formulas I-V or a pharmaceutically acceptable salt or prodrug thereof in an amount effective to treat said hyperproliferative disorder.
In a further aspect the present invention provides treating or preventing an MEK-mediated condition, comprising administering to a human or animal in need thereof a pharmaceutical composition comprising a compound of Formula I-V or a pharmaceutically-acceptable salt or in vivo cleavable prodrug thereof in an amount effective to treat or prevent said MEK-mediated condition.
2o The inventive compounds may further be used advantageously in combination with other known therapeutic agents.
The invention also relates to pharmaceutical compositions comprising an effective amount of an agent selected from compounds of Formulas I-V or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.
Additional advantages and novel features of this invention shall be set forth in part in the description that follows, and in part will become apparent to those skilled in the art upon examination of the following specification or may be learned by the practice of the invention. The advantages of the invention may be realized and attained by means of the instrumentalities, combinations, compositions, and methods particularly pointed out in the appended claims.
BRIEF DESCRIPTION OF THE FIGURES
The accompanying drawings, which are incorporated herein and form a part of the specification, illustrate non-limiting embodiments of the present invention, and together with the description, serve to explain the principles of the invention.
In the Figures:
Figure 1 shows a reaction scheme for the synthesis of compound 10a.
Figure 2 shows a reaction scheme for the synthesis of compound 12a.
1o Figure 3 shows a reaction scheme for the synthesis of compound 13a.
Figure 4 shows a reaction scheme for the synthesis of compound 12b.
Figure 5 shows a reaction scheme for the synthesis of compound 19.
Figure 6 shows a reaction scheme for the synthesis of compound 21.
Figure 7 shows a reaction scheme for the synthesis of compound 30.
Figure 8 shows a reaction scheme for the synthesis of compound 31.
Figure 9 shows a reaction scheme for the synthesis of compound 33a.
Figure 10 shows a reaction scheme for the synthesis of compounds-36-38.
Figure 11 shows a reaction scheme for the synthesis of compound 39.
Figure 12 shows a reaction scheme for the synthesis of compounds 44a and 2o 44b.
Figure 13 shows a reaction scheme for the synthesis of compounds 47a and 47b.
Figure 14 shows a reaction scheme for the synthesis of compounds 53a, 53b and 54a.
Figure 15 shows a reaction scheme for the synthesis of compounds 57a and 57b.
Figure 16 shows a reaction scheme for the synthesis of compound 63.
Figure 17 shows a reaction scheme for the synthesis of compounds 73a and 73b.
Figure 18 shows a reaction scheme for the synthesis of compound 74.
Figures 19A-19G illustrate specific compounds of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The inventive compounds of the Formulas I-V and the pharmaceutically acceptable salts and prodrugs thereof of this invention are useful in the treatment of hyperproliferative diseases. Specifically, one aspect the present invention relates to compounds of Formula I-V that act as MEK inhibitors. In general, one aspect of the invention relates to compounds having the general Formula I:
Ri° y R
R~ \ R9 ~~R8 N-p R
I
and pharmaceutically accepted salts, prodrugs and solvates thereof, where:
Rl, RZ, R7, R8, R9, and Rl° are independently hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -ORS, -C(O)R3, -C(O)ORS, NR4C(O)OR6, -OC(O)R3, -NR4SOzR6, -SOZNR3R4, -NR4C(O)R3, -C(O)NR3R4, -1VRSC(O)NR3R4, -NRSC(NCN)NR3R4, -NR3R4, C1-C1° alkyl, CZ-Clo alkenyl, CZ-C,° alkynyl, C3-C1° cycloalky~l, C3-C,°
cycloalkylalkyl, -S(O)~(C1-C6 alkyl), -S(O)~(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m aryl, -NR4(CR4R5)m aryl, -O(CR4R5)m heteroaryl, -NR4(CR4R5)m heteroaryl, -O(CR4R5)m heterocyclyl or -NR4(CR4R5)m heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SOzR6, -SO2NR3R4, -C(O)R3, -C(O)ORS, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NRSC(O)NR3R4, -NRSC(NCN)NR3R4, -ORS, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is hydrogen, trifluoromethyl, C1-Clo alkyl, CZ-Clo alkenyl, C2-Clo alkynyl, C3-C10 cycloalkyl, C3-C,o cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate, or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, to heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOZR~~~, -S02NRR~, -C(O)R, C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SR', -S(O)R"", -S OZR ~~~, -NR R ~, -NR C(O)NR"R ~~, -NR C(NCl~NR ~R ~~, -OR , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, heteroaryl or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRS02R~~~, -SOZNRR~, -C(O)R, -C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SOZR~~~, -NRR~, -NRC(O)NR~R~~, -NRC(NCI~NR~R~~, -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R"' independently are hydrogen, lower alkyl, lower alkenyl, aryl or arylalkyl, and R"" is lower alkyl, lower alkenyl, aryl or arylalkyl, or any two of R', R", R"' or R"" together with the atom to which they are attached form a 4 to membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl carbocyclic rings, heteroaryl rings or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and RS independently are hydrogen or C1-C6 alkyl, or R4 and RS together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein said alkyl or any of said carbocyclic, heteroaryl and heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOZR~~~, -S02NRR~, -C(O)R~~~, -C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SOzR~~~, -NRR~, -NR C(O)NR ~R ~~, -NR C(NCI~NR ~R ~~, -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
1o R6 is trifluoromethyl, C1-C~o alkyl, C3-Clo cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOZR~~~, -SOZNRR~, -C(O)R, -C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SOZR~~~, -NRR, -NR C(O)NR ~R ~~, -NR C(NCI~NR ~R ~~, -OR , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, heterocyclyl, -C(O)ORS, -C(O)NR3R4, -C(O)NR40R3, -C(O)R40R3, -C(O)(C3-C,o cycloalkyl), -C(O)(C1-Cm alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SOZ)CH3 or CR30R3, wherein any of said heteroaryl, heterocyclyl, -C(O)ORS, -C(O)NR3R4, -C(O)NR40R3, -C(O)R40R3, -C(O)(C3-Clo cycloalkyl), -C(O)(C~-Clo alkyl), -C(O)(aryl), -C(O)(heteroaryl) -C(O)(heterocyclyl), -CONH(SOz)CH3 and CR30R3 are optionally substituted with one or more groups independently selected from -NR3R4, -ORS, -R2, C~-Clo alkyl, CZ-Clo alkenyl, and CZ-Coo alkynyl, wherein any of said C~-Coo alkyl, CZ-C1o alkenyl, and CZ-Coo alkynyl are optionally substituted with 1 or more groups independently selected from NR3R4 and -ORS;
mis0,1,2,3,4or5;
j is 0, 1 or 2; and \\\DE - 80248/0026 - 214630 v1 Y is a linker.
Preferred embodiments of Formula I have a structure wherein: (a) R' is 2-Cl;
(b) R' is Me, NH2 or H; (c) R8 is Br or Cl; (d) R~ is F; (e) W is -C(O)OH, -C(O)NHOCHZ-(cyclopropyl), -C(O)NHO(CH2)ZOH, or -CONH(SOz)CH3; or (f) or combinations of the above.
A "linker" is a molecular entity that connects two or more molecular entities through covalent or non-covalent interactions. Examples of linkers include, but are not limited to, NR3, O, S, S(O), S(O)2, C(O), and CH2, where R3 is as defined above.
Figures 1-6 show non-limiting examples of the synthesis of compounds of this 1o invention having the general Formula I.
In addition to compounds of the general Formula I, this invention further includes compounds of the general Formula II:
w R
R N
R7 R9 I I'~~R$
~N Rz Rt ~
II
where R1, RZ, R3, R4, R5, R~, R7, Rg, R9, Rlo, R., R.., R..., R...., W, y, m and j are as defined above, and R" is hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -ORS, -C(O)R3, -C(O)ORS, NR4C(O)OR6, -OC(O)R3, -NR4SOZR6, -SOZNR3R4, -NR4C(O)R3, -C(O)NR3R4, -NRSC(O)NR3R4, -NRSC(NCl~NR3R4, -NR3R4, C,-Clo alkyl, CZ-Clo alkenyl, CZ-Clo alkynyl, C3-C,o cycloalkyl, C3-C,o cycloalkylalkyl, -S(O)~(C~-C6 alkyl), -S(O)~(CR4R5)m aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m aryl, -NR4(CR4R5)m aryl, -O(CR4R5)m heteroaryl, -NR4(CR4R5)m heteroaryl, -O(CR4R5)m heterocyclyl or -NR4(CR4R5)m-heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SOZR6, -SOZNR3R4, -C(O)R3, -C(O)ORS, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R , -NRSC(O)NR3R4, -NRSC(NCN)NR3R4, -ORS, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl.
Preferred embodiments of Formula II have a structure wherein: (a) R1 is Cl;
(b) R' is H, 1-(4-methylpiperazinyl), morpholinyl, -NMe2, or -CHZ(piperidinyl); (c) R8 is Cl or Br; (d) R9 is Cl or H; (e) W is -COOH, -C(O)NHOCHZ-(cyclopropyl) or -C(O)NHO(CHZ)ZOH; or (fj or combinations of the above.
Figures 7-13 show non-limiting examples of the synthesis of compounds of this invention having the general Formula II. Figure 18 shows the synthesis of a phosphate prodrug of a compound having the general Formula II.
In another embodiment, this invention relates to compounds of the general Formula III:
R' / '.
R' o 9~~ s R~-N ~R Rz R
III
where R~, R2, R3, R4, R5, R~, R7, R8, R9, Rlo, R., R.., R..., R...., W, y, m 2o and j are as defined above.
Preferred embodiments of Formula III have a structure wherein: (a) RI is Cl;
(b) R' is methyl or benzyl; (c) R$ is Br; (d) R9 is Cl; (e) W is -C(O)NHOCH2-(cyclopropyl) or -C(O)NHO(CHZ)zOH; or (f) or combinations of the above.
Figure 14 shows a non-limiting example of the synthesis of compounds of this invention having the general Formula III.
In another embodiment, this invention relates to compounds of the general Formula IV:
W Ri Rio R~ ~ R9 ~ ~ Rs O _N R
IV
where Rl, R2, R3, R4, R5, R6, R', R8, R9, Rio, R., R.., R..., R...., W, y, m and j are as defined above.
Preferred embodiments of Formula IV have a structure wherein: (a) Rl is 2-Cl;
(b) R' is methyl; (c) R9 is F; (d) W is -COOH or -C(O)NHO(CHZ)zOH; or (e) or combinations of the above.
l0 Figure 15 shows a non-limiting example of the synthesis of compounds of this invention having the general Formula IV.
In another embodiment, this invention relates to compounds of the general Formula V:
Rlo Y R
R~ / N- _R9 /~R8 Rz -N
R~~
V
where R', Rz, R3, R4, R5, R6, R7, R8, R9, Rlo, Ry R., R.., R..., R,.,., W, y, m and j are as defined above. Figures 16-17 show non-limiting examples of the synthesis of compounds of this invention having the general Formula V.
Preferred embodiments of Formula V have a structure wherein: (a) Rl is 2-Cl, 2-H, or 2-F; (b) R8 is Cl or Br; (c) R9 is H, F or Cl; (d) W is -C(O)OH, -C(O)NHOCHZ-(cyclopropyl), -C(O)NHO(CHz)zOH, or -CONH(SOZ)CH3, or (e) or combinations of the above.
The terms "C~-Clo alkyl", "alkyl" and "lower alkyl" as used herein refer to a saturated linear or branched-chain monovalent hydrocarbon radical having one to ten carbon atoms, wherein the alkyl radical may be optionally substituted independently with one or more substituents described below. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, heptyl, octyl, and the like.
The terms "C2-Coo alkenyl", "lower alkenyl" and "alkenyl" refer to linear or to branched-chain monovalent hydrocarbon radical having two to 10 carbon atoms and at least one double bond, and include, but is not limited to, ethenyl, propenyl, 1-but-3 enyl, 1-pent-3-enyl, 1-hex-5-enyl and the like, wherein the alkenyl radical may be optionally substituted independently with one or more substituents described herein, and includes radicals having "cis" and "traps" orientations, or alternatively, "E" and "Z" orientations.
The terms "CZ-Clo alkynyl," "lower alkynyl" and "alkynyl" refer to a linear or branched monovalent hydrocarbon radical of two to twelve carbon atoms containing at least one triple bond. Examples include, but are not limited to, ethynyl, propynyl, butynyl, pentyn-2-yl and the like, wherein the alkynyl radical may be optionally substituted independently with one or more substituents described herein.
The term "allyl" refers to a radical having the formula RC=CHCHR, wherein R is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or any substituent as defined herein, wherein the allyl may be optionally substituted independently with one or more substituents described herein.
The terms "carbocycle," "carbocyclyl," "cycloalkyl" or "C3-C1o cycloalkyl"
refer to saturated or partially unsaturated cyclic hydrocarbon radical having from three to ten carbon atoms. The term "cycloalkyl" includes monocyclic and polycyclic (e.g., bicyclic and tricyclic) cycloalkyl structures, wherein the polycyclic structures optionally include a saturated or partially unsaturated cycloalkyl fused to a saturated or partially unsaturated cycloalkyl or heterocycloalkyl ring or an aryl or heteroaryl ring. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. The cycloalkyl may be optionally substituted independently in one or more substitutable positions with various groups. For example, such cycloalkyl groups may be optionally substituted with, for example, C~-C6 alkyl, C~-C6 alkoxy, halo, hydroxy, cyano, nitro, amino, mono(C~-C6)alkylamino, di(C1-C6)alkylamino, CZ-C6alkenyl, CZ-C6alkynyl, C~-C~
haloalkyl, C~-C6 haloalkoxy, amino(C~-C6)alkyl, mono(CI-C6)alkylamino(C1-C6)alkyl or di(C1-C6)alkylamino(C~-C6)alkyl.
The term "heteroalkyl" refers to saturated linear or branched-chain monovalent 1o hydrocarbon radical of one to twelve carbon atoms, wherein at least one of the carbon atoms is replaced with a heteroatom selected from N, O, or S, and wherein the radical may be a carbon radical or heteroatom radical (i.e., the heteroatom may appear in the middle or at the end of the radical). The heteroalkyl radical may be optionally substituted independently with one or more substituents described herein. The term "heteroalkyl" encompasses alkoxy and heteroalkoxy radicals.
The terms "heterocycloalkyl," "heterocycle" or "hetercyclyl" refer to a saturated or partially unsaturated carbocyclic radical of 3 to 8 ring atoms in which at least one ring atom is a heteroatom selected from nitrogen, oxygen and sulfur, the remaining ring atoms being C, where one or more ring atoms may be optionally 2o substituted independently with one or more substituent described below. The radical may be a carbon radical or heteroatom radical. The term further includes fused ring systems which include a heterocycle fused to an aromatic group.
"Heterocycloalkyl"
also includes radicals where heterocycle radicals are fused with aromatic or heteroaromatic rings. Examples of heterocycloalkyl rings include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-3o pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinylimidazolinyl, imidazolidinyl, 3-\\\DE - 80248/0026 - 214630 v1 azabicyco[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 3H-indolyl and quinolizinyl. Spiro moieties are also included within the scope of this definition. The foregoing groups, as derived from the groups listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached). An example of a heterocyclic group wherein 2 ring carbon atoms are substituted with oxo (=O) moieties is 1,1-dioxo-thiomorpholinyl. The heterocycle groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups. For example, such heterocycle groups may be optionally substituted with, for example, C1-C6 alkyl, C1-C6 alkoxy, halo, hydroxy, cyano, nitro, amino, mono(C1-C6)alkylamino, di(C1-C6)alkylamino, CZ-C6alkenyl, CZ-C~alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, amino(C~-C6)alkyl, mono(C~-C6)alkylamino(C,-C6)alkyl or di(C1-C6)alkylamino(C1-C6)alkyl.
The term "aryl" refers to a monovalent aromatic carbocyclic radical having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl), which is optionally mono-, di-, or trisubstituted with, e.g., halo, lower alkyl, lower alkoxy, trifluoromethyl, aryl, heteroaryl, and hydroxy.
2o The term "heteroaryl" refers to a monovalent aromatic radical of 5-, 6-, or membered rings which includes fused ring systems (at least one of which is aromatic) of 5-10 atoms containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur. Examples of heteroaryl groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and 3o furopyridinyl. Spiro moieties are also included within the scope of this definition.
Heteroaryl groups are optionally mono-, di-, or trisubstituted with, e.g., halo, lower alkyl, lower alkoxy, haloalkyl, aryl, heteroaryl, and hydroxy.
The term " halo" includes fluoro, bromo, chloro, and iodo substituents.
The term "arylalkyl" means an alkyl moiety (as defined above) substituted with one or more aryl moiety (also as defined above). More preferred arylalkyl radicals are aryl-C~_3-alkyls. Examples include benzyl, phenylethyl, and the like.
The term "heteroarylalkyl" means an alkyl moiety (as defined above) substituted with a heteroaryl moiety (also as defined above). More preferred heteroarylalkyl radicals are 5- or 6-membered heteroaryl-C1_3-alkyls. Examples include, oxazolylmethyl, pyridylethyl and the like.
to The term "heterocyclylalkyl" means an alkyl moiety (as defined above) substituted with a heterocyclyl moiety (also defined above). More preferred heterocyclylalkyl radicals are 5- or 6-membered heterocyclyl-C1_3-alkyls.
Examples include tetrahydropyranylmethyl.
The term "cycloalkylalkyl" means an alkyl moiety (as defined above) substituted with a cycloalkyl moiety (also defined above). More preferred heterocyclyl radicals are 5- or 6-membered cycloalkyl-C1_3-alkyls. Examples include cyclopropylmethyl.
The term "Me" means methyl, "Et" means ethyl, "Bu" means butyl and "Ac"
means acetyl.
2o In general, the various moieties or functional groups of the compounds of Formulas I-V may be optionally substituted by one or more substituents.
Examples of substituents suitable for purposes of this invention include, but are not limited to, oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SOzR6, -SOZNR3R4, -C(O)R3, -C(O)~R3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NRSC(O)NR3R4, -NRSC(NCI~NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where R3, R4, RS and R6 are as defined herein.
It is to be understood that in instances where two or more radicals are used in succession to define a substituent attached to a structure, the first named radical is considered to be terminal and the last named radical is considered to be attached to the structure in question. Thus, for example, the radical arylalkyl is attached to the structure in question by the alkyl group.
In the compounds of the present invention, where terms such as (CR4R5)m or (CR4R5)t are used, R4 and RS may vary with each iteration of m or t above 1.
For instance, where m or t is 2, the terms (CR4R5)m or (CR4R5)~ may equal -CHZCHZ-or -CH(CH3)C(CHZCH3)(CHzCHzCH3)- or any number of similar moieties falling within the scope of the definitions of R4 and R5.
The compounds of this invention may possess one or more asymmetric l0 centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers, diastereomers mixtures, racemic or otherwise, thereof.
Accordingly, this invention also includes all such isomers, including diastereomeric mixtures and pure enantiomers of the Formulas I-V. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization. Enantiomers can be separated by converting the enantiomer mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. The methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition, J. March, John Wiley and Sons, New York, 1992).
This invention also encompasses pharmaceutical compositions containing a compound of Formula I-V and methods of treating proliferative disorders, or abnormal cell growth, by administering compounds of the present invention.
Compounds of the present invention having free amino, amido, hydroxy or carboxylic 3o groups can be converted into pharmaceutically acceptable prodrugs.
The term "prodrug" means compounds that are rapidly transformed in vivo to yield the parent compound of Formula I-V, for example, by hydrolysis of a functional group of a Formula I-V compound in blood. A "pharmaceutically acceptable prodrug" is a compound that may be converted under physiological conditions or by solvolysis to the specified compound or to a pharmaceutically acceptable salt of such compound. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the present invention. The amino acid 1 o residues include but are not limited to the 20 naturally occurnng amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutyric acid, cirtulline, homocysteine, homoserine, ornithine and methionine sulfone. One preferred prodrug of this invention is a compound of Formula I-V covalently joined to a phosphate residue. Another preferred prodrug of this invention is a compound of Formula I-V covalently joined to a valine residue.
Additional types of prodrugs are also encompassed. For instance, a compound of Formula I-V having free carboxyl groups can be derivatized as amides or alkyl esters. A compound of Formula I-V having free hydroxy groups may be derivatized using groups including but not limited to phosphate esters, hemisuccinates, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of compounds of Formula I-V having hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate ester and sulfate ester prodrugs of compounds of Formula I-V
having hydroxy groups. Derivatization of hydroxy groups to provide (acyloxy)methyl and (acyloxy)ethyl ether prodrugs of compounds of Formula I-V, wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also encompassed. Prodrugs of this type are 3o described in .l. Med. Chem., 1996, 39, 10. Compound of Formula I-V having free amines can also be derivatized as amides, sulfonamides or phosphonamides prodrugs.
All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
In addition, the invention also includes solvates, pharmaceutically active metabolites, and pharmaceutically acceptable salts of compounds of Formulas I-V.
The term "solvate" refers to an aggregate of a molecule with one or more solvent molecules.
A "pharmaceutically active metabolite" is a pharmacologically active product produced through metabolism in the body of a specified compound or salt thereof.
Metabolites of a compound may be identified using routine techniques known in the to art and their activities determined using tests such as those described herein.
Prodrugs and active metabolites of a compound may be identified using routine techniques known in the art. Various forms of prodrugs are known in the art.
For examples of such prodrug derivatives, see, for example, a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p.
309-396, edited by K. Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter "Design and Application of Prodrugs," by H. Bundgaard p. 113-191 (1991); c) H.
Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); d) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77:285 (1988); and e) N. Kakeya, et al., 2o Chem. Pharm. Bull., 32: 692 (1984), each of which is specifically incorporated herein by reference.
A "pharmaceutically acceptable salt" as used herein, unless otherwise indicated, includes salts that retain the biological effectiveness of the free acids and bases of the specified compound and that are not biologically or otherwise undesirable. A compound of the invention may possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention 3o with a mineral or organic acid or an inorganic base, such salts including sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyn-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitromenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, pheylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, 'y hydroxybutyrates, glycollates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1-sulfonates, 1o naphthalene-2-sulfonates, and mandelates. Since a single compound of the present invention may include more than one acidic or basic moieties, the compounds of the present invention may include mono, di or tri-salts in a single compound.
If the inventive compound is a base, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an acidic compound, particularly an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, malefic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alphahydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.
If the inventive compound is an acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base. Preferred inorganic salts are those formed with alkali and alkaline earth metals such as lithium, sodium, potassium, barium and calcium. Preferred organic base salts include, for example, ammonium, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium, phenylethylbenzylamine, dibenzyl-ethylenediamine, and the like salts. Other salts of acidic moieties may include, for example, those salts formed with procaine, quinine and N-methylglusoamine, plus salts formed with basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine and arginine.
The inventive compounds may be prepared using the reaction routes and synthesis schemes as described below, employing the techniques available in the art using starting materials that are readily available or can be synthesized using methods known in the art.
Illustrations of the preparation of compounds of the present invention are shown in Schemes 1-9.
HO O X
HO O H
\ F F \ N \
\ -Br I / F I / _ Br I / F I /
F Br ~ F F
F
,O O H X ,O O H X
\ N \ \ N \
Br I / F I / / I / F I
F R F
i0 O H X ,O O X ~O O H X
H
\ N \ \ N \ \ N \
R I / F I / R I / F I / R \ I / F I / Y
HO O
H X
I \ N I \
R \ / F / Y
N-O
H R"
H R'~ ,N O ~~N O
R~~O~N O H X O S O H X R H X
\ N \ \ N \ \ N \
R \ I / F I / Y R \ I / F I / Y R \ I / F I / Y
N-O N-O N-O
110 111 .112 ~.O O H X ,O O
H X
\ N \ \ N \
Br I r F I r NC I ~ F
F F
,O O H X ,O O
H X
N '~ \ N \
i I ~ I I
HzN \ F HZN \ r F ~ Y
N-O N-O
R~~O~N O X
H
N \
HzN \ I / F I r Y
N-O
O OH O Cl Et0 ~~ HO I
I ~
N OH ~N~CI
HO O
H X
N
I / Y
~O O H X Me0 O X
H
N N
I / Y W I Cl I ~~ Y
NHz 120 Cl 122 HO O Me0 O X
H X H
/ N ~ / N
N I I / Nw I Cl I / y ~ ~Z Y
~N NHZ 123 HO O X
H
N
H N/ I I /
R~ ,N O Z ~, O H X ~N
I N I j 124 ~ 'Z Br N
Me0 O
H X
~~R~~
N
I / + Bt~Bt 'Z Y ' ~I'~~R~~
H
Me0 O X R~O~N O X
H H
N INI/ /1N1\
R"R'N~~ Z Y R"R'N~~ Z /
N ~N
Bt = benzotriazole H H
R~O~N O X R~O~N O
H H
N N
N I I ~ N I I ~
\Z Y R"R,N~N 'Z Y
R"'O O H X R"'O O H X
N N
N I I ~ N I I ~
OHC~ ~ ~Z Y R"R'N~ ~ 'Z Y
N N
H
R""~O~N O X
H
N
N I I
~Z Y
R"R'N~N
R"O O R"O O H X R"O O H X
H X
N N N
I I / ~ I I / N I I /
~Z Y O ~Z Y R~ ~ ~Z Y
Cl R~N,NH \\N-N
H
HO O H X R'~O~N O H X
N N
N I I / N I I /
R~ I ~Z Y R~ ~ ~Z Y
\\N_N \\N_N
H
,O O H X ~O O H X R'~O~N O H X
\N~\ /INI\ /IN
/ Y / /' Y / /' Y /
O F O-N O-N
~ N02 _ I ~ NH2 I ~ NHZ
CI N / NJ / N~Z
H X
Br ~ / ~ N
/~N~ ~Z
-N
147 ~ HO O X
H
NHZ , N
~I
N Z / N Z ~ Y
-N -N
.NO~ ~ N w / N- 'Z I ~ Y
-N
Y
H
R'wO, N O X
H
N ~ W
/ N~Z ~ Y
-N
Scheme 1 illustrates one method of preparing compounds of the Formula I.
Carboxylic acid 102 can be prepared from arene 101 by deprotonation at low temperature (-100 to -60 °C) in the appropriate ethereal solvent such as THF or diethyl ether followed by carbon dioxide quench, which can be performed with solid dry ice. The deprotonation can be accomplished with LDA in THF at -78 °C. One quench method comprises adding the aryllithium THF solution via cannula to a saturated solution of dry carbon dioxide in THF at -78 °C and then warming to room temperature. Aniline 103 can be prepared by deprotonation of an appropriate 2-substituted aniline with KHMDS, LiHMDS, NaHMDS or LDA at low temperature (-100 to -60 °C) in an appropriate ethereal solvent such as THF or diethyl ether, followed by addition of carboxylic acid 102 and warming to room temperature.
In one embodiment, deprotonation is accomplished with LDA at -78 °C in THF, followed by addition of carboxylic acid 102 and warming to room temperature.
Ester 104 can be prepared by standard methods including, but not limited to, Fisher esterification (MeOH, H2S04), reaction with TMSCHN2 or TMSCI in MeOH.
Acetylene derivative 105 is prepared by Sonagashria coupling of bromide 104 using an appropriatly substituted acetylene, CuI, an amine base, palladium catalyst and organic solvent such as DME, THF, or DMF at temperatures between 25 and 100 °C.
Suitable palladium catalysts include, but are not limited to, PdCl2(dppf), Pd(Ph3P)4, 2o and Pd2dba3fdppf. Suitable amine bases include, but are not limited, to Et3N, Hunig's base, and diisopropyl amine. In one embodiment, the Pd(0) mediated coupling to prepare acetylene 105 is accomplished with Pd(PPh3)ZCIz, CuI, diisopropyl amine, and the appropriate substituted acetylene in THF at room temperature.
Hydrolysis of acetylene 105 to prepare ketone 106 can be accomplished by standard methods including but not limited to HZS04, TFA, trifluorosulfonamide, FeCl3, or HgSOa/HzSOa. Benzisoxazole 107 can be prepared in a two step procedure from ketone 106. Addition of the potassium salt of acetone oxime in suitable organic solvent such as THF or Et20 at temperatures ranging from -78 to 5 °C is followed by acid catalyzed cyclization. The acetone oxime addition is most easily performed by 3o addition of a THF solution of ketone 106 to the salt at 0 °C. The cyclization can be accomplished with a variety of acidic aqueous conditions at a range of temperatures.
In one embodiment cyclization is accomplished by treatment of the isopropylideneaminooxybenzoic acid methyl ester with 5% aqueous HCl in MeOH at reflux. Halogenation to form benzisoxazole 108 is accomplished using standard procedures such as NCS or NBS in DMF. Hydrolysis of ester 108 to form carboxylic acid 109 can be performed under standard conditions. The acid can be converted to hydroxamate 110 or amide 112 by standard coupling procedures including but not limited to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxyl amine or amine.
Alternatively, hydroxamate 110 or amide 112 can be prepared in two steps by initial conversion to the acid chloride by standard methods followed by addition of the 1o hydroxyl amine or amine. Acyl sulfonamide 111 can be synthesized by preparing an activated ester of carboxylic acid 109 followed by treatment with the appropriate sulfonamide and tertiary amine base in a suitable organic solvent such as THF.
In one embodiment, acyl sulfonamide 111 is prepared by treatment of carboxylic acid with CDI at elevated temperature (50 °C) in THF followed treatment with the appropriate sulfonamide and DBU.
Scheme 2 illustrates an alternative method for synthesizing compounds of the Formula I. Nitrile 113 can be prepared by palladium mediated coupling of bromide 104 with zinc cyanide in suitable organic solvent such as DMA, NMP or DMF at elevated temperatures ranging from 50 to 120 °C. Several palladium catalysts may be 2o employed including but not limited to Pd(PPh3)4, PdCl2(dppf), or Pdzdba3 with ligands such as dppe, dppp, dppf or BINAP. In one embodiment, nitrite 113 is prepared from bromide 104 by treatment with zinc cyanide, Pd2dba3, and dppf in NMP at 120 °C. Amino benzisoxazole 114 can be prepared in a two step procedure from nitrite 113 by the addition of the potassium salt of acetone oxime in suitable organic solvent such as THF or Et20 at temperatures ranging from -78 to 5 °C
followed by acid catalyzed cyclization. In one embodiment the acetone oxime addition can be performed by addition of a THF solution of nitrite 113 to the salt at 0 °C in THF followed by warming to room temperature. The cyclization can be accomplished under a variety of acidic conditions at a range of temperatures.
In one embodiment the cyclization method comprises treatment of the oxime addition product in MeOH with 2 M HCl in Et20. Halogenation to form benzisoxazole 115 is accomplished using standard procedures such as NCS or NBS in DMF. Compound 116 is prepared in a two step procedure comprising hydrolysis of ester 115 under standard conditions to form the corresponding carboxylic acid, followed by conversion of the carboxylic acid to hydroxamate 116 by standard coupling procedures, including but not limited, to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxyl amine.
Scheme 3 illustrates one method of synthesizing compounds of the Formula II.
4,6-Dichloronicotinic acid 118 can be prepared from 4,6-dihydroxynicotinic acid ethyl ester 117 in two steps. In the first step, 4,6-dihydroxynicotinic acid ethyl ester 117 is chlorinated using an appropriate reagent such as POC13, oxalyl chloride or thionyl chloride. In one embodiment, chlorination is accomplished with POC13 and Et3N at elevated temperatures. Hydrolysis of the resulting dichloroethyl ester to provide compound 118 can be performed under standard conditions. Aniline 119 can be prepared by deprotonation of the properly substituted aniline with KHMDS, LiHMDS, NaHMDS or LDA at low temperature (-100 to -60 °C) in appropriate ethereal solvent such as THF or diethyl ether followed by addition of carboxylic acid 118 and warming to room temperature. In one embodiment, deprotonation is accomplished with LiHMDS at -78 °C in THF, followed by addition of carboxylic acid 118 and warming to room temperature. Amino pyridine 120 is prepared in three 2o steps from aniline 119. In the first step, the tert-butyl ester is prepared by treating the acid 119 with 2-tert-butyl-1,3-diisopropylisourea in THF at temperatures ranging from 25 to 75 °C. In the second step, sodium azide is added to the tert-butyl ester in DMF at 80 °C. The amino pyridine 120 is prepared by reduction of the azide under standard conditions including but not limited to Zn dust/AcOH, Pt/C or Pt02 in the presence of HZ gas, Ph3P or SnCl2/MeOH. In one embodiment, the azide reduction is accomplished by treatment with Zn dust in a mixture of methylene chloride and acetic acid. Imidazo pyridine 121 where Z = F is prepared in two steps from amino pyridine 120. In the first step, fluorination is accomplished by treatment of the amino pyridine 120 with SELECTFLUORTM in a mixture of MeOH and water or pH 7 phosphate 3o buffer. Cyclization to form imidazo pyridine 121 (Z = H or F) can be accomplished by treatment with chloro or bromo acetaldehyde in suitable organic solvent such as DMF or EtOH at elevated temperatures (50 to 120 °C). In one embodiment, cyclization is realized by treatment with chloroacetaldehyde in EtOH at 70 °C.
Alternatively, aniline 119 can be converted to dichloroester 122 in two steps.
In the first step, chlorination is performed under standard conditions such as NCS in DMF.
In the second step, esterification can be achieved by standard methods including but not limited to Fisher esterification (MeOH, HZS04), reaction with TMSCHNZ or TMSCI in MeOH. Aminopyridine 123 can be prepared as described above for aminopyridine 120 with the exception that the sodium azide addition can be accomplished at room temperature. Cyclization (achieved as described above for 1o imidazopyridine 121) followed by standard basic saponification gives imidazo pyridine 124. Hydroxamate 125 can be prepared from either imidazo pyridine 121 or 124 using standard coupling procedures including but not limited to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxylamine. Alternatively, hydroxamate can be prepared in two steps by initial conversion to the acid chloride by standard methods followed by addition of the hydroxylamine.
Scheme 4 illustrates an alternative method of preparing compounds of Formula II. An appropriately functionalized 2-aminopyridine 126 in a suitable organic solvent such as dichloromethane or dichloroethane is reacted with a Lewis acid such as zinc bromide and condensation product (127) as disclosed by Katritzky et 2o al. (J. Org. Chem., 2003, 68, 4935-4937: J. Org. Chem., 1990, 55, 3209-3213) to provide the 3-dialkyaminoimidazo[1,2-a]pyridine ring system 128. Condensation products 127 (i.e., condensation of a glyoxal, benzotriazole and a secondary amine) can be generated using benzotriazole, glyoxal and any appropriate secondary amine including, but not limited to dimethylamine, diethylamine, pyrrolidine, piperidine, morpholine, 1-methylpiperazine, N-methyl allylamine, diallyamine, and N-methyl benzylamine. The ester 128 is hydrolyzed by standard saponification methods, and the resulting acid can be converted to hydroxamate 129 by standard coupling procedures including but not limited to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxylamine. Alternatively, hydroxamate 129 can be prepared in two steps by initial conversion of the carboxylic acid to the acid chloride or activated ester by standard methods followed by addition of the hydroxylamine.
Scheme 5 illustrates an alternative method of preparing compounds of the Formula II. The preparation of 3-aminomethylimidazo[1,2-a]pyridines 131 using the modified Mannich reaction procedure developed by Kercher et al. (manuscript in preparation) is illustrated. The reaction is generally carried out by combining 37%
aqueous formaldehyde and a suitable amine in 6:1 acetonitrile/water. Several secondary amines can be employed including but not limited to pyrrolidine, piperadine, morpholine, dimethylamine, N-BOC-piperazine and 1-methylpiperazine.
The solution of amine and formaldehyde is stirred for approximately half an hour after which time scandium triflate and the appropriate imidazo[1,2-a]pyridine 130 are 1o sequentially added. The Mannich reaction is preferentially catalyzed by a group IIIA
lanthanide triflate, preferably scandium triflate, though alternatively it may be performed using an excess of protic acid (AcOH or HCl) or elevated temperatures.
Scheme 6 illustrates an alternative method of preparing compounds of Formula II. In Scheme 6, the preparation of 3-aminomethylimidazo[1,2-a]pyridines 134 via reductive alkylation is illustrated. In step 1, the 3-aminomethylimidazo[1,2-a]pyridine 133 is prepared from the appropriate 3-formyl-imidazo[1,2-a]pyridine 132 and a suitable amine using standard reduction methods such as Na(CN)BH3, Na(OAc)3BH, NMe4BH(OAc)3 with or without the addition of acetic acid in a suitable nonreactive organic solvent such as methylene chloride, acetonitrile or 2o tetrahydrofuran. The reductive amination is generally accomplished by treatment of the aldehyde derivative 132 with the amine and acetic acid in tetrahydrofuran at room temperature followed by the addition of Na(OAc)3BH. In cases where R" = H, the corresponding secondary amine 133 can optionally be protected, for example with an acid labile protecting group such as tert-butyl carbamate (BOC) to facilitate handling in subsequent steps. In step 2, the ester is hydrolyzed by standard saponification methods, and the resulting acid can be converted to hydroxamate 134 by standard coupling procedures including but not limited to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxylamine. Alternatively, hydroxamate 134 can be prepared in two steps by initial conversion of the carboxylic acid to the acid chloride or activated ester 3o by standard methods followed by addition of the hydroxylamine. Protecting groups, if present, are removed after coupling. .
Scheme 7 illustrates one method of preparing compounds of Formula III. In Scheme 7 the preparation of 3-alkyl-[1,2,4]triazolo[4,3-a]pyridine derivatives is illustrated. Compound 136 is prepared from compound 135 in a two step process.
A
suitably functionalized 2-chloropyridine derivative 135 is converted to the 2-hydrazinopyridine by reaction with hydrazine. The reaction is generally accomplished by reaction of hydrazine with 2-chloropyridine derivative 135 in an unreactive organic solvent such as DMF or DMA at elevated temperature (50 to °C). The 2-hydrazinopyridine is then acylated with the appropriate carboxylic acid halide such as fluoride, chloride or bromide, or the appropriate carboxylic acid anhydride or mixed anhydride in a suitable unreactive organic solvent such as dichloromethane, and in the presence of a suitable base such as triethylamine, diisopropylethylamine or pyridine, to provide intermediate 136. Acylation of the 2-hydrazinopyridine can alternatively be accomplished by standard peptide coupling procedures with the appropriate carboxylic acid and appropriate coupling reagent, including but not limited to EDCI/HOBt, PyBOP, or DIC. The intermediate 136 is converted to 3-alkyl-[ 1,2,4]triazolo[4,3-a]pyridine 137 by treatment with an excess of phosphorus oxychloride in refluxing dichloromethane. The ester 137 is hydrolyzed by standard saponification methods, and the resulting acid 138 can be converted to hydroxamate 139 by standard peptide coupling procedures including but not limited 2o to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxyl amine.
Alternatively, hydroxamate 139 can be prepared in two steps by initial conversion of the carboxylic acid to the acid chloride or activated ester by standard methods followed by addition of the hydroxylamine.
Scheme 8 illustrates one method of preparing compounds of the Formula IV.
In Scheme 8, the synthesis of 3-methyl-benzo[c]isoxazole derivatives is illustrated.
Compound 141 is prepared from compound 140 in a two step process. Methyl ester 140 is treated with sodium azide in 3:1 acetone/water at elevated temperature (reflux) to effect nucleophilic substitution. The 4-azido derivative is then isolated and heated in water at reflux to effect cyclization to the benzo[c]isoxazole ring system 141. The ester 141 is hydrolyzed by standard saponification methods, and the resulting carboxylic acid can be converted to hydroxamate 142 by standard peptide coupling procedures including but not limited to EDCIfHOBt, PyBOP, or DIC and the appropriate hydroxylamine. Alternatively, hydroxamate 142 can be prepared in two steps by initial conversion of the carboxylic acid to the acid chloride or activated ester by standard methods followed by addition of the hydroxylamine.
Scheme 9 illustrates one method of preparing compounds of Formula V. 2-Chloro-4-methyl-5-nitropyridine '143 can be converted to amino pyridine 144 in a three step sequence. In the first step, Sonagashria coupling using TMS-acetylene, CuI, amine base, palladium catalyst and organic solvent such as DME, THF, or DMF
at temperatures from 25 to 100 °C gives the nitroacetylenic pyridine.
Suitable 1o palladium catalysts include, but are not limited to, PdCl2(dppf), Pd(Ph3P)4, Pd(PPh3)ZC12 and PdZdba3ldppf. Suitable amine bases include, but are not limited to, Et3N, Hunig's base, and diisopropyl amine. The amino pyridine 144 is then prepared by removal of the TMS group under standard conditions such as KZC03 in MeOH, followed by reduction of the nitro group using either Zn dusdAcOH, Fe or SnCl2lMeOH. For Z = H, amino pyridine 144 is used directly in the cyclization reaction. When Z = Cl, aminopyridine 144 is halogenated under standard conditions with NCS in DMF and then earned forward to the cyclization. When Z = F, the 2-chloro-3-aminopyridine intermediate is treated with KF, Kryptofix in DMSO to prepare amino pyridine 145. Cyclization to give pyrazolo[1,5-a]pyridine 146 is 2o accomplished by treating aminopyridine 145 with O-(4-nitrophenyl)-hydroxylamine in a suitable organic solvent such as DMF at room temperature in presence of a base such as KZC03. Carboxylic acid 149 can be prepared, for example, using one the following routes. One route involves palladium mediated cross-coupling with appropriately substituted bromobenzene and aminopyrazolo[1,5-a]pyridine 146.
In this case, the cross-coupling can be accomplished with palladium catalyst and organic solvent such as DME, THF, dioxane, and toluene at temperatures from 60 to 120 °C.
Suitable palladium catalysts include, but are not limited to, Pd(OAc)z, PdCl2(dpp~, Pd2(bda)3, and Pd(dba)2. Suitable ligands include, but are not limited to, BINAP, DPPF, and (o-tol)3P. Suitable amine bases include, but are not limited to, NaOt-Bu, KOt-Bu, and CsZC03. The second route involves SNAr reaction with aminopyrazolo[1,5-a]pyridine 146 and the appropriately substituted 2-fluoronitrobenzene. In this case, the coupling can be accomplished by mixing the two components in a suitable organic solvent such as xylenes, toluene, DMSO or DMF
at elevated temperatures (80 to 150 °C). Optionally, a base can be employed in the SNAr coupling such as KZC03 or Cs2C03. The carboxylic acid 149 is then prepared by functionalization of the aromatic ring followed by oxidation. In the first case, functionalization involves halogenation under standard conditions with either NCS or NBS in DMF. In the second case, functionalization involves Sandmeyer chemistry to convert the nitroarene into the desired arene or arylhalide (nitro group reduction;
diazonation; halogentation or protonation). In both routes, the last step to prepare carboxylic acid 149 is oxidation of the toluyl moiety. This can be achieved using standard methods including but not limited to KMn04, NaOCI/RuCl3 or Na2Crz07/HCI. The resulting carboxylic acid 149 can be converted to hydroxamate 150 by standard peptide coupling procedures including but not limited to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxylamine. Alternatively, hydroxamate 150 can be prepared in two steps by initial conversion of the carboxylic acid to the acid chloride or activated ester by standard methods followed by addition of the hydroxylamine.
The invention also relates to a pharmaceutical composition for the treatment of a hyperproliferative disorder in a mammal which comprises a therapeutically effective 2o amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier. In one embodiment, said pharmaceutical composition is for the treatment of cancer such as brain, lung, squamous cell, bladder, gastic, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, esophageal, testicular, gynecological or thyroid cancer. In another embodiment, said pharmaceutical composition is for the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g., benign prostatic hypertrophy (BPH)).
The invention also relates to a pharmaceutical composition for the treatment of pancreatitis or kidney disease (including proliferative glomerulonephritis and diabetes-induced renal disease) or the treatment of pain in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable Garner.
The invention also relates to a pharmaceutical composition for the prevention of blastocyte implantation in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier.
The invention also relates to a pharmaceutical composition for treating a disease related to vasculogenesis or angiogenesis in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier. In one embodiment, said pharmaceutical composition is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
The invention also relates to a method of treating a hyperproliferative disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof. In one embodiment, said method relates to the treatment of cancer such as brain, lung, squamous cell, bladder, gastic, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, esophageal, testicular, gynecological or thyroid cancer. 1n another embodiment, said method relates to the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g., benign prostatic hypertrophy (BPH)).
The invention also relates to a method for the treatment of a hyperproliferative disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or 'a pharmaceutically acceptable salt, prodrug or hydrate thereof, in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens.
The invention also relates to a method of treating pancreatitis or kidney disease in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
The invention also relates to a method of preventing blastocyte implantation in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
The invention also relates to a method of treating diseases related to vasculogenesis or angiogenesis in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof. In one embodiment, said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
Patients that can be treated with compounds of the present invention, or pharmaceutically acceptable salts, prodrugs and hydrates of said compounds, according to the methods of this invention include, for example, patients that have been diagnosed as having psoriasis, restenosis, atherosclerosis, BPH, lung cancer, bone cancer, CMML, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, testicular, 3o gynecologic tumors (e.g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (e.g., cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of the urethra, cancer s of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter (e.g., renal cell carcinoma, carcinoma of the renal pelvis), or neoplasms of the central nervous system (e.g., primary CNS lymphona, spinal axis tumors, brain stem gliomas or pituitary adenomas).
1o This invention also relates to a pharmaceutical composition for inhibiting abnormal cell growth in a mammal which comprises an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate or prodrug thereof, in combination with an amount of a chemotherapeutic, wherein the amounts of the compound, salt, solvate, or prodrug, and of the chemotherapeutic are together is effective in inhibiting abnormal cell growth. Many chemotherapeutics are presently known in the art. In one embodiment, the chemotherapeutic is selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis 20 inhibitors, and anti-androgens.
This invention further relates to a method for inhibiting abnormal cell growth in a mammal or treating a hyperproliferative disorder which method comprises administering to the mammal an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate or prodrug thereof, in combination with 25 radiation therapy, wherein the amounts of the compound, salt, solvate, or prodrug, is in combination with the radiation therapy effective in inhibiting abnormal cell growth or treating the hyperproliferative disorder in the mammal. Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapy described herein. The administration of the compound of 3o the invention in this combination therapy can be determined as described herein.
It is believed that the compounds of the present invention can render abnormal cells more sensitive to treatment with radiation for purposes of killing and/or inhibiting the growth of such cells. Accordingly, this invention further relates to a method for sensitizing abnormal cells in a mammal to treatment with radiation which comprises administering to the mammal an amount of a compound of the present invention or pharmaceutically acceptable salt or solvate or prodrug thereof, which amount is effective in sensitizing abnormal cells to treatment with radiation.
The amount of the compound, salt, or solvate in this method can be determined according to the means for ascertaining effective amounts of such compounds described herein.
The invention also relates to a method of and to a pharmaceutical composition of inhibiting abnormal cell growth in a mammal which comprises an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof, a prodrug thereof, or an isotopically-labeled derivative thereof, and an amount of one or more substances selected from anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents.
Anti-angiogenesis agents, such as MMP-2 (matrix-metalloprotienase 2) inhibitors, MMP-9 (matrix-metalloprotienase 9) inhibitors, and COX-II
(cyclooxygenase II) inhibitors, can be used in conjunction with a compound of the present invention and pharmaceutical compositions described herein. Examples of useful COX-II inhibitors include CELEBREX~ (alecoxib), valdecoxib, etoricoxib, lumiracoxib and rofecoxib. Examples of useful matrix metalloprotienase inhibitors are described in WO 96/33172 (published October 24, 1996), WO 96/27583 (published March 7, 1996), European Patent Application No. 97304971.1 (filed July 8, 1997), European Patent Application No. 99308617.2 (filed October 29, 1999), WO
98/07697 (published February 26, 1998), WO 98/03516 (published January 29, 1998), WO 98/34918 (published August 13, 1998), WO 98/34915 (published August 13, 1998), WO 98/33768 (published August 6, 1998), WO 98/30566 (published July 16, 1998), European Patent Publication 606,046 (published July 13, 1994), European Patent Publication 931,788 (published July 28, 1999), WO 90/05719 (published May 31, 1990), WO 99/52910 (published October 21, 1999), WO 99/52889 (published 3o October 21, 1999), WO 99/29667 (published June 17, 1999), PCT International Application No. PCT/IB98/01113 (filed July 21, 1998), European Patent Application No. 99302232.1 (filed March 25, 1999), Great Britain Patent Application No.
9912961.1 (filed June 3, 1999), United States Provisional Application No.
60/148,464 (filed August 12, 1999), United States Patent 5,863,949 (issued January 26, 1999), United States Patent 5,861,510 (issued January 19, 1999), and European Patent Publication 780,386 (published June 25, 1997), all of which are incorporated herein in their entireties by reference. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP-2 and/or MMP-9 relative to the other matrix-metalloproteinases (i.e., MMP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, 1o MMP-12, and MMP-13).
The terms "abnormal cell growth" and "hyperproliferative disorder" are used interchangeably in this application.
"Abnormal cell growth," as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes, for example, the abnormal growth of (1) tumor cells (tumors) that proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; (2) benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; (3) any tumors that proliferate by receptor tyrosine kinases; (4) any tumors that proliferate by aberrant 2o serine/threonine kinase activation; and (5) benign and malignant cells of other proliferative diseases in which aberrant serine/theroine kinase activation occurs.
The term "treating," as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment," as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above.
The amount of a given agent that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (e. g., weight) of the mammal in need of treatment, but can 3o nevertheless be routinely determined by one skilled in the art. "Treating"
is intended to mean at least the mitigation of a disease condition in a mammal, such as a human, that is affected, at least in part, by the activity of MEK, and includes, but is not limited to, preventing the disease condition from occurnng in a mammal, particularly when the mammal is found to be predisposed to having the disease condition but has not yet been diagnosed as having it; modulating and/or inhibiting the disease condition; and/or alleviating the disease condition.
In order to use a compound of the Formula I-V or a pharmaceutically acceptable salt or prodrug thereof, for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in 1o accordance with standard pharmaceutical practice as a pharmaceutical composition.
According to this aspect of the invention there is provided a pharmaceutical composition that comprises a compound of the Formula I-V, or a pharmaceutically acceptable salt or prodrug thereof, as defined hereinbefore in association with a ' pharmaceutically acceptable diluent or carrier.
The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, or intramuscular dosing or as a suppository for rectal dosing). For example, compositions intended for oral use may contain, for example, one or more coloring, sweetening, flavoring and/or preservative agents.
Suitable pharmaceutically-acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-3o hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability andlor appearance, in either case, using conventional coating agents and procedures well known in the art.
Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium 1o carboxymethylcellulose, methylcellulose, hydroxypropyhnethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), coloring agents, flavoring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
3o Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives.
Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurnng gums to such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavoring and preservative agents.
Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavoring and/or coloring agent.
The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irntating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.
Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedures well known in the art.
Compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example, 30 ~m or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose. The powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50 mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.
Compositions for administration by inhalation may be in the form of a to conventional pressurized aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
For further information on formulations, see Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990, which is specifically incorporated herein by reference.
The amount of a compound of this invention that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the subject treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician.
However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 0.5 to about 35 mglkg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g/day, preferably about 0.05 to about 2.5 glday. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day. For further information on routes of administration and dosage regimes, see 3o Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch;
Chairman of Editorial Board), Pergamon Press 1990, which is specifically incorporated herein by reference.
The size of the dose for therapeutic or prophylactic purposes of a compound of Formula I-V will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.
The compounds of this invention may be used alone in combination with other drugs and therapies used in the treatment of disease states which would benefit from the inhibition of MEK. For example, a compound of this invention may be applied in l0 combination with one or more other anti-tumor substances, including, but not limited to, mitotic inhibitors such as vinblastine; alkylating agents such as cis-platin, carboplatin and cyclophosphamide; anti-metabolites such as 5-fluorouracil, cytosine arabinside and hydroxyurea; or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No. 239362 such as N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid;
growth factor inhibitors; signal transduction inhibitors, such as agents that can inhibit EGFR (epiderman growth factor receptor) responses, such as EGRF antibodies, EGF
anitbodies and molecules that are EGFR inhibitors such as the compounds ZD-(AstraZeneca) and BIBX-1382 (Boehringer Ingelheim); VEGF inhibitors such as SU-6668 (Sugen Inc. of South San Francisco, California, USA) or the anit-VEGF
monoclonal antibody of Genentech, Inc. of South San Francisco, California;
cell cycle inhibitors; intercalating antibiotics such as adriamycin and bleomycin;
enzymes, for example, interferon; and anti-hormone such as anti-estrogens such as NolvadexTM (tamoxifen); or, for example anti-androgens such as CasodexTM (4' cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3' (trifluoromethyl)propionanilide). Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of treatment.
Although the compounds of Formula I-V are primarily of value as therapeutic 3o agents for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit the effects of MEK. Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.
The activity of the compounds of the present invention may be determined by the following procedure. N-terminal 6 His-tagged, constitutively active MEK-1 (2-393) is expressed in E. coli and protein is purified by conventional methods (Ahn et al., Science 1994, 265, 966-970). The activity of MEKl is assessed by measuring the incorporation of y-33P-phosphate from Y_33P-ATP onto N-terminal His tagged ERK2, which is expressed in E. coli and is purified by conventional methods, in the presence of MEK-1. The assay is carried out in 96-well polypropylene plate. The incubation to mixture (100 pL) comprises of 25 mM Hepes, pH 7.4, 10 mM MgCl2, 5 mM (3-glycerolphosphate, 100 pM Na-orthovanadate, 5 mM DTT, 5 nM MEK1, and 1 pM
ERK2. Inhibitors are suspended in DMSO, and all reactions, including controls are performed at a final concentration of 1 % DMSO. Reactions are initiated by the addition of 10 p.M ATP (with 0.5 pCi ~y-33P-ATPlwell) and incubated at ambient temperature for 45 minutes. Equal volume of 25% TCA is added to stop the reaction and precipitate the proteins. Precipitated proteins are trapped onto glass fiber B
filterplates, and excess labeled ATP washed off using a Tomtec MACH III
harvestor.
Plates are allowed to air-dry prior to adding 30 pL/well of Packard Microscint 20, and _ plates are counted using a Packard TopCount. In this assay, compounds of the invention exhibited an ICSO of less than 50 micromolar.
Representative compounds of.the present invention, which are encompassed by the present invention include, but are not limited to the compounds of the examples and their pharmaceutically acceptable acid or base addition salts or prodrugs thereof. The examples presented below are intended to illustrate particular embodiments of the invention, and are not intended to limit the scope of the specification or the claims in any way.
The disclosures in this application of all articles and references, including patents, are incorporated herein by reference.
EXAMPLES
In order to illustrate the invention, the following examples are included.
However, it is to be understood that these examples do not limit the invention and are only meant to suggest a method of practicing the invention. Persons skilled in the art will recognize that the chemical reactions described may be readily adapted to prepare a number of other MEK inhibitors of the invention, and alternative methods for preparing the compounds of this invention are deemed to be within the scope of this invention. For example, the synthesis of non-exemplified compounds according to the invention may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art other than those described, and/or by making l0 routine modifications of reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the invention.
In the examples described below, unless otherwise indicated all temperatures are set forth in degrees Celsius. Reagents were purchased from commercial suppliers such as Aldrich Chemical Company, Lancaster, TCI or Maybridge, and were used without further purification unless otherwise indicated. Tetrahydrofuran (THF), N,N-dimethylformamide (DMF), dichloromethane, toluene, dioxane and 1,2-difluoroethane were purchased from Aldrich in Sure seal bottles and used as received.
The reactions set forth below were done generally under a positive pressure of nitrogen or argon or with a drying tube (unless otherwise stated) in anhydrous solvents, and the reaction flasks were typically fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried.
Column chromatography was done on a Biotage system (Manufacturer: Dyax Corporation) having a silica gel column or on a silica SepPak cartridge (Waters).
'H-NMR spectra were recorded on a Bruker instrument operating at 300 MHz or on a Varian instrument operating at 400 MHz. 1H-NMR spectra were obtained as CDCl3 solutions (reported in ppm), using chloroform as the reference standard (7.25 ppm). Other NMR solvents were used as needed. When peak multiplicities are 3o reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets). Coupling constants, when given, are reported in Hertz (Hz).
Example 1 HO O CI
H
N
~F Br N-O
Synthesis of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3 methylbenzo[d]isoxazole-5-carboxylic acid (9a) The reaction scheme for the synthesis of compound 9a is shown in Figure 1.
Step A: Preparation of 5-bromo-2,3,4-trifluorobenzoic acid (2): To a solution of 1-bromo-2,3,4-trifluorobenzene (1) (5.0 mL, 41.7 mmol) in THF (120 mL) was added LiHMDS (2.0 M solution, 21 mL, 42 mmol) at -78 °C. After stirnng for 1 hour at -78 °C, the mixture was added to a solution of COZ in THF (1 L). The dry-ice bath was removed and the reaction mixture stirred overnight at room temperature.
The reaction mixture was quenched with 10% aqueous HCl (835 mL), concentrated, and washed with ether (250 mL). The combined organics were washed with 5%
aqueous NaOH (300 mL) and water (100 mL). The aqueous layer was acidified (pH
0) with concentrated HCI. The resulting suspension was extracted with ether (2 x 300 mL), dried over MgS04, filtered, concentrated under reduced pressure to afford 7.70 g (72% yield) of the desired product (2).
Step B: Preparation of S-bromo-2-(2-chlorophenylamino)-3,4-difluorobenzoic acid 3 : To a solution of LiHMDS (49.0 mL, 2 M in THF/heptane) in THF (40 mL) was added 2-chlorophenylamine (6.50 mL, 60.6 mmol) at -78 °C. After vigorous stirring for 10 minutes, a solution of 5-bromo-2,3,4-trifluoro-benzoic acid (2) (7.70 g, 30.2 mmol) in THF (60 mL) was added. The dry-ice bath was removed and the reaction mixture stirred for 4 hours at room temperature. The mixture was concentrated, treated with 10% aqueous HCl (75 mL), and extracted with EtOAc.
The combined organic extracts were dried over MgS04, filtered, and concentrated.
Purification by trituration with boiling CHZC12 gave 7.24 g (66%) of the desired acid (3) as a yellow solid Step C: Preparation of 5-bromo-2~2-chlorophenylamino)-3,4-difluorobenzoic acid methyl ester (4): To a solution of 5-bromo-2-(2-chlorophenylamino)-3,4 difluorobenzoic acid (3) (4.50 g, 12.4 mmol) in a 3:1 mixture of THF:MeOH (32 mL) was added (trimethylsilyl)-diazomethane (8.10 ml of a 2 M solution in hexanes) at room temperature. After stirnng for 2 hours, the reaction mixture was quenched with acetic acid, diluted with EtOAc, and washed with water. The organic layer was dried (MgS04) and concentrated under reduced pressure to give 4.35 g (93%) of the desired methyl ester (4).
Step D: Preparation of 2-(2-chlorophenylamino)-3,4-difluoro-5-trimethylsilan l~ynylbenzoic acid methyl ester (5): A mixture of 5-bromo-2-(2-chlorophenylamino)-3,4-difluorobenzoic acid methyl ester (4) (101 mg, 0.268 mmol), TMS-acetylene (0.045 mL, 0.31 mmol), Pd(PPh3)ZC12 (18.7 mg, 0.0261 mmol), CuI
(5.1 mg, 0.027 mmol), and i-Pr2NH (0.075 mL, 0.53 mmol) in THF (1.5 mL) was stirred for 16 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and diluted with EtOAc. The organic layer was washed with saturated aqueous NH4C1 and brine, dried over MgS04, and concentrated.
Purification by flash column chromatography using the Biotage system (100%
hexane to 1 % EtOAc in hexane) gave 81.3 mg (77% yield) of the desired product (5).
Step E: Preparation of 5-acetyl-2-(2-chlorophenylamino)-3,4-difluorobenzoic acid methyl ester (6): A mixture of 2-(2-chlorophenylamino)-3,4-difluoro-5-trimethylsilanylethynylbenzoic acid methyl ester (5) (79.4 mg, 0.20 mmol), HgS04 (59.8 mg, 2.0 mmol), and conc. HzS04 (0.02 mL, 0.40 mmol) in 80% aqueous acetone (2.5 mL), were refluxed for 48 hours. The reaction was concentrated under reduced pressure, and diluted with EtOAc. The organic layer was washed with water and brine, dried over MgS04 and concentrated to give 50.1 mg (73%) of the desired product (6).
Step F: Preparation of 6-(2-chloro_phenylamino)-7-fluoromethylbenzo[d]isoxazole-5-carboxylic acid methyl ester (7): t-BuOK (0.47 mL, 1.0 M in THF) was added to propan-2-one oxime (35 mg, 0.47 mmol). After stirring for 30 minutes, THF (0.5 mL) was added, and the reaction mixture was cooled to °C. A solution of 5-acetyl-2-(2-chlorophenylamino)-3,4-difluorobenzoic acid methyl ester (6) (50.0 mg, 0.147 mmol) in THF (1 mL) was added. The reaction mixture was slowly warmed to 0 °C and stirred for 2 hours. The reaction mixture was quenched with saturated aqueous NH4Cl, diluted with EtOAc and water. The aqueous layer was separated and extracted with EtOAc. The combined organic extracts were dried over MgS04, filtered, and concentrated in vacuo to give the 5-acetyl-2-(2-to chlorophenylamino)-3-fluoro-4-isopropylideneaminooxybenzoic acid methyl ester.
The recovered oxime was suspended in a 1:1 mixture of 5% aqueous HCl and MeOH
(30 ml) and heated to reflux. After 1 hour, the reaction mixture was cooled to room temperature and diluted with EtOAc. The organic layer was washed with water, dried (MgS04) and concentrated. Purification by flash column chromatography using the Biotage system (40% methylene chloride in hexanes) provided 17 mg (35% for two steps) of the desired product (7).
Step G: Preparation of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[dlisoxazole-5-carboxylic acid methyl ester (8a): 6-(2-Chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid methyl 2o ester (7) (18.6 mg, 0.0556 mmol) and N-bromosuccinimide (12.0 mg, 0.0667 mmol) were stirred in DMF (1 mL) for 16 hours. The reaction mixture was diluted with EtOAc, and washed with water (2x). The organic layer was dried over MgS04, filtered, and concentrated. Purification by flash column chromatography using the Biotage system (10% EtOAc in hexanes) provided 12.6 mg (55%) of the desired product (8a).
Step H: Preparation of 6-(4-bromo-2-chloro~henylamino)-7-fluoro-3-methXlbenzo[dlisoxazole-5-carboxylic acid (9a): To a solution of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid methyl ester (8a) (200 mg, 0.48 mmol) in THF-water (3 mL/1.5 mL) was added aqueous 3o LiOH (1 M, 1.00 mL) at room temperature. After 15 hours, the reaction mixture was acidified to pH 1 with aqueous HCl (1 M), diluted with water, and extracted with EtOAc/THF. The organic layer was washed with water, dried over MgS04, filtered, and concentrated in vacuo to give 191.5 mg (99%) of the crude acid (9a) which was used without further purification. MS APCI (-) m/z 397, 399 (M+, Br, Cl pattern) detected. 'H NMR (400 MHz, DMSO-d6) b 9.55 (s, 1H), 8.37 (s, 1H), 7.75 (s, 1H), 7.42 (d, 1H), 6.97 (t, 1H), 2.60 (s, 3H): '9F NMR (376 MHz, DMSO-d6) -140.15 (s).
Example 2 H
~O~ N O H CI
~ F ~ Br N-O
1o Synthesis of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid cyclopropylmethoxyamide (10a) The reaction scheme for the synthesis of compound 10a is shown in Figure 1.
To a solution of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (9a) (50.0 mg, 0.125 mmol) in DMF (1 mL) was added HOBt (24.6 mg, 0.161 mmol), Et3N (0.060 mL, 0.43 mmol), O-cyclopropylmethyl-hydroxylamine (15.5 mg, 0.178 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (32.2 mg, 0.168 mmol) at room temperature. After 6 days, the reaction mixture was diluted with EtOAc, washed with saturated aqueous NH4Cl, brine, saturated aqueous NaHC03, 2o and brine. The organic layer was dried over MgS04, filtered, concentrated in vacuo, and purified by flash column chromatography using the Biotage system (0.5%
MeOH
in CHZC12) to give 27.6 mg (47% yield) of the desired product (10a). MS APCI (-) m/z 466, 468 (M+, Br, C1 pattern) detected. 'H NMR (400 MHz, CD30D) 8 7.82 (s, 1H), 7.57 (d, 1H), 7.31 (dd, 1H), 6.74 (dd, 1H), 3.73 (d, 2H), 2.60 (s, 3H), 1.16 (m, 1H), 0.55 (m, 2H), 0.28 (m, 2H):'9F NMR (376 MHz, CD30D) -140.96 (s).
Example 3 H
HO~O,N O CI
H
~ N
~ F ~ Br N-O
Synthesis of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (2-hydroxyethoxy)-amide (12a) The reaction scheme for the synthesis of compound 12a is shown in Figure 2.
Step A: Preparation of 6-(4-bromo-2-chlorophenylamino)-?-fluoro-3-methyl-benzo(_dlisoxazole-5-carboxylic acid (2-vinyloxyethoxy)-amide (11a): To a solution of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (10a) (75.2 mg, 0.188 mmol) in DMF (1.5 mL) was added HOBt (38.2 mg, 0.249 mmol), Et3N (0.080 mL, 0.571 mmol), O-(2-vinyloxyethyl)hydroxylamine (28.5 mg, 0.276 mmol), and EDCI (47.2 mg, 0.246 mmol) at room temperature. After 6 days, the reaction mixture was diluted with EtOAc, washed with saturated aqueous NH4Cl, brine, saturated aqueous NaHC03, and brine. The organic layer was dried over MgS04, filtered, concentrated in vacuo, and purified by flash column chromatography using the Biotage system (3% MeOH
in CHZCIz) to give 57.8 mg (63%) of the desired product (1 la).
Step B: Preparation of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-2o methylbenzojdlisoxazole-5-carboxXlic acid (2-hydroxyethoxy)-amide (12a): A
solution of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazo1e-5-carboxylic acid (2-vinyloxyethoxy) amide (11a) (55.4 mg, 0.114 mmol) and aqueous HCl (1 M, 0.23 mL) in EtOH (3 mL) was stirred for 2 hours at room temperature. The pH of the reaction mixture was adjusted to 6-7 with aqueous NaOH
(2 M). The reaction was diluted with EtOAc. The organic layer was washed with water, dried over MgS04, filtered, and concentrated in vacuo to give 50.2 mg (96%
yield) of the desired product (12a). MS APCI (-) m/z 456, 458 (M+, Br, Cl pattern) detected. 1H NMR (400 MHz, CD30D) b 7.87 (s, 1H), 7.57 (d, 1H), 7.31 (dd, 1H), 6.74 (dd, 1H), 4.01 (t, 2H), 3.74 (t, 2H), 2.60 (s, 3H): 19F NMR (376 MHz, CD30D) -140.85 (s).
Example 4 H
~S~ N O CI
O H
O ~ \ N ~ \
F ~ Br N-O
Synthesis of N-[6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-to methylbenzo[d]isoxazole-5-carbonyl]-methanesulfonamide (13a) The reaction scheme for the synthesis of compound 13a is shown in Figure 3.
A mixture of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazo1e-5-carboxylic acid (9a) (41 mg, 0.102 mmol) and carbonyldiimidazole (23 mg, 0.140 mmol) in THF (1 mL) was stirred at 50 °C in a sealed tube reactor. The reaction mixture was cooled to room temperature and methanesulfonamide (17 mg, 0.179 mmol) was added followed by DBU (0.025 mL, 0.164 mmol). After stirnng at 50 °C
for 1 hour, the reaction mixture was cooled to room temperature, and diluted with EtOAc. The organic layer was washed with water, 1 N HCI, and brine. The organic layer was dried (MgS04) and concentrated. Purification by flash column chromatography using the Biotage system (7% MeOH in CHZC12) provided 34 mg (65% yield) of the desired product (13a). MS APCI (-) m/z 474, 476 (M+, Br, Cl pattern) detected. 'H NMR (400 MHz, CD30D) 8 8.27 (s, 1H), 7.53 (s, 1H), 7.27 (d, 1H), 6.73 (t, 1H), 3.11 (s, 3H), 2.55 (s, 3H): 19F NMR (376 MHz, CD30D) -141.84 (s).
Example 5 HO O CI
H
F ~ CI
N-O
Synthesis of 6-(2,4-dichloro-phenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (9b) The reaction scheme for the synthesis of compound 9b is shown in Figure 1.
Step A: Preparation of 6-(2,4-dichlorophenylamino)-7-fluoro-3-methylbenzo[d~isoxazole-5-carboxylic acid methyl ester (8b): 6-(2-Chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid methyl to ester (7) (129 mg, 0.384 mmol) and N chlorosuccinimide (57 mg, 0.421 mmol) were stirred in DMF (5 mL) for 16 hours. Concentrated HCl (3 ~.L) was added and the reaction mixture stirred 2 hours. The reaction mixture was diluted with EtOAc, and washed with water (2x). The organic layer was dried over MgS04, filtered, and concentrated. Purification by flash column chromatography using the Biotage system (S% EtOAc in hexanes) provided 73 mg (52%) the desired product (8b).
Step B: Preparation of 6-(2,4-dichlorophen 1~)-7-fluoro-3-methylbenzofdlisoxazole-5-carboxylic acid (9b): Compound 9b was prepared according to Step H of Example 1 using 6-(2,4-dichlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid methyl ester (8b) to provide 68 mg (98%
yield) of the desired product (9b). MS APCI (-) m/z 353, 355 (M+, Br, Cl pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.58 (s, 1H), 8.34 (s, 1H), 7.65 (d, 1H), 7.31 (dd, 1H), 7.04 (dd, 1H), 2.60 (s, 3H): 19F NMR (376 MHz, DMSO-d6) -140.36 (s).
Example 6 HO~O~N O CI
H
\ N I \
~ F ~ CI
N-O
Synthesis of 6-(2,4-dichlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (2-hydroxyethoxy)amide (12b) The reaction scheme for the synthesis of compound 12b, as shown in Figure 4, was carried out according to Steps A and B of Example 3 using 6-(2,4-dichlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (9b) as the starting material to provide 29 mg (38% yield for two steps) of 12b. MS
APCI (-) to m/z 412, 414 (M+, Br, Cl pattern) detected. 1H NMR (400 MHz, CD30D) b 7.87 (s, 1H), 7.45 (m, 1H), 7.19 (m, 1H), 6.80 (m, 1H), 4.02 (t, 2H), 3.75 (t, 2H), 2.60 (s, 3H):
i9F NMR (376 MHz, CD30D) -141.05 (s).
Example 7 HO O
H CI
\ N I \
H2N ~ / F ~ Br N-O
Synthesis of 3-amino-6-(4-bromo-2-chlorophenylamino)-7 fluorobenzo[d]isoxazole-5-carboxylic acid (19) The reaction scheme for the synthesis of compound 19 is shown in Figure 5.
Step A: Preparation of 2-(2-chlorophenYlamino)-5-cyano-3 4-difluorobenzoic acid metal ester (15): A mixture of 5-bromo-2-(2-chlorophenylamino)-3,4-difluorobenzoic acid methyl ester (14) (3.01 g, 7.99 mmol), 1,1'-bis(diphenylphosphino) ferrocene (dppf) (93 mg, 0.162 mmol), Pd2dba3 (73 mg, 0.080 mmol) and Zn(CN)Z (573 mg, 4.78 mmol) in 1-methyl-2-pyrrolidinone (NMP: 4.5 mL) was heated in a sealed tube reactor. After 20 hours, the reaction mixture was cooled to room temperature, quenched by the addition of 8 mL 4:1:4 (volume) mixture of saturated NH4C1, concentrated NH40H and water, and extracted with a mixture of EtOAc/THF. The combined organic extracts were washed with 4:1:4 (volume) mixture of saturated NH4C1, concentrated NH40H and water, and brine.
The organic layer was dried (MgS04) and concentrated. Purification by flash column chromatography using the Biotage system (twice: 100% hexanes to 35% CHZC12 in hexanes, then 30% CHZCl2 in hexanes) provided 1.33 g (52%) of the desired product (15).
Step B: Preparation of 3-amino-6-(2-chlorophenylaminoL
fluorobenzojdlisoxazole-5-carboxylic acid methyl ester (17): t-BuOK (3.80 mL
of a 1.0 M solution in THF) was added to a stirred solution of propan-2-one oxime (285 mg, 3.82 mmol) in THF (5 mL) at room temperature. The reaction mixture was further diluted with THF (20 mL) and after 30 minutes cooled to 0 °C. A
solution of 2-(2-chlorophenylamino)-5-cyano-3,4-difluorobenzoic acid methyl ester (15) (600 mg, 1.86 mmol) in THF (5 mL) was added. The reaction mixture was slowly warmed to room temperature. After 90 minutes, the reaction mixture was quenched with 2o saturated NH4C1 and diluted with EtOAc. The organic layer was washed with saturated NH4Cl and brine, dried (MgS04) and concentrated. The residue (16) was diluted with MeOH (10 mL) and a solution of 2 M HCl in diethyl ether (10 mL) was added. After 16 hours, the reaction mixture was diluted with EtOAc, washed with water, saturated NaHC03 and water. The organic layer was dried (MgS04) and concentrated. Purification by flash column chromatography using the Biotage system (1.5% MeOH in CHzCIz) provided 399 mg (64%) of the desired product (17).
Step C: Preparation of 3-amino-6-(4-bromo-2-chlorophen 1~)-7-fluorobenzo[dlisoxazole-5-carboxylic acid methyl ester (18): Compound 18 was prepared according to Step G of Example 1 using compound 17 as the starting material.
Step D: Preparation of 3-amino-6-(4-bromo-2-chlorophenylamino)-7-fluorobenzofdlisoxazole-5-carboxylic acid (19): Compound 19 was prepared according to Step H of Example 1 using 3-amino-6-(4-bromo-2-chlorophenylamino)-7-fluorobenzo[dJisoxazole-5-carboxylic acid methyl ester (18) as the starting material to provide 188 mg (98% yield) of compound 19. MS APCI (-) m/z 398, 400 (M+, Br, Cl pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.47 (s, 1H), 8.49 (s, 1H), 7.73 (m, 1H), 7.41 (dd, 1H), 6.92 (t, 1H), 6.76 (s, 2H): 19F NMR (376 MHz, DMSO-d6) -141.48 (s).
Example 8 H
HO~O,N O CI
H
N
HzN ~ l / F I ~ Br N-O
Synthesis of 3-amino-6-(4-bromo-2-chloro-phenylamino)-7 fluorobenzo[d]isoxazole-5-carboxylic acid (2-hydroxyethoxy)-amide (21) The reaction scheme for the synthesis of compound 21, as shown in Figure 6, was accomplished according to Steps A and B of Example 3 using 3-amino-6-(4-bromo-2-chlorophenylamino)-7-fluorobenzo[d]isoxazole-5-carboxylic acid (19) as the starting material to provide 16 mg (23% yield for two steps) of compound 21.
MS
APCI (-) m/z 457, 459 (M+, Br, Cl pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 11.92 (s, 1H), 8.59 (s, 1H), 7.94 (s, 1H), 7.69 (s, 1H), 7.36 (d, 1H), 6.75 (dd, 1H), 6.71 (s, 2H), 4.73 (s, 1H), 3.87 (s, 2H), 3.59 (s, 2H): 19F NMR (376 MHz, DMSO-d6) -140.64 (s).
Example 9 HO O
CI
N
N
CI Br N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (30) The reaction scheme for the synthesis of compound 30 is shown in Figure 7.
Step A: Preparation of 4,6-dichloronicotinic acid ethyl ester (22): POC13 (100 mL, 1092 mmol) was added to 4,6-dihydroxynicotinic acid ethyl ester (.I.
Heterocyclic Chem. 1983, 20, 1363) (20.0 g, 109 mmol). The resulting suspension to was cooled to 0 °C and triethylamine (15.2 mL, 109 mmol) was added dropwise at such a rate as to maintain the internal reaction mixture temperature below 25 °C.
Upon completion of addition, the reaction mixture was warmed to room temperature and then to 80 °C. After 4 hours, the reaction mixture was cooled to room temperature and stirred for 16 hours. The reaction mixture was carefully poured onto 2 L crushed ice. The mixture was extracted with EtOAc and diethyl ether. The combined organic extracts were washed with brine, dried (NaZS04) and concentrated.
The dark brown liquid was purified by passing through a plug of silica gel (CHZC12) to give the desired product (22) as a low melting yellow solid (18.7 g, 78%).
Step B: Preparation of 4,6-dichloronicotinic acid (23): Sodium hydroxide (40 2o mL, 6.25 M solution) was added to a stirred solution of 4,6-dichloronicotinic acid ethyl ester (22) (25.95 g, 118 mmol) in 4:1:1 THF/MeOH/water (600 mL). After minutes, the reaction mixture was acidified to pH 2 with concentrated HCI, diluted with 1:1 EtOAc/Et20 and washed with water and brine. The organic layer was dried (Na2S04) and concentrated. The resulting off white solid was twice concentrated from toluene to give the desired product (23) as a white solid (21.73 g, 96%).
Step C: Preparation of 4-(4-bromo-2-chlorophenylamino)-6-chloronicotinic acid hydrochloride salt (24~ LiHMDS (261 mL of a 1 M solution in hexanes) was added dropwise over 30 minutes to a solution of 4-bromo-2-chlorophenylamine (35.0 g, 172 mmol) in THF (80 mL) at -78 °C. After 1 hour, 4,6-dichloronicotinic acid (23) (15.7 g, 81.7 mmol) was added dropwise over 30 minutes. The reaction mixture was slowly warmed to room temperature and stirred 16 hours. The reaction mixture was quenched with water, diluted with EtOAc and acidified with 1 M HCI. The resulting precipitate was isolated by filtration and washed with EtOAc. The solids were twice concentrated from toluene, triturated with CHZC12 and collected by filtration.
The solids were further concentrated from toluene (3x) followed by drying in vacuo to 1o give the desired product (24) containing a small amount of water (36.0 g).
Step D. Preparation of 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid (25): N Chlorosuccinimide was (13.0 g, 99.0 mmol) added to a suspension of 4-(4-bromo-2-chlorophenylamino)-6-chloronicotinic acid (24) (32.54 g, 89.9 mmol) in DMF (500 mL). The suspension was allowed to stir at room temperature overnight. The reaction mixture was diluted with saturated sodium bisulfate (200 mL) and water (1L) resulting in formation of a thick white precipitate which was isolated by filtration and washed with water. The solids were dissolved into THF. Two volumes of diethyl ether were added and the organic solution washed with brine, dried over NaS04, filtered, and concentrated in vacuo to provide an orange 2o solid. The solid was triturated with diethyl ether to provide the desired product as an off white solid (25) (13.34 g, 37%). MS (APCI-) m/z 393, 395, 397 (M-; Cl, Br pattern) detected.
Alternatively, 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid (25) can be synthesized by the route and procedure described below.
~O O ~0 O ~O O
OH NCS ~ OH TEA ~ CI
I I I
NY MeOH NCI POCI3 NCI
IOH OH CI
HO O NHz HO O
NaOH ~ CI LHMDS H CI
CI I ~ N
THF/MeOH N~ ~ THF N~ I i \C1 Br CI Br CI CI
N Chlorosuccinimide (56.5 g, 423 mmol) was added portionwise to a suspension of 4,6-dihydroxynicotinic acid ethyl ester (70.5 g, 385 mmol) in DMF
(705 mL). Concentrated HCl (3.20 mL, 38.5 mmol) was added. After stirnng for 2.5 hours, the product was precipitated with water and Na2Sz03 (70 mL). The slurry was acidified to pH 3 with 2 M HCl (30 mL). 5-Chloro-4,6-dihydroxynicotinic acid ethyl ester, the desired product was isolated as a pale yellow solid (75.7 g, 90%) by filtration. MS ESI (+) m~z 218, 220 (M+, Cl pattern) detected.
to S-(:hloro-4,6-dihydroxynicotinic acid ethyl ester (8.05 g, 37 mmol) was suspended in phosphorous oxychloride (30 mL, 296 mmol). The mixture was cooled to 0 °C and triethylamine (5.16 mL, 37.0 mmol) was added. The reaction was heated to 60 °C for three hours. The solution was cooled to room temperature, poured unto ice,. stirred for 15 minutes and extracted with ethyl acetate (2x) and diethyl ether (lx).
The combined organic extracts were washed with brine (3x), dried over NaZS04 and concentrated to a brown liquid. The crude product was passed through a plug of silica gel eluting with dichloromethane. 4,5,6-Trichloronicotinic acid ethyl ester, the desired product was obtained as a yellow liquid (7.76 g, 82%).
Sodium hydroxide (1.0 M solution, 61.0 mL, 61.0 mmol) was added to a solution of 4,5,6-trichloro-nicotinic acid ethyl ester (7.76 g, 30.5 mmol) in 4:1 THF/MeOH (150 mL). After stirring for 30 minutes, the reaction was acidified to pH
1 by addition of concentrated HCI, diluted with ethyl acetate, washed with water (3x) and brine (2x), dried over NaZSOa and concentrated to provide the desired product, 4,5,6-trichloronicotinic acid, as an off white solid (6.77 g, 98%).
LiHMDS (1.0 M solution in hexanes, 53.0 mL, 53.0 mmol) was added dropwise to a stirred solution of 4-bromo-2-chlorophenylamine (7.10 g, 35.0 mmol) in THF (15 mL) cooled to -78 °C . After one hour, 4,5,6-trichloronicotinic acid (3.73 g, 16.5 mmol) was added dropwise as a solution in THF (12 mL). The reaction was allowed to warm to room temperature slowly while stirring overnight. The suspension was diluted with 1 M HCl and ethyl acetate, and the aqueous phase was extracted with ethyl acetate (3x). The combined organic phases were dried over Na2S04 and concentrated to a tan solid. The solid was triturated with diethyl ether overnight and the solids were isolated by filtration to provide the desired product (25) l0 as a tan-colored solid (4.85 g, 75%). MS APCI (-) m/z 395, 397 (M-, Cl, Br pattern) detected.
Step E. Preparation of 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid methyl ester (26): Trimethylsilyldiazomethane (2.0 M
solution in hexanes, 37 mL, 74 mmol) was added slowly to a suspension of 4-(4-bromo-2-chloro-phenylamino)-5,6-dichloro-nicotinic acid (25) (14.67 g, 37 mmol). After the addition was complete the resulting slurry was diluted with hexanes (600 mL) and the solids isolated by filtration washing with hexanes. The desired product was isolated as an off white solid (10.06 g). The hexanes washes were concentrated and the solids passed through a plug of silica gel eluting with dichloromethane.
Concentration of 2o the product-containing fractions provided an additional 3.83 g desired product (26) for a total of 13.89 g (91 %). MS (APCI+) m/z 409, 411, 413 (M+; Cl, Br pattern) detected.
Step F. Preparation of 6-azido-4-(4-bromo-2-chlorophenylamino)-5-chloronicotinic acid methyl ester (~27): Sodium azide (4.4 g, 68 mmol) was added to a suspension of 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid methyl ester (26) (13.89 g, 33.8 mmol) in DMF (200 mL) and the mixture allowed to stir at room temperature overnight. The solution was diluted with water (600 mL) and the resulting white precipitate was collected by filtration and washed with water.
The solids were dissolved into THF. Two volumes of diethyl ether were added and the organic solution washed with brine, dried over NaS04, filtered, and concentrated in vacuo to the desired product (27) as a light yellow solid ( 12.94 g, 92%).
Step G. Preparation of 6-Amino-4-(~4-bromo-2-chlorophe~lamino)-S-chloro-nicotinic acid methyl ester X28): Zinc powder (10 g, 155 mmol) was added portionwise to a suspension of 6-azido-4-(4-bromo-2-chlorophenylamino)-5-chloronicotinic acid methyl ester (27) (12.94 g, 31 mmol) in 3:1 dichloromethane/acetic acid (300 mL). After fifteen minutes the reaction mixture was poured into 700 mL ethyl acetate, washed with water, saturated sodium bicarbonate and brine. The organic solution was dried over NaS04, filtered, and concentrated in vacuo to provide the desired product (28) as an off white solid (11.85 g, 98%). MS (APCI+) m/z 390, 392, 394 (M+; Cl, Br pattern) detected.
1o Step H. Preparation of 7-(,4-bromo-2-chlorophenylamino)-8-chloroimidazof 1.2-alnvridine-6-carboxylic acid methyl ester (29):
Chloroacetaldehyde (50% aqueous solution, 0.70 mL, 5.7 mmol) was added to a suspension of 6-amino-4-(4-bromo-2-chlorophenylamino)-5-chloronicotinic acid methyl ester (28) in DMF (7 mL) contained in a sealed tube. The reaction mixture was heated at 80°C for four hours and then allowed to cool to room temperature and stir overnight. The dark brown solution was diluted with water (70 mL) the resulting light brown precipitate was collected by filtration and washed with water. The solids were dissolved into THF. Two volumes of ethyl acetate were added and the organic solution washed with brine, dried over NaS04, filtered, and concentrated in vacuo to provide a brown solid. The aqueous filtrate was extracted with ethyl acetate and the organic extracts were dried over NaS04, filtered, and concentrated in vacuo.
This material was combined with the previously isolated brown solid and the combined material subjected to column chromatography (dichloromethane, followed by 20:1 dichloromethane/methanol). The desired product (29) was isolated as a light yellow solid (0.752 g, 64%). MS (APCI+) m/z 414, 416, 418 (M+; Cl, Br pattern) detected.
Step I. Preparation of 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-alpyridine-6-carboxylic acid (30): Sodium hydroxide (1.0 M
aqueous solution, 14.6 mL, 14.6 mmol) was added to a solution of 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (29) in methanol (30 mL) and the solution allowed to stir at room temperature overnight. Methanol was removed by rotary evaporation and the solution diluted with water and acidified to pH 2 by addition of 1.0 M HCI. The aqueous suspension was extracted with 4:1 ethyl acetate/THF. The organic extracts were washed with brine, dried over NaS04, filtered, and concentrated in vacuo to provide the desired product as a light orange solid (30). MS (APCI+) m/z 400, 402, 404 (M+: Cl, Br pattern) detected. 'H NMR (400 MHz, methanol-d4) 8 9.01 (s, 1H), 7.83 (s, 1H), 7.51 (s, 2H), 7.25 (d, 1H), 6.60 (d, 1H).
The following compounds were synthesized in a similar manner as shown in Figure 7.
HO O CI
H
N
N I I /
~ ~CI CI
N
8-Chloro-7-(2,4-dichlorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 356, 358 (M+, Cl pattern) detected. 1H NMR (400 MHz, CD30D) 8 9.16 (s, 1 H), 8.00 (d, 1 H), 7.72 (d, 1 H), 7.51 (d, 1 H), 7.25 (dd, 1 H), 7.02 (d, 1 H).
HO O
H
N
N
~ ~CI I
~N
8-Chloro-7-(2-fluoro-4-iodophenylamino)-imidazo(1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 432, 434 (M+, C1 pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.31 (s, 1H), 8.11 (s, 1H), 7.71 (s, 1H), 7.61 (d, 1H), 7.37 (d, 1H), 6.62 (t, 1 H).
HO O
F
H
N
N I I ~
CI ~ F
8-Chloro-7-(2,4-difluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 324, 326 (M+, Cl pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 9.27 (s, 1 H), 8.06 (s, 1 H), 7.65 (s, 1 H), 7.29 (t, 1 H), 6.96 (m, 2H). ' 9F
(376 MHz, DMSO-d6) -118.9 (s), -124.8 (s).
HO O
H
N
N I I ~
~~ CI ~ Br 7-(4-Bromo-2-methylphenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid to MS APCI (+) m/z 380, 382 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 9.31 (s, 1H), 8.09 (s, 1H), 7.69 (s, 1H), 7.42 (s, 1H), 7.24 (d, 1H), 6.64 (d, 1H), 2.28 (s, 3H).
Example 10 Me O CI
H
N
N
c ~CI Br ~N
1-(7-(4-Bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridin-6-yl]-ethanone This compound is prepared from compound 29, the product of Example 9, Step H. Tebbe reagent (p-chloro-p-2o methylene[bis(cyclopentadienyl)titanium]dimethyl-aluminum, 1 M solution in toluene, 0.12 mL, 0.12 mmol) was added to a solution of 7-(4-bromo-2-chloro-phenylamino)-8-chloro-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (29) (25 mg, 0.061 mmol) in THF (1 mL) cooled to 0 °C. The reaction mixture was warmed to room temperature and stirred for 1.5 hours. HCl (10% aqueous solution, 1 mL) was added and the mixture stirred for 16 hours. The reaction was diluted with ethyl acetate, washed with saturated aqueous sodium carbonate, dried over MgS04, and concentrated. The crude material was purified by flash column chromoatography (dichloromethane to 100:1 dichloromethane/methanol) to provide the desired product (6.8 mg, 28%). MS APCI (-) m/z 396, 398, 400 (M-, Cl, Br pattern) detected. 'H
NMR (400 MHz, CDC13) 8 9.05 (br s, 1H), 8.81 (s, 1H), 7.71 (s, 2H), 7.55 (d, 1H), 7.22 (dd, 1H), 6.55 (d, 1H), 2.67 (s, 3H).
Example 11 H
HO~O,N O CI
H
N
N
Br~~ ~CI Br N
3-Bromo-7-(4-bromo-2-chlorophenylamino)-8-chloro-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide The reaction scheme for the synthesis of this compound is shown below.
O O O O HO O
H CI NBS / H CI NaOH H CI
N ~ ~ , N ~ ~ / N
I
\'I I \ I
~ CI ~ gr CHC13 Br~ CI ~ gr MeOH gr~ CI ~ Br N N N
H H
~O~O.NHZ ~O~O.N O H CI HCI HO~O-N O H CI
N N
EDCI, HOBt N I I , MeOH N
DIEA, DMF Br'~ ~ ~CI Br Br'~ ~ ~CI Br ~N ~N
Step A: Pre,~aration of 3-bromo-7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo~l 2-a~pyridine-6-carboxylic acid methyl ester. N
bromosuccinimide (14 mg, 0.080 mmol) was added to a solution of 7-(4-bromo-2-chlorophenylamino)-chloroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (30 mg, 0.072 mmol) in chloroform (1.0 mL). After stirnng for five hours the reaction was diluted with ethyl acetate, washed with NaHS03, brine, dried over NaZS04, and concentrated to a yellow solid (33 mg, 92%). MS APCI (+) m/z 494, 496, 498 (M+, Cl, Br pattern) detected.
1H NMR (400 MHz, CDCl3) 8 8.82 (s, 1H), 8.65 (s, 1H), 7.67 (s, 1H), 7.55 (dd, 1H), 7.22 (dd, 1H), 6.53 (d, 1H), 3.98 (s, 3H).
Step B: Preparation of 3-bromo-7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo~l2-a~pyridine-6-carboxylic acid 2-hydroxyethoxy)-amide. The synthesis of the title compound was carned out according to Step H of Example 1 and Steps A and B of Example 3 using 3-bromo-?-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester as the starting material to provide 20 mg of desired product as a light yellow solid. MS APCI (+) m/z 539, 541, 543 (M+, Cl, Br pattern) detected.
2p , Example 12 H
~O~ N O H CI
N
N
'CI Br N
7-(4-Bromo-2-chlorophenylamino)-8-chloro-3-methyl-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxy-amide The reaction scheme for the synthesis of this compound is shown below.
\\1DE - 80248/0026 - 214630 v1 O O
HO O CI ~ N CI OH
O ~ ~ ~ ~NHz TEA
ACN
+ ~H~N~ THF N ~ I CI I ~ Br ~CI Br CI
CI
O O ~O O CI
CI TPAP I ~ N ~ H SO
NMO ~ I z a N~ ~. --, NCI ~ Br ACN ~NH CI Br HO' vNH O
H
HO O CI EDCI ~O.N O H CI
HOBt N ~ I CI I ~ Br NHz TEA ~ ~ CI ~ Br ~N DMF N
Step A: Preparation of 4-(4-bromo-2-chlorophen~amino)-5,6-dichloronicotinic acid tert-butyl ester. 2-tent-Butyl-1,3-diisopropyl-isourea (10.6 g, 53 mmol) was added to a solution of 4-(4-bromo-2-chloro-phenylamino)-5,6-dichloro-nicotinic acid (4.21 g, 10.6 mmol) in THF (200 mL). The reaction was heated to reflux. After 30 minutes the reaction was cooled to room temperature and diluted with EtOAc. The organic layer was washed with saturated K2C03 (2x), brine, dried to over Na2SOa and concentrated. The yellow solid was triturated with dichloromethane and white solids were removed by filtration. The filtrate was concentrated in vacuo to yield the desired product as a yellow solid (5.53 g, 97%). MS APCI (-) m/z 451, 453 (M-, Cl, Br pattern) detected.
Step B: Preparation of 4-(4-bromo-2-chlorophenylamino)-5-chloro-6-(2-h~droxypropylamino)-nicotinic acid tent-but, l~. 1-Amino-propan-2-of (2.44 g, 30.3 mmol) and triethylamine (0.42 mL, 3.03 mmol) were added to a solution of 4-(4-bromo-2-chlorophenylamino)-5,6-dichloro-nicotinic acid tert-butyl ester (1.37 g, 3.03 mmol) in acetonitrile (30 mL). The reaction was heated to reflux. After 23 hours the reaction was cooled to room temperature and diluted with EtOAc, washed with saturated NaHC03, water, brine, dried over Na2S04 and concentrated to a white solid.
Purification by flash column chromatography (20:1 dichloromethane/methanol) provided the desired product as a white solid (1.11 g, 75%). MS APCI (+) m/z 492, 494 (M+, Cl, Br pattern) detected.
Step C: Preparation of 4-(4-bromo-2-chlorophenylamino)-5-chloro-6-(2-oxopropylamino~-nicotinic acid tert-butyl ester. To a solution of 4-(4-bromo-2-chlorophenylamino)-5-chloro-6-(2-hydroxypropylamino)-nicotinic acid tent-butyl ester (0.28 g, 0.57 mmol) in acetonitrile (1.1 mL) was added 4~ molecular sieves and N methylmorpholine (0.10 g, 0.85 mmol). The mixture was cooled to 0 °C and 1o tetrapropylammonium perruthenate (0.030 g, 0.085 mmol) was added. After stirnng for one hour, the reaction was filtered through a plug of silica gel, washing with EtOAc. The filtrate was concentrated. Purification by flash column chromatography (20:1 hexanes/ethyl acetate) provided the desired product as a white solid (86 mg, 31 %). MS APCI (+) m/z 490, 492 (M+, Cl, Br pattern) detected.
Step D: Preparation of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methyl-imidazo[1,2-a]pyridine-6-carboxylic acid. 4-(4-Bromo-2-chlorophenylamino)-5-chloro-6-(2-oxopropylamino)-nicotinic acid tert-butyl ester (0.075 g, 0.15 mmol) was dissolved into concentrated HZS04 (0.50 mL). After ten minutes, ice and water were and the mixture was stirred for ten minutes. The mixture was diluted with EtOAc, neutralized with 1 M NaOH, washed with brine, dried over NazS04 and concentrated to provide the desired product as an off white solid. MS APCI (+) m/z 416, 418 (M+, Cl, Br pattern) detected.
Step E: Preparation of 7-(4bBromo-2-chlorophenylamino)-8-chloro-3-methvlimidazof 1.2-alnvridine-6-carboxylic acid cvclonronvlmethoxv-amide. The synthesis of the title compound was carried out according to Example 2 using 7-(4 bromo-2-chlorophenylamino)-8-chloro-3-methylimidazo[ 1,2-a]pyridine-6-carboxylic acid as the starting material to provide 8 mg (18%) of desired product as a yellow solid. MS APCI (+) m/z 485, 487 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, CDC13) 8 8.68 (s, 1H), 7.72 (m, 1H), 7.54 (m, 1H), 7.20 (dd, 1H), 6.42 (d, 1H), 3.58 (d, 2H), 2.57 (s, 3H), 0.64 (m, 1H), 0.57 (m, 2H), 0.23 (m, 2H).
Example 13 H
~O~N O H CI
N
N
'CI Br N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (31) Figure 8 shows the reaction scheme for the synthesis of compound 31, which was prepared according to the method of Example 2, using 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (30) as the to starting material to provide 4.1 g (53% yield) of compound 31. MS (APCI-) m/z 467, 469, 471 (M-: Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) 8 8.76 (s, 1H), 7.95 (d; 1H), 7.64 (d, 1H), 7.56 (d, 1H), 7.26 (dd, 1H), 6.56 (d, 1H), 3.57 (d, 2H), 1.10 (m, 1 H), 0.54 (m, 2H), 0.24 (m, 2H).
The following compounds were synthesized in a similar manner as shown in Figure 7, 8, and 9 using the appropriate aniline in Step C of Example 9.
H
~O. N O F
H
N
N
~CI Br N
7-(4-Bromo-2-fluorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide 2o MS ESI (+) m/z 453, 455, 457 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) 8 8.70 (s, 1 H), 7.95 (s, 1 H), 7.67 (s, 1 H), 7.34 (m, 1 H), 7.20 (m, 1 H), 6.79 (m, 1H), 3.49 (m, 2H), 1.08 (m, 1H), 0.55 (m, 2H), 0.26 (m, 2H). 19F NMR
(376 MHz, CD30D) 8 -127.4.
H
~O. N O
H
N
N
~ ~CI
N
8-chloro-7-(2-fluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxy-amide MS ESI (+) m/z 375, 377 (M+, Cl pattern) detected. 'H NMR (400 MHz, CD30D) b 8.70 (s, 1 H), 7.91 (s, 1 H), 7.60 (s, 1 H), 7.09 (m, 1 H), 7.00 (m, 1 H), 6.95 (m, 1H), 6.77 (m, 1H), 3.47 (d, 2H), 1.05 (m, 1H), 0.51 (m, 2H), 0.22 (m, 2H).
NMR (376 MHz, CD30D) 8 -132.1.
H
HO~O,N O
H
N
N
~CI Br N
7-(4-bromo-2-fluorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide MS ESI (+) m/z 443, 445, 447 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) b 8.74 (s, 1H), 7.91 (s, 1H), 7.61 (s, 1H), 7.32 (m, 1H), 7.16 (m, 1H), 6.68 (m, 1H), 3.84 (t, 2H), 3.66 (t, 2H). 19F NMR (376 MHz, CD30D) S -128.9.
H
HO~O,N O
H
N
N I I ~
~~ ~CI
N
8-Chloro-7-(2-fluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide MS ESI (+) m/z 365, 367 (M+, Cl pattern) detected. 'H NMR (400 MHz, CD30D) 8 8.73 (s, 1H), 7.89 (s, 1H), 7.59 (s, 1H), 7.10 (m, 1H), 7.00 (m, 1H), 6.94 (m, 1H), 6.77 (m, 1H), 3.78 (t, 2H), 3.62 (t, 2H). '9F NMR (376 MHz, CD30D) 8 -131.9.
H
HO~O.N O H CI
N
I~
~CI CI
io 8-chloro-7-(2,4-dichlorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy) amide MS APCI (-) m/z 413, 415, 417 (M-, Cl pattern) detected. 'H NMR (400 MHz, CD30D) 8 8.78 (s, 1H), 7.90 (s, 1H), 7.87 (s, 1H), 7.10 (dd, 1H), 6.61 (d, 1H), 4.0 (m, 2H), 3.72 (m, 2H).
HO OH F
/~N~~
C1 Br N
7-(4-Bromo-2-fluorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid MS ESI (+) m/z 384, 386, 388 (M+, C1, Br pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 9.29 (s, 1H), 8.10 (s, 1H), 7.68 (s, 1H), 7.53 (m, 1H), 7.23 (m, 1H), 6.75 (m, 1H). 19F NMR (376 MHz, DMSO-d6) 8-127.9.
HO O H F
N
CI
l0 8-Chloro-7-(2-fluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid MS ESI (+) m/z 306, 308 (M+, Cl pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 9.30 (s, 1H), 8.09 (s, 1H), 7.67 (s, 1H), 7.22 (dd, 1H), 7.06 (dd, 1H), 6.98 (m, 1H), 6.84 (m, 1H). 19F NMR (376 MHz, DMSO-d6) b-130.5.
HO O
H
N
N
~ ~CI CI
N
8-Chloro-7-(4-chloro-2-fluorophenylamino)-imidazo[1,2-aJpyridine-6-carboxylic acid MS ESI (+) m/z 340, 342 (M+, Cl pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.29 (s, 1H), 8.10 (s, 1H). 7.68 (s, 1H), 7.43 (m, 1H), 7.12 (m, 1H), 6.83 (m, 1H). 19F NMR (376 MHz, DMSO-d6) 8 -127.8.
H
~O. N O F
H
N
N
~CI CI
N
8-Chloro-7-(4-chloro-2-fluorophenylamino)-imidazo(1,2-aJpyridine-6-carboxylic acid cyclopropylmethoxyamide MS ESI (+) m/z 409, 411 (M+, Cl pattern) detected. 1H NMR (400 MHz, CD30D) 8 9.97 (br s, 1 H), 8.82 (s, 1 H). 7.73 (s, 1 H), 7.71 (s, 1 H), 7.18 (m, 1 H), 6.97 (m, 1 H), 6.56 (m, 1 H), 6.47 (br s, 1 H), 3.60 (m, 2H), 1.00 (m, 1 H), 0. S 6 (m, 2H), 0.24 (m, 2H). 19F NMR (376 MHz, CD30D) b-128.7.
Example 14 H
HO~O, N O H CI
N
N
~ 'CI Br N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide (33a) The reaction scheme for the synthesis of compound 33a is shown in Figure 9, which was prepared according to Steps A and B of Example 3 using 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (30) to provide 44 mg (40% yield for two steps) of the desired.product. MS (APCI+) m/z l0 459, 461, 463 (M+: Cl, Br pattern) detected. 1H NMR (400 MHz, methanol-d4) 8 8.90 (s, 1H), 8.08 (s, 1H), 7.93 (s, 1H), 7.69 (s, 1H), 7.45, (d, 1H), 7.06 (m, 1H), 3.86 (br s, 2H), 3.72 (br s, 2H).
Example 15 H
~O.N ~ H CI
N ~ N
' N~~CI Br ~5 N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-(4-methylpiperazin-1-yl)-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (36) The reaction scheme for the synthesis of compound 36 is shown in Figure 10.
20 Step A:. 7-(4-Bromo-2-chlorophenylamino)-8-chloro-3-(4-methylpiperazin-1-y1)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (34): Preparation was accomplished by modification of the procedure of Katritzky et al. (J. Org.
Chem., 2003, 68, 4935-4937: .l. Org. Chem., 1990, 55, 3209-3213).
Bis(benzotriazazole) adduct (formed with 1-methylpiperazine) (106 mg, 0.230 mmol) was added to a suspension of 6-amino-4-(4-bromo-2-chlorophenylamino)-5-chloronicotinic acid methyl ester (28) (30 mg, 0.076 mmol) in dichloroethylene (1 mL) followed by the addition of ZnBrz (52 mg, 0.230 mmol). The reaction mixture was stirred at reflux for hours and then at room temperature for 16 hours. The reaction mixture was diluted with CHZCl2 and filtered. The filtrate was washed with water. The aqueous layer was extracted with CHZC12. The combined organic extracts were washed with brine, dried (NazS04) and concentrated. Purification by flash column chromatography using the 10 Biotage system (60:1 CHZCI2iMeOH) provided the desired product (34) as a yellow solid (31 mg, 79%).
Step B: 7-(4-Bromo-2-chlorophe~lamino)-8-chloro-3~4-meth~piperazin-1-yl -imidazo[1,2-a]pyridine-6-carboxylic acid cyclopr~ylmethoxyamide (36):
Sodium hydroxide (59 p,L, 1 M solution) was added to a suspension of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-(4-methylpiperazin-1-yl)-imidazo[1,2-a]pyridine-carboxylic acid methyl ester (34) in MeOH (1 mL). After stirnng 18 hours, the reaction mixture was concentrated to dryness. The residue (35) was diluted with toluene and concentrated (repeated), and 31 mg of the recovered yellow residue (35) was carried forward without purification. The residue (35) was suspended in (1 mL), cooled to 0 °C and oxalyl chloride (150 ~,L of a 2 M solution in CHZC12) was added. One drop of DMF was added and the reaction mixture warmed to room temperature. After 10 minutes, concentration of the mixture was followed by concentrating from toluene twice and then drying in vacuo. The resulting yellow solid was suspended in CHZC12 (1 mL), cooled to 0 °C and cyclopropylmethylhydroxylamine (16 mg, 0.180 mmol) was added. After the reaction mixture was warmed to room temperature and stirred for 16 hours, it was diluted with EtOAc. The organic layer was washed with saturated NaHC03 and brine, dried (Na2S04) and concentrated. Purification by flash column chromatography using the Biotage system (15:1 CHzCl2/MeOH) provided the desired 3o product (36) as a pale yellow solid (12 mg, 37%). MS ESI (+) m/z 567, 569, (M+, Cl, Br pattern) detected. 'H NMR (400 MHz, CD30D) S 8.35 (s, 1H), 7.55 (d, 1 H), 7.3 8 (s, 1 H), 7.25 (dd, 1 H), 6. S 4 (d, 1 H), 3 . 5 9 (d, 2H), 3 .17 (t, 4H), 2. 74 (m, 4H), 2.43 (s, 3H), 1.09 (m, 1H), 0.54 (m, 2H), 0.24 (m, 2H).
Example 16 H
~O'N ~ H CI
N
I~
~N-~ N CI Br Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-morpholin-4-yl-imidazo(1,2-a]-pyridine-6-carboxylic acid cyclopropylmethoxyamide (37) The reaction scheme for the synthesis of compound 37 is shown in Figure 10.
1o Compound 37 was prepared according to Steps A and B of Example 15 using 6-amino-4-(4-bromo-2-chlorophenylamino)-5-chloronicotinic acid methyl ester (28) and the bis(benzotriazazole) adduct (formed with morpholine) to provide 2 mg (8%
yield for two steps) of the desired product (37). MS ESI (+) m/z 554, 556, 558 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) b 8.41 (s, 1H), 7.55 (d, 1H), is 7.38 (s, 1H), 7.26 (dd, 1H), 6.54 (d, 1H), 3.91 (t, 4H), 3.59 (d, 2H), 3.11 (t, 4H), 1.08 (m, 1H), 0.54 (m, 2H), 0.24 (m, 2H).
Example 17 H
~O'N O H CI
N
NT
N-~ ~ CI Br N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-dimethylaminoimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (38) The reaction scheme for the synthesis of compound 38 is shown in Figure 10.
Compound 38 was prepared according to Steps A and B of Example 15 using 6-amino-4-(4-bromo-2-chlorophenylamino)-5-chloronicotinic acid methyl ester (28) and the bis(benzotriazazole) adduct (formed with dimethylamine) providing 16 mg (37% yield for two steps) of the desired product (38). MS ESI (+) m/z 512, 514, 516 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) 8 8.37 (s, 1H), 7.54 (d, 1H), 7.30 (s, 1H), 7.24 (dd, 1H), 6.52 (d, 1H), 3.59 (d, 2H), 2.86 (s, 6H), 1.07 (m, 1H), 0.53 (m, 2H), 0.23 (m, 2H).
Example 18 H
HO~O.N O H CI
N
N~ I i N~N CI Br Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-piperidin-1-ylmethylimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy) amide (39) The reaction scheme for the synthesis of compound 39 is shown in Figure 11.
Compound 39 was prepared by a modification of the procedure of T. Kercher et al.
(manuscript in preparation). Piperidine (4 p,L, 0.043 mmol) and 37% aqueous formaldehyde (5 ~,L, 0.065 mmol) were dissolved in 6:1 MeCN/water (0.5 ml), and stirred 30 minutes. 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)amide (33a) (10 mg, 0.022 mmol) was added followed by scandium triflate (1 mg, 0.002 mmol). After stirring 16 hours, additional scandium triflate (1 mg), piperidine (3.8 ~,L) and aqueous formaldehyde (3.8 ~,L) were added. After about 60 hours, the reaction mixture was diluted with EtOAc and washed with water, 10% K2C03, and brine. The organic layer was dried (NaZS04) and concentrated. Purification by flash column chromatography using the Biotage system (40:1 CHZCl2/MeOH to 20:1 CHZC12/MeOH to 9:1 CHZCIZ:MeOH) provided the desired product (39) as a white solid (6 mg, 50%). MS APCI (+) m/z 556, 558, 560 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) b 8.83 (s, 1H), 7.56 (s, 1H), 7.54 (s, 1H), 7.27 (dd, 1H), 6.56 (d, 1H), 3.91 (m, 4H), 3.70 (m, 2H), 2.51 (broad s, 4H), 1.60 (broad s, 4H), 1.50 (broad s, 2H).
The following compounds were synthesized in a similar manner as shown in Figure 11.
H
~O~ N O H CI
N
N
~CI Br N~N
O
7-(4-Bromo-2-chlorophenylamino)-8-chloro-3-morpholin-4-ylmethyl-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxy-amide The reaction scheme for the synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-morpholin-4-ylmethylimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxy-amide is similar to that shown in Figure 11 using 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)amide (33a) and morpholine to provide the desired product. MS
APCI (+) m/z 568, 570, 572 (M+, Cl, Br pattern) detected; 'H NMR (400 MHz, CDC13) 8 8.76 (s, 1H), 8.04 (s, 1H), 7.56 (d, 1H), 7.21 (dd, 1H), 6.68 (d, 1H), 4.51 (s, 2H), 4.00 (m, 4H), 3.78 (d, 2H), 1.68 (m, 1H), 0.56 (m, 2H), 0.26 (m, 2H).
H
~O~ N O H CI
N
N
~CI Br ~N~N
7-(4-Bromo-2-chlorophenylamino)-8-chloro-3-dimethylaminomethylimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide The reaction scheme for the synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-dimethylaminomethylimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide was similar to that shown in Figure 11, using 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)amide (33a) and dimethylamine to provide the desired product. MS
APCI (+) m/z 528, 530, 532 (M+, Cl, Br pattern) detected; 1H NMR (400 MHz, 1o CD30D) 8 8.71 (s, 1H), 7.50 (d, 1H), 7.44 (s, 1H), 7.20 (dd, 1H), 6.55 (d, 1H), 3.80 (s, 2H), 3.74 (d, 2H), 2.04 (s, 6H), 1.18 (m, 1H), 0.51 (m, 2H), 0.27 (m, 2H).
H
~O~ N O H ' CI
V N
N
~CI Br ~N~N
N--/
~O~
\\O
4-[7-(4-Bromo-2-chlorophenylamino)-8-chloro-6-cyclopropylmethoxycarbamoylimidazo[1,2-a]pyridin-3-ylmethyl]-piperazine-1-carboxylic acid tert-butyl ester The reaction scheme for the synthesis of 4-[7-(4-bromo-2-chlorophenylamino)-8-chloro-6-cyclopropylinethoxycarbamoylimidazo[ 1,2-a]pyridin-3-ylmethyl]-piperazine-1-carboxylic acid tert-butyl ester was similar to that 2o shown in Figure 11, using 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)amide (33a) and piperazine-1-carboxylic acid tert-butyl ester to provide the desired product. MS APCI (+) m/z 669, 671, 673 (M+, Cl, Br pattern) detected; 1H NMR (400 MHz, CDCl3) 8 8.80 (s, 1H), 8.00 (s, 1H), 7.56 (d, 1H), 7.27 (dd, 1H), 6.67 (d, 1H), 4.54 (s, 2H), 3.76 (d, 4H), 3.27 (m, 4H), 1.50 (s, 9H), 1.12 (m, 1H), 0.55 (m, 2H), 0.28 (m, 2H).
H
~O~N O H CI
N
N
~CI Br ~N~N
N
7-(4-Bromo-Z-chlorophenylamino)-8-chloro-3-(4-methylpiperazin-1-ylmethyl)-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide The reaction scheme for the synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-(4-methylpiperazin-1-ylinethyl)-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide was similar to that shown in Figure 11 using 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)amide (33a) and 1-methylpiperazine to provide the desired product.
MS APCI (+) m/z 581, 583, 585 (M+, Cl, Br pattern) detected; 1H NMR (400 MHz, CDCl3) 8 8.90 (s, 1H), 7.57 (s, 1H), 7.56 (d, 1H), 7.22 (dd, 1H), 6.47 (d, 1H), 3.83 (s, 2H), 3.60 (d, 2H), 2.47 (m, 8H), 2.31 (s, 3H), 1.02 (m, 1H), 0.56 (m, 2H), 0.26 (m, 2H).
H
~O. N O F
H
N
N
~ ~F Br N '=N
O
7-(4-Bromo-2-fluorophenylamino)-8-tluoro-3-morpholin-4-ylmethylimidazo[1,2-a]pyridine-6-carboxylic acid ethoxyamide The reaction scheme for the synthesis of 7-(4-bromo-2-fluorophenylamino)-8-fluoro-3-morpholin-4-ylmethyl-imidazo[1,2-a]pyridine-6-carboxylic acid ethoxy-amide is similar to that shown in Figure 11 using 7-(4-bromo-2-fluoro-phenylamino)-8-fluoro-imidazo[1,2-a]pyridine-6-carboxylic acid ethoxyamide and morpholine to provide the desired product. MS ESI (+) m/z 510, 512 (M+, Br pattern) detected. 'H
NMR (400 MHz, CD30D) 8 8.72 (s, 1H), 7.39 (s, 1H), 7.29 (dd, 1H), 7.1? (d, 1H), 6.76 (m, 1H), 3.99 (q, 2H), 3.85 (s, 2H), 3.68 (m, 4H), 2.49 (br s, 4H), 1.29 (t, 3H).
19F NMR (376 MHz, CD30D) -129.97 (s, 1F), -142.85 (s, 1F).
1o Example 19 H
~O.N O H Cl N
I~
Br Synthesis of 7-(4-bromo-2-chlorophenylamino)-imidazo(1,2-a] pyridine-6-carboxylic acid cyclopropylmethoxyamide (44a) The reaction scheme for the synthesis of compound 44a is shown in Figure 12.
Step A: Preparation of 4-f~.4-bromo-2-chlorophenylamino)-6-chloronicotinic acid tent-butyl ester (40): 2-tent-Butyl-1,3-diisopropylisourea (8.04 g, 40.1 mmol) was added to a suspension of 4-(4-bromo-2-chlorophenylamino)-6-chloronicotinic acid hydrochloride salt (24) (2.91 g, 7.31 mmol) in THF (165 mL). After stirnng for hours at room temperature and 30 minutes at reflux, the reaction mixture was cooled to room temperature and diluted with EtOAc. The organic layer was washed with 10% KZC03 and brine, dried (NaZS04) and concentrated. The resulting residue was dissolved in CHZC12 and filtered. The filtrate was concentrated and purified by flash column chromatography using the Biotage system (CHZCl2) to give the desired product (40) (3.28 g, 78%).
Step B: Preparation of 6-azido-4~4-bromo-2-chlorophenyl-amino)nicotinic acid tert-butyl ester (41): Sodium azide (1.51 g, 23.2 mmol) was added to a mixture of 4-(4-bromo-2-chlorophenylamino)-6-chloronicotinic acid tert-butyl ester (40) (3.23 g, 7.73 mmol) in DMF (60 mL). The reaction mixture was heated to 80 °C
and stirred for 16 hours. After cooling to room temperature, the reaction was diluted with EtOAc and washed with water, saturated NaHC03 and brine. The organic layer was dried (NaZS04) and concentrated. Purification by flash column chromatography using the Biotage system (CHZC12) (repeated) provided the desired product (41) (1.41 g, 43%).
Step C: Preparation of 6-amino-4-(4-bromo-2-chlorophenylamino)-nicotinic acid tert-butyl ester (42): Compound 42 was prepared as described in Step G of 1o Example 9 using 6-azido-4-(4-bromo-2-chlorophenylamino)nicotinic acid tert-butyl ester (41 ).
Step D: Preparation of 7-(4-bromo-2-chlorophenylamino)imidazo[1,2-alpyridine-6-carboxylic acid (43): Chloroacetaldehyde (12 ~.L, 0.188 mmol) was added to a mixture of 6-amino-4-(4-bromo-2-chlorophenylamino)-nicotinic acid tert-butyl ester (42) (50 mg, 0.125 mmol) in EtOH (630 ~,L). After stirnng the reaction mixture at 80 °C for 5 hours, an additional 12 ~.L of chloroacetaldehyde were added and heating was continued for 10 hours. The reaction mixture was cooled to room temperature and diluted with EtOAc to give a cloudy semi-solution. The ~
organic layer was washed with water, saturated NaHC03 and brine. The organic layer 2o contains a precipitate, which was collected by filtration to give the desired product (43) (15 mg, 33%). MS APCI (-) m/z 364, 366, (M-, Cl, Br pattern) detected. 'H
NMR (400 MHz, DMSO-d6) 8 9.12 (s, 1H), 8.31 (s, 1H), 7.91 (s, 1H), 7.80 (s, 1H), 7.65-7.54 (m, 2H), 6.91 (s, 1H).
Step E: Preparation of 7-144-bromo-2-chlorophen~rlamino -imidazo[1,2-a]pyridine-6-carboxylic acid cyclopro~ylmethoxyamide (44a): Oxalyl chloride (2.0 M solution in CHzCl2, 102 ~,L) was added to a stirred suspension of 7-(4-bromo-chlorophenylamino)imidazo[1,2-a]pyridine-6-carboxylic acid (43) (15 mg, 0.041 mmol) in CHZC12 (1 mL) at 0 °C. One drop of DMF was added. The reaction mixture was warmed to room temperature, stirred for 25 minutes, and then concentrated.
The 3o residue was twice concentrated from toluene and dried in vacuo. The residue was suspended in CHZC12 (1 mL), cooled to 0 °C and cyclopropylmethylhydroxylamine (36 mg, 0.409 mmol) was added. The reaction mixture was warmed to room temperature, stirred for 2 hours and diluted with EtOAc. The organic layer was washed with saturated NaHC03 and brine, dried (Na2S04) and concentrated.
Purification by flash column chromatography using the Biotage system (40:1 CH2Clz/MeOH to 20:1 CHZCIz/MeOH) provided the desired product (44a) as a tan solid (6 mg, 31%). MS APCI (-) m/z 433, 435 (M-, Cl, Br pattern) detected. 'H
NMR
(400 MHz, CDC13) b 8.68 (s, 1H), 7.69 (m, 1H), 7.67 (d, 1H), 7.52-7.44 (m, 3H), 7.08 (s, 1H), 3.83 (d, 2H), 0.90 (m, 1H), 0.62 (m, 2H), 0.35 (m, 2H).
The following compounds were synthesized in a similar manner as shown in 1o Figure 12 using the appropriate aniline in Step C of Example 9.
HO O
H
N
N I I /
Br N
7-(4-Bromo-2-fluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid MS ESI (+) m/z 350, 352 (M+, Br pattern) detected. (400 MHz, DMSO-d6) 8 9.13 (s, 1 H), 7.94 (d, 1 H). 7.70 (dd, 1 H), 7.67 (d, 1 H), 7.59 (t, 1 H), 7.47 (m, 1 H), 6.84 (s, 1H). '9F NMR (376 MHz, DMSO-d6) 8 -128.9.
H
~O. N O F
H
N
N
Br N
7-(4-Bromo-2-Iluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide MS ESI (+) m/z 419, 421 (M+, Br pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 11.91 (br s, 1H), 8.79 (s, 1H), 8.72 (br s, 1H), 7.81 (s, 2H), 7.64 (m, 1 H), 7.50 (m, 1 H), 7.45 (m, 1 H), 7.3 9 (m, 1 H), 6.90 (s, 1 H), 3.74 (d, 2H), 1.14 (m, 1H), 0.55 (m, 2H), 0.29 (m, 2H). 19F NMR (376 MHz, DMSO-d6~ 8 -124.3.
H
HO~O,N O
H
N
N I I /
~~ Br '-N
7-(4-bromo-2-fluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide MS ESI (+) m/z 409, 411 (M+, Br pattern) detected. 1H NMR (400 MHz, DMSO-d6) b 12.02 (br s, 1H), 8.83 (s, 1H), 7.80 (s, 1H), 7.63 (s, 1H), 7.51 (m, 1H), 7.45 (m, 1H), 7.39 (m, 1H), 6.91 (s, 1H), 4.79 (br s, 1H), 3.94 (t, 2H), 3.64 (t, 2H).
19F NMR (376 MHz, DMSO-d6) 8 -124.4.
Example 20 H
~O.N ~ H CI
N
I~
~F Br Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (47a) The reaction scheme for the synthesis of compound 47a is shown in Figure 13.
Step A: Preparation of 6-amino-4-(4-bromo-2-chlorophenylamino)-5-fluoronicotinic acid tert-butyl ester (45~: 1-Chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (889 mg, 2.508 mmol) was added to a mixture of 6-amino-4-(4-bromo-2-chlorophenylamino)nicotinic acid tert-butyl ester (42) (1.00 g, 2.51 mmol) in 1:1 MeOH/water (25 mL). After about 2 hours, the reaction mixture was diluted with EtOAc and water. The layers were separated and the organic layer washed with 0.5 N HCl and brine. The aqueous washes were back extracted with EtOAc. The combined organic extracts were dried (Na2S04) and concentrated. Purification by flash column chromatography using the Biotage system (20:1 hexanes/EtOAc to 15:1 hexanes/EtOAc) provided the desired product (45) as a yellow solid (75 mg, 7%).
Step B: Preparation of 7-(4-bromo-2-chlorophen lay mino)-8-io fluoroimidazo[1,2-a]pyridine-6-carboxylic acid (46): Chloroacetaldehyde (23 ~,L, 0.360 mmol) was added to a mixture of 6-amino-4-(4-bromo-2-chlorophenylamino)-5-fluoronicotinic acid tert-butyl ester (45) (75 mg, 0.180 mmol) in EtOH (1 mL).
After stirring the reaction mixture at 70 °C for 10 hours, an additional 10 ~.L
chloroacetaldehyde was added and heating was continued for 33 hours. The reaction mixture was cooled to room temperature and desired product (46) was collected by filtration. The filtrate was diluted with EtOAc and washed with water, saturated NaHC03 and brine. The organic layer was dried (Na2S04) and concentrated to give additional product (46) (S1 mg, 74% combined recovery). MS APCI (-) m/z 382, 384, 386 (M-, Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) 8 8.86 (s, 1H), 7.85 (s, 1H), 7.53 (s, 2H), 7.32 (d, 1H), 6.82 (t, 1H). 19F NMR (376 MHz, CD30D) -148.3 (s).
7-(4-Bromo-2-chlorophenylamino)-8-fluoroimidazo[ 1,2-a]pyridine-6-carboxylic acid (46) was alternatively synthesized by the route shown below.
HO O NH HO O CI ~O O CI
\ CI \ CI LHMDS N TMSCHN2 \ \ \ \
or OxCI, DMF
/ F / THF / F / Br followed by / F / Br CI gr CI MeOH CI
/O O CI /O O CI HO O CI
1. NaN3 \ N \ CICHzCHO i / N \ NaOH / N \
2. Zn ~~F ~ / Br EtOH N~F ~ / Br cN~F ~ / Br NHp ~N~' ~N
In the first step of this alternative procedure, 4,6-dichloro-5-fluoronicotinic acid (J. Heterocyclic Chemistry 1993, 30, 855-859) was used to synthesize 4-(4-bromo-2-chlorophenylamino)-5-bromo-6-chloronicotinic acid according to the alternate procedure described in Example 9, Step B.
Step C: Preparation of 7-(4-bromo-2-chlorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (47a):
Compound 47 was prepared as described in Step E of Example 19 using 7-(4-bromo-2-chlorophenylamino)-8-fluoroimidazo[1,2-aJpyridine-6-carboxylic acid (46) to give 1 S mg (24%) of the desired product (47a) as a white solid. MS APCI (+) m/z 453, 455, 457 (M+, Cl, Br pattern) detected. 'H NMR (400 MHz, CD30D) 8 8.66 (s, 1H), 7.93 (m, 1H), 7.61 (s, 1H), 7.56 (d, 1H), 7.32 (dd, 1H), 6.73 (q, 1H) 3.70 (d, 2H), 1.14 (m, 1H), 0.56 (m, 2H), 0.26 (m, 2H): '9F (400 MHz, CD30D) -139.4 (s).
The following compounds were synthesized in a similar manner as shown in Figure 13.
H
HO~\O,N O CI
H
N
N
_F Br N
7-(4-Bromo-2-chlorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxy-ethoxy)amide MS APCI (+) m/z 443, 445, 447 (M+, Cl, Br pattern) detected; 'H NMR (400 MHz, CD30D) 8 8.69 (s, 1H), 7.89 (m, 1H), 7.59 (s, 1H), 7.55 (d, 1H), 7.31 (dd, 1H), 6.72 (q, 1 H), 4.01 (t, 2H), 3.76 (t, 2H); ' 9F (400 MHz, CD30D) -139.7 (s).
HO O F
H
N
N
~F Br N
7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo [1,2-a] pyridine-6-carboxylic acid MS ESI (+) m/z 368, 370 (M+, Br pattern) detected. 'H NMR (400 MHz, 1o DMSO-d6) 8 9.21 (s, 1H), 8.08 (m, 1H), 7.66 (s, 1H), 7.55 (dd, 1H), 7.29 (d, 1H), 6.92 (m, 1H). '9F (376 MHz, DMSO-d6) -127.9 (s, 1F), -141.1 (s, 1F) H
~O.N O F
H
N
N
~F Br N
7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide MS ESI (+) m/z 437, 439 (M+, Br pattern) detected. 'H NMR (400 MHz, CD30D) S 9.55 (br s, 1H), 8.57 (s, 1H). 7.68 (s, 2H), 7.65 (s, 1H), 7.28 (m, 1H), 7.14 (m, 1H), 6.78 (br s, 1H), 6.63 (m, 1H), 3.72 (m, 2H), 1.07 (m, 1H), 0.59 (m, 2H), 0.28 (m, 2H). '9F NMR (376 MHz, CD30D) 8 -128.9 (s, 1F), -138.1 (s, 1F).
HO O
H
N
N I ~ \
F ~ Br 7-(4-Bromo-2-methylphenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 364, 366 (M+, Br pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.22 (s, 1H), 8.07 (m, 1H), 7.68 (s, 1H), 7.42 (d, 1H), 7.28 (dd, 1H), 6.78 (t, 1H), 2.29 (s, 3H). '9F (376 MHz, DMSO-d6) -142.5 (s).
HO O CI
H
N
N I
~ ~F CI
N
7-(2,4-dichlorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 440, 442 (M+, Cl pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.27 (s, 1H), 8.13 (s, 1H), 7.71 (s, 1H), 7.62 (s, 1H), 7.32 (dd, 1H), 6.95 (t, 1H). '9F (376 MHz, DMSO-d6) -129.9 (s).
HO O
F
H
N
N I I ~
~~ ~F
8-Fluoro-7-(2-fluoro-4-methylphenylamino)-imidazo(1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 304 (M+1) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.48 (br s, 1H), 9.32 (s, 1H), 8.12 (s, 1H), 7.86 (s, 1H), 7.12 (m, 2H), 6.98 (d, 1H), 2.31 (s, 3H). '9F (376 MHz, DMSO-d6) -128.1 (s, 1F), -148.8 (s, 1F).
HO O
H F
N
N
F ~ CI
7-(4-Chloro-2-fluorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 324, 326 (M+, Cl pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.19 (s, 1H), 8.07 (m, 1H), 7.64 (s, 1H), 7.45 (dd, 1H), 7.17 (d, 1H), 6.98 (m, 1H). 19F (376 MHz, CD30D) -128.8 (s, 1F), -154.8 (s, 1F).
Example 21 H
HO~O,N O CI
H
N
N
CI~~ ~F CI
N
3-Chloro-7-(2,4-dichlorophenylamino)-8-fluoroimidazo(1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide The reaction scheme for the synthesis of this compound is shown below.
H CI cat HCI O O H CI LHMDS
i N W / N ~ + ~O~ .NHZ -/I I /I I o F ~ CI DMF CI' /N F ~ CI THF
N ~~N
~O~O,N O H CI HCI HO~O-N O H CI
N -, N
N I I ~ MeOH N
CI~~ ~F CI CI~~ ~F CI
N N
Step A: Preparation of 3-chloro-7-(2,4-dichlorophenylamino)-8-fluoroimidazo[1,2-alpyridine-6-carboxylic acid methxl ester. 7-(2,4-Dichloro-phenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (57.0 mg, 0.16 mmol), which was synthesized in a manner similar to the alternate procedure described in Example 20, Step B, was dissolved into DMF (3 mL). Added N
chlorosuccinimide (17.0 mg, 0.13 mmol) and HCl (1.0 M aqueous solution, 16 p,L, 0.016 mmol). After stirring for 16 hours, the suspension was diluted with ethyl acetate, washed with NaHS03, water (2x), brine, dried over Na2S04 and concentrated to a yellow solid. Purification by flash column chromatography (4:1 hexanes/ethyl acetate) provided the desired product as a light yellow solid (40 mg, 64%). MS
APCI
(+) m/z 388, 390 (M+, Cl pattern) detected. 1H NMR (400 MHz, CDC13) 8 8.70 (s, H), 7.58 (s, 1H), 7.40 (d, 1H), 7.14 (dd, 1H), 6.77 (t, 1H), 4.02 (s, 3H): '~F
NMR
(376 MHz, CDC13) -135.84 (s).
Step B: Preparation of 3-chloro-7-(2,4-dichlor-phenylamino)-8-fluoroimidazojl,2-a]pyridine-6-carboxylic acid (2-vinyloxyethoxy)-amide.
LiHMDS
(1.0 M in hexanes, 0.34 mL, 0.34 mmol) was added to a solution 3-chloro-7-(2,4-dichlorophenylamino)-8-fluoro-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (38 mg, 0.098 mmol) and O-(2-vinylox-ethyl)-hydroxylamine (25 mg, 0.24 mmol) in THF (1.0 mL) cooled to 0 °C. The solution was allowed to warm to room 2o temperature and stir for 16 hours. The solution was diluted with ethyl acetate, washed with saturated NaHC03, water (3x), brine, dried over Na2S04 and concentrated to a yellow liquid. Purification by flash column chromatography (20:1 to 10:1 dichloromethane/MeOH) provided the desired product as a yellow solid (42 mg, 93%). MS APCI (+) m/z 459, 461 (M+, Cl pattern) detected.
Step C: Preparation of 3-chloro-7-(2,4-dichlorophenylamino)-8-fluoroimidazof 1,2-alpvridine-6-carboxvlic acid (2-hvdroxv-ethoxv)-amide. 3-Chloro-7-(2,4-dichloro-phenylamino)-8-fluoro-imidazo[1,2-a]pyridine-6-carboxylic acid (2-vinyloxy-ethoxy)-amide was converted to the desired product according to Example 3, Step B, to provide 31 mg (78%) of desired product as a light yellow solid.
MS
3o APCI (+) m/z 433, 435 (M+, Cl pattern) detected. 1H NMR (400 MHz, CD30D) 8 8.52 (s, 1 H), 7.57 (s, 1 H), 7.42 (d, 1 H), 7.16 (dd, 1 H), 6.79 (dd, 1 H), 4.07 (m, 2H), 3.80 (m, 2H). t9F NMR (376 MHz, CD30D) -140.83 (s).
Example 22 H
~,O,N O F
H
N
N I I /
~F
N
7-(4-Ethyl-2-fluorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid ethoxyamide The reaction scheme for the synthesis of this compound is shown below.
i0 O F ~O O F i0 O F
z / ~ N ~ '~ ~BFgK / ~ N ~ \ 10% Pd/C / ~ N ~ \
~~F / I PdClz(dppf)-CHzCIz \N~F / / EtOH N~F
( NEt3, iPrOH/THF
N . reflux H
~O~NHZ.HCI ~O~N O F
H
LHMDS / N \
THF N F /
~N
Step A. Preparation of 8-fluoro-7-(2-fluoro-4-vinylphenylamino)-imidazo f 1 2-a]pyridine-6-carboxylic acid methyl ester. 8-Fluoro-7-(2-fluoro-iodophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (250 mg, 0.58 mmol), which was synthesized in a similar manner to the alternative synthesis set forth in Example 20 Step B, was suspended in isopropyl alcohol (6 mL) and tetrahydrofuran (1 mL). Potassium vinyltrifluoroborate (90 mg, 0.67 mmol) and triethylamine (0.165 mL, 1.2 mmol) were added, at which time the reaction mixture became a solution. The reaction mixture was sparged with NZ. PdClz(dppf)-CHzCIZ
(2 mol %, 9 mg) was then added and the reaction was heated to 90 °C and stirred under Nz for 16 hours. The reaction mixture was cooled to room temperature and diluted with water, followed by extraction with ethyl acetate (2x). The combined organic layers were washed with saturated aqueous NaCI, dried over Na2S04 and concentrated. Purification of the crude product by flash column chromatography (30:1 dichloromethane/methanol) provided the desired product (143 mg, 81%) as a dark yellow solid. MS ESI (+) m/z 330 (M+1) detected.
Step B. Preparation of 7-(4-ethyl-2-fluoro-phenylamino)-8-1o fluoroimidazof 1,2-a]pyridine-6-carboxylic acid methyl ester. 8-Fluoro-7-(2-fluoro-4-vinyl-phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (165 mg, 0.50 mmol) was suspended in ethanol (5 mL), added 10% Pd/C (267 mg, 0.25 mmol) and placed under an atmosphere of H2. The reaction mixture was stirred vigorously at room temperature for 16 hours. The reaction mixture was filtered through celite, washed with ethanol and tetrahydrofuran and the filtrate concentrated to a yellow oil.
Purification of the crude product by flash column chromatography (gradient of dichloromethane to 20:1 dichloromethane/methanol) provided the desired product (110 mg, 66%) as a dark yellow solid. MS ESI (+) m/z 332 (M+1) detected.
Step C: Preparation of 7-(4-ethyl-2-fluorophenylamino)-8-fluoroimidazo[1,2-2o alpyr'idine-6-carboxylic acid ethox -~. 7-(4-Ethyl-2-fluorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (40 mg, 0.12 mmol) was converted to the desired product according to procedure of Step B of Example 21, using O-ethyl-hydroxylamine-HCl salt, to provide the desired product as a yellow colored solid (31 mg, 71%). MS ESI (+) m/z 361 (M+1) detected. 'H NMR (400 MHz, CD30D) 8 8.62 (s, 1H), 7.86 (s, 1H), 7.56 (s, 1H), 6.97 (d, 1H), 6.90 -6.80 (m, 2H), 3.88 (q, 2H), 2.60 (q, 2H), 1.23 (m, 9H). 19F (376 MHz, CD30D) -132.7 (s, 1F), -145.2 (s, 1F).
became a solution. The reaction mixture was sparged with N2. PdCl2(dppf)-(2 mol %, 9 mg) was then added and the reaction was heated to 90 °C and stirred under NZ for 16 hours. The reaction mixture was cooled to room temperature and diluted with water, followed by extraction with ethyl acetate (2x). The combined organic layers were washed with saturated aqueous NaCI, dried over Na2S04 and concentrated. Purification of the crude product by flash column chromatography (30:1 dichloromethane/methanol) provided the desired product (143 mg, 81%) as a dark yellow solid. MS ESI (+) m/z 330 (M+1) detected.
Step B. Preparation of 7-(4-ethyl-2-fluoro-phenylaminoL
1o fluoroimidazo(1,2-a]pyridine-6-carboxylic acid meth, 1~. 8-Fluoro-7-(2-fluoro-4-vinyl-phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (165 mg, 0.50 mmol) was suspended in ethanol (S mL), added 10% Pd/C (267 mg, 0.25 mmol) and placed under an atmosphere of H2. The reaction mixture was stirred vigorously at room temperature for 16 hours. The reaction mixture was filtered through celite, washed with ethanol and tetrahydrofuran and the filtrate concentrated to a yellow oil.
Purification of the crude product by flash column chromatography (gradient of dichloromethane to 20:1 dichloromethane/methanol) provided the desired product (110 mg, 66%) as a dark yellow solid. MS ESI (+) m/z 332 (M+1) detected.
Step C: Preparation of 7-(4-ethyl-2-fluorophen l~o~-8-fluoroimidazo[1,2-2o a]pyridine-6-carboxylic acid ethoxy-amide. 7-(4-Ethyl-2-fluorophenylamino)-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (40 mg, 0.12 mmol) was converted to the desired product according to procedure of Step B of Example 21, using O-ethyl-hydroxylamine-HCl salt, to provide the desired product as a yellow colored solid (31 mg, 71%). MS ESI (+) m/z 361 (M+1) detected. 1H NMR (400 MHz, CD30D) 8 8.62 (s, 1H), 7.86 (s, 1H), 7.56 (s, 1H), 6.97 (d, 1H), 6.90 -6.80 (m, 2H), 3.88 (q, 2H), 2.60 (q, 2H), 1.23 (m, 9H). 19F (376 MHz, CD30D) -132.7 (s, 1F), -145.2 (s, 1F).
Example 23 H
HO~O, N O F
H
N
N
~F Me N
3-Ethyl-8-fluoro-7-(2-fluoro-4-methylphenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide The reaction scheme for the synthesis of this compound is shown below.
PdCl2(PPh3)z O O O O Cul H F NIS ~ H F diisopropylamine N ~ ~ , N ~ + H = TMS
cN ~ I F I ~ Me ACN I N / I F I ~ Me THF
~N ~N
~O O F ~O 0 F Hz ~0 0 H F
H KpC03 H 10% Pd/C N
N w ~ N
y - ~~ I - N
TMS = \N / F ~ Me MeOH ~ \N ~ F ~ Me MeOH ~ ~ F Me N N N
H H
~O~O.NHZ ~O~O.N 0 H F HCI H0~0-N O H F
N ~ N
LHMDS ~ I F I ~ Me MeOH ~ I F I ~ Me THF ~N ~N
Step A: Preparation of 8-Fluoro-7-(2-fluoro-4-methyl-phenylamino)-3-iodo-imidazo[1,2-~pyridine-6-carboxylic acid methyl ester. N iodosuccinimide (134 mg, 0.60 mmol) was added in a single portion to a solution of 8-fluoro-7-(2-fluoro-methyl-phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (172 mg, 0.54 mmol) in acetonitrile (10 mL) resulting in a thick precipitate after ten minutes of stirnng. The suspension was diluted with ethyl acetate, washed with NaHS03, saturated NaHC03, water, brine, and dried over NaZSOa. Concentration provided the desired product as a yellow solid (241 mg, 100%). MS APCI (+) m/z 444 (M+1) detected. 1H NMR (400 MHz, CD30D) 8 8.78 (s, 1H), 7.62 (s, 1H), 6.95 (m, 3H), 4.00 (s, 3H), 2.33 (s, 3H). '9F NMR (376 MHz, CD30D) -131.11 (s, 1F), -146.71 (s, 1 F).
Step B: Preparation of 8-fluoro-7-y2-fluoro-4-meth~phenylamino~3-trimethylsilanyleth~nyl-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester.
THF
(1.0 mL), diisopropylamine (95 pL, 0.68 mmol) and trimethylsilylacetylene (38 pL, 0.27 mmol) were added to a mixture of 8-fluoro-7-(2-fluoro-4-methyl-phenylamino)-3-iodo-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (100 mg, 0.23 mmol), 1o CuI (4.0 mg, 0.023 mmol) and PdCl2(PPh3)2 (16 mg, 0.023 mmol). The solution was stirred at room temperature for 16 hours. The reaction was diluted with ethyl acetate, washed with saturated NaHC03 (3x), brine (2x), dried over NazS04 and concentrated to a dark brown solid. Flash column chromatography (40:1 dichloromethane/MeOH) provide desired product (30 mg, 32%) as a yellow liquid. MS APCI (+) m/z 414 (M+1) detected. 'H NMR (400 MHz, CDCl3) 8 8.77 (s, 1H), 8.61 (s, 1H), 7.80 (s, 1H), 6.90 (m, 3H), 4.00 (s, 3H), 2.32 (s, 3H), 0.33 (s, 9H). '9F NMR (376 MHz, CDCl3) -129.12 (s, 1F), -141.99 (s, 1F).
Step C: Preparation of 3-ethynyl-8-fluoro-7-(2-fluoro-4-meth~phenylamino~
imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester. Potassium carbonate (70 mg, 0.51 mmol) was added to a solution of 8-fluoro-7-(2-fluoro-4-methyl-phenylamino)-3-trimethylsilanylethynyl-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester in MeOH (S mL) and stirred at room temperature for two hours. The mixture was diluted with ethyl acetate, washed with brine (2x), dried over NaZS04 and concentrated to a brown residue. Flash column chromatography (dichloromethane to 80:1 dichloromethane/MeOH) provided the desired product (16 mg, 65%) as a yellow liquid. MS APCI (+) m/z 342 (M+1) detected.
Step D: Preparation of 3-ethyl-8-fluoro-7-(2-fluoro-4-meth~phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester. A mixture of 3-ethynyl-fluoro-7-(2-fluoro-4-methyl-phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid 3o methyl ester (16 mg, 0.047 mmol) and 10% Pd/C (5 mg) under an atmosphere of hydrogen (balloon) was stirred vigorously for one hour. The mixture was filtered through a plug of rinsing with dichloromethane and concentrated to provide the desired product (14 mg, 86%) as a yellow foam. MS APCI (+) m/z 346 (M+1) detected. 1H NMR (400 MHz, CDCl3) 8 8.51 (s, 1H), 8.31 (s, 1H), 7.38 (s, 1H), 6.91 (d, 1H), 6.84 (s, 2H), 3.97 (s, 3H), 2.86 (q, 2H), 2.30 (s, 3H), 1.43 (t, 3H).
Step E: Preparation of 3-ethyl-8-fluoro-7-(2-fluoro-4-methyl-phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxy-ethoxy)-amide. 3-Ethyl-8-fluoro-7-(2-fluoro-4-methyl-phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (14 mg, 0.041 mmol) was converted to the desired product according to 1o the Step A of example 21 and Step B of Example 3, Step B to provide the desired product (hydrochloride salt) as a tan colored solid (9 mg, 51 % over two steps). MS
APCI (+) m/z 391 (M+1) detected. 1H NMR (400 MHz, CD30D) 8 8.63 (s, 1H), 7.65 (s, 1H), 7.16 (m, 1H), 7.01 (m, 2H), 4.04 (br s, 2H), 3.79 (br s, 2H), 2.97 (q, 2H), 2.35 (2, 3H), 1.45 (t, 3H). 19F NMR (376 MHz, CD30D) -127.69 (s, 1F), -155.07 (s, 1F).
Example 24 H
~O'N ~H CI
N
~CI Br N-N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methyl-[1,2,4]-2o triazolo-[4,3-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (53a) The reaction scheme for the synthesis of compound 53a is shown in Figure 14.
Step A: Preparation of 4-(4-bromo-2-chloro~hen 1~)-5-chloro-6-hydrazinonicotinic acid ethyl ester (49): 4-(4-Bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid ethyl ester (48) was prepared by standard methods from 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid. Hydrazine monohydrate (0.59 mL, 12.16 mmol) was added to a solution of 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid ethyl ester (48) (1.72 g, 4.05 mmol) in N,N-dimethylacetamide (20 mL). After stirnng at 90 °C for 1 hour, the reaction mixture was cooled to room temperature and diluted with EtOAc. The organic layer was washed with water and brine, dried (Na2S04) and concentrated. Purification by flash column chromatography using the Biotage system (20:1 CH2C12/EtOAc) provided the desired product (49) (307 mg, 18%).
Step B: Preparation of 7-(4-bromo-2-chlorophen lamino~8-chloro-3-meth ~~l-I1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid ether ester (51a): Acetic anhydride (22 ~,L, 0.238 mmol) was added to a solution of 4-(4-bromo-2-chlorophenylamino)-5-l0 chloro-6-hydrazinonicotinic acid ethyl ester (49) (0.100 g, 0.238 mmol) and triethylamine (66 ~.L, 0.476 mmol) in CHZC12 (2.5 mL) at 0 °C, and then the solution was warmed to room temperature to provide compound SOa (not isolated). After minutes, POC13 (87 ~,L, 0.952 mmol) was added dropwise and the reaction mixture was warmed to room temperature. After 16 hours, the reaction mixture was heated to 1 5 reflux and stirred for 3 days. The reaction mixture was cooled to room temperature and concentrated. The residue was diluted with EtOAc and saturated NaHC03 was added and the mixture stirred for 20 minutes. The layers were separated and the organic layer was washed with brine. The aqueous washings were back extracted with EtOAc. The combined organic extracts were dried (NaZS04) and concentrated.
2o Purification by flash column chromatography using the Biotage system (9:1 CHZC12/EtOAc) provided compound S l a (80 mg, 75%).
Step C: Preparation of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid (52a): Sodium hydroxide (715 ~.L of a 1 M solution) was added to a solution of 7-(4-bromo-2-chlorophenylamino)-8-25 chloro-3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid ethyl ester (51a) (79 mg, 179 mmol) in 3:1 THF:water (4.5 mL). After 16 hours, the reaction mixture was poured into a separatory funnel, diluted with brine and acidified with 1 M HCl to about pH 2. The aqueous layer was extracted with 1:1 EtOAc/THF. The combined organic extracts were dried (Na2S04) and concentrated and the residue (52a) was 30 carned forward without further purification.
Step D: Preparation of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-meth ~~-1-1,2,41triazolo f 4,3-alpyridine-6-carboxylic acid cyclopropylmethoxyamide 53a):
Compound 53a was prepared as described in Example 2 using 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methyl-[ 1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid (52a) to give 2 mg (S%) of the desired product. MS APCI (-) m/z 482, 484, (M-, Cl, Br pattern) detected.
Example 25 H
HO~O.N O H CI
N
N~ I i CI Br N-N
1o Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide (54a) The reaction scheme for the synthesis of compound 54a is shown in Figure 14.
Compound 54a was prepared as described herein starting with 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methyl-[ 1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid (52a) to give 1 mg (2% for the two steps) desired product (54a). MS APCI
(-) m/z 472, 474, 476 (M-, Cl, Br pattern) detected.
Example 26 H
~O'N OH CI
N I N I ~
~CI Br j N-N
Synthesis of 3-benzyl-7-(4-bromo-2-chlorophenylamino)-8-chloro [1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (53b) The reaction scheme for the synthesis of compound 53b is shown in Figure 14.
Step A: Preparation of 3-benzyl7-(,4-bromo-2-chlorophen~amino)-8-chloro-f 1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid meths ester (51b):
Phenylacetyl chloride (152 ~,L, 1.148 mmol) was added to a solution of 4-(4-bromo-2-chlorophenylamino)-5-chloro-6-hydrazinonicotinic acid methyl ester (49) (0.233 g, 0.574 mmol) and triethylamine (160 ~,L, 1.148 mmol) in CHZC12 (5.7 mL) at 0 °C.
After warming to room temperature, an additional 75 p.L phenylacetyl chloride was added. After 6 hours, the reaction mixture was concentrated and diluted with EtOAc.
The organic layer was washed with water and brine, dried (Na2S04) and concentrated.
1o The residue (50b) was diluted with dichloroethylene (2 mL) and POCl3 (465 p.L, 5.082 mmol) was added. After stirring at reflux for 12 hours, the reaction mixture was cooled to room temperature and concentrated. The residue was diluted with EtOAc and saturated NaHC03 was added and the mixture stirred for 20 minutes.
The resulting solid was collected by filtrate to give the desired product (51b) (97 mg, 30%).
Step B: Preparation of 3-benzyl-7-(4-bromo-2-chlorophenylamino)-8-chloro-j1,2,4]triazolo[4,3-alpyridine-6-carboxylic acid c~pro~ylmethoxyamide (53b):
Compound 53b was prepared as described in Step C of Example 24 and Example 2 using 3-benzyl-7-(4-bromo-2-chlorophenylamino)-8-chloro-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid methyl ester (51b) as the starting material to give 5 mg (4% for the two steps) of the desired product (53b). MS APCI (-) m/z 558, 560, (M-, Cl, Br pattern) detected. 'H NMR (400 MHz, CDC13) 8 8.22 (s, 1H), 7.30 (m, 6H), 6.50 (d, 1H), 4.53 (s, 2H), 3.49 (m, 2H), 0.94 (m, 1H), 0.51 (m, 2H), 0.19 (m, 2H).
Example 27 HO O
H CI
N
,F
p-N
Synthesis of 6-(2-chlorophenylamino)-7-fluoro-3-methylbenzo[c]isoxazole-5-carboxylic acid (56) The synthesis of compound 56 is shown in Figure 15.
Step A: Preparation of 6-(2-chlorophenylaminol-7-fluoro-3-methyl-benzo[cl-isoxazole-5-carboxylic acid methyl ester (55~ Sodium azide (128 mg, 1.95 mmol) was added to a mixture of S-acetyl-2-(2-chlorophenylamino)-3,4-difluorobenzoic acid l0 methyl ester (6) (601 mg, 1.59 mmol) in 3:1 acetone:water (16 ml) and heated to reflux. After 16 hours, the reaction mixture was cooled to room temperature, and diluted with EtOAc and water. The organic layer was washed with water, dried (MgS04) and concentrated. The resulting residue was diluted with water (8 mL) and heated to reflux. After 5 hours, the mixture was cooled to room temperature and diluted with EtOAc. The organic layer was washed with water, dried (MgS04) and concentrated. Purification by flash column chromatography using the Biotage system (20% EtOAc in hexanes) provided the desired product (55) (410 mg, 77%).
Step B: Preparation of 6-(2-chlorophenylamino)-7-fluoro-3-methylbenzolcl-isoxazole-5-carboxylic acid (56~, To a solution of 6-(2-chlorophenylamino)-7-fluoro-3-methyl-benzo[cJ-isoxazole-5-carboxylic acid methyl ester (55) (100 mg, 0.299 mmol) in 6:1 THF/water (3.5 mL) was added LiOH (0.60 ml of a 1 M solution in water). After 1 hour, the reaction was acidified to pH 1 with 1 N HCI, diluted with water and extracted with EtOAc. The combined organic extracts were washed with water, dried (MgS04) and concentrated to give the desired product (56) (87 mg, 91%).
MS APCI (-) m/z 319, 321 (M+, Cl pattern) detected. 1H NMR (400 MHz, CD30D) 8 8.45 (s, 1H), 7.38 (dd, 1H), 7.20 (m, 1H), 6.91 (m, 2H), 2.88 (s, 3H): ~9F NMR
(376 MHz, CD30D) -136.40 (s).
Example 28 H
HO~O~ N O CI
H
N
i ~ ~F
O-N
Synthesis of 6-(2-chlorophenylamino)-7-fluoro-3-methylbenzo[c]isoxazole-5-carboxylic acid (2-hydroxyethoxy)amide (57a) Compound 57a was prepared as shown in Figure 15 using 6-(2-chlorophenylamino)-7-fluoro-3-methylbenzo[c]isoxazole-5-carboxylic acid (56) to l0 give 35 mg (44%) desired product. MS APCI (-) m/z 388, 390 (M+, Cl pattern) detected; 1H NMR (400 MHz, CD30D) 8 7.73 (s, 1H), 7.36 (d, 1H), 7.17 (t, 1H), 6.89 (t, 1H), 6.81 (dd, 1H), 3.72(d, 2H), 2.87 (s, 3H), 1.15 (m, 1H), 0.54 (d, 2H), 0.26 (d, 2H); 19F NMR (376 MHz, CD30D) -135.08 (s).
Example 29 H
~O~ N O H CI
N
/ ~ ~F
O-N
Synthesis of 6-(2-chlorophenylamino)-7-fluoro-3-methylbenzo[c]isoxazole-5-carboxylic acid cyclopropylmethoxy-amide (57b) Compound 57b was prepared as shown in Figure 15 and described in Example 2 using 6-(2-chlorophenylamino)-7-fluoro-3-methylbenzo[c]isoxazole-5-carboxylic acid (56) to give 35 mg (44%) desired product. MS APCI (-) m/z 388, 390 (M+, Cl pattern) detected; 'H NMR (400 MHz, CD30D) 8 7.73 (s, 1H), 7.36 (d, 1H), 7.17 (t, 1 H), 6.89 (t, 1 H), 6.81 (dd, 1 H), 3.72(d, 2H), 2.87 (s, 3H), 1.1 S (m, 1 H), 0.54 (d, 2H), 0.26 (d, 2H); 19F NMR (376 MHz, CD30D) -135.08 (s).
Example 30 H
~O, N 0 H CI
N
N
~CI Br N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methylaminomethyl imidazo(1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxy-amide (63) to The synthesis of compound 63 is shown in Figure 16.
Step A: Preparation of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-formylimidazo~l,2-alpyridine-6-carboxylic acid methyl ester (58): A suspension of 6-amino-4-(4-bromo-2-chlorophenylamino)-5-chloro-nicotinic acid methyl ester (28) (1.06 g, 2.72 mmol) and 2-chloro-malonaldehyde (587 mg, 5.43 mmol) was heated to 80 °C for 45 minutes. The solution was allowed to cool to room temperature, and then washed with saturated aqueous NaHC03, and brine. The organic layer was dried over NaS04, filtered, concentrated in vacuo, and purified by column chromatography (20:1 methylene chloride/methanol) to give the desired product as a dark yellow solid.
The solid was triturated with ethyl acetate and isolated by filtration to provide the desired product as a yellow solid (0.436 g, 36%). MS (APCI+) m/z 442, 444, 446 (M+; Cl, Br pattern) detected.
Step B: Preparation of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methylaminomethyl-imidazo[1 2-a]pyridine-6-carboxylic acid methyl ester (59):
A
suspension of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-formylimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (58) (25 mg, 0.056 mmol), acetic acid (7 p,L, 0.11 mmol), and methylamine (2.0 M solution in THF, 56 pL, 0.11 mmol) was stirred for 0.5 hours. Sodium triacetoxyborohydride (36 mg, 0.17 mmol) was added and the solution allowed to stir overnight. The reaction mixture was concentrated to dryness and purified by flash column chromatography (dichloromethane followed by 10:1 dichloromethane/methanol) to provide the desired product as a yellow solid (12 mg, 46%). MS (APCI+) m/z 455, 457, 459 (M+; Cl, Br pattern) detected.
Step C: Preparation of 7-(4-bromo-2-chlorophenylamino)-3-[(tert butoxycarbonyl-methyl-amino)-methyll-8-chloroimidazof 1,2-a]pyridine-6-carboxylic acid methyl ester (60): Di-tert-butyl dicarbonate (6 mg, 0.029 mmol) and triethylamine (4 ~L, 0.029 mmol) were added to a solution of 7-(4-bromo-2 chlorophenylamino)-8-chloro-3-methyaminomethylimidazo[1,2-a]pyridine-6 carboxylic acid methyl ester (59) (12 mg, 0.026 mmol) in dichloromethane. The solution was stirred at room temperature for 0.5 hr after which time HPLC
analysis indicated the reaction had gone to completion. The solution was rotovapped to dryness to provide the desired product as a yellow foam (15 mg, quantitative).
MS
(APCI+) m/z 557, 559, 561 (M+; Cl, Br pattern) detected.
Step D: Preparation of 7-(4-bromo-2-chlorophenylamino)-3-[(tert-butox carbonyl-methylamino)-methyl]-8-chloroimidazo[1,2-alpyridine-6-carboxylic acid 61 : Sodium hydroxide (1.0 M aqueous solution, 0.16 mL, 0.16 mmol) was added to a solution of 7-(4-bromo-2-chlorophenylamino)-3-[(tert-butoxycarbonylmethylamino)-methyl]-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (60) (15 mg, 0.026 mmol) in 4:1 MeOH/water (5 mL). When the reaction was complete, the solution was diluted with water, acidified to pH 3 by addition of 1.0 M aqueous HCI, and extracted with ethyl acetate. The organic extracts were dried over NaS04, filtered, concentrated in vacuo to provide the desired product as a white crystalline solid (12 mg, 84%). MS (APCI-) m/z 541, 543, 545 (M-;
Cl, Br pattern) detected.
Step E: Preparation of [7-(4-bromo-2-chlorophenylamino)-8-chloro-6-cyclopropylmethoxycarbamoylimidazo[1,2-a]p~rridin-3- 1~~1-methylcarbamic acid tert-butyl ester (62): EDCI (6 mg, 0.033 mmol) and HOBt (5 mg, 0.033 mmol) were added to a solution of 7-(4-bromo-2-chlorophenylamino)-3-[(tert-butoxycarbonylmethylamino)-methyl]-8-chloro-imidazo[ 1,2-a]pyridine-6-carboxylic acid (61) in dimethylacetamide (0.4 mL). The yellow solution was allowed to stir at room temperature for 0.5 hours after which time O-cyclopropylmethyl-hydroxylamine (6 mg, 0.066 mmol) and triethylamine (6 ~L, 0.044 mmol) were added and the solution allowed to stir overnight. The reaction mixture was diluted with ethyl acetate, washed with water, saturated aqueous ammonium chloride, saturated aqueous potassium carbonate and brine. The organic phase was dried over NaS04, filtered, concentrated in vacuo to provide the desired product as a yellow residue (11.5 mg, 85%). MS (APCI+) m/z 612, 614, 616 (M+; Cl, Br pattern) detected.
Step F: Preparation of 7-(4-bromo-2-chlorophenylaminol-8-chloro-3-methylaminomethylimidazo[1,2-a]pyridine-6-carboxylic acid c~propylmethoxyamide (63): A solution of [7-(4-bromo-2-chlorophenylamino)-8-chloro-6-cyclopropylmethoxy-carbamoyl-imidazo[ 1,2-a]pyridin-3-ylmethyl]-methyl-carbamic acid tent-butyl ester (62) in 1:1 dichloromethane/trifluoroacetic acid was stirred for two hours. Solvent was removed under reduced pressure and the residue redissolved into ethyl acetate. The organic solution was washed with saturated aqueous potassium carbonate and brine. The aqueous washes were back-extracted with ethyl acetate. The combined organic extracts are dried over NaS04, filtered, and concentrated in vacuo to provide the desired product as a yellow solid (8 mg, 83%).
MS (APCI+) m/z 512, 514, 516 (M+; Cl, Br pattern) detected. 1H NMR (400 MHz, methanol-d4) b 8.72 (s, 1H), 7.58 (s, 1H), 7.54 (s, 1H), 7.25 (d, 1H), 6.55 (d, 1H), 4.23 (s, 2H), 3.67 (d, 2H), 2.51 (s, 3H), 1.13 (m, 1H), 0.50 (d, 2H), 0.24 (d, 2H).
Example 31 H
HO~O,N O CI
H
N
/ ~N Br -N
Synthesis of 6-(4-bromo-2-chlorophenylamino)-pyrazolo[1,5-aJpyridine-5-carboxylic acid (2-hydroxyethoxy)amide (73a) Compound 73a, where W = Br, Y = Cl, and X = H, can be prepared as shown in Figure 17.
s Example 32 H
HO.~O,N O CI
H
N
~N F Br ~N
Synthesis of 6-(4-bromo-2-chlorophenylamino)-7-fluoropyrazolo[1,5-a]pyridine-5-carboxylic acid (2-hydroxyethoxy)-amide (73b) to Compound 73b, where W = Br, Y = Cl, and X = F, can be prepared as shown in Figure 17.
Example 33 H
HO
HO'P~O~O~N O H CI
O N I N I W
CI ~ Br N
Synthesis of phosphoric acid mono-(2-{[7-(4-bromo-2-chlorophenylamino)-8 chloroimidazo[1,2-a]pyridine-6-carbonyl]-aminooxy}-ethyl) ester (74) The synthesis of compound 74 is shown in Figure 18. 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide (33a) (100 mg, 0.234 mmol), tetrazole (23 mg, 0.327 mmol) and di-tert-butyl diisopropylphosphoramidite (0.096 mL, 0.304 mmol) were dissolved/suspended in 30 mL of anhydrous DMF under an atmosphere of dry N2.
The reaction mixture was stirred for about 3 hours, after which time the reaction was cooled to -78 °C and tert-butyl hydrogen peroxide (0.100 mL of 70%
solution in water) was added. The cooling bath was then taken away and the reaction was slowly warmed up to room temperature and reacted over night. The reaction mixture was then partitioned between a solution of ethyl ether/ethyl acetate (5:1) and saturated aqueous NaHC03. The organic layer was saved and successively washed with 10%
aqueous sodium sulfite, 3 times with water and finally with brine. The resulting organic layer was dried over MgS04, filtered and concentrated under vacuum.
The residue was dissolved in 3 mL of a solution of TFA/DCM (2:1) under an atmosphere of dry NZ. The reaction was stirred at room temperature for about 2 hours after which time it was concentrated under vacuum and the resulting residue was stirred in methanol for about 1 hour. The off white solid was collected via suction filtration, washed with methanol followed by ethyl ether and then air-dried to give the desired compound (74).
. Example 34 HO O
CI
H
N
N I I ~
Br N
7-(4-Bromo-2-chlorophenylamino)-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid The compound was synthesized by the route shown below.
HO O HO O O O
NHZ CI ~ H CI
CI ~ CI LHMDS ~ N ~ TMSCHN2 \ N
THF ~~ ~ / or OxCI, DMF N 1 I /
gr followed by ~ \ gr CI gr CI MeOH CI
/O O CI ,O O CI HO O CI
1. NaN3 ~ N ~ CICH2CH0 / N ~ NaOH / N
2. Zn t~~ ~ / EtOH N~ ~ / N~ ~ /
Br ~ ~~ \ Br NHZ N N
4,6-Dichloro-5-methylnicotinic acid (J. Heterocyclic Chemistry 1999, 36, 953-957) was converted to 7-(4-bromo-2-chlorophenylamino)-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid according to the steps described in the alternate synthesis of Step D, Example 9. It was determined that addition of sodium azide to the 4-(4-bromo-2-chloro-phenylamino)-6-chloro-5-methyl-nicotinic acid methyl ester intermediate required heating to 50 °C, which results in a separable mixture of the desired methyl to ester, 6-azido-4-(4-bromo-2-chlorophenylamino)-5-methyl-nicotinic acid methyl ester, and the corresponding carboxylic acid. MS ESI (+) m/z 380, 382 (M+, Cl, Br pattern) detected. tH NMR (400 MHz, DMSO-d~) b 9.46 (s, 1H), 9.40 (br s, 1H), 8.25 (d, 1H), 8.12 (d, 1H), 7.79 (m, 1H), 7.42 (dd, 1H), 6.80 (d, 1H), 2.07 (s, 3H).
The following compound was prepared as described in the above example using 4-bromo-2-fluorophenylamine in the first step:
HO O
H
N
N I I /
Br N
7-(4-Bromo-2-fluorophenylamino)-8-methyl-imidazo[1,2-a]pyridine-6-carboxylic acid MS ESI (+) m/z 364, 366 (M+, Cl, Br pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.40 (s, 1H), 9.26 (br s, 1H), 8.22 (d, 1H), 8.10 (d, 1H), 7.61 (dd, 1H), 7.29 (dd, 1H), 6.87 (t, 1H), 2.14 (s, 3H). t9F (376 MHz, DMSO-d6) -125.7 (s).
Example 35 [6-(5-Amino-[1,3,4]oxadiazol-2-yl)-8-chloroimidazo[1,2-a]pyridin-7-yl]-(4-bromo-2-fluorophenyl)-amine 1o The compound was synthesized by the route shown below.
HO O
HZNNHZ _ / I I \ EDCI, HOBt HZN N
N / ~ H v ' CI Br NEt3, DMF HzN'N O H F BrCN 0 N H F
N
N I \ NaHC03 / ~ N ~ \
diox O N /
/O 0 H F HZN~ ~~CI Br ~~CI Br N N
/ ~ N I \ EtOH
N reflux ~~CI / Br N
Step A: Preparation of 7-(4-Bromo-2-fluorophenylamino)-8-chloroimidazof 1,2-alpyridine-6-carboxylic acid hydrazide. 7-(4-Bromo-2-fluoro-phenylamino)-8-chloro-imidazo[1,2-a]pyridine-6-carboxylic acid was converted to the hydrazide according to the coupling conditions described in Step A of Example 3.
Alternatively, the hydrazide can be prepared directly from 7-(4-Bromo-2-fluorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester by refluxing with hydrazine in ethanol. MS ESI (+) m/z 398, 400 (M+, Cl, Br pattern) detected.
Step B: Preparation of [6-(5-Amino-[1,3,4]oxadiazol-2-yl)-8-chloroimidazo[1,2-al>pyridin-7-~l-(4-bromo-2-fluoro-phenyl)-amine. 7-(4-Bromo-fluoro-phenylamino)-8-chloro-imidazo[1,2-a]pyridine-6-carboxylic acid hydrazide (100 mg, 0.25 mmol) was suspended in dioxane (2 mL). Cyanogen bromide (27 mg, 0.253 mmol) was added, followed by a solution of sodium bicarbonate (21 mg, 0.25 mmol) in HZO (1.2 mL). The reaction mixture was stirred at room temperature for 16 1o hours. The reaction mixture was diluted with ethyl acetate and washed with water and saturated aqueous NaCI, dried over Na2S04 and concentrated to yield the desired product (97 mg, 91%) as a white solid. MS ESI (+) m/z 423, 425 (M+, Cl, Br pattern) detected. 'H NMR (400 MHz, CD30D) 8 8.98 (s, 1H), 7.95 (s, 1H), 7.61 (s, 1H), 7.33 (d, 1H), 7.17 (d, 1H), 6.78 (t, 1H). 19F (376 MHz, CD30D) -128.6 (t).
Example 36 5-[7-(4-Bromo-2-fluorophenylamino)-8-chloro-imidazo[1,2-a]pyridin-6-yl]-[1,3,4] oxadiazole-2-thiol The compound was synthesized by the route shown below.
HS~
N
,N O O ~N
HzN H F CSz H F
/ N \ KOH / N \
C\N CI / Br EtOH ~ CI / Br ~N N
7-(4-Bromo-2-fluorophenylamino)-8-chloroimidazo[ 1,2-a]pyridine-6-carboxylic acid hydrazide (50 mg, 0.13 mmol) was suspended in ethanol (2.5 mL) and cooled to 0 °C. Carbon disulfide (22 mg, 0.29 mmol) was added, followed by powdered potassium hydroxide (7 mg, 0.13 mmol). The reaction mixture was stirred under NZ for 1 hour at 0 °C and then for 30 minutes at room temperature. The reaction mixture was then brought to reflux and stirred under N2 for 5 days.
The reaction mixture was diluted with water and acidified to pH 1-2 with aqueous 1 M
HCI. This mixture was then extracted with ethyl acetate (2x). The combined organic layers were washed with saturated aqueous NaHC03, saturated aqueous NaCI, dried over Na2S04 and concentrated. Purification of the crude product was achieved by flash column chromatography (gradient of dichloromethane to 15:1 dichloromethane/methanol) and then trituration with diethyl ether and dichloromethane to yield the desired product (17 mg, 31%) as a yellow solid.
MS ESI
(+) m/z 440, 442 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 9.29 (s, 1 H), 8.16 (s, 1 H), 8.08 (br s, 1 H), 7.73 (s, 1 H), 7.49 (d, 1 H), 7.15 (d, 1 H), 6.59 (t, 1H). ~~F (376 MHz, DMSO-d6) -128.7 (s).
Example 37 ~NH
O ,N
F
H
N
N ~ ~ /
~F Br ~N
5-[7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo [1,2-a] pyridin-6-yl]-3H
[1,3,4]oxadiazol-2-one The compound was synthesized by the route shown below.
H
H N~N O F carbonyldiimidazole H DMF, RT
N or N I I
F gr phosgene / toluene, reflux N
7-(4-bromo-2-fluorophenylamino)-8-fluoroimidazo[ 1,2-a]pyridine-6-carboxylic acid hydrazide (373 mg, 0.98 mmol), which was prepared according to Step A, Example 35, was dissolved into dimethylformamide (5 mL).
Carbonyldiimidazole (166 mg, 1.02 mmol) was added as a solid. The reaction mixture was stirred for 1 hour at room temperature. It was then diluted with ethyl acetate and washed with water. The aqueous layer was back-extracted with ethyl acetate (3x). The combined organic layers were washed with saturated aqueous NaCI, 1o dried over Na2SOa and concentrated. Purification of the crude product was achieved by trituration with ethyl acetate and diethyl ether. The resulting solid was filtered, washed with diethyl ether, collected and dried under vacuum. The filtrate was concentrated and the trituration procedure was repeated. The solids were combined to yield the desired product (334 mg, 84%) as a yellow solid. MS ESI (+) m/z 408, 1s (M+, Br pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 12.69 (br s, 1H), 9.05 (s, 1 H), 8.11 (d, 1 H), 7.89 (s, 1 H), 7.67 (s, 1 H), 7.51 (dd, 1 H), 7.20 (d, 1 H), 6.77 (m, .
1H). 19F (376 MHz, DMSO-d6) -128.9 (t, 1F ), -139.5 (s, 1F).
Example 38 HzN
/~-N
O /N
F
H
N
N I I ~
~CI Br [6-(5-Aminomethyl-[1,3,4]oxadiazol-2-yl)-8-chloroimidazo[1,2-a]pyridin-7-yl]-(4-bromo-2-fluorophenyl)-amine The compound was synthesized by the route shown below.
c1 H O H ~=N
H N~N O F O CI~N~N O F O ~ N F
/ I N I \ CI' v Cl H / I N \ POCI3 / I N I \
\N~CI / Br ~ N- \N~CI I / Br 100C, 4h ~~CI / Br cH2clZ, oc N
O ~N
F
NH3 in MeOH
KI N I I /
THF ~~ SCI Br Step A: Preparation of 7-(4-bromo-2-fluorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid N'-(2-chloro-acetyl)-hydrazide.
7-(4-Bromo-2-fluorophenylamino)-8-chloro-imidazo[1,2-a]pyridine-6-carboxylic acid hydrazide (100 mg, 0.25 mmol) of Step A, Example 35 was suspended in 1o dichloromethane (2 mL) and 4-Me morpholine (0.040 mL, 0.36 mmol) was added.
The mixture was cooled to 0 °C and then chloroacetyl chloride (0.029 mL, 0.36 mmol) was added dropwise. The reaction mixture was warmed to room temperature and stirred for 1 hour under N2. Rinsed reaction mixture into a separatory funnel with a small amount of tetrahydrofuran and methanol and then diluted with ethyl acetate.
The organic layer was washed with water and saturated aqueous NaCI, dried over Na2S04 and concentrated. Purification of the crude product was achieved by flash column chromatography (20:1 dichloromethane/methanol) to yield the desired product (64 mg, 54%) as a yellow solid. MS ESI (+) m/z 474, 476 (M+, Cl, Br pattern) detected.
2o Step B: Preparation of (4-bromo-2-fluorophenyl)-[8-chloro-6-(5-chloromethyl-[1,3,4]oxadiazol-2-yl -imidazo[1,2-a]pyridin-7-yl]-amine. 7-(4-Bromo-2-fluorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid N'-(2-chloro-acetyl)-hydrazide (63 mg, 0.13 mmol) was suspended in POC13 (1 mL). The reaction mixture was heated to 100 °C for 8 hours, during which time it became a bright red solution. The reaction mixture was cooled to room temperature and the solvent evaporated under reduced pressure. The residue was dissolved in ethyl acetate and washed with saturated aqueous NaHC03, saturated aqueous NaCI, dried over NazS04 and concentrated. The crude product (38 mg, 62%) was used without further purification in next step. MS ESI (+) m/z 456, 458 (M+, Cl, Br pattern) detected.
to Step C: Preparation of [6~5-aminomethyl-[1,3,41oxadiazol-2-yl)-8-chloroimidazo~l,2-a]pyridin-7-yl]-(4-bromo-2-fluoro-phenyl)-amine. (4-Bromo-2-fluoro-phenyl)-[8-chloro-6-(5-chloromethyl-[ 1,3,4]oxadiazol-2-yl)-imidazo[
1,2-a]pyridin-7-yl]-amine (38 mg, 0.083 mmol) was dissolved in tetrahydrofuran (1 mL).
Potassium iodide (14 mg, 0.083 mmol) was added and then ammonia (7 M solution in methanol, 0.30 mL, 2.08 mmol). The reaction mixture was stirred at room temperature for 16 hours. The solvent was removed under reduced pressure and the crude product was purified by flash column chromatography (gradient of 20:1 dichloromethane/methanol to 5:1 ) to yield the desired product (26 mg, 71 %) as a yellow solid. MS ESI (+) m/z 437, 439 (M+, Cl, Br pattern) detected. 1H NMR
(400 MHz, DMSO-d6) 8 9.35 (s, 1H), 8.33 (s, 1H), 8.17 (d, 1H), 7.70 (d, 1H), 7.51 (dd, 1H), 7.16 (d, 1H), 6.65 (t, 1H), 3.94 (s, 2H). 19F (376 MHz, DMSO-d6) -128.3 (t).
Example 39 HO~
NH
~N
O/ / N
H F
N
N
~F Br 2-{5-[7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo[1,2-a]pyridin-6-yl]-[1,3,4]oxadiazol-2-ylamino}-ethanol The compound was synthesized by the route shown below.
~NH OII H
O , N F HO~N~N~N O F
H OOH H H H PPhs N ~ HzN / N ~ NEt3, CCI, EtOH N ~ / CHZCI2, ref N F ~ ~ Br reflux I F Br ~N
5-[7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo[ 1,2-a]pyridin-6-yl]-3H-[1,3,4]oxadiazol-2-one of Example 37 was converted in two steps to the desired product following the procedures described in WO 04/056789. MS ESI (+) m/z 451, 453 (M+, Br pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 8.96 (s, 1H), 8.42 (s, 1 H), 8.13 (d, 1 H), 7.98 (t, 1 H), 7.64 (d, 1 H), 7.5 S (dd, 1 H), 7.26 (d, 1 H), 6.87 (m, 1H), 4.78 (t, 1H), 3.56 (q, 2H), 3.30 (m, 2H). '9F (376 MHz, DMSO-d6) -128.3 (t, 1F), -139.6 (s, 1F) Example 40 N-{5-[7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo[1,2-a]pyridin-6-yl]-[1,3,4] oxadiazol-2-yl}-N'-methyl-ethane-1,2-diamine The compound was synthesized by the route shown below.
m Boc ~ H 1. PPh3 O N
Boc /NON N~N O F NEt3, CCIQ ~ F
N
~NH2 H H / N ~ CHzCh, refluxreflux /
reOx \N F ~ / gr 2. NCI, MeOH \N~F ~ / gr 5-[7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo[ 1,2-a]pyridin-6-yl]-3H-[1,3,4]oxadiazol-2-one of Example 37 was converted in three steps to the desired product, isolated as the HCl salt, following the procedures described in WO
04/056789. MS ESI (+) m/z 464, 466 (M+, Br pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 9.26 (s, 1H), 8.95 (br s, 1H), 8.86 (br s, 2H), 8.39 (t, 1H), 8.25 (s, 1 H), 7.93 (s, 1 H), 7.64 (dd, 1 H), 7.36 (d, 1 H), 7.13 (m, 1 H), 3.5 9 (q, 2H), 3.17 (m, io 2H), 2.59 (t, 3H).
Example 41 Preparation of Hydroxylamines Hydroxylamines useful for synthesizing compounds of the present invention may be prepared as follows:
TBSO~sy~O,NH2 TBSO~O.NH2 (i). (S)-O-[2-(tert-Butyl-dimethylsilanyloxy)-propyl]-hydroxylamine and (R)-O-[2-(tert-Butyl-dimethyl-silanyloxy)-propyl]-hydroxylamine (S)-O-[2-(tert-Butyl-dimethyl-silanyloxy)-propyl]-hydroxylamine and (R)-O-[2-(tert-Butyl-dimethyl-silanyloxy)-propyl]-hydroxylamine were prepared from (S)-(--propylene oxide and (R)-(+)-propylene oxide respectively by the following procedure:
Step A: Preparation of (S)-1-iodopropan-2-of and (R)-1-Iodo-propan-2-ol.
Acetic acid (12.8 mL, 224 mmol) and (S)-(-)- or (R)-(+)-propylene oxide (16.0 mL, 224 mmol) were added sequentially to a solution of lithium iodide (15.0 g, 112 mmol) in THF (200 mL) cooled to 0 °C. The resulting thick suspension was allowed to warm to room temperature and stir for 16 hours. The suspension was diluted with ether, washed with water (3x), saturated NaHC03 (3x), brine, dried over Na2S04, and concentrated to provide the desired product as a yellow liquid (19.5 g, 94%).
Step B: Preparation of (S)-tert-but ~~-1-(2-iodo-1-methyl-ethoxy)-dimethyl-silane and (R)-tert-Butyl-(2-iodo-1-methyl-ethoxX)-dimethyl-silane. Pyridine (9.50 1o mL, 118 mmol) was added to a solution of (S)- or (R)-1-iodo-propan-2-of (19.9 g, 107 mmol) and TBSCI (17.0 g, 113 mmol) in DMF (100 mL) cooled to 0 °C.
After stirnng for two days, the solution was diluted with hexanes, washed with water (3x) and brine. The aqueous washes were back-extracted with 1:1 hexanes/ethyl acetate.
The combined organic phases were dried over Na2S04. Concentration provided the desired product as a yellow liquid (26.7 g, 83%).
Step C: Preparation of (S)-2-[2-(tert-Butyl-dimethyl-silanyloxy)-propoxyl-isoindole-1.3-dione and (R1- 2-f2-(tert-Butyl-dimethvl-silanvloxv)-pro ox isoindole-1,3-dione. A solution of (S)- or (R)-tert-butyl-(2-iodo-1-methyl-ethoxy)-dimethyl-silane (22.7 g, 75.4 mmol), N hydroxyphthalimide (14.8 g, 90.5 mmol) and 2o diisopropylethylamine (15.8 mL, 90.5 mmol) was heated at 75 °C for 48 hours. The solution was cooled to room temperature, diluted with water and extracted with 1:1 hexanes/ethyl acetate (2x) and diethyl ether (2x). The combined organic extracts were washed with water (3x), brine (2x), dried over Na2S04 and concentrated to a red liquid. The crude product was purified by flash column chromatography (dichloromethane) to provide the desired product as a yellow liquid (12.8 g, 50%).
Step D: Preparation of (~-O-[2-(tert-Butyl-dimethyl-silanyloxy)-propyll-hvdroxvlamine or (R)-O-f2-(tert-Butyl-dimethvl-silanvloxv)-nropvll-hvdroxvlamine.
Methyl hydrazine (2.12 mL, 39.9 mmol) was added to a solution of (S)- or (R)-2-[2-(tert-butyl-dimethyl-silanyloxy)-propoxy]-isoindole-1,3-dione (12.8 g, 38.0 mmol) in 3o dichloromethane (100 mL) and the resulting suspension was stirred for 16 hours.
The suspension was filtered to remove solids and the filtrate was concentrated to a yellow liquid. Flash column chromatography (2:1 hexanes/ethyl acetate) provided the desired product as a light yellow liquid (6.37 g, 82%). MS APCI (+) m/z 206 (M+1) detected. 1H NMR (400 MHz, CDC13) 8 5.44 (br s, 2H), 4.03 (m, 1H), 3.58 (m, 1H), 3.51 (m, 1H), 1.12 (d, 3H), 0.90 (s, 9H), 0.08 (s, 6H).
(ii). The following hydroxylamines were prepared similarly starting with the appropriate terminal epoxide. The isoindol-1,3-diones intermediates and the final hydroxylamines were purified by flash column chromatography.
TBSO.~Sy~O,NH2 TBSO R O,NH2 (S)-O-[2-(tert-butyl-dimethyl-silanyloxy)-butyl]-hydroxylamine and (R)-O-[2-(tert-butyl-dimethyl-silanyloxy)-butyl]-hydroxylamine The hydroxylamines (S)-O-[2-(tert-butyl-dimethyl-silanyloxy)-butyl]-hydroxylamine and (R)-O-[2-(tent-butyl-dimethyl-silanyloxy)-butyl]-hydroxylamine were prepared from the homochiral terminal epoxides (S)- and (R)-1,2-epoxybutane respectively, which were obtained by kinetic resolution of 1,2-epoxybutane as described within J. Am. Chem. Soc., 2002, 124:1307. MS APCI (+) mlz 220 (M+1) detected. 1H NMR (400 MHz, CDC13) 8 5.41 (br s, 2H), 3.79 (m, 1H), 3.60 (m, 2H), 1.54 (m, 1H), 1.44 (m, 1H), 0.90 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H).
TBSO O,NH2 D-[2-(tert-butyl-dimethyl-silanyloxy)-3-methyl-butyl]-hydroxylamine MS APCI (+) m/z 234 (M+1) detected. 'H NMR (400 MHz, CDC13) 8 5.38 (br s, 2H), 3.64 (m, 3H), 1.75 (m, 1H), 0.90 (m, 15H), 0.08 (s, 3H), 0.05 (s, 3H).
HO O,NH2 I
(iii). 1-Aminooxy-3,3-dimethyl-butan-2-of Step A: Preparation of 2-(2-H~y-3 3-dimeth~-butoxy)-isoindole-1,3-dione. To a solution of 3,3-dimethyl-1,2-epoxybutane (5.0 mL, 41.0 mmol) in DMF
(100 mL) was added N hydroxyphthalimide (8.03 g, 49.2 mmol) and triethylamine (6.90 mL, 49.2 mmol). The solution was heated at 75 °C for two days.
The solution was cooled to room temperature, diluted with ethyl acetate and washed with water (2x), saturated potassium carbonate (3x), brine (2x), dried over NaZS04 and 1o concentrated to an orange solid. Purification using flash column chromatography (dichloromethane) provided the desired product as a white solid (1.50 g, 14%).
Step B: Preparation of 1-Aminooxy-3,3-dimethyl-butan-2-ol. To a solution of 2-(2-hydroxy-3,3-dimethyl-butoxy)-isoindole-1,3-dione (1.47 g, 5.60 mmol) in dichloromethane (20 mL) cooled to 0 °C was added methylhydrazine (0.31 mL, 5.90 mmol). The white suspension was allowed to stir for 16 hours at room temperature.
Diethyl ether (50 mL) was added and the solids were removed by filtration. The filtrate was concentrated, diluted with diethyl ether and the solids were removed by filtration. This procedure was repeated twice more and the final filtrate was concentrated to provide the desired product as a yellow liquid (0.643 g, 86%).
'H
2o NMR (400 MHz, CDCl3) 8 4.87 (br s, 2H), 3.85 (q, 1H), 3.58 (q, 2H), 0.93 (s, 9H).
O
~O~N~O,NH2 H
(iv). (2-Aminooxy-ethyl)-carbamic acid tert-butyl ester Step A: Preparation of Methanesulfonic acid 2-tert-butoxycarbonylamino-ethyl ester. Methanesulfonyl chloride (0.60 mL, 7.76 mmol) was added to a solution of (2-hydroxy-ethyl)-carbamic acid tert-butyl ester (1.04 g, 6.46 mmol) and triethylamine (1.35 mL, 9.70 mmol) in dichloromethane (35 mL) cooled to 0 °C. The solution was stirred for one hour, after which time it was diluted with ethyl acetate, washed with saturated NaHC03 (2x), brine, dried over NaZS04 and concentrated to a thick colorless liquid (1.37 g, 89%).
Step B: Preparation of [2 ~1 3-Dioxo-1 3-dih~dro-isoindol-2-yloxy)-ethyll-carbamic acid tert-but, 1~ ester. Added N hydroxyphthalimide (1.12 g, 6.87 mmol) and triethylamine (0.96 mL, 6.87 mmol) to a solution of methanesulfonic acid 2-tert-butoxycarbonylamino-ethyl ester (1.37 g, 5.73 mmol) in DMF (20 mL). The solution was heated to 50 °C for 16 hours after which time it was cooled to room temperature.
The solution was diluted with ethyl acetate, washed with water (2x), saturated KZC03, dried over Na2S04 and concentrated to an orange solid (747 mg, 43%) which was taken on without purification.
Step C: Preparation of (2-Aminooxy-ethyl)-carbamic acid tert-but l~.
The synthesis of the title compound was carned out according to STEP D of Example 41 (i) using [2-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-ethyl]-carbamic acid tert-butyl ester as the starting material to provide 255 mg (71 %) of the desired compound as a yellow liquid. 'H NMR (400 MHz, CDCl3) 8 5.50 (br s, 2H), 5.02 (br s, 1H), 3.71 (t, 2H), 3.36 (q, 2H), 1.45 (s, 9H).
The following hydroxylamine was prepared similarly using (3-hydroxypropyl)-carbamic acid tert-butyl ester as the starting material.
O
~O~N~O~NH2 H
(3-Aminooxy-propyl)-carbamic acid tert-butyl ester 1H NMR (400 MHz, CDC13) 8 5.41 (br s, 2H), 4.76 (br s, 1H), 3.73 (t, 2H), 3.21 (q, 2H), 1.78 (m, 2H), 1.44 (s, 9H).
O
~O~ N O~ N H2 H /~~
(v). (3-Aminooxy-2,2-dimethylpropyl)-carbamic acid tert-butyl ester Step A: Preparation of (3-Hydroxy-2,2-dimethyl-propyl)-carbamic acid tert-butyl ester. Boc-anhydride (13.07 g, 59.9 mmol) in THF (10 mL) was added dropwise to a solution of 3-amino-2,2-dimethyl-propan-1-of (5.15 g, 49.9 mmol) and NaOH (2.40 g, 59.9 mmol) dissolved into 1:1 THF/water (50 mL). The solution was stirred at room temperature for 72 hours. The solution was concentrated under reduced pressure to about one half of the reaction volume. The remaining solution l0 was acidified to pH 6 and was then extracted with ethyl acetate (2x). The organic extracts were washed with water, brine, dried over NazS04 and concentrated to provide the desired product ( 10.2 g, quantitative) as a white solid.
Step B: Preparation of ~3-(1,3-Dioxo-1,3-dihydro-isoindol-2-yloxy)-2 2-dimeth ~~1-propyl]-carbamic acid tert-butyl ester. Diethylazodicarboxylate (8.26 mL, 52.4 mmol) was added to a solution of (3-hydroxy-2,2-dimethyl-propyl)-carbamic acid tert-butyl ester (10.2 g, 49.9 mmol), N hydroxyphthalimide (8.15 g, 49.9 mmol) and triphenylphosphine (13.1 g, 49.9 mmol) in THF (200 mL). The solution was stirred at room temperature for 16 hours after which time it was diluted with dichloromethane and passed through a plug of silica gel, eluting with dichloromethane. The product containing fractions were concentrated to a yellow liquid, which was further purified by flash column chromatography (dichloromethane to 4:1 dichloromethane/ethyl acetate) to provide pure desired product ( 1.98 g, 11 %) as a waxy white solid.
Step C: Preparation of (3-Aminooxy-2,2-dimeth ~~1-propel)-carbamic acid tert-butyl ester. The synthesis of the title compound was carried out according to Step D
of the Example 41 using [3-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester as the starting material to provide 998 mg (80%) desired product as a pale yellow liquid. 1H NMR (400 MHz, CDCl3) 8 5.45 (br s, 2H), 4.94 (br s, 1H), 3.44 (s, 2H), 3.03 (br d, 2H), 1.45 (s, 9H), 0.88 (s, 6H).
O
~O~ N ~O, N H2 H
(vi). (3-Aminooxy-1-methylpropyl)-carbamic acid tert-butyl ester Step A: Preparation of 3-amino-butan-1-ol. Lithium aluminum hydride (1.0 M in THF, 43.8 mL, 43.8 mmol) was added dropwise over one hour to a suspension of 3-aminobutyric acid (2.26 g, 21.9 mmol) in THF (100 mL) cooled to 0 °C. The solution was then refluxed for 16 hours after which time it was cooled to 0 °C and quenched by the careful sequential addition of water (2 mL), 15% aqueous NaOH
(2 1o mL) and water (2 mL). The mixture was stirred for 15 minutes and was filtered through Celite~, washing the filter pad with THF. Concentration of the filtrated provided the desired product (1.43 g, 73%) as a clear oil.
Step B: Preparation of (3-Aminooxy-1-methyl-propyl)-carbamic acid tert-butyl ester. The synthesis of the title compound was carned out according to Steps A, B and C of Example 41(iii) above using 3-amino-butan-1-of as the starting material to provide 998 mg (80%) desired product as a pale yellow liquid. 1H NMR (400 MHz, CDC13) 8 5.39 (br s, 2H), 4.52 (br s, 1H), 3.72 (m, 3H), 1.70 (m, 2H), 1.43 (2, 9H), 1.14 (d, 3H).
(vii). The following hydroxylamines were prepared as described in WO
02/06213: O-(2-vinyloxy-ethyl)-hydroxylamine; O-(2-methoxy-ethyl)-hydroxylamine; 2-aminooxy-propan-1-ol; 3-aminooxy-propan-1-ol; 1-aminooxy-2-methyl-propan-2-ol; 1-aminooxy-3-methoxy-propan-2-ol; 3-aminooxy-1,1,1-trifluoro-propan-2-ol; 2-aminooxy-2-methyl-propan-1-ol; (2-aminooxy-ethyl)-methyl-carbamic acid tert-butyl ester; (R)-O-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-hydroxylamine;
(S)-O-2,2-dimethyl-[1,3]dioxolan-4-ylinethyl)-hydroxylamine.
(viii). The isoindole-1,3-dione intermediates of the following hydroxylamines are prepared from the appropriate alkyl halide and N hydroxyphthalimide by the procedure described within J. Heterocyclic Chemistry 2000, 37, 827-830: O-propyl-hydroxylamine; O-isopropyl-hydroxylamine; O-cyclopropylmethyl-hydroxylamine.
The isoindole-1,3-diones are deprotected by the procedure described above.
(ix). The following hydroxylamines were obtained from commercial sources:
methoxylamine hydrochloride; D-ethylhydroxylamine hydrochloride; O-(tert butyl)amine hydrochloride; O-allylamine hydrochloride.
Additional compounds of the present invention are shown in Figurses 19A-19G.
The foregoing description is considered as illustrative only of the principles of the invention. Further, since numerous modifications and changes will be readily 1o apparent to those skilled in the art, it is not desired to limit the invention to the exact construction and process shown as described above. Accordingly, all suitable modifications and equivalents may be resorted to falling within the scope of the invention as defined by the claims that follow.
The words "comprise," "comprising," "include," "including," and "includes"
when used in this specification and in the following claims are intended to specify the presence of stated features, integers, components, or steps, but they do not preclude the presence or addition of one or more other features, integers, components, steps, or groups thereof.
1o R6 is trifluoromethyl, C1-C~o alkyl, C3-Clo cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSOZR~~~, -SOZNRR~, -C(O)R, -C(O)OR, -OC(O)R, -NRC(O)OR~~~, -NRC(O)R~, -C(O)NRR~, -SOZR~~~, -NRR, -NR C(O)NR ~R ~~, -NR C(NCI~NR ~R ~~, -OR , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, heterocyclyl, -C(O)ORS, -C(O)NR3R4, -C(O)NR40R3, -C(O)R40R3, -C(O)(C3-C,o cycloalkyl), -C(O)(C1-Cm alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SOZ)CH3 or CR30R3, wherein any of said heteroaryl, heterocyclyl, -C(O)ORS, -C(O)NR3R4, -C(O)NR40R3, -C(O)R40R3, -C(O)(C3-Clo cycloalkyl), -C(O)(C~-Clo alkyl), -C(O)(aryl), -C(O)(heteroaryl) -C(O)(heterocyclyl), -CONH(SOz)CH3 and CR30R3 are optionally substituted with one or more groups independently selected from -NR3R4, -ORS, -R2, C~-Clo alkyl, CZ-Clo alkenyl, and CZ-Coo alkynyl, wherein any of said C~-Coo alkyl, CZ-C1o alkenyl, and CZ-Coo alkynyl are optionally substituted with 1 or more groups independently selected from NR3R4 and -ORS;
mis0,1,2,3,4or5;
j is 0, 1 or 2; and \\\DE - 80248/0026 - 214630 v1 Y is a linker.
Preferred embodiments of Formula I have a structure wherein: (a) R' is 2-Cl;
(b) R' is Me, NH2 or H; (c) R8 is Br or Cl; (d) R~ is F; (e) W is -C(O)OH, -C(O)NHOCHZ-(cyclopropyl), -C(O)NHO(CH2)ZOH, or -CONH(SOz)CH3; or (f) or combinations of the above.
A "linker" is a molecular entity that connects two or more molecular entities through covalent or non-covalent interactions. Examples of linkers include, but are not limited to, NR3, O, S, S(O), S(O)2, C(O), and CH2, where R3 is as defined above.
Figures 1-6 show non-limiting examples of the synthesis of compounds of this 1o invention having the general Formula I.
In addition to compounds of the general Formula I, this invention further includes compounds of the general Formula II:
w R
R N
R7 R9 I I'~~R$
~N Rz Rt ~
II
where R1, RZ, R3, R4, R5, R~, R7, Rg, R9, Rlo, R., R.., R..., R...., W, y, m and j are as defined above, and R" is hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -ORS, -C(O)R3, -C(O)ORS, NR4C(O)OR6, -OC(O)R3, -NR4SOZR6, -SOZNR3R4, -NR4C(O)R3, -C(O)NR3R4, -NRSC(O)NR3R4, -NRSC(NCl~NR3R4, -NR3R4, C,-Clo alkyl, CZ-Clo alkenyl, CZ-Clo alkynyl, C3-C,o cycloalkyl, C3-C,o cycloalkylalkyl, -S(O)~(C~-C6 alkyl), -S(O)~(CR4R5)m aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m aryl, -NR4(CR4R5)m aryl, -O(CR4R5)m heteroaryl, -NR4(CR4R5)m heteroaryl, -O(CR4R5)m heterocyclyl or -NR4(CR4R5)m-heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SOZR6, -SOZNR3R4, -C(O)R3, -C(O)ORS, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R , -NRSC(O)NR3R4, -NRSC(NCN)NR3R4, -ORS, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl.
Preferred embodiments of Formula II have a structure wherein: (a) R1 is Cl;
(b) R' is H, 1-(4-methylpiperazinyl), morpholinyl, -NMe2, or -CHZ(piperidinyl); (c) R8 is Cl or Br; (d) R9 is Cl or H; (e) W is -COOH, -C(O)NHOCHZ-(cyclopropyl) or -C(O)NHO(CHZ)ZOH; or (fj or combinations of the above.
Figures 7-13 show non-limiting examples of the synthesis of compounds of this invention having the general Formula II. Figure 18 shows the synthesis of a phosphate prodrug of a compound having the general Formula II.
In another embodiment, this invention relates to compounds of the general Formula III:
R' / '.
R' o 9~~ s R~-N ~R Rz R
III
where R~, R2, R3, R4, R5, R~, R7, R8, R9, Rlo, R., R.., R..., R...., W, y, m 2o and j are as defined above.
Preferred embodiments of Formula III have a structure wherein: (a) RI is Cl;
(b) R' is methyl or benzyl; (c) R$ is Br; (d) R9 is Cl; (e) W is -C(O)NHOCH2-(cyclopropyl) or -C(O)NHO(CHZ)zOH; or (f) or combinations of the above.
Figure 14 shows a non-limiting example of the synthesis of compounds of this invention having the general Formula III.
In another embodiment, this invention relates to compounds of the general Formula IV:
W Ri Rio R~ ~ R9 ~ ~ Rs O _N R
IV
where Rl, R2, R3, R4, R5, R6, R', R8, R9, Rio, R., R.., R..., R...., W, y, m and j are as defined above.
Preferred embodiments of Formula IV have a structure wherein: (a) Rl is 2-Cl;
(b) R' is methyl; (c) R9 is F; (d) W is -COOH or -C(O)NHO(CHZ)zOH; or (e) or combinations of the above.
l0 Figure 15 shows a non-limiting example of the synthesis of compounds of this invention having the general Formula IV.
In another embodiment, this invention relates to compounds of the general Formula V:
Rlo Y R
R~ / N- _R9 /~R8 Rz -N
R~~
V
where R', Rz, R3, R4, R5, R6, R7, R8, R9, Rlo, Ry R., R.., R..., R,.,., W, y, m and j are as defined above. Figures 16-17 show non-limiting examples of the synthesis of compounds of this invention having the general Formula V.
Preferred embodiments of Formula V have a structure wherein: (a) Rl is 2-Cl, 2-H, or 2-F; (b) R8 is Cl or Br; (c) R9 is H, F or Cl; (d) W is -C(O)OH, -C(O)NHOCHZ-(cyclopropyl), -C(O)NHO(CHz)zOH, or -CONH(SOZ)CH3, or (e) or combinations of the above.
The terms "C~-Clo alkyl", "alkyl" and "lower alkyl" as used herein refer to a saturated linear or branched-chain monovalent hydrocarbon radical having one to ten carbon atoms, wherein the alkyl radical may be optionally substituted independently with one or more substituents described below. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, heptyl, octyl, and the like.
The terms "C2-Coo alkenyl", "lower alkenyl" and "alkenyl" refer to linear or to branched-chain monovalent hydrocarbon radical having two to 10 carbon atoms and at least one double bond, and include, but is not limited to, ethenyl, propenyl, 1-but-3 enyl, 1-pent-3-enyl, 1-hex-5-enyl and the like, wherein the alkenyl radical may be optionally substituted independently with one or more substituents described herein, and includes radicals having "cis" and "traps" orientations, or alternatively, "E" and "Z" orientations.
The terms "CZ-Clo alkynyl," "lower alkynyl" and "alkynyl" refer to a linear or branched monovalent hydrocarbon radical of two to twelve carbon atoms containing at least one triple bond. Examples include, but are not limited to, ethynyl, propynyl, butynyl, pentyn-2-yl and the like, wherein the alkynyl radical may be optionally substituted independently with one or more substituents described herein.
The term "allyl" refers to a radical having the formula RC=CHCHR, wherein R is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or any substituent as defined herein, wherein the allyl may be optionally substituted independently with one or more substituents described herein.
The terms "carbocycle," "carbocyclyl," "cycloalkyl" or "C3-C1o cycloalkyl"
refer to saturated or partially unsaturated cyclic hydrocarbon radical having from three to ten carbon atoms. The term "cycloalkyl" includes monocyclic and polycyclic (e.g., bicyclic and tricyclic) cycloalkyl structures, wherein the polycyclic structures optionally include a saturated or partially unsaturated cycloalkyl fused to a saturated or partially unsaturated cycloalkyl or heterocycloalkyl ring or an aryl or heteroaryl ring. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. The cycloalkyl may be optionally substituted independently in one or more substitutable positions with various groups. For example, such cycloalkyl groups may be optionally substituted with, for example, C~-C6 alkyl, C~-C6 alkoxy, halo, hydroxy, cyano, nitro, amino, mono(C~-C6)alkylamino, di(C1-C6)alkylamino, CZ-C6alkenyl, CZ-C6alkynyl, C~-C~
haloalkyl, C~-C6 haloalkoxy, amino(C~-C6)alkyl, mono(CI-C6)alkylamino(C1-C6)alkyl or di(C1-C6)alkylamino(C~-C6)alkyl.
The term "heteroalkyl" refers to saturated linear or branched-chain monovalent 1o hydrocarbon radical of one to twelve carbon atoms, wherein at least one of the carbon atoms is replaced with a heteroatom selected from N, O, or S, and wherein the radical may be a carbon radical or heteroatom radical (i.e., the heteroatom may appear in the middle or at the end of the radical). The heteroalkyl radical may be optionally substituted independently with one or more substituents described herein. The term "heteroalkyl" encompasses alkoxy and heteroalkoxy radicals.
The terms "heterocycloalkyl," "heterocycle" or "hetercyclyl" refer to a saturated or partially unsaturated carbocyclic radical of 3 to 8 ring atoms in which at least one ring atom is a heteroatom selected from nitrogen, oxygen and sulfur, the remaining ring atoms being C, where one or more ring atoms may be optionally 2o substituted independently with one or more substituent described below. The radical may be a carbon radical or heteroatom radical. The term further includes fused ring systems which include a heterocycle fused to an aromatic group.
"Heterocycloalkyl"
also includes radicals where heterocycle radicals are fused with aromatic or heteroaromatic rings. Examples of heterocycloalkyl rings include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-3o pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinylimidazolinyl, imidazolidinyl, 3-\\\DE - 80248/0026 - 214630 v1 azabicyco[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 3H-indolyl and quinolizinyl. Spiro moieties are also included within the scope of this definition. The foregoing groups, as derived from the groups listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached). An example of a heterocyclic group wherein 2 ring carbon atoms are substituted with oxo (=O) moieties is 1,1-dioxo-thiomorpholinyl. The heterocycle groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups. For example, such heterocycle groups may be optionally substituted with, for example, C1-C6 alkyl, C1-C6 alkoxy, halo, hydroxy, cyano, nitro, amino, mono(C1-C6)alkylamino, di(C1-C6)alkylamino, CZ-C6alkenyl, CZ-C~alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, amino(C~-C6)alkyl, mono(C~-C6)alkylamino(C,-C6)alkyl or di(C1-C6)alkylamino(C1-C6)alkyl.
The term "aryl" refers to a monovalent aromatic carbocyclic radical having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl), which is optionally mono-, di-, or trisubstituted with, e.g., halo, lower alkyl, lower alkoxy, trifluoromethyl, aryl, heteroaryl, and hydroxy.
2o The term "heteroaryl" refers to a monovalent aromatic radical of 5-, 6-, or membered rings which includes fused ring systems (at least one of which is aromatic) of 5-10 atoms containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur. Examples of heteroaryl groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and 3o furopyridinyl. Spiro moieties are also included within the scope of this definition.
Heteroaryl groups are optionally mono-, di-, or trisubstituted with, e.g., halo, lower alkyl, lower alkoxy, haloalkyl, aryl, heteroaryl, and hydroxy.
The term " halo" includes fluoro, bromo, chloro, and iodo substituents.
The term "arylalkyl" means an alkyl moiety (as defined above) substituted with one or more aryl moiety (also as defined above). More preferred arylalkyl radicals are aryl-C~_3-alkyls. Examples include benzyl, phenylethyl, and the like.
The term "heteroarylalkyl" means an alkyl moiety (as defined above) substituted with a heteroaryl moiety (also as defined above). More preferred heteroarylalkyl radicals are 5- or 6-membered heteroaryl-C1_3-alkyls. Examples include, oxazolylmethyl, pyridylethyl and the like.
to The term "heterocyclylalkyl" means an alkyl moiety (as defined above) substituted with a heterocyclyl moiety (also defined above). More preferred heterocyclylalkyl radicals are 5- or 6-membered heterocyclyl-C1_3-alkyls.
Examples include tetrahydropyranylmethyl.
The term "cycloalkylalkyl" means an alkyl moiety (as defined above) substituted with a cycloalkyl moiety (also defined above). More preferred heterocyclyl radicals are 5- or 6-membered cycloalkyl-C1_3-alkyls. Examples include cyclopropylmethyl.
The term "Me" means methyl, "Et" means ethyl, "Bu" means butyl and "Ac"
means acetyl.
2o In general, the various moieties or functional groups of the compounds of Formulas I-V may be optionally substituted by one or more substituents.
Examples of substituents suitable for purposes of this invention include, but are not limited to, oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SOzR6, -SOZNR3R4, -C(O)R3, -C(O)~R3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NRSC(O)NR3R4, -NRSC(NCI~NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where R3, R4, RS and R6 are as defined herein.
It is to be understood that in instances where two or more radicals are used in succession to define a substituent attached to a structure, the first named radical is considered to be terminal and the last named radical is considered to be attached to the structure in question. Thus, for example, the radical arylalkyl is attached to the structure in question by the alkyl group.
In the compounds of the present invention, where terms such as (CR4R5)m or (CR4R5)t are used, R4 and RS may vary with each iteration of m or t above 1.
For instance, where m or t is 2, the terms (CR4R5)m or (CR4R5)~ may equal -CHZCHZ-or -CH(CH3)C(CHZCH3)(CHzCHzCH3)- or any number of similar moieties falling within the scope of the definitions of R4 and R5.
The compounds of this invention may possess one or more asymmetric l0 centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers, diastereomers mixtures, racemic or otherwise, thereof.
Accordingly, this invention also includes all such isomers, including diastereomeric mixtures and pure enantiomers of the Formulas I-V. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization. Enantiomers can be separated by converting the enantiomer mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. The methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition, J. March, John Wiley and Sons, New York, 1992).
This invention also encompasses pharmaceutical compositions containing a compound of Formula I-V and methods of treating proliferative disorders, or abnormal cell growth, by administering compounds of the present invention.
Compounds of the present invention having free amino, amido, hydroxy or carboxylic 3o groups can be converted into pharmaceutically acceptable prodrugs.
The term "prodrug" means compounds that are rapidly transformed in vivo to yield the parent compound of Formula I-V, for example, by hydrolysis of a functional group of a Formula I-V compound in blood. A "pharmaceutically acceptable prodrug" is a compound that may be converted under physiological conditions or by solvolysis to the specified compound or to a pharmaceutically acceptable salt of such compound. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the present invention. The amino acid 1 o residues include but are not limited to the 20 naturally occurnng amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutyric acid, cirtulline, homocysteine, homoserine, ornithine and methionine sulfone. One preferred prodrug of this invention is a compound of Formula I-V covalently joined to a phosphate residue. Another preferred prodrug of this invention is a compound of Formula I-V covalently joined to a valine residue.
Additional types of prodrugs are also encompassed. For instance, a compound of Formula I-V having free carboxyl groups can be derivatized as amides or alkyl esters. A compound of Formula I-V having free hydroxy groups may be derivatized using groups including but not limited to phosphate esters, hemisuccinates, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of compounds of Formula I-V having hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate ester and sulfate ester prodrugs of compounds of Formula I-V
having hydroxy groups. Derivatization of hydroxy groups to provide (acyloxy)methyl and (acyloxy)ethyl ether prodrugs of compounds of Formula I-V, wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also encompassed. Prodrugs of this type are 3o described in .l. Med. Chem., 1996, 39, 10. Compound of Formula I-V having free amines can also be derivatized as amides, sulfonamides or phosphonamides prodrugs.
All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
In addition, the invention also includes solvates, pharmaceutically active metabolites, and pharmaceutically acceptable salts of compounds of Formulas I-V.
The term "solvate" refers to an aggregate of a molecule with one or more solvent molecules.
A "pharmaceutically active metabolite" is a pharmacologically active product produced through metabolism in the body of a specified compound or salt thereof.
Metabolites of a compound may be identified using routine techniques known in the to art and their activities determined using tests such as those described herein.
Prodrugs and active metabolites of a compound may be identified using routine techniques known in the art. Various forms of prodrugs are known in the art.
For examples of such prodrug derivatives, see, for example, a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p.
309-396, edited by K. Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter "Design and Application of Prodrugs," by H. Bundgaard p. 113-191 (1991); c) H.
Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); d) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77:285 (1988); and e) N. Kakeya, et al., 2o Chem. Pharm. Bull., 32: 692 (1984), each of which is specifically incorporated herein by reference.
A "pharmaceutically acceptable salt" as used herein, unless otherwise indicated, includes salts that retain the biological effectiveness of the free acids and bases of the specified compound and that are not biologically or otherwise undesirable. A compound of the invention may possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention 3o with a mineral or organic acid or an inorganic base, such salts including sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyn-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitromenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, pheylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, 'y hydroxybutyrates, glycollates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1-sulfonates, 1o naphthalene-2-sulfonates, and mandelates. Since a single compound of the present invention may include more than one acidic or basic moieties, the compounds of the present invention may include mono, di or tri-salts in a single compound.
If the inventive compound is a base, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an acidic compound, particularly an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, malefic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alphahydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.
If the inventive compound is an acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base. Preferred inorganic salts are those formed with alkali and alkaline earth metals such as lithium, sodium, potassium, barium and calcium. Preferred organic base salts include, for example, ammonium, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium, phenylethylbenzylamine, dibenzyl-ethylenediamine, and the like salts. Other salts of acidic moieties may include, for example, those salts formed with procaine, quinine and N-methylglusoamine, plus salts formed with basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine and arginine.
The inventive compounds may be prepared using the reaction routes and synthesis schemes as described below, employing the techniques available in the art using starting materials that are readily available or can be synthesized using methods known in the art.
Illustrations of the preparation of compounds of the present invention are shown in Schemes 1-9.
HO O X
HO O H
\ F F \ N \
\ -Br I / F I / _ Br I / F I /
F Br ~ F F
F
,O O H X ,O O H X
\ N \ \ N \
Br I / F I / / I / F I
F R F
i0 O H X ,O O X ~O O H X
H
\ N \ \ N \ \ N \
R I / F I / R I / F I / R \ I / F I / Y
HO O
H X
I \ N I \
R \ / F / Y
N-O
H R"
H R'~ ,N O ~~N O
R~~O~N O H X O S O H X R H X
\ N \ \ N \ \ N \
R \ I / F I / Y R \ I / F I / Y R \ I / F I / Y
N-O N-O N-O
110 111 .112 ~.O O H X ,O O
H X
\ N \ \ N \
Br I r F I r NC I ~ F
F F
,O O H X ,O O
H X
N '~ \ N \
i I ~ I I
HzN \ F HZN \ r F ~ Y
N-O N-O
R~~O~N O X
H
N \
HzN \ I / F I r Y
N-O
O OH O Cl Et0 ~~ HO I
I ~
N OH ~N~CI
HO O
H X
N
I / Y
~O O H X Me0 O X
H
N N
I / Y W I Cl I ~~ Y
NHz 120 Cl 122 HO O Me0 O X
H X H
/ N ~ / N
N I I / Nw I Cl I / y ~ ~Z Y
~N NHZ 123 HO O X
H
N
H N/ I I /
R~ ,N O Z ~, O H X ~N
I N I j 124 ~ 'Z Br N
Me0 O
H X
~~R~~
N
I / + Bt~Bt 'Z Y ' ~I'~~R~~
H
Me0 O X R~O~N O X
H H
N INI/ /1N1\
R"R'N~~ Z Y R"R'N~~ Z /
N ~N
Bt = benzotriazole H H
R~O~N O X R~O~N O
H H
N N
N I I ~ N I I ~
\Z Y R"R,N~N 'Z Y
R"'O O H X R"'O O H X
N N
N I I ~ N I I ~
OHC~ ~ ~Z Y R"R'N~ ~ 'Z Y
N N
H
R""~O~N O X
H
N
N I I
~Z Y
R"R'N~N
R"O O R"O O H X R"O O H X
H X
N N N
I I / ~ I I / N I I /
~Z Y O ~Z Y R~ ~ ~Z Y
Cl R~N,NH \\N-N
H
HO O H X R'~O~N O H X
N N
N I I / N I I /
R~ I ~Z Y R~ ~ ~Z Y
\\N_N \\N_N
H
,O O H X ~O O H X R'~O~N O H X
\N~\ /INI\ /IN
/ Y / /' Y / /' Y /
O F O-N O-N
~ N02 _ I ~ NH2 I ~ NHZ
CI N / NJ / N~Z
H X
Br ~ / ~ N
/~N~ ~Z
-N
147 ~ HO O X
H
NHZ , N
~I
N Z / N Z ~ Y
-N -N
.NO~ ~ N w / N- 'Z I ~ Y
-N
Y
H
R'wO, N O X
H
N ~ W
/ N~Z ~ Y
-N
Scheme 1 illustrates one method of preparing compounds of the Formula I.
Carboxylic acid 102 can be prepared from arene 101 by deprotonation at low temperature (-100 to -60 °C) in the appropriate ethereal solvent such as THF or diethyl ether followed by carbon dioxide quench, which can be performed with solid dry ice. The deprotonation can be accomplished with LDA in THF at -78 °C. One quench method comprises adding the aryllithium THF solution via cannula to a saturated solution of dry carbon dioxide in THF at -78 °C and then warming to room temperature. Aniline 103 can be prepared by deprotonation of an appropriate 2-substituted aniline with KHMDS, LiHMDS, NaHMDS or LDA at low temperature (-100 to -60 °C) in an appropriate ethereal solvent such as THF or diethyl ether, followed by addition of carboxylic acid 102 and warming to room temperature.
In one embodiment, deprotonation is accomplished with LDA at -78 °C in THF, followed by addition of carboxylic acid 102 and warming to room temperature.
Ester 104 can be prepared by standard methods including, but not limited to, Fisher esterification (MeOH, H2S04), reaction with TMSCHN2 or TMSCI in MeOH.
Acetylene derivative 105 is prepared by Sonagashria coupling of bromide 104 using an appropriatly substituted acetylene, CuI, an amine base, palladium catalyst and organic solvent such as DME, THF, or DMF at temperatures between 25 and 100 °C.
Suitable palladium catalysts include, but are not limited to, PdCl2(dppf), Pd(Ph3P)4, 2o and Pd2dba3fdppf. Suitable amine bases include, but are not limited, to Et3N, Hunig's base, and diisopropyl amine. In one embodiment, the Pd(0) mediated coupling to prepare acetylene 105 is accomplished with Pd(PPh3)ZCIz, CuI, diisopropyl amine, and the appropriate substituted acetylene in THF at room temperature.
Hydrolysis of acetylene 105 to prepare ketone 106 can be accomplished by standard methods including but not limited to HZS04, TFA, trifluorosulfonamide, FeCl3, or HgSOa/HzSOa. Benzisoxazole 107 can be prepared in a two step procedure from ketone 106. Addition of the potassium salt of acetone oxime in suitable organic solvent such as THF or Et20 at temperatures ranging from -78 to 5 °C is followed by acid catalyzed cyclization. The acetone oxime addition is most easily performed by 3o addition of a THF solution of ketone 106 to the salt at 0 °C. The cyclization can be accomplished with a variety of acidic aqueous conditions at a range of temperatures.
In one embodiment cyclization is accomplished by treatment of the isopropylideneaminooxybenzoic acid methyl ester with 5% aqueous HCl in MeOH at reflux. Halogenation to form benzisoxazole 108 is accomplished using standard procedures such as NCS or NBS in DMF. Hydrolysis of ester 108 to form carboxylic acid 109 can be performed under standard conditions. The acid can be converted to hydroxamate 110 or amide 112 by standard coupling procedures including but not limited to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxyl amine or amine.
Alternatively, hydroxamate 110 or amide 112 can be prepared in two steps by initial conversion to the acid chloride by standard methods followed by addition of the 1o hydroxyl amine or amine. Acyl sulfonamide 111 can be synthesized by preparing an activated ester of carboxylic acid 109 followed by treatment with the appropriate sulfonamide and tertiary amine base in a suitable organic solvent such as THF.
In one embodiment, acyl sulfonamide 111 is prepared by treatment of carboxylic acid with CDI at elevated temperature (50 °C) in THF followed treatment with the appropriate sulfonamide and DBU.
Scheme 2 illustrates an alternative method for synthesizing compounds of the Formula I. Nitrile 113 can be prepared by palladium mediated coupling of bromide 104 with zinc cyanide in suitable organic solvent such as DMA, NMP or DMF at elevated temperatures ranging from 50 to 120 °C. Several palladium catalysts may be 2o employed including but not limited to Pd(PPh3)4, PdCl2(dppf), or Pdzdba3 with ligands such as dppe, dppp, dppf or BINAP. In one embodiment, nitrite 113 is prepared from bromide 104 by treatment with zinc cyanide, Pd2dba3, and dppf in NMP at 120 °C. Amino benzisoxazole 114 can be prepared in a two step procedure from nitrite 113 by the addition of the potassium salt of acetone oxime in suitable organic solvent such as THF or Et20 at temperatures ranging from -78 to 5 °C
followed by acid catalyzed cyclization. In one embodiment the acetone oxime addition can be performed by addition of a THF solution of nitrite 113 to the salt at 0 °C in THF followed by warming to room temperature. The cyclization can be accomplished under a variety of acidic conditions at a range of temperatures.
In one embodiment the cyclization method comprises treatment of the oxime addition product in MeOH with 2 M HCl in Et20. Halogenation to form benzisoxazole 115 is accomplished using standard procedures such as NCS or NBS in DMF. Compound 116 is prepared in a two step procedure comprising hydrolysis of ester 115 under standard conditions to form the corresponding carboxylic acid, followed by conversion of the carboxylic acid to hydroxamate 116 by standard coupling procedures, including but not limited, to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxyl amine.
Scheme 3 illustrates one method of synthesizing compounds of the Formula II.
4,6-Dichloronicotinic acid 118 can be prepared from 4,6-dihydroxynicotinic acid ethyl ester 117 in two steps. In the first step, 4,6-dihydroxynicotinic acid ethyl ester 117 is chlorinated using an appropriate reagent such as POC13, oxalyl chloride or thionyl chloride. In one embodiment, chlorination is accomplished with POC13 and Et3N at elevated temperatures. Hydrolysis of the resulting dichloroethyl ester to provide compound 118 can be performed under standard conditions. Aniline 119 can be prepared by deprotonation of the properly substituted aniline with KHMDS, LiHMDS, NaHMDS or LDA at low temperature (-100 to -60 °C) in appropriate ethereal solvent such as THF or diethyl ether followed by addition of carboxylic acid 118 and warming to room temperature. In one embodiment, deprotonation is accomplished with LiHMDS at -78 °C in THF, followed by addition of carboxylic acid 118 and warming to room temperature. Amino pyridine 120 is prepared in three 2o steps from aniline 119. In the first step, the tert-butyl ester is prepared by treating the acid 119 with 2-tert-butyl-1,3-diisopropylisourea in THF at temperatures ranging from 25 to 75 °C. In the second step, sodium azide is added to the tert-butyl ester in DMF at 80 °C. The amino pyridine 120 is prepared by reduction of the azide under standard conditions including but not limited to Zn dust/AcOH, Pt/C or Pt02 in the presence of HZ gas, Ph3P or SnCl2/MeOH. In one embodiment, the azide reduction is accomplished by treatment with Zn dust in a mixture of methylene chloride and acetic acid. Imidazo pyridine 121 where Z = F is prepared in two steps from amino pyridine 120. In the first step, fluorination is accomplished by treatment of the amino pyridine 120 with SELECTFLUORTM in a mixture of MeOH and water or pH 7 phosphate 3o buffer. Cyclization to form imidazo pyridine 121 (Z = H or F) can be accomplished by treatment with chloro or bromo acetaldehyde in suitable organic solvent such as DMF or EtOH at elevated temperatures (50 to 120 °C). In one embodiment, cyclization is realized by treatment with chloroacetaldehyde in EtOH at 70 °C.
Alternatively, aniline 119 can be converted to dichloroester 122 in two steps.
In the first step, chlorination is performed under standard conditions such as NCS in DMF.
In the second step, esterification can be achieved by standard methods including but not limited to Fisher esterification (MeOH, HZS04), reaction with TMSCHNZ or TMSCI in MeOH. Aminopyridine 123 can be prepared as described above for aminopyridine 120 with the exception that the sodium azide addition can be accomplished at room temperature. Cyclization (achieved as described above for 1o imidazopyridine 121) followed by standard basic saponification gives imidazo pyridine 124. Hydroxamate 125 can be prepared from either imidazo pyridine 121 or 124 using standard coupling procedures including but not limited to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxylamine. Alternatively, hydroxamate can be prepared in two steps by initial conversion to the acid chloride by standard methods followed by addition of the hydroxylamine.
Scheme 4 illustrates an alternative method of preparing compounds of Formula II. An appropriately functionalized 2-aminopyridine 126 in a suitable organic solvent such as dichloromethane or dichloroethane is reacted with a Lewis acid such as zinc bromide and condensation product (127) as disclosed by Katritzky et 2o al. (J. Org. Chem., 2003, 68, 4935-4937: J. Org. Chem., 1990, 55, 3209-3213) to provide the 3-dialkyaminoimidazo[1,2-a]pyridine ring system 128. Condensation products 127 (i.e., condensation of a glyoxal, benzotriazole and a secondary amine) can be generated using benzotriazole, glyoxal and any appropriate secondary amine including, but not limited to dimethylamine, diethylamine, pyrrolidine, piperidine, morpholine, 1-methylpiperazine, N-methyl allylamine, diallyamine, and N-methyl benzylamine. The ester 128 is hydrolyzed by standard saponification methods, and the resulting acid can be converted to hydroxamate 129 by standard coupling procedures including but not limited to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxylamine. Alternatively, hydroxamate 129 can be prepared in two steps by initial conversion of the carboxylic acid to the acid chloride or activated ester by standard methods followed by addition of the hydroxylamine.
Scheme 5 illustrates an alternative method of preparing compounds of the Formula II. The preparation of 3-aminomethylimidazo[1,2-a]pyridines 131 using the modified Mannich reaction procedure developed by Kercher et al. (manuscript in preparation) is illustrated. The reaction is generally carried out by combining 37%
aqueous formaldehyde and a suitable amine in 6:1 acetonitrile/water. Several secondary amines can be employed including but not limited to pyrrolidine, piperadine, morpholine, dimethylamine, N-BOC-piperazine and 1-methylpiperazine.
The solution of amine and formaldehyde is stirred for approximately half an hour after which time scandium triflate and the appropriate imidazo[1,2-a]pyridine 130 are 1o sequentially added. The Mannich reaction is preferentially catalyzed by a group IIIA
lanthanide triflate, preferably scandium triflate, though alternatively it may be performed using an excess of protic acid (AcOH or HCl) or elevated temperatures.
Scheme 6 illustrates an alternative method of preparing compounds of Formula II. In Scheme 6, the preparation of 3-aminomethylimidazo[1,2-a]pyridines 134 via reductive alkylation is illustrated. In step 1, the 3-aminomethylimidazo[1,2-a]pyridine 133 is prepared from the appropriate 3-formyl-imidazo[1,2-a]pyridine 132 and a suitable amine using standard reduction methods such as Na(CN)BH3, Na(OAc)3BH, NMe4BH(OAc)3 with or without the addition of acetic acid in a suitable nonreactive organic solvent such as methylene chloride, acetonitrile or 2o tetrahydrofuran. The reductive amination is generally accomplished by treatment of the aldehyde derivative 132 with the amine and acetic acid in tetrahydrofuran at room temperature followed by the addition of Na(OAc)3BH. In cases where R" = H, the corresponding secondary amine 133 can optionally be protected, for example with an acid labile protecting group such as tert-butyl carbamate (BOC) to facilitate handling in subsequent steps. In step 2, the ester is hydrolyzed by standard saponification methods, and the resulting acid can be converted to hydroxamate 134 by standard coupling procedures including but not limited to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxylamine. Alternatively, hydroxamate 134 can be prepared in two steps by initial conversion of the carboxylic acid to the acid chloride or activated ester 3o by standard methods followed by addition of the hydroxylamine. Protecting groups, if present, are removed after coupling. .
Scheme 7 illustrates one method of preparing compounds of Formula III. In Scheme 7 the preparation of 3-alkyl-[1,2,4]triazolo[4,3-a]pyridine derivatives is illustrated. Compound 136 is prepared from compound 135 in a two step process.
A
suitably functionalized 2-chloropyridine derivative 135 is converted to the 2-hydrazinopyridine by reaction with hydrazine. The reaction is generally accomplished by reaction of hydrazine with 2-chloropyridine derivative 135 in an unreactive organic solvent such as DMF or DMA at elevated temperature (50 to °C). The 2-hydrazinopyridine is then acylated with the appropriate carboxylic acid halide such as fluoride, chloride or bromide, or the appropriate carboxylic acid anhydride or mixed anhydride in a suitable unreactive organic solvent such as dichloromethane, and in the presence of a suitable base such as triethylamine, diisopropylethylamine or pyridine, to provide intermediate 136. Acylation of the 2-hydrazinopyridine can alternatively be accomplished by standard peptide coupling procedures with the appropriate carboxylic acid and appropriate coupling reagent, including but not limited to EDCI/HOBt, PyBOP, or DIC. The intermediate 136 is converted to 3-alkyl-[ 1,2,4]triazolo[4,3-a]pyridine 137 by treatment with an excess of phosphorus oxychloride in refluxing dichloromethane. The ester 137 is hydrolyzed by standard saponification methods, and the resulting acid 138 can be converted to hydroxamate 139 by standard peptide coupling procedures including but not limited 2o to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxyl amine.
Alternatively, hydroxamate 139 can be prepared in two steps by initial conversion of the carboxylic acid to the acid chloride or activated ester by standard methods followed by addition of the hydroxylamine.
Scheme 8 illustrates one method of preparing compounds of the Formula IV.
In Scheme 8, the synthesis of 3-methyl-benzo[c]isoxazole derivatives is illustrated.
Compound 141 is prepared from compound 140 in a two step process. Methyl ester 140 is treated with sodium azide in 3:1 acetone/water at elevated temperature (reflux) to effect nucleophilic substitution. The 4-azido derivative is then isolated and heated in water at reflux to effect cyclization to the benzo[c]isoxazole ring system 141. The ester 141 is hydrolyzed by standard saponification methods, and the resulting carboxylic acid can be converted to hydroxamate 142 by standard peptide coupling procedures including but not limited to EDCIfHOBt, PyBOP, or DIC and the appropriate hydroxylamine. Alternatively, hydroxamate 142 can be prepared in two steps by initial conversion of the carboxylic acid to the acid chloride or activated ester by standard methods followed by addition of the hydroxylamine.
Scheme 9 illustrates one method of preparing compounds of Formula V. 2-Chloro-4-methyl-5-nitropyridine '143 can be converted to amino pyridine 144 in a three step sequence. In the first step, Sonagashria coupling using TMS-acetylene, CuI, amine base, palladium catalyst and organic solvent such as DME, THF, or DMF
at temperatures from 25 to 100 °C gives the nitroacetylenic pyridine.
Suitable 1o palladium catalysts include, but are not limited to, PdCl2(dppf), Pd(Ph3P)4, Pd(PPh3)ZC12 and PdZdba3ldppf. Suitable amine bases include, but are not limited to, Et3N, Hunig's base, and diisopropyl amine. The amino pyridine 144 is then prepared by removal of the TMS group under standard conditions such as KZC03 in MeOH, followed by reduction of the nitro group using either Zn dusdAcOH, Fe or SnCl2lMeOH. For Z = H, amino pyridine 144 is used directly in the cyclization reaction. When Z = Cl, aminopyridine 144 is halogenated under standard conditions with NCS in DMF and then earned forward to the cyclization. When Z = F, the 2-chloro-3-aminopyridine intermediate is treated with KF, Kryptofix in DMSO to prepare amino pyridine 145. Cyclization to give pyrazolo[1,5-a]pyridine 146 is 2o accomplished by treating aminopyridine 145 with O-(4-nitrophenyl)-hydroxylamine in a suitable organic solvent such as DMF at room temperature in presence of a base such as KZC03. Carboxylic acid 149 can be prepared, for example, using one the following routes. One route involves palladium mediated cross-coupling with appropriately substituted bromobenzene and aminopyrazolo[1,5-a]pyridine 146.
In this case, the cross-coupling can be accomplished with palladium catalyst and organic solvent such as DME, THF, dioxane, and toluene at temperatures from 60 to 120 °C.
Suitable palladium catalysts include, but are not limited to, Pd(OAc)z, PdCl2(dpp~, Pd2(bda)3, and Pd(dba)2. Suitable ligands include, but are not limited to, BINAP, DPPF, and (o-tol)3P. Suitable amine bases include, but are not limited to, NaOt-Bu, KOt-Bu, and CsZC03. The second route involves SNAr reaction with aminopyrazolo[1,5-a]pyridine 146 and the appropriately substituted 2-fluoronitrobenzene. In this case, the coupling can be accomplished by mixing the two components in a suitable organic solvent such as xylenes, toluene, DMSO or DMF
at elevated temperatures (80 to 150 °C). Optionally, a base can be employed in the SNAr coupling such as KZC03 or Cs2C03. The carboxylic acid 149 is then prepared by functionalization of the aromatic ring followed by oxidation. In the first case, functionalization involves halogenation under standard conditions with either NCS or NBS in DMF. In the second case, functionalization involves Sandmeyer chemistry to convert the nitroarene into the desired arene or arylhalide (nitro group reduction;
diazonation; halogentation or protonation). In both routes, the last step to prepare carboxylic acid 149 is oxidation of the toluyl moiety. This can be achieved using standard methods including but not limited to KMn04, NaOCI/RuCl3 or Na2Crz07/HCI. The resulting carboxylic acid 149 can be converted to hydroxamate 150 by standard peptide coupling procedures including but not limited to EDCI/HOBt, PyBOP, or DIC and the appropriate hydroxylamine. Alternatively, hydroxamate 150 can be prepared in two steps by initial conversion of the carboxylic acid to the acid chloride or activated ester by standard methods followed by addition of the hydroxylamine.
The invention also relates to a pharmaceutical composition for the treatment of a hyperproliferative disorder in a mammal which comprises a therapeutically effective 2o amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier. In one embodiment, said pharmaceutical composition is for the treatment of cancer such as brain, lung, squamous cell, bladder, gastic, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, esophageal, testicular, gynecological or thyroid cancer. In another embodiment, said pharmaceutical composition is for the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g., benign prostatic hypertrophy (BPH)).
The invention also relates to a pharmaceutical composition for the treatment of pancreatitis or kidney disease (including proliferative glomerulonephritis and diabetes-induced renal disease) or the treatment of pain in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable Garner.
The invention also relates to a pharmaceutical composition for the prevention of blastocyte implantation in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier.
The invention also relates to a pharmaceutical composition for treating a disease related to vasculogenesis or angiogenesis in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier. In one embodiment, said pharmaceutical composition is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
The invention also relates to a method of treating a hyperproliferative disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof. In one embodiment, said method relates to the treatment of cancer such as brain, lung, squamous cell, bladder, gastic, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, esophageal, testicular, gynecological or thyroid cancer. 1n another embodiment, said method relates to the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g., benign prostatic hypertrophy (BPH)).
The invention also relates to a method for the treatment of a hyperproliferative disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or 'a pharmaceutically acceptable salt, prodrug or hydrate thereof, in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens.
The invention also relates to a method of treating pancreatitis or kidney disease in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
The invention also relates to a method of preventing blastocyte implantation in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
The invention also relates to a method of treating diseases related to vasculogenesis or angiogenesis in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof. In one embodiment, said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
Patients that can be treated with compounds of the present invention, or pharmaceutically acceptable salts, prodrugs and hydrates of said compounds, according to the methods of this invention include, for example, patients that have been diagnosed as having psoriasis, restenosis, atherosclerosis, BPH, lung cancer, bone cancer, CMML, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, testicular, 3o gynecologic tumors (e.g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (e.g., cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of the urethra, cancer s of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter (e.g., renal cell carcinoma, carcinoma of the renal pelvis), or neoplasms of the central nervous system (e.g., primary CNS lymphona, spinal axis tumors, brain stem gliomas or pituitary adenomas).
1o This invention also relates to a pharmaceutical composition for inhibiting abnormal cell growth in a mammal which comprises an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate or prodrug thereof, in combination with an amount of a chemotherapeutic, wherein the amounts of the compound, salt, solvate, or prodrug, and of the chemotherapeutic are together is effective in inhibiting abnormal cell growth. Many chemotherapeutics are presently known in the art. In one embodiment, the chemotherapeutic is selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis 20 inhibitors, and anti-androgens.
This invention further relates to a method for inhibiting abnormal cell growth in a mammal or treating a hyperproliferative disorder which method comprises administering to the mammal an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate or prodrug thereof, in combination with 25 radiation therapy, wherein the amounts of the compound, salt, solvate, or prodrug, is in combination with the radiation therapy effective in inhibiting abnormal cell growth or treating the hyperproliferative disorder in the mammal. Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapy described herein. The administration of the compound of 3o the invention in this combination therapy can be determined as described herein.
It is believed that the compounds of the present invention can render abnormal cells more sensitive to treatment with radiation for purposes of killing and/or inhibiting the growth of such cells. Accordingly, this invention further relates to a method for sensitizing abnormal cells in a mammal to treatment with radiation which comprises administering to the mammal an amount of a compound of the present invention or pharmaceutically acceptable salt or solvate or prodrug thereof, which amount is effective in sensitizing abnormal cells to treatment with radiation.
The amount of the compound, salt, or solvate in this method can be determined according to the means for ascertaining effective amounts of such compounds described herein.
The invention also relates to a method of and to a pharmaceutical composition of inhibiting abnormal cell growth in a mammal which comprises an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof, a prodrug thereof, or an isotopically-labeled derivative thereof, and an amount of one or more substances selected from anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents.
Anti-angiogenesis agents, such as MMP-2 (matrix-metalloprotienase 2) inhibitors, MMP-9 (matrix-metalloprotienase 9) inhibitors, and COX-II
(cyclooxygenase II) inhibitors, can be used in conjunction with a compound of the present invention and pharmaceutical compositions described herein. Examples of useful COX-II inhibitors include CELEBREX~ (alecoxib), valdecoxib, etoricoxib, lumiracoxib and rofecoxib. Examples of useful matrix metalloprotienase inhibitors are described in WO 96/33172 (published October 24, 1996), WO 96/27583 (published March 7, 1996), European Patent Application No. 97304971.1 (filed July 8, 1997), European Patent Application No. 99308617.2 (filed October 29, 1999), WO
98/07697 (published February 26, 1998), WO 98/03516 (published January 29, 1998), WO 98/34918 (published August 13, 1998), WO 98/34915 (published August 13, 1998), WO 98/33768 (published August 6, 1998), WO 98/30566 (published July 16, 1998), European Patent Publication 606,046 (published July 13, 1994), European Patent Publication 931,788 (published July 28, 1999), WO 90/05719 (published May 31, 1990), WO 99/52910 (published October 21, 1999), WO 99/52889 (published 3o October 21, 1999), WO 99/29667 (published June 17, 1999), PCT International Application No. PCT/IB98/01113 (filed July 21, 1998), European Patent Application No. 99302232.1 (filed March 25, 1999), Great Britain Patent Application No.
9912961.1 (filed June 3, 1999), United States Provisional Application No.
60/148,464 (filed August 12, 1999), United States Patent 5,863,949 (issued January 26, 1999), United States Patent 5,861,510 (issued January 19, 1999), and European Patent Publication 780,386 (published June 25, 1997), all of which are incorporated herein in their entireties by reference. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP-2 and/or MMP-9 relative to the other matrix-metalloproteinases (i.e., MMP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, 1o MMP-12, and MMP-13).
The terms "abnormal cell growth" and "hyperproliferative disorder" are used interchangeably in this application.
"Abnormal cell growth," as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes, for example, the abnormal growth of (1) tumor cells (tumors) that proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; (2) benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; (3) any tumors that proliferate by receptor tyrosine kinases; (4) any tumors that proliferate by aberrant 2o serine/threonine kinase activation; and (5) benign and malignant cells of other proliferative diseases in which aberrant serine/theroine kinase activation occurs.
The term "treating," as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment," as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above.
The amount of a given agent that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (e. g., weight) of the mammal in need of treatment, but can 3o nevertheless be routinely determined by one skilled in the art. "Treating"
is intended to mean at least the mitigation of a disease condition in a mammal, such as a human, that is affected, at least in part, by the activity of MEK, and includes, but is not limited to, preventing the disease condition from occurnng in a mammal, particularly when the mammal is found to be predisposed to having the disease condition but has not yet been diagnosed as having it; modulating and/or inhibiting the disease condition; and/or alleviating the disease condition.
In order to use a compound of the Formula I-V or a pharmaceutically acceptable salt or prodrug thereof, for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in 1o accordance with standard pharmaceutical practice as a pharmaceutical composition.
According to this aspect of the invention there is provided a pharmaceutical composition that comprises a compound of the Formula I-V, or a pharmaceutically acceptable salt or prodrug thereof, as defined hereinbefore in association with a ' pharmaceutically acceptable diluent or carrier.
The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, or intramuscular dosing or as a suppository for rectal dosing). For example, compositions intended for oral use may contain, for example, one or more coloring, sweetening, flavoring and/or preservative agents.
Suitable pharmaceutically-acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-3o hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability andlor appearance, in either case, using conventional coating agents and procedures well known in the art.
Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium 1o carboxymethylcellulose, methylcellulose, hydroxypropyhnethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), coloring agents, flavoring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
3o Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives.
Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurnng gums to such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavoring and preservative agents.
Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavoring and/or coloring agent.
The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irntating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.
Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedures well known in the art.
Compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example, 30 ~m or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose. The powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50 mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.
Compositions for administration by inhalation may be in the form of a to conventional pressurized aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
For further information on formulations, see Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990, which is specifically incorporated herein by reference.
The amount of a compound of this invention that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the subject treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician.
However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 0.5 to about 35 mglkg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g/day, preferably about 0.05 to about 2.5 glday. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day. For further information on routes of administration and dosage regimes, see 3o Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch;
Chairman of Editorial Board), Pergamon Press 1990, which is specifically incorporated herein by reference.
The size of the dose for therapeutic or prophylactic purposes of a compound of Formula I-V will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.
The compounds of this invention may be used alone in combination with other drugs and therapies used in the treatment of disease states which would benefit from the inhibition of MEK. For example, a compound of this invention may be applied in l0 combination with one or more other anti-tumor substances, including, but not limited to, mitotic inhibitors such as vinblastine; alkylating agents such as cis-platin, carboplatin and cyclophosphamide; anti-metabolites such as 5-fluorouracil, cytosine arabinside and hydroxyurea; or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No. 239362 such as N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid;
growth factor inhibitors; signal transduction inhibitors, such as agents that can inhibit EGFR (epiderman growth factor receptor) responses, such as EGRF antibodies, EGF
anitbodies and molecules that are EGFR inhibitors such as the compounds ZD-(AstraZeneca) and BIBX-1382 (Boehringer Ingelheim); VEGF inhibitors such as SU-6668 (Sugen Inc. of South San Francisco, California, USA) or the anit-VEGF
monoclonal antibody of Genentech, Inc. of South San Francisco, California;
cell cycle inhibitors; intercalating antibiotics such as adriamycin and bleomycin;
enzymes, for example, interferon; and anti-hormone such as anti-estrogens such as NolvadexTM (tamoxifen); or, for example anti-androgens such as CasodexTM (4' cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3' (trifluoromethyl)propionanilide). Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of treatment.
Although the compounds of Formula I-V are primarily of value as therapeutic 3o agents for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit the effects of MEK. Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.
The activity of the compounds of the present invention may be determined by the following procedure. N-terminal 6 His-tagged, constitutively active MEK-1 (2-393) is expressed in E. coli and protein is purified by conventional methods (Ahn et al., Science 1994, 265, 966-970). The activity of MEKl is assessed by measuring the incorporation of y-33P-phosphate from Y_33P-ATP onto N-terminal His tagged ERK2, which is expressed in E. coli and is purified by conventional methods, in the presence of MEK-1. The assay is carried out in 96-well polypropylene plate. The incubation to mixture (100 pL) comprises of 25 mM Hepes, pH 7.4, 10 mM MgCl2, 5 mM (3-glycerolphosphate, 100 pM Na-orthovanadate, 5 mM DTT, 5 nM MEK1, and 1 pM
ERK2. Inhibitors are suspended in DMSO, and all reactions, including controls are performed at a final concentration of 1 % DMSO. Reactions are initiated by the addition of 10 p.M ATP (with 0.5 pCi ~y-33P-ATPlwell) and incubated at ambient temperature for 45 minutes. Equal volume of 25% TCA is added to stop the reaction and precipitate the proteins. Precipitated proteins are trapped onto glass fiber B
filterplates, and excess labeled ATP washed off using a Tomtec MACH III
harvestor.
Plates are allowed to air-dry prior to adding 30 pL/well of Packard Microscint 20, and _ plates are counted using a Packard TopCount. In this assay, compounds of the invention exhibited an ICSO of less than 50 micromolar.
Representative compounds of.the present invention, which are encompassed by the present invention include, but are not limited to the compounds of the examples and their pharmaceutically acceptable acid or base addition salts or prodrugs thereof. The examples presented below are intended to illustrate particular embodiments of the invention, and are not intended to limit the scope of the specification or the claims in any way.
The disclosures in this application of all articles and references, including patents, are incorporated herein by reference.
EXAMPLES
In order to illustrate the invention, the following examples are included.
However, it is to be understood that these examples do not limit the invention and are only meant to suggest a method of practicing the invention. Persons skilled in the art will recognize that the chemical reactions described may be readily adapted to prepare a number of other MEK inhibitors of the invention, and alternative methods for preparing the compounds of this invention are deemed to be within the scope of this invention. For example, the synthesis of non-exemplified compounds according to the invention may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art other than those described, and/or by making l0 routine modifications of reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the invention.
In the examples described below, unless otherwise indicated all temperatures are set forth in degrees Celsius. Reagents were purchased from commercial suppliers such as Aldrich Chemical Company, Lancaster, TCI or Maybridge, and were used without further purification unless otherwise indicated. Tetrahydrofuran (THF), N,N-dimethylformamide (DMF), dichloromethane, toluene, dioxane and 1,2-difluoroethane were purchased from Aldrich in Sure seal bottles and used as received.
The reactions set forth below were done generally under a positive pressure of nitrogen or argon or with a drying tube (unless otherwise stated) in anhydrous solvents, and the reaction flasks were typically fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried.
Column chromatography was done on a Biotage system (Manufacturer: Dyax Corporation) having a silica gel column or on a silica SepPak cartridge (Waters).
'H-NMR spectra were recorded on a Bruker instrument operating at 300 MHz or on a Varian instrument operating at 400 MHz. 1H-NMR spectra were obtained as CDCl3 solutions (reported in ppm), using chloroform as the reference standard (7.25 ppm). Other NMR solvents were used as needed. When peak multiplicities are 3o reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets). Coupling constants, when given, are reported in Hertz (Hz).
Example 1 HO O CI
H
N
~F Br N-O
Synthesis of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3 methylbenzo[d]isoxazole-5-carboxylic acid (9a) The reaction scheme for the synthesis of compound 9a is shown in Figure 1.
Step A: Preparation of 5-bromo-2,3,4-trifluorobenzoic acid (2): To a solution of 1-bromo-2,3,4-trifluorobenzene (1) (5.0 mL, 41.7 mmol) in THF (120 mL) was added LiHMDS (2.0 M solution, 21 mL, 42 mmol) at -78 °C. After stirnng for 1 hour at -78 °C, the mixture was added to a solution of COZ in THF (1 L). The dry-ice bath was removed and the reaction mixture stirred overnight at room temperature.
The reaction mixture was quenched with 10% aqueous HCl (835 mL), concentrated, and washed with ether (250 mL). The combined organics were washed with 5%
aqueous NaOH (300 mL) and water (100 mL). The aqueous layer was acidified (pH
0) with concentrated HCI. The resulting suspension was extracted with ether (2 x 300 mL), dried over MgS04, filtered, concentrated under reduced pressure to afford 7.70 g (72% yield) of the desired product (2).
Step B: Preparation of S-bromo-2-(2-chlorophenylamino)-3,4-difluorobenzoic acid 3 : To a solution of LiHMDS (49.0 mL, 2 M in THF/heptane) in THF (40 mL) was added 2-chlorophenylamine (6.50 mL, 60.6 mmol) at -78 °C. After vigorous stirring for 10 minutes, a solution of 5-bromo-2,3,4-trifluoro-benzoic acid (2) (7.70 g, 30.2 mmol) in THF (60 mL) was added. The dry-ice bath was removed and the reaction mixture stirred for 4 hours at room temperature. The mixture was concentrated, treated with 10% aqueous HCl (75 mL), and extracted with EtOAc.
The combined organic extracts were dried over MgS04, filtered, and concentrated.
Purification by trituration with boiling CHZC12 gave 7.24 g (66%) of the desired acid (3) as a yellow solid Step C: Preparation of 5-bromo-2~2-chlorophenylamino)-3,4-difluorobenzoic acid methyl ester (4): To a solution of 5-bromo-2-(2-chlorophenylamino)-3,4 difluorobenzoic acid (3) (4.50 g, 12.4 mmol) in a 3:1 mixture of THF:MeOH (32 mL) was added (trimethylsilyl)-diazomethane (8.10 ml of a 2 M solution in hexanes) at room temperature. After stirnng for 2 hours, the reaction mixture was quenched with acetic acid, diluted with EtOAc, and washed with water. The organic layer was dried (MgS04) and concentrated under reduced pressure to give 4.35 g (93%) of the desired methyl ester (4).
Step D: Preparation of 2-(2-chlorophenylamino)-3,4-difluoro-5-trimethylsilan l~ynylbenzoic acid methyl ester (5): A mixture of 5-bromo-2-(2-chlorophenylamino)-3,4-difluorobenzoic acid methyl ester (4) (101 mg, 0.268 mmol), TMS-acetylene (0.045 mL, 0.31 mmol), Pd(PPh3)ZC12 (18.7 mg, 0.0261 mmol), CuI
(5.1 mg, 0.027 mmol), and i-Pr2NH (0.075 mL, 0.53 mmol) in THF (1.5 mL) was stirred for 16 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and diluted with EtOAc. The organic layer was washed with saturated aqueous NH4C1 and brine, dried over MgS04, and concentrated.
Purification by flash column chromatography using the Biotage system (100%
hexane to 1 % EtOAc in hexane) gave 81.3 mg (77% yield) of the desired product (5).
Step E: Preparation of 5-acetyl-2-(2-chlorophenylamino)-3,4-difluorobenzoic acid methyl ester (6): A mixture of 2-(2-chlorophenylamino)-3,4-difluoro-5-trimethylsilanylethynylbenzoic acid methyl ester (5) (79.4 mg, 0.20 mmol), HgS04 (59.8 mg, 2.0 mmol), and conc. HzS04 (0.02 mL, 0.40 mmol) in 80% aqueous acetone (2.5 mL), were refluxed for 48 hours. The reaction was concentrated under reduced pressure, and diluted with EtOAc. The organic layer was washed with water and brine, dried over MgS04 and concentrated to give 50.1 mg (73%) of the desired product (6).
Step F: Preparation of 6-(2-chloro_phenylamino)-7-fluoromethylbenzo[d]isoxazole-5-carboxylic acid methyl ester (7): t-BuOK (0.47 mL, 1.0 M in THF) was added to propan-2-one oxime (35 mg, 0.47 mmol). After stirring for 30 minutes, THF (0.5 mL) was added, and the reaction mixture was cooled to °C. A solution of 5-acetyl-2-(2-chlorophenylamino)-3,4-difluorobenzoic acid methyl ester (6) (50.0 mg, 0.147 mmol) in THF (1 mL) was added. The reaction mixture was slowly warmed to 0 °C and stirred for 2 hours. The reaction mixture was quenched with saturated aqueous NH4Cl, diluted with EtOAc and water. The aqueous layer was separated and extracted with EtOAc. The combined organic extracts were dried over MgS04, filtered, and concentrated in vacuo to give the 5-acetyl-2-(2-to chlorophenylamino)-3-fluoro-4-isopropylideneaminooxybenzoic acid methyl ester.
The recovered oxime was suspended in a 1:1 mixture of 5% aqueous HCl and MeOH
(30 ml) and heated to reflux. After 1 hour, the reaction mixture was cooled to room temperature and diluted with EtOAc. The organic layer was washed with water, dried (MgS04) and concentrated. Purification by flash column chromatography using the Biotage system (40% methylene chloride in hexanes) provided 17 mg (35% for two steps) of the desired product (7).
Step G: Preparation of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[dlisoxazole-5-carboxylic acid methyl ester (8a): 6-(2-Chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid methyl 2o ester (7) (18.6 mg, 0.0556 mmol) and N-bromosuccinimide (12.0 mg, 0.0667 mmol) were stirred in DMF (1 mL) for 16 hours. The reaction mixture was diluted with EtOAc, and washed with water (2x). The organic layer was dried over MgS04, filtered, and concentrated. Purification by flash column chromatography using the Biotage system (10% EtOAc in hexanes) provided 12.6 mg (55%) of the desired product (8a).
Step H: Preparation of 6-(4-bromo-2-chloro~henylamino)-7-fluoro-3-methXlbenzo[dlisoxazole-5-carboxylic acid (9a): To a solution of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid methyl ester (8a) (200 mg, 0.48 mmol) in THF-water (3 mL/1.5 mL) was added aqueous 3o LiOH (1 M, 1.00 mL) at room temperature. After 15 hours, the reaction mixture was acidified to pH 1 with aqueous HCl (1 M), diluted with water, and extracted with EtOAc/THF. The organic layer was washed with water, dried over MgS04, filtered, and concentrated in vacuo to give 191.5 mg (99%) of the crude acid (9a) which was used without further purification. MS APCI (-) m/z 397, 399 (M+, Br, Cl pattern) detected. 'H NMR (400 MHz, DMSO-d6) b 9.55 (s, 1H), 8.37 (s, 1H), 7.75 (s, 1H), 7.42 (d, 1H), 6.97 (t, 1H), 2.60 (s, 3H): '9F NMR (376 MHz, DMSO-d6) -140.15 (s).
Example 2 H
~O~ N O H CI
~ F ~ Br N-O
1o Synthesis of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid cyclopropylmethoxyamide (10a) The reaction scheme for the synthesis of compound 10a is shown in Figure 1.
To a solution of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (9a) (50.0 mg, 0.125 mmol) in DMF (1 mL) was added HOBt (24.6 mg, 0.161 mmol), Et3N (0.060 mL, 0.43 mmol), O-cyclopropylmethyl-hydroxylamine (15.5 mg, 0.178 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (32.2 mg, 0.168 mmol) at room temperature. After 6 days, the reaction mixture was diluted with EtOAc, washed with saturated aqueous NH4Cl, brine, saturated aqueous NaHC03, 2o and brine. The organic layer was dried over MgS04, filtered, concentrated in vacuo, and purified by flash column chromatography using the Biotage system (0.5%
MeOH
in CHZC12) to give 27.6 mg (47% yield) of the desired product (10a). MS APCI (-) m/z 466, 468 (M+, Br, C1 pattern) detected. 'H NMR (400 MHz, CD30D) 8 7.82 (s, 1H), 7.57 (d, 1H), 7.31 (dd, 1H), 6.74 (dd, 1H), 3.73 (d, 2H), 2.60 (s, 3H), 1.16 (m, 1H), 0.55 (m, 2H), 0.28 (m, 2H):'9F NMR (376 MHz, CD30D) -140.96 (s).
Example 3 H
HO~O,N O CI
H
~ N
~ F ~ Br N-O
Synthesis of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (2-hydroxyethoxy)-amide (12a) The reaction scheme for the synthesis of compound 12a is shown in Figure 2.
Step A: Preparation of 6-(4-bromo-2-chlorophenylamino)-?-fluoro-3-methyl-benzo(_dlisoxazole-5-carboxylic acid (2-vinyloxyethoxy)-amide (11a): To a solution of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (10a) (75.2 mg, 0.188 mmol) in DMF (1.5 mL) was added HOBt (38.2 mg, 0.249 mmol), Et3N (0.080 mL, 0.571 mmol), O-(2-vinyloxyethyl)hydroxylamine (28.5 mg, 0.276 mmol), and EDCI (47.2 mg, 0.246 mmol) at room temperature. After 6 days, the reaction mixture was diluted with EtOAc, washed with saturated aqueous NH4Cl, brine, saturated aqueous NaHC03, and brine. The organic layer was dried over MgS04, filtered, concentrated in vacuo, and purified by flash column chromatography using the Biotage system (3% MeOH
in CHZCIz) to give 57.8 mg (63%) of the desired product (1 la).
Step B: Preparation of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-2o methylbenzojdlisoxazole-5-carboxXlic acid (2-hydroxyethoxy)-amide (12a): A
solution of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazo1e-5-carboxylic acid (2-vinyloxyethoxy) amide (11a) (55.4 mg, 0.114 mmol) and aqueous HCl (1 M, 0.23 mL) in EtOH (3 mL) was stirred for 2 hours at room temperature. The pH of the reaction mixture was adjusted to 6-7 with aqueous NaOH
(2 M). The reaction was diluted with EtOAc. The organic layer was washed with water, dried over MgS04, filtered, and concentrated in vacuo to give 50.2 mg (96%
yield) of the desired product (12a). MS APCI (-) m/z 456, 458 (M+, Br, Cl pattern) detected. 1H NMR (400 MHz, CD30D) b 7.87 (s, 1H), 7.57 (d, 1H), 7.31 (dd, 1H), 6.74 (dd, 1H), 4.01 (t, 2H), 3.74 (t, 2H), 2.60 (s, 3H): 19F NMR (376 MHz, CD30D) -140.85 (s).
Example 4 H
~S~ N O CI
O H
O ~ \ N ~ \
F ~ Br N-O
Synthesis of N-[6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-to methylbenzo[d]isoxazole-5-carbonyl]-methanesulfonamide (13a) The reaction scheme for the synthesis of compound 13a is shown in Figure 3.
A mixture of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazo1e-5-carboxylic acid (9a) (41 mg, 0.102 mmol) and carbonyldiimidazole (23 mg, 0.140 mmol) in THF (1 mL) was stirred at 50 °C in a sealed tube reactor. The reaction mixture was cooled to room temperature and methanesulfonamide (17 mg, 0.179 mmol) was added followed by DBU (0.025 mL, 0.164 mmol). After stirnng at 50 °C
for 1 hour, the reaction mixture was cooled to room temperature, and diluted with EtOAc. The organic layer was washed with water, 1 N HCI, and brine. The organic layer was dried (MgS04) and concentrated. Purification by flash column chromatography using the Biotage system (7% MeOH in CHZC12) provided 34 mg (65% yield) of the desired product (13a). MS APCI (-) m/z 474, 476 (M+, Br, Cl pattern) detected. 'H NMR (400 MHz, CD30D) 8 8.27 (s, 1H), 7.53 (s, 1H), 7.27 (d, 1H), 6.73 (t, 1H), 3.11 (s, 3H), 2.55 (s, 3H): 19F NMR (376 MHz, CD30D) -141.84 (s).
Example 5 HO O CI
H
F ~ CI
N-O
Synthesis of 6-(2,4-dichloro-phenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (9b) The reaction scheme for the synthesis of compound 9b is shown in Figure 1.
Step A: Preparation of 6-(2,4-dichlorophenylamino)-7-fluoro-3-methylbenzo[d~isoxazole-5-carboxylic acid methyl ester (8b): 6-(2-Chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid methyl to ester (7) (129 mg, 0.384 mmol) and N chlorosuccinimide (57 mg, 0.421 mmol) were stirred in DMF (5 mL) for 16 hours. Concentrated HCl (3 ~.L) was added and the reaction mixture stirred 2 hours. The reaction mixture was diluted with EtOAc, and washed with water (2x). The organic layer was dried over MgS04, filtered, and concentrated. Purification by flash column chromatography using the Biotage system (S% EtOAc in hexanes) provided 73 mg (52%) the desired product (8b).
Step B: Preparation of 6-(2,4-dichlorophen 1~)-7-fluoro-3-methylbenzofdlisoxazole-5-carboxylic acid (9b): Compound 9b was prepared according to Step H of Example 1 using 6-(2,4-dichlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid methyl ester (8b) to provide 68 mg (98%
yield) of the desired product (9b). MS APCI (-) m/z 353, 355 (M+, Br, Cl pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.58 (s, 1H), 8.34 (s, 1H), 7.65 (d, 1H), 7.31 (dd, 1H), 7.04 (dd, 1H), 2.60 (s, 3H): 19F NMR (376 MHz, DMSO-d6) -140.36 (s).
Example 6 HO~O~N O CI
H
\ N I \
~ F ~ CI
N-O
Synthesis of 6-(2,4-dichlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (2-hydroxyethoxy)amide (12b) The reaction scheme for the synthesis of compound 12b, as shown in Figure 4, was carried out according to Steps A and B of Example 3 using 6-(2,4-dichlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (9b) as the starting material to provide 29 mg (38% yield for two steps) of 12b. MS
APCI (-) to m/z 412, 414 (M+, Br, Cl pattern) detected. 1H NMR (400 MHz, CD30D) b 7.87 (s, 1H), 7.45 (m, 1H), 7.19 (m, 1H), 6.80 (m, 1H), 4.02 (t, 2H), 3.75 (t, 2H), 2.60 (s, 3H):
i9F NMR (376 MHz, CD30D) -141.05 (s).
Example 7 HO O
H CI
\ N I \
H2N ~ / F ~ Br N-O
Synthesis of 3-amino-6-(4-bromo-2-chlorophenylamino)-7 fluorobenzo[d]isoxazole-5-carboxylic acid (19) The reaction scheme for the synthesis of compound 19 is shown in Figure 5.
Step A: Preparation of 2-(2-chlorophenYlamino)-5-cyano-3 4-difluorobenzoic acid metal ester (15): A mixture of 5-bromo-2-(2-chlorophenylamino)-3,4-difluorobenzoic acid methyl ester (14) (3.01 g, 7.99 mmol), 1,1'-bis(diphenylphosphino) ferrocene (dppf) (93 mg, 0.162 mmol), Pd2dba3 (73 mg, 0.080 mmol) and Zn(CN)Z (573 mg, 4.78 mmol) in 1-methyl-2-pyrrolidinone (NMP: 4.5 mL) was heated in a sealed tube reactor. After 20 hours, the reaction mixture was cooled to room temperature, quenched by the addition of 8 mL 4:1:4 (volume) mixture of saturated NH4C1, concentrated NH40H and water, and extracted with a mixture of EtOAc/THF. The combined organic extracts were washed with 4:1:4 (volume) mixture of saturated NH4C1, concentrated NH40H and water, and brine.
The organic layer was dried (MgS04) and concentrated. Purification by flash column chromatography using the Biotage system (twice: 100% hexanes to 35% CHZC12 in hexanes, then 30% CHZCl2 in hexanes) provided 1.33 g (52%) of the desired product (15).
Step B: Preparation of 3-amino-6-(2-chlorophenylaminoL
fluorobenzojdlisoxazole-5-carboxylic acid methyl ester (17): t-BuOK (3.80 mL
of a 1.0 M solution in THF) was added to a stirred solution of propan-2-one oxime (285 mg, 3.82 mmol) in THF (5 mL) at room temperature. The reaction mixture was further diluted with THF (20 mL) and after 30 minutes cooled to 0 °C. A
solution of 2-(2-chlorophenylamino)-5-cyano-3,4-difluorobenzoic acid methyl ester (15) (600 mg, 1.86 mmol) in THF (5 mL) was added. The reaction mixture was slowly warmed to room temperature. After 90 minutes, the reaction mixture was quenched with 2o saturated NH4C1 and diluted with EtOAc. The organic layer was washed with saturated NH4Cl and brine, dried (MgS04) and concentrated. The residue (16) was diluted with MeOH (10 mL) and a solution of 2 M HCl in diethyl ether (10 mL) was added. After 16 hours, the reaction mixture was diluted with EtOAc, washed with water, saturated NaHC03 and water. The organic layer was dried (MgS04) and concentrated. Purification by flash column chromatography using the Biotage system (1.5% MeOH in CHzCIz) provided 399 mg (64%) of the desired product (17).
Step C: Preparation of 3-amino-6-(4-bromo-2-chlorophen 1~)-7-fluorobenzo[dlisoxazole-5-carboxylic acid methyl ester (18): Compound 18 was prepared according to Step G of Example 1 using compound 17 as the starting material.
Step D: Preparation of 3-amino-6-(4-bromo-2-chlorophenylamino)-7-fluorobenzofdlisoxazole-5-carboxylic acid (19): Compound 19 was prepared according to Step H of Example 1 using 3-amino-6-(4-bromo-2-chlorophenylamino)-7-fluorobenzo[dJisoxazole-5-carboxylic acid methyl ester (18) as the starting material to provide 188 mg (98% yield) of compound 19. MS APCI (-) m/z 398, 400 (M+, Br, Cl pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.47 (s, 1H), 8.49 (s, 1H), 7.73 (m, 1H), 7.41 (dd, 1H), 6.92 (t, 1H), 6.76 (s, 2H): 19F NMR (376 MHz, DMSO-d6) -141.48 (s).
Example 8 H
HO~O,N O CI
H
N
HzN ~ l / F I ~ Br N-O
Synthesis of 3-amino-6-(4-bromo-2-chloro-phenylamino)-7 fluorobenzo[d]isoxazole-5-carboxylic acid (2-hydroxyethoxy)-amide (21) The reaction scheme for the synthesis of compound 21, as shown in Figure 6, was accomplished according to Steps A and B of Example 3 using 3-amino-6-(4-bromo-2-chlorophenylamino)-7-fluorobenzo[d]isoxazole-5-carboxylic acid (19) as the starting material to provide 16 mg (23% yield for two steps) of compound 21.
MS
APCI (-) m/z 457, 459 (M+, Br, Cl pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 11.92 (s, 1H), 8.59 (s, 1H), 7.94 (s, 1H), 7.69 (s, 1H), 7.36 (d, 1H), 6.75 (dd, 1H), 6.71 (s, 2H), 4.73 (s, 1H), 3.87 (s, 2H), 3.59 (s, 2H): 19F NMR (376 MHz, DMSO-d6) -140.64 (s).
Example 9 HO O
CI
N
N
CI Br N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (30) The reaction scheme for the synthesis of compound 30 is shown in Figure 7.
Step A: Preparation of 4,6-dichloronicotinic acid ethyl ester (22): POC13 (100 mL, 1092 mmol) was added to 4,6-dihydroxynicotinic acid ethyl ester (.I.
Heterocyclic Chem. 1983, 20, 1363) (20.0 g, 109 mmol). The resulting suspension to was cooled to 0 °C and triethylamine (15.2 mL, 109 mmol) was added dropwise at such a rate as to maintain the internal reaction mixture temperature below 25 °C.
Upon completion of addition, the reaction mixture was warmed to room temperature and then to 80 °C. After 4 hours, the reaction mixture was cooled to room temperature and stirred for 16 hours. The reaction mixture was carefully poured onto 2 L crushed ice. The mixture was extracted with EtOAc and diethyl ether. The combined organic extracts were washed with brine, dried (NaZS04) and concentrated.
The dark brown liquid was purified by passing through a plug of silica gel (CHZC12) to give the desired product (22) as a low melting yellow solid (18.7 g, 78%).
Step B: Preparation of 4,6-dichloronicotinic acid (23): Sodium hydroxide (40 2o mL, 6.25 M solution) was added to a stirred solution of 4,6-dichloronicotinic acid ethyl ester (22) (25.95 g, 118 mmol) in 4:1:1 THF/MeOH/water (600 mL). After minutes, the reaction mixture was acidified to pH 2 with concentrated HCI, diluted with 1:1 EtOAc/Et20 and washed with water and brine. The organic layer was dried (Na2S04) and concentrated. The resulting off white solid was twice concentrated from toluene to give the desired product (23) as a white solid (21.73 g, 96%).
Step C: Preparation of 4-(4-bromo-2-chlorophenylamino)-6-chloronicotinic acid hydrochloride salt (24~ LiHMDS (261 mL of a 1 M solution in hexanes) was added dropwise over 30 minutes to a solution of 4-bromo-2-chlorophenylamine (35.0 g, 172 mmol) in THF (80 mL) at -78 °C. After 1 hour, 4,6-dichloronicotinic acid (23) (15.7 g, 81.7 mmol) was added dropwise over 30 minutes. The reaction mixture was slowly warmed to room temperature and stirred 16 hours. The reaction mixture was quenched with water, diluted with EtOAc and acidified with 1 M HCI. The resulting precipitate was isolated by filtration and washed with EtOAc. The solids were twice concentrated from toluene, triturated with CHZC12 and collected by filtration.
The solids were further concentrated from toluene (3x) followed by drying in vacuo to 1o give the desired product (24) containing a small amount of water (36.0 g).
Step D. Preparation of 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid (25): N Chlorosuccinimide was (13.0 g, 99.0 mmol) added to a suspension of 4-(4-bromo-2-chlorophenylamino)-6-chloronicotinic acid (24) (32.54 g, 89.9 mmol) in DMF (500 mL). The suspension was allowed to stir at room temperature overnight. The reaction mixture was diluted with saturated sodium bisulfate (200 mL) and water (1L) resulting in formation of a thick white precipitate which was isolated by filtration and washed with water. The solids were dissolved into THF. Two volumes of diethyl ether were added and the organic solution washed with brine, dried over NaS04, filtered, and concentrated in vacuo to provide an orange 2o solid. The solid was triturated with diethyl ether to provide the desired product as an off white solid (25) (13.34 g, 37%). MS (APCI-) m/z 393, 395, 397 (M-; Cl, Br pattern) detected.
Alternatively, 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid (25) can be synthesized by the route and procedure described below.
~O O ~0 O ~O O
OH NCS ~ OH TEA ~ CI
I I I
NY MeOH NCI POCI3 NCI
IOH OH CI
HO O NHz HO O
NaOH ~ CI LHMDS H CI
CI I ~ N
THF/MeOH N~ ~ THF N~ I i \C1 Br CI Br CI CI
N Chlorosuccinimide (56.5 g, 423 mmol) was added portionwise to a suspension of 4,6-dihydroxynicotinic acid ethyl ester (70.5 g, 385 mmol) in DMF
(705 mL). Concentrated HCl (3.20 mL, 38.5 mmol) was added. After stirnng for 2.5 hours, the product was precipitated with water and Na2Sz03 (70 mL). The slurry was acidified to pH 3 with 2 M HCl (30 mL). 5-Chloro-4,6-dihydroxynicotinic acid ethyl ester, the desired product was isolated as a pale yellow solid (75.7 g, 90%) by filtration. MS ESI (+) m~z 218, 220 (M+, Cl pattern) detected.
to S-(:hloro-4,6-dihydroxynicotinic acid ethyl ester (8.05 g, 37 mmol) was suspended in phosphorous oxychloride (30 mL, 296 mmol). The mixture was cooled to 0 °C and triethylamine (5.16 mL, 37.0 mmol) was added. The reaction was heated to 60 °C for three hours. The solution was cooled to room temperature, poured unto ice,. stirred for 15 minutes and extracted with ethyl acetate (2x) and diethyl ether (lx).
The combined organic extracts were washed with brine (3x), dried over NaZS04 and concentrated to a brown liquid. The crude product was passed through a plug of silica gel eluting with dichloromethane. 4,5,6-Trichloronicotinic acid ethyl ester, the desired product was obtained as a yellow liquid (7.76 g, 82%).
Sodium hydroxide (1.0 M solution, 61.0 mL, 61.0 mmol) was added to a solution of 4,5,6-trichloro-nicotinic acid ethyl ester (7.76 g, 30.5 mmol) in 4:1 THF/MeOH (150 mL). After stirring for 30 minutes, the reaction was acidified to pH
1 by addition of concentrated HCI, diluted with ethyl acetate, washed with water (3x) and brine (2x), dried over NaZSOa and concentrated to provide the desired product, 4,5,6-trichloronicotinic acid, as an off white solid (6.77 g, 98%).
LiHMDS (1.0 M solution in hexanes, 53.0 mL, 53.0 mmol) was added dropwise to a stirred solution of 4-bromo-2-chlorophenylamine (7.10 g, 35.0 mmol) in THF (15 mL) cooled to -78 °C . After one hour, 4,5,6-trichloronicotinic acid (3.73 g, 16.5 mmol) was added dropwise as a solution in THF (12 mL). The reaction was allowed to warm to room temperature slowly while stirring overnight. The suspension was diluted with 1 M HCl and ethyl acetate, and the aqueous phase was extracted with ethyl acetate (3x). The combined organic phases were dried over Na2S04 and concentrated to a tan solid. The solid was triturated with diethyl ether overnight and the solids were isolated by filtration to provide the desired product (25) l0 as a tan-colored solid (4.85 g, 75%). MS APCI (-) m/z 395, 397 (M-, Cl, Br pattern) detected.
Step E. Preparation of 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid methyl ester (26): Trimethylsilyldiazomethane (2.0 M
solution in hexanes, 37 mL, 74 mmol) was added slowly to a suspension of 4-(4-bromo-2-chloro-phenylamino)-5,6-dichloro-nicotinic acid (25) (14.67 g, 37 mmol). After the addition was complete the resulting slurry was diluted with hexanes (600 mL) and the solids isolated by filtration washing with hexanes. The desired product was isolated as an off white solid (10.06 g). The hexanes washes were concentrated and the solids passed through a plug of silica gel eluting with dichloromethane.
Concentration of 2o the product-containing fractions provided an additional 3.83 g desired product (26) for a total of 13.89 g (91 %). MS (APCI+) m/z 409, 411, 413 (M+; Cl, Br pattern) detected.
Step F. Preparation of 6-azido-4-(4-bromo-2-chlorophenylamino)-5-chloronicotinic acid methyl ester (~27): Sodium azide (4.4 g, 68 mmol) was added to a suspension of 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid methyl ester (26) (13.89 g, 33.8 mmol) in DMF (200 mL) and the mixture allowed to stir at room temperature overnight. The solution was diluted with water (600 mL) and the resulting white precipitate was collected by filtration and washed with water.
The solids were dissolved into THF. Two volumes of diethyl ether were added and the organic solution washed with brine, dried over NaS04, filtered, and concentrated in vacuo to the desired product (27) as a light yellow solid ( 12.94 g, 92%).
Step G. Preparation of 6-Amino-4-(~4-bromo-2-chlorophe~lamino)-S-chloro-nicotinic acid methyl ester X28): Zinc powder (10 g, 155 mmol) was added portionwise to a suspension of 6-azido-4-(4-bromo-2-chlorophenylamino)-5-chloronicotinic acid methyl ester (27) (12.94 g, 31 mmol) in 3:1 dichloromethane/acetic acid (300 mL). After fifteen minutes the reaction mixture was poured into 700 mL ethyl acetate, washed with water, saturated sodium bicarbonate and brine. The organic solution was dried over NaS04, filtered, and concentrated in vacuo to provide the desired product (28) as an off white solid (11.85 g, 98%). MS (APCI+) m/z 390, 392, 394 (M+; Cl, Br pattern) detected.
1o Step H. Preparation of 7-(,4-bromo-2-chlorophenylamino)-8-chloroimidazof 1.2-alnvridine-6-carboxylic acid methyl ester (29):
Chloroacetaldehyde (50% aqueous solution, 0.70 mL, 5.7 mmol) was added to a suspension of 6-amino-4-(4-bromo-2-chlorophenylamino)-5-chloronicotinic acid methyl ester (28) in DMF (7 mL) contained in a sealed tube. The reaction mixture was heated at 80°C for four hours and then allowed to cool to room temperature and stir overnight. The dark brown solution was diluted with water (70 mL) the resulting light brown precipitate was collected by filtration and washed with water. The solids were dissolved into THF. Two volumes of ethyl acetate were added and the organic solution washed with brine, dried over NaS04, filtered, and concentrated in vacuo to provide a brown solid. The aqueous filtrate was extracted with ethyl acetate and the organic extracts were dried over NaS04, filtered, and concentrated in vacuo.
This material was combined with the previously isolated brown solid and the combined material subjected to column chromatography (dichloromethane, followed by 20:1 dichloromethane/methanol). The desired product (29) was isolated as a light yellow solid (0.752 g, 64%). MS (APCI+) m/z 414, 416, 418 (M+; Cl, Br pattern) detected.
Step I. Preparation of 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-alpyridine-6-carboxylic acid (30): Sodium hydroxide (1.0 M
aqueous solution, 14.6 mL, 14.6 mmol) was added to a solution of 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (29) in methanol (30 mL) and the solution allowed to stir at room temperature overnight. Methanol was removed by rotary evaporation and the solution diluted with water and acidified to pH 2 by addition of 1.0 M HCI. The aqueous suspension was extracted with 4:1 ethyl acetate/THF. The organic extracts were washed with brine, dried over NaS04, filtered, and concentrated in vacuo to provide the desired product as a light orange solid (30). MS (APCI+) m/z 400, 402, 404 (M+: Cl, Br pattern) detected. 'H NMR (400 MHz, methanol-d4) 8 9.01 (s, 1H), 7.83 (s, 1H), 7.51 (s, 2H), 7.25 (d, 1H), 6.60 (d, 1H).
The following compounds were synthesized in a similar manner as shown in Figure 7.
HO O CI
H
N
N I I /
~ ~CI CI
N
8-Chloro-7-(2,4-dichlorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 356, 358 (M+, Cl pattern) detected. 1H NMR (400 MHz, CD30D) 8 9.16 (s, 1 H), 8.00 (d, 1 H), 7.72 (d, 1 H), 7.51 (d, 1 H), 7.25 (dd, 1 H), 7.02 (d, 1 H).
HO O
H
N
N
~ ~CI I
~N
8-Chloro-7-(2-fluoro-4-iodophenylamino)-imidazo(1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 432, 434 (M+, C1 pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.31 (s, 1H), 8.11 (s, 1H), 7.71 (s, 1H), 7.61 (d, 1H), 7.37 (d, 1H), 6.62 (t, 1 H).
HO O
F
H
N
N I I ~
CI ~ F
8-Chloro-7-(2,4-difluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 324, 326 (M+, Cl pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 9.27 (s, 1 H), 8.06 (s, 1 H), 7.65 (s, 1 H), 7.29 (t, 1 H), 6.96 (m, 2H). ' 9F
(376 MHz, DMSO-d6) -118.9 (s), -124.8 (s).
HO O
H
N
N I I ~
~~ CI ~ Br 7-(4-Bromo-2-methylphenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid to MS APCI (+) m/z 380, 382 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 9.31 (s, 1H), 8.09 (s, 1H), 7.69 (s, 1H), 7.42 (s, 1H), 7.24 (d, 1H), 6.64 (d, 1H), 2.28 (s, 3H).
Example 10 Me O CI
H
N
N
c ~CI Br ~N
1-(7-(4-Bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridin-6-yl]-ethanone This compound is prepared from compound 29, the product of Example 9, Step H. Tebbe reagent (p-chloro-p-2o methylene[bis(cyclopentadienyl)titanium]dimethyl-aluminum, 1 M solution in toluene, 0.12 mL, 0.12 mmol) was added to a solution of 7-(4-bromo-2-chloro-phenylamino)-8-chloro-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (29) (25 mg, 0.061 mmol) in THF (1 mL) cooled to 0 °C. The reaction mixture was warmed to room temperature and stirred for 1.5 hours. HCl (10% aqueous solution, 1 mL) was added and the mixture stirred for 16 hours. The reaction was diluted with ethyl acetate, washed with saturated aqueous sodium carbonate, dried over MgS04, and concentrated. The crude material was purified by flash column chromoatography (dichloromethane to 100:1 dichloromethane/methanol) to provide the desired product (6.8 mg, 28%). MS APCI (-) m/z 396, 398, 400 (M-, Cl, Br pattern) detected. 'H
NMR (400 MHz, CDC13) 8 9.05 (br s, 1H), 8.81 (s, 1H), 7.71 (s, 2H), 7.55 (d, 1H), 7.22 (dd, 1H), 6.55 (d, 1H), 2.67 (s, 3H).
Example 11 H
HO~O,N O CI
H
N
N
Br~~ ~CI Br N
3-Bromo-7-(4-bromo-2-chlorophenylamino)-8-chloro-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide The reaction scheme for the synthesis of this compound is shown below.
O O O O HO O
H CI NBS / H CI NaOH H CI
N ~ ~ , N ~ ~ / N
I
\'I I \ I
~ CI ~ gr CHC13 Br~ CI ~ gr MeOH gr~ CI ~ Br N N N
H H
~O~O.NHZ ~O~O.N O H CI HCI HO~O-N O H CI
N N
EDCI, HOBt N I I , MeOH N
DIEA, DMF Br'~ ~ ~CI Br Br'~ ~ ~CI Br ~N ~N
Step A: Pre,~aration of 3-bromo-7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo~l 2-a~pyridine-6-carboxylic acid methyl ester. N
bromosuccinimide (14 mg, 0.080 mmol) was added to a solution of 7-(4-bromo-2-chlorophenylamino)-chloroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (30 mg, 0.072 mmol) in chloroform (1.0 mL). After stirnng for five hours the reaction was diluted with ethyl acetate, washed with NaHS03, brine, dried over NaZS04, and concentrated to a yellow solid (33 mg, 92%). MS APCI (+) m/z 494, 496, 498 (M+, Cl, Br pattern) detected.
1H NMR (400 MHz, CDCl3) 8 8.82 (s, 1H), 8.65 (s, 1H), 7.67 (s, 1H), 7.55 (dd, 1H), 7.22 (dd, 1H), 6.53 (d, 1H), 3.98 (s, 3H).
Step B: Preparation of 3-bromo-7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo~l2-a~pyridine-6-carboxylic acid 2-hydroxyethoxy)-amide. The synthesis of the title compound was carned out according to Step H of Example 1 and Steps A and B of Example 3 using 3-bromo-?-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester as the starting material to provide 20 mg of desired product as a light yellow solid. MS APCI (+) m/z 539, 541, 543 (M+, Cl, Br pattern) detected.
2p , Example 12 H
~O~ N O H CI
N
N
'CI Br N
7-(4-Bromo-2-chlorophenylamino)-8-chloro-3-methyl-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxy-amide The reaction scheme for the synthesis of this compound is shown below.
\\1DE - 80248/0026 - 214630 v1 O O
HO O CI ~ N CI OH
O ~ ~ ~ ~NHz TEA
ACN
+ ~H~N~ THF N ~ I CI I ~ Br ~CI Br CI
CI
O O ~O O CI
CI TPAP I ~ N ~ H SO
NMO ~ I z a N~ ~. --, NCI ~ Br ACN ~NH CI Br HO' vNH O
H
HO O CI EDCI ~O.N O H CI
HOBt N ~ I CI I ~ Br NHz TEA ~ ~ CI ~ Br ~N DMF N
Step A: Preparation of 4-(4-bromo-2-chlorophen~amino)-5,6-dichloronicotinic acid tert-butyl ester. 2-tent-Butyl-1,3-diisopropyl-isourea (10.6 g, 53 mmol) was added to a solution of 4-(4-bromo-2-chloro-phenylamino)-5,6-dichloro-nicotinic acid (4.21 g, 10.6 mmol) in THF (200 mL). The reaction was heated to reflux. After 30 minutes the reaction was cooled to room temperature and diluted with EtOAc. The organic layer was washed with saturated K2C03 (2x), brine, dried to over Na2SOa and concentrated. The yellow solid was triturated with dichloromethane and white solids were removed by filtration. The filtrate was concentrated in vacuo to yield the desired product as a yellow solid (5.53 g, 97%). MS APCI (-) m/z 451, 453 (M-, Cl, Br pattern) detected.
Step B: Preparation of 4-(4-bromo-2-chlorophenylamino)-5-chloro-6-(2-h~droxypropylamino)-nicotinic acid tent-but, l~. 1-Amino-propan-2-of (2.44 g, 30.3 mmol) and triethylamine (0.42 mL, 3.03 mmol) were added to a solution of 4-(4-bromo-2-chlorophenylamino)-5,6-dichloro-nicotinic acid tert-butyl ester (1.37 g, 3.03 mmol) in acetonitrile (30 mL). The reaction was heated to reflux. After 23 hours the reaction was cooled to room temperature and diluted with EtOAc, washed with saturated NaHC03, water, brine, dried over Na2S04 and concentrated to a white solid.
Purification by flash column chromatography (20:1 dichloromethane/methanol) provided the desired product as a white solid (1.11 g, 75%). MS APCI (+) m/z 492, 494 (M+, Cl, Br pattern) detected.
Step C: Preparation of 4-(4-bromo-2-chlorophenylamino)-5-chloro-6-(2-oxopropylamino~-nicotinic acid tert-butyl ester. To a solution of 4-(4-bromo-2-chlorophenylamino)-5-chloro-6-(2-hydroxypropylamino)-nicotinic acid tent-butyl ester (0.28 g, 0.57 mmol) in acetonitrile (1.1 mL) was added 4~ molecular sieves and N methylmorpholine (0.10 g, 0.85 mmol). The mixture was cooled to 0 °C and 1o tetrapropylammonium perruthenate (0.030 g, 0.085 mmol) was added. After stirnng for one hour, the reaction was filtered through a plug of silica gel, washing with EtOAc. The filtrate was concentrated. Purification by flash column chromatography (20:1 hexanes/ethyl acetate) provided the desired product as a white solid (86 mg, 31 %). MS APCI (+) m/z 490, 492 (M+, Cl, Br pattern) detected.
Step D: Preparation of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methyl-imidazo[1,2-a]pyridine-6-carboxylic acid. 4-(4-Bromo-2-chlorophenylamino)-5-chloro-6-(2-oxopropylamino)-nicotinic acid tert-butyl ester (0.075 g, 0.15 mmol) was dissolved into concentrated HZS04 (0.50 mL). After ten minutes, ice and water were and the mixture was stirred for ten minutes. The mixture was diluted with EtOAc, neutralized with 1 M NaOH, washed with brine, dried over NazS04 and concentrated to provide the desired product as an off white solid. MS APCI (+) m/z 416, 418 (M+, Cl, Br pattern) detected.
Step E: Preparation of 7-(4bBromo-2-chlorophenylamino)-8-chloro-3-methvlimidazof 1.2-alnvridine-6-carboxylic acid cvclonronvlmethoxv-amide. The synthesis of the title compound was carried out according to Example 2 using 7-(4 bromo-2-chlorophenylamino)-8-chloro-3-methylimidazo[ 1,2-a]pyridine-6-carboxylic acid as the starting material to provide 8 mg (18%) of desired product as a yellow solid. MS APCI (+) m/z 485, 487 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, CDC13) 8 8.68 (s, 1H), 7.72 (m, 1H), 7.54 (m, 1H), 7.20 (dd, 1H), 6.42 (d, 1H), 3.58 (d, 2H), 2.57 (s, 3H), 0.64 (m, 1H), 0.57 (m, 2H), 0.23 (m, 2H).
Example 13 H
~O~N O H CI
N
N
'CI Br N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (31) Figure 8 shows the reaction scheme for the synthesis of compound 31, which was prepared according to the method of Example 2, using 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (30) as the to starting material to provide 4.1 g (53% yield) of compound 31. MS (APCI-) m/z 467, 469, 471 (M-: Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) 8 8.76 (s, 1H), 7.95 (d; 1H), 7.64 (d, 1H), 7.56 (d, 1H), 7.26 (dd, 1H), 6.56 (d, 1H), 3.57 (d, 2H), 1.10 (m, 1 H), 0.54 (m, 2H), 0.24 (m, 2H).
The following compounds were synthesized in a similar manner as shown in Figure 7, 8, and 9 using the appropriate aniline in Step C of Example 9.
H
~O. N O F
H
N
N
~CI Br N
7-(4-Bromo-2-fluorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide 2o MS ESI (+) m/z 453, 455, 457 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) 8 8.70 (s, 1 H), 7.95 (s, 1 H), 7.67 (s, 1 H), 7.34 (m, 1 H), 7.20 (m, 1 H), 6.79 (m, 1H), 3.49 (m, 2H), 1.08 (m, 1H), 0.55 (m, 2H), 0.26 (m, 2H). 19F NMR
(376 MHz, CD30D) 8 -127.4.
H
~O. N O
H
N
N
~ ~CI
N
8-chloro-7-(2-fluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxy-amide MS ESI (+) m/z 375, 377 (M+, Cl pattern) detected. 'H NMR (400 MHz, CD30D) b 8.70 (s, 1 H), 7.91 (s, 1 H), 7.60 (s, 1 H), 7.09 (m, 1 H), 7.00 (m, 1 H), 6.95 (m, 1H), 6.77 (m, 1H), 3.47 (d, 2H), 1.05 (m, 1H), 0.51 (m, 2H), 0.22 (m, 2H).
NMR (376 MHz, CD30D) 8 -132.1.
H
HO~O,N O
H
N
N
~CI Br N
7-(4-bromo-2-fluorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide MS ESI (+) m/z 443, 445, 447 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) b 8.74 (s, 1H), 7.91 (s, 1H), 7.61 (s, 1H), 7.32 (m, 1H), 7.16 (m, 1H), 6.68 (m, 1H), 3.84 (t, 2H), 3.66 (t, 2H). 19F NMR (376 MHz, CD30D) S -128.9.
H
HO~O,N O
H
N
N I I ~
~~ ~CI
N
8-Chloro-7-(2-fluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide MS ESI (+) m/z 365, 367 (M+, Cl pattern) detected. 'H NMR (400 MHz, CD30D) 8 8.73 (s, 1H), 7.89 (s, 1H), 7.59 (s, 1H), 7.10 (m, 1H), 7.00 (m, 1H), 6.94 (m, 1H), 6.77 (m, 1H), 3.78 (t, 2H), 3.62 (t, 2H). '9F NMR (376 MHz, CD30D) 8 -131.9.
H
HO~O.N O H CI
N
I~
~CI CI
io 8-chloro-7-(2,4-dichlorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy) amide MS APCI (-) m/z 413, 415, 417 (M-, Cl pattern) detected. 'H NMR (400 MHz, CD30D) 8 8.78 (s, 1H), 7.90 (s, 1H), 7.87 (s, 1H), 7.10 (dd, 1H), 6.61 (d, 1H), 4.0 (m, 2H), 3.72 (m, 2H).
HO OH F
/~N~~
C1 Br N
7-(4-Bromo-2-fluorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid MS ESI (+) m/z 384, 386, 388 (M+, C1, Br pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 9.29 (s, 1H), 8.10 (s, 1H), 7.68 (s, 1H), 7.53 (m, 1H), 7.23 (m, 1H), 6.75 (m, 1H). 19F NMR (376 MHz, DMSO-d6) 8-127.9.
HO O H F
N
CI
l0 8-Chloro-7-(2-fluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid MS ESI (+) m/z 306, 308 (M+, Cl pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 9.30 (s, 1H), 8.09 (s, 1H), 7.67 (s, 1H), 7.22 (dd, 1H), 7.06 (dd, 1H), 6.98 (m, 1H), 6.84 (m, 1H). 19F NMR (376 MHz, DMSO-d6) b-130.5.
HO O
H
N
N
~ ~CI CI
N
8-Chloro-7-(4-chloro-2-fluorophenylamino)-imidazo[1,2-aJpyridine-6-carboxylic acid MS ESI (+) m/z 340, 342 (M+, Cl pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.29 (s, 1H), 8.10 (s, 1H). 7.68 (s, 1H), 7.43 (m, 1H), 7.12 (m, 1H), 6.83 (m, 1H). 19F NMR (376 MHz, DMSO-d6) 8 -127.8.
H
~O. N O F
H
N
N
~CI CI
N
8-Chloro-7-(4-chloro-2-fluorophenylamino)-imidazo(1,2-aJpyridine-6-carboxylic acid cyclopropylmethoxyamide MS ESI (+) m/z 409, 411 (M+, Cl pattern) detected. 1H NMR (400 MHz, CD30D) 8 9.97 (br s, 1 H), 8.82 (s, 1 H). 7.73 (s, 1 H), 7.71 (s, 1 H), 7.18 (m, 1 H), 6.97 (m, 1 H), 6.56 (m, 1 H), 6.47 (br s, 1 H), 3.60 (m, 2H), 1.00 (m, 1 H), 0. S 6 (m, 2H), 0.24 (m, 2H). 19F NMR (376 MHz, CD30D) b-128.7.
Example 14 H
HO~O, N O H CI
N
N
~ 'CI Br N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide (33a) The reaction scheme for the synthesis of compound 33a is shown in Figure 9, which was prepared according to Steps A and B of Example 3 using 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (30) to provide 44 mg (40% yield for two steps) of the desired.product. MS (APCI+) m/z l0 459, 461, 463 (M+: Cl, Br pattern) detected. 1H NMR (400 MHz, methanol-d4) 8 8.90 (s, 1H), 8.08 (s, 1H), 7.93 (s, 1H), 7.69 (s, 1H), 7.45, (d, 1H), 7.06 (m, 1H), 3.86 (br s, 2H), 3.72 (br s, 2H).
Example 15 H
~O.N ~ H CI
N ~ N
' N~~CI Br ~5 N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-(4-methylpiperazin-1-yl)-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (36) The reaction scheme for the synthesis of compound 36 is shown in Figure 10.
20 Step A:. 7-(4-Bromo-2-chlorophenylamino)-8-chloro-3-(4-methylpiperazin-1-y1)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (34): Preparation was accomplished by modification of the procedure of Katritzky et al. (J. Org.
Chem., 2003, 68, 4935-4937: .l. Org. Chem., 1990, 55, 3209-3213).
Bis(benzotriazazole) adduct (formed with 1-methylpiperazine) (106 mg, 0.230 mmol) was added to a suspension of 6-amino-4-(4-bromo-2-chlorophenylamino)-5-chloronicotinic acid methyl ester (28) (30 mg, 0.076 mmol) in dichloroethylene (1 mL) followed by the addition of ZnBrz (52 mg, 0.230 mmol). The reaction mixture was stirred at reflux for hours and then at room temperature for 16 hours. The reaction mixture was diluted with CHZCl2 and filtered. The filtrate was washed with water. The aqueous layer was extracted with CHZC12. The combined organic extracts were washed with brine, dried (NazS04) and concentrated. Purification by flash column chromatography using the 10 Biotage system (60:1 CHZCI2iMeOH) provided the desired product (34) as a yellow solid (31 mg, 79%).
Step B: 7-(4-Bromo-2-chlorophe~lamino)-8-chloro-3~4-meth~piperazin-1-yl -imidazo[1,2-a]pyridine-6-carboxylic acid cyclopr~ylmethoxyamide (36):
Sodium hydroxide (59 p,L, 1 M solution) was added to a suspension of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-(4-methylpiperazin-1-yl)-imidazo[1,2-a]pyridine-carboxylic acid methyl ester (34) in MeOH (1 mL). After stirnng 18 hours, the reaction mixture was concentrated to dryness. The residue (35) was diluted with toluene and concentrated (repeated), and 31 mg of the recovered yellow residue (35) was carried forward without purification. The residue (35) was suspended in (1 mL), cooled to 0 °C and oxalyl chloride (150 ~,L of a 2 M solution in CHZC12) was added. One drop of DMF was added and the reaction mixture warmed to room temperature. After 10 minutes, concentration of the mixture was followed by concentrating from toluene twice and then drying in vacuo. The resulting yellow solid was suspended in CHZC12 (1 mL), cooled to 0 °C and cyclopropylmethylhydroxylamine (16 mg, 0.180 mmol) was added. After the reaction mixture was warmed to room temperature and stirred for 16 hours, it was diluted with EtOAc. The organic layer was washed with saturated NaHC03 and brine, dried (Na2S04) and concentrated. Purification by flash column chromatography using the Biotage system (15:1 CHzCl2/MeOH) provided the desired 3o product (36) as a pale yellow solid (12 mg, 37%). MS ESI (+) m/z 567, 569, (M+, Cl, Br pattern) detected. 'H NMR (400 MHz, CD30D) S 8.35 (s, 1H), 7.55 (d, 1 H), 7.3 8 (s, 1 H), 7.25 (dd, 1 H), 6. S 4 (d, 1 H), 3 . 5 9 (d, 2H), 3 .17 (t, 4H), 2. 74 (m, 4H), 2.43 (s, 3H), 1.09 (m, 1H), 0.54 (m, 2H), 0.24 (m, 2H).
Example 16 H
~O'N ~ H CI
N
I~
~N-~ N CI Br Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-morpholin-4-yl-imidazo(1,2-a]-pyridine-6-carboxylic acid cyclopropylmethoxyamide (37) The reaction scheme for the synthesis of compound 37 is shown in Figure 10.
1o Compound 37 was prepared according to Steps A and B of Example 15 using 6-amino-4-(4-bromo-2-chlorophenylamino)-5-chloronicotinic acid methyl ester (28) and the bis(benzotriazazole) adduct (formed with morpholine) to provide 2 mg (8%
yield for two steps) of the desired product (37). MS ESI (+) m/z 554, 556, 558 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) b 8.41 (s, 1H), 7.55 (d, 1H), is 7.38 (s, 1H), 7.26 (dd, 1H), 6.54 (d, 1H), 3.91 (t, 4H), 3.59 (d, 2H), 3.11 (t, 4H), 1.08 (m, 1H), 0.54 (m, 2H), 0.24 (m, 2H).
Example 17 H
~O'N O H CI
N
NT
N-~ ~ CI Br N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-dimethylaminoimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (38) The reaction scheme for the synthesis of compound 38 is shown in Figure 10.
Compound 38 was prepared according to Steps A and B of Example 15 using 6-amino-4-(4-bromo-2-chlorophenylamino)-5-chloronicotinic acid methyl ester (28) and the bis(benzotriazazole) adduct (formed with dimethylamine) providing 16 mg (37% yield for two steps) of the desired product (38). MS ESI (+) m/z 512, 514, 516 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) 8 8.37 (s, 1H), 7.54 (d, 1H), 7.30 (s, 1H), 7.24 (dd, 1H), 6.52 (d, 1H), 3.59 (d, 2H), 2.86 (s, 6H), 1.07 (m, 1H), 0.53 (m, 2H), 0.23 (m, 2H).
Example 18 H
HO~O.N O H CI
N
N~ I i N~N CI Br Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-piperidin-1-ylmethylimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy) amide (39) The reaction scheme for the synthesis of compound 39 is shown in Figure 11.
Compound 39 was prepared by a modification of the procedure of T. Kercher et al.
(manuscript in preparation). Piperidine (4 p,L, 0.043 mmol) and 37% aqueous formaldehyde (5 ~,L, 0.065 mmol) were dissolved in 6:1 MeCN/water (0.5 ml), and stirred 30 minutes. 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)amide (33a) (10 mg, 0.022 mmol) was added followed by scandium triflate (1 mg, 0.002 mmol). After stirring 16 hours, additional scandium triflate (1 mg), piperidine (3.8 ~,L) and aqueous formaldehyde (3.8 ~,L) were added. After about 60 hours, the reaction mixture was diluted with EtOAc and washed with water, 10% K2C03, and brine. The organic layer was dried (NaZS04) and concentrated. Purification by flash column chromatography using the Biotage system (40:1 CHZCl2/MeOH to 20:1 CHZC12/MeOH to 9:1 CHZCIZ:MeOH) provided the desired product (39) as a white solid (6 mg, 50%). MS APCI (+) m/z 556, 558, 560 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) b 8.83 (s, 1H), 7.56 (s, 1H), 7.54 (s, 1H), 7.27 (dd, 1H), 6.56 (d, 1H), 3.91 (m, 4H), 3.70 (m, 2H), 2.51 (broad s, 4H), 1.60 (broad s, 4H), 1.50 (broad s, 2H).
The following compounds were synthesized in a similar manner as shown in Figure 11.
H
~O~ N O H CI
N
N
~CI Br N~N
O
7-(4-Bromo-2-chlorophenylamino)-8-chloro-3-morpholin-4-ylmethyl-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxy-amide The reaction scheme for the synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-morpholin-4-ylmethylimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxy-amide is similar to that shown in Figure 11 using 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)amide (33a) and morpholine to provide the desired product. MS
APCI (+) m/z 568, 570, 572 (M+, Cl, Br pattern) detected; 'H NMR (400 MHz, CDC13) 8 8.76 (s, 1H), 8.04 (s, 1H), 7.56 (d, 1H), 7.21 (dd, 1H), 6.68 (d, 1H), 4.51 (s, 2H), 4.00 (m, 4H), 3.78 (d, 2H), 1.68 (m, 1H), 0.56 (m, 2H), 0.26 (m, 2H).
H
~O~ N O H CI
N
N
~CI Br ~N~N
7-(4-Bromo-2-chlorophenylamino)-8-chloro-3-dimethylaminomethylimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide The reaction scheme for the synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-dimethylaminomethylimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide was similar to that shown in Figure 11, using 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)amide (33a) and dimethylamine to provide the desired product. MS
APCI (+) m/z 528, 530, 532 (M+, Cl, Br pattern) detected; 1H NMR (400 MHz, 1o CD30D) 8 8.71 (s, 1H), 7.50 (d, 1H), 7.44 (s, 1H), 7.20 (dd, 1H), 6.55 (d, 1H), 3.80 (s, 2H), 3.74 (d, 2H), 2.04 (s, 6H), 1.18 (m, 1H), 0.51 (m, 2H), 0.27 (m, 2H).
H
~O~ N O H ' CI
V N
N
~CI Br ~N~N
N--/
~O~
\\O
4-[7-(4-Bromo-2-chlorophenylamino)-8-chloro-6-cyclopropylmethoxycarbamoylimidazo[1,2-a]pyridin-3-ylmethyl]-piperazine-1-carboxylic acid tert-butyl ester The reaction scheme for the synthesis of 4-[7-(4-bromo-2-chlorophenylamino)-8-chloro-6-cyclopropylinethoxycarbamoylimidazo[ 1,2-a]pyridin-3-ylmethyl]-piperazine-1-carboxylic acid tert-butyl ester was similar to that 2o shown in Figure 11, using 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)amide (33a) and piperazine-1-carboxylic acid tert-butyl ester to provide the desired product. MS APCI (+) m/z 669, 671, 673 (M+, Cl, Br pattern) detected; 1H NMR (400 MHz, CDCl3) 8 8.80 (s, 1H), 8.00 (s, 1H), 7.56 (d, 1H), 7.27 (dd, 1H), 6.67 (d, 1H), 4.54 (s, 2H), 3.76 (d, 4H), 3.27 (m, 4H), 1.50 (s, 9H), 1.12 (m, 1H), 0.55 (m, 2H), 0.28 (m, 2H).
H
~O~N O H CI
N
N
~CI Br ~N~N
N
7-(4-Bromo-Z-chlorophenylamino)-8-chloro-3-(4-methylpiperazin-1-ylmethyl)-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide The reaction scheme for the synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-(4-methylpiperazin-1-ylinethyl)-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide was similar to that shown in Figure 11 using 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)amide (33a) and 1-methylpiperazine to provide the desired product.
MS APCI (+) m/z 581, 583, 585 (M+, Cl, Br pattern) detected; 1H NMR (400 MHz, CDCl3) 8 8.90 (s, 1H), 7.57 (s, 1H), 7.56 (d, 1H), 7.22 (dd, 1H), 6.47 (d, 1H), 3.83 (s, 2H), 3.60 (d, 2H), 2.47 (m, 8H), 2.31 (s, 3H), 1.02 (m, 1H), 0.56 (m, 2H), 0.26 (m, 2H).
H
~O. N O F
H
N
N
~ ~F Br N '=N
O
7-(4-Bromo-2-fluorophenylamino)-8-tluoro-3-morpholin-4-ylmethylimidazo[1,2-a]pyridine-6-carboxylic acid ethoxyamide The reaction scheme for the synthesis of 7-(4-bromo-2-fluorophenylamino)-8-fluoro-3-morpholin-4-ylmethyl-imidazo[1,2-a]pyridine-6-carboxylic acid ethoxy-amide is similar to that shown in Figure 11 using 7-(4-bromo-2-fluoro-phenylamino)-8-fluoro-imidazo[1,2-a]pyridine-6-carboxylic acid ethoxyamide and morpholine to provide the desired product. MS ESI (+) m/z 510, 512 (M+, Br pattern) detected. 'H
NMR (400 MHz, CD30D) 8 8.72 (s, 1H), 7.39 (s, 1H), 7.29 (dd, 1H), 7.1? (d, 1H), 6.76 (m, 1H), 3.99 (q, 2H), 3.85 (s, 2H), 3.68 (m, 4H), 2.49 (br s, 4H), 1.29 (t, 3H).
19F NMR (376 MHz, CD30D) -129.97 (s, 1F), -142.85 (s, 1F).
1o Example 19 H
~O.N O H Cl N
I~
Br Synthesis of 7-(4-bromo-2-chlorophenylamino)-imidazo(1,2-a] pyridine-6-carboxylic acid cyclopropylmethoxyamide (44a) The reaction scheme for the synthesis of compound 44a is shown in Figure 12.
Step A: Preparation of 4-f~.4-bromo-2-chlorophenylamino)-6-chloronicotinic acid tent-butyl ester (40): 2-tent-Butyl-1,3-diisopropylisourea (8.04 g, 40.1 mmol) was added to a suspension of 4-(4-bromo-2-chlorophenylamino)-6-chloronicotinic acid hydrochloride salt (24) (2.91 g, 7.31 mmol) in THF (165 mL). After stirnng for hours at room temperature and 30 minutes at reflux, the reaction mixture was cooled to room temperature and diluted with EtOAc. The organic layer was washed with 10% KZC03 and brine, dried (NaZS04) and concentrated. The resulting residue was dissolved in CHZC12 and filtered. The filtrate was concentrated and purified by flash column chromatography using the Biotage system (CHZCl2) to give the desired product (40) (3.28 g, 78%).
Step B: Preparation of 6-azido-4~4-bromo-2-chlorophenyl-amino)nicotinic acid tert-butyl ester (41): Sodium azide (1.51 g, 23.2 mmol) was added to a mixture of 4-(4-bromo-2-chlorophenylamino)-6-chloronicotinic acid tert-butyl ester (40) (3.23 g, 7.73 mmol) in DMF (60 mL). The reaction mixture was heated to 80 °C
and stirred for 16 hours. After cooling to room temperature, the reaction was diluted with EtOAc and washed with water, saturated NaHC03 and brine. The organic layer was dried (NaZS04) and concentrated. Purification by flash column chromatography using the Biotage system (CHZC12) (repeated) provided the desired product (41) (1.41 g, 43%).
Step C: Preparation of 6-amino-4-(4-bromo-2-chlorophenylamino)-nicotinic acid tert-butyl ester (42): Compound 42 was prepared as described in Step G of 1o Example 9 using 6-azido-4-(4-bromo-2-chlorophenylamino)nicotinic acid tert-butyl ester (41 ).
Step D: Preparation of 7-(4-bromo-2-chlorophenylamino)imidazo[1,2-alpyridine-6-carboxylic acid (43): Chloroacetaldehyde (12 ~.L, 0.188 mmol) was added to a mixture of 6-amino-4-(4-bromo-2-chlorophenylamino)-nicotinic acid tert-butyl ester (42) (50 mg, 0.125 mmol) in EtOH (630 ~,L). After stirnng the reaction mixture at 80 °C for 5 hours, an additional 12 ~.L of chloroacetaldehyde were added and heating was continued for 10 hours. The reaction mixture was cooled to room temperature and diluted with EtOAc to give a cloudy semi-solution. The ~
organic layer was washed with water, saturated NaHC03 and brine. The organic layer 2o contains a precipitate, which was collected by filtration to give the desired product (43) (15 mg, 33%). MS APCI (-) m/z 364, 366, (M-, Cl, Br pattern) detected. 'H
NMR (400 MHz, DMSO-d6) 8 9.12 (s, 1H), 8.31 (s, 1H), 7.91 (s, 1H), 7.80 (s, 1H), 7.65-7.54 (m, 2H), 6.91 (s, 1H).
Step E: Preparation of 7-144-bromo-2-chlorophen~rlamino -imidazo[1,2-a]pyridine-6-carboxylic acid cyclopro~ylmethoxyamide (44a): Oxalyl chloride (2.0 M solution in CHzCl2, 102 ~,L) was added to a stirred suspension of 7-(4-bromo-chlorophenylamino)imidazo[1,2-a]pyridine-6-carboxylic acid (43) (15 mg, 0.041 mmol) in CHZC12 (1 mL) at 0 °C. One drop of DMF was added. The reaction mixture was warmed to room temperature, stirred for 25 minutes, and then concentrated.
The 3o residue was twice concentrated from toluene and dried in vacuo. The residue was suspended in CHZC12 (1 mL), cooled to 0 °C and cyclopropylmethylhydroxylamine (36 mg, 0.409 mmol) was added. The reaction mixture was warmed to room temperature, stirred for 2 hours and diluted with EtOAc. The organic layer was washed with saturated NaHC03 and brine, dried (Na2S04) and concentrated.
Purification by flash column chromatography using the Biotage system (40:1 CH2Clz/MeOH to 20:1 CHZCIz/MeOH) provided the desired product (44a) as a tan solid (6 mg, 31%). MS APCI (-) m/z 433, 435 (M-, Cl, Br pattern) detected. 'H
NMR
(400 MHz, CDC13) b 8.68 (s, 1H), 7.69 (m, 1H), 7.67 (d, 1H), 7.52-7.44 (m, 3H), 7.08 (s, 1H), 3.83 (d, 2H), 0.90 (m, 1H), 0.62 (m, 2H), 0.35 (m, 2H).
The following compounds were synthesized in a similar manner as shown in 1o Figure 12 using the appropriate aniline in Step C of Example 9.
HO O
H
N
N I I /
Br N
7-(4-Bromo-2-fluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid MS ESI (+) m/z 350, 352 (M+, Br pattern) detected. (400 MHz, DMSO-d6) 8 9.13 (s, 1 H), 7.94 (d, 1 H). 7.70 (dd, 1 H), 7.67 (d, 1 H), 7.59 (t, 1 H), 7.47 (m, 1 H), 6.84 (s, 1H). '9F NMR (376 MHz, DMSO-d6) 8 -128.9.
H
~O. N O F
H
N
N
Br N
7-(4-Bromo-2-Iluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide MS ESI (+) m/z 419, 421 (M+, Br pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 11.91 (br s, 1H), 8.79 (s, 1H), 8.72 (br s, 1H), 7.81 (s, 2H), 7.64 (m, 1 H), 7.50 (m, 1 H), 7.45 (m, 1 H), 7.3 9 (m, 1 H), 6.90 (s, 1 H), 3.74 (d, 2H), 1.14 (m, 1H), 0.55 (m, 2H), 0.29 (m, 2H). 19F NMR (376 MHz, DMSO-d6~ 8 -124.3.
H
HO~O,N O
H
N
N I I /
~~ Br '-N
7-(4-bromo-2-fluorophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide MS ESI (+) m/z 409, 411 (M+, Br pattern) detected. 1H NMR (400 MHz, DMSO-d6) b 12.02 (br s, 1H), 8.83 (s, 1H), 7.80 (s, 1H), 7.63 (s, 1H), 7.51 (m, 1H), 7.45 (m, 1H), 7.39 (m, 1H), 6.91 (s, 1H), 4.79 (br s, 1H), 3.94 (t, 2H), 3.64 (t, 2H).
19F NMR (376 MHz, DMSO-d6) 8 -124.4.
Example 20 H
~O.N ~ H CI
N
I~
~F Br Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (47a) The reaction scheme for the synthesis of compound 47a is shown in Figure 13.
Step A: Preparation of 6-amino-4-(4-bromo-2-chlorophenylamino)-5-fluoronicotinic acid tert-butyl ester (45~: 1-Chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (889 mg, 2.508 mmol) was added to a mixture of 6-amino-4-(4-bromo-2-chlorophenylamino)nicotinic acid tert-butyl ester (42) (1.00 g, 2.51 mmol) in 1:1 MeOH/water (25 mL). After about 2 hours, the reaction mixture was diluted with EtOAc and water. The layers were separated and the organic layer washed with 0.5 N HCl and brine. The aqueous washes were back extracted with EtOAc. The combined organic extracts were dried (Na2S04) and concentrated. Purification by flash column chromatography using the Biotage system (20:1 hexanes/EtOAc to 15:1 hexanes/EtOAc) provided the desired product (45) as a yellow solid (75 mg, 7%).
Step B: Preparation of 7-(4-bromo-2-chlorophen lay mino)-8-io fluoroimidazo[1,2-a]pyridine-6-carboxylic acid (46): Chloroacetaldehyde (23 ~,L, 0.360 mmol) was added to a mixture of 6-amino-4-(4-bromo-2-chlorophenylamino)-5-fluoronicotinic acid tert-butyl ester (45) (75 mg, 0.180 mmol) in EtOH (1 mL).
After stirring the reaction mixture at 70 °C for 10 hours, an additional 10 ~.L
chloroacetaldehyde was added and heating was continued for 33 hours. The reaction mixture was cooled to room temperature and desired product (46) was collected by filtration. The filtrate was diluted with EtOAc and washed with water, saturated NaHC03 and brine. The organic layer was dried (Na2S04) and concentrated to give additional product (46) (S1 mg, 74% combined recovery). MS APCI (-) m/z 382, 384, 386 (M-, Cl, Br pattern) detected. 1H NMR (400 MHz, CD30D) 8 8.86 (s, 1H), 7.85 (s, 1H), 7.53 (s, 2H), 7.32 (d, 1H), 6.82 (t, 1H). 19F NMR (376 MHz, CD30D) -148.3 (s).
7-(4-Bromo-2-chlorophenylamino)-8-fluoroimidazo[ 1,2-a]pyridine-6-carboxylic acid (46) was alternatively synthesized by the route shown below.
HO O NH HO O CI ~O O CI
\ CI \ CI LHMDS N TMSCHN2 \ \ \ \
or OxCI, DMF
/ F / THF / F / Br followed by / F / Br CI gr CI MeOH CI
/O O CI /O O CI HO O CI
1. NaN3 \ N \ CICHzCHO i / N \ NaOH / N \
2. Zn ~~F ~ / Br EtOH N~F ~ / Br cN~F ~ / Br NHp ~N~' ~N
In the first step of this alternative procedure, 4,6-dichloro-5-fluoronicotinic acid (J. Heterocyclic Chemistry 1993, 30, 855-859) was used to synthesize 4-(4-bromo-2-chlorophenylamino)-5-bromo-6-chloronicotinic acid according to the alternate procedure described in Example 9, Step B.
Step C: Preparation of 7-(4-bromo-2-chlorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (47a):
Compound 47 was prepared as described in Step E of Example 19 using 7-(4-bromo-2-chlorophenylamino)-8-fluoroimidazo[1,2-aJpyridine-6-carboxylic acid (46) to give 1 S mg (24%) of the desired product (47a) as a white solid. MS APCI (+) m/z 453, 455, 457 (M+, Cl, Br pattern) detected. 'H NMR (400 MHz, CD30D) 8 8.66 (s, 1H), 7.93 (m, 1H), 7.61 (s, 1H), 7.56 (d, 1H), 7.32 (dd, 1H), 6.73 (q, 1H) 3.70 (d, 2H), 1.14 (m, 1H), 0.56 (m, 2H), 0.26 (m, 2H): '9F (400 MHz, CD30D) -139.4 (s).
The following compounds were synthesized in a similar manner as shown in Figure 13.
H
HO~\O,N O CI
H
N
N
_F Br N
7-(4-Bromo-2-chlorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxy-ethoxy)amide MS APCI (+) m/z 443, 445, 447 (M+, Cl, Br pattern) detected; 'H NMR (400 MHz, CD30D) 8 8.69 (s, 1H), 7.89 (m, 1H), 7.59 (s, 1H), 7.55 (d, 1H), 7.31 (dd, 1H), 6.72 (q, 1 H), 4.01 (t, 2H), 3.76 (t, 2H); ' 9F (400 MHz, CD30D) -139.7 (s).
HO O F
H
N
N
~F Br N
7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo [1,2-a] pyridine-6-carboxylic acid MS ESI (+) m/z 368, 370 (M+, Br pattern) detected. 'H NMR (400 MHz, 1o DMSO-d6) 8 9.21 (s, 1H), 8.08 (m, 1H), 7.66 (s, 1H), 7.55 (dd, 1H), 7.29 (d, 1H), 6.92 (m, 1H). '9F (376 MHz, DMSO-d6) -127.9 (s, 1F), -141.1 (s, 1F) H
~O.N O F
H
N
N
~F Br N
7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide MS ESI (+) m/z 437, 439 (M+, Br pattern) detected. 'H NMR (400 MHz, CD30D) S 9.55 (br s, 1H), 8.57 (s, 1H). 7.68 (s, 2H), 7.65 (s, 1H), 7.28 (m, 1H), 7.14 (m, 1H), 6.78 (br s, 1H), 6.63 (m, 1H), 3.72 (m, 2H), 1.07 (m, 1H), 0.59 (m, 2H), 0.28 (m, 2H). '9F NMR (376 MHz, CD30D) 8 -128.9 (s, 1F), -138.1 (s, 1F).
HO O
H
N
N I ~ \
F ~ Br 7-(4-Bromo-2-methylphenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 364, 366 (M+, Br pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.22 (s, 1H), 8.07 (m, 1H), 7.68 (s, 1H), 7.42 (d, 1H), 7.28 (dd, 1H), 6.78 (t, 1H), 2.29 (s, 3H). '9F (376 MHz, DMSO-d6) -142.5 (s).
HO O CI
H
N
N I
~ ~F CI
N
7-(2,4-dichlorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 440, 442 (M+, Cl pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.27 (s, 1H), 8.13 (s, 1H), 7.71 (s, 1H), 7.62 (s, 1H), 7.32 (dd, 1H), 6.95 (t, 1H). '9F (376 MHz, DMSO-d6) -129.9 (s).
HO O
F
H
N
N I I ~
~~ ~F
8-Fluoro-7-(2-fluoro-4-methylphenylamino)-imidazo(1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 304 (M+1) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.48 (br s, 1H), 9.32 (s, 1H), 8.12 (s, 1H), 7.86 (s, 1H), 7.12 (m, 2H), 6.98 (d, 1H), 2.31 (s, 3H). '9F (376 MHz, DMSO-d6) -128.1 (s, 1F), -148.8 (s, 1F).
HO O
H F
N
N
F ~ CI
7-(4-Chloro-2-fluorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid MS APCI (+) m/z 324, 326 (M+, Cl pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.19 (s, 1H), 8.07 (m, 1H), 7.64 (s, 1H), 7.45 (dd, 1H), 7.17 (d, 1H), 6.98 (m, 1H). 19F (376 MHz, CD30D) -128.8 (s, 1F), -154.8 (s, 1F).
Example 21 H
HO~O,N O CI
H
N
N
CI~~ ~F CI
N
3-Chloro-7-(2,4-dichlorophenylamino)-8-fluoroimidazo(1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide The reaction scheme for the synthesis of this compound is shown below.
H CI cat HCI O O H CI LHMDS
i N W / N ~ + ~O~ .NHZ -/I I /I I o F ~ CI DMF CI' /N F ~ CI THF
N ~~N
~O~O,N O H CI HCI HO~O-N O H CI
N -, N
N I I ~ MeOH N
CI~~ ~F CI CI~~ ~F CI
N N
Step A: Preparation of 3-chloro-7-(2,4-dichlorophenylamino)-8-fluoroimidazo[1,2-alpyridine-6-carboxylic acid methxl ester. 7-(2,4-Dichloro-phenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (57.0 mg, 0.16 mmol), which was synthesized in a manner similar to the alternate procedure described in Example 20, Step B, was dissolved into DMF (3 mL). Added N
chlorosuccinimide (17.0 mg, 0.13 mmol) and HCl (1.0 M aqueous solution, 16 p,L, 0.016 mmol). After stirring for 16 hours, the suspension was diluted with ethyl acetate, washed with NaHS03, water (2x), brine, dried over Na2S04 and concentrated to a yellow solid. Purification by flash column chromatography (4:1 hexanes/ethyl acetate) provided the desired product as a light yellow solid (40 mg, 64%). MS
APCI
(+) m/z 388, 390 (M+, Cl pattern) detected. 1H NMR (400 MHz, CDC13) 8 8.70 (s, H), 7.58 (s, 1H), 7.40 (d, 1H), 7.14 (dd, 1H), 6.77 (t, 1H), 4.02 (s, 3H): '~F
NMR
(376 MHz, CDC13) -135.84 (s).
Step B: Preparation of 3-chloro-7-(2,4-dichlor-phenylamino)-8-fluoroimidazojl,2-a]pyridine-6-carboxylic acid (2-vinyloxyethoxy)-amide.
LiHMDS
(1.0 M in hexanes, 0.34 mL, 0.34 mmol) was added to a solution 3-chloro-7-(2,4-dichlorophenylamino)-8-fluoro-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (38 mg, 0.098 mmol) and O-(2-vinylox-ethyl)-hydroxylamine (25 mg, 0.24 mmol) in THF (1.0 mL) cooled to 0 °C. The solution was allowed to warm to room 2o temperature and stir for 16 hours. The solution was diluted with ethyl acetate, washed with saturated NaHC03, water (3x), brine, dried over Na2S04 and concentrated to a yellow liquid. Purification by flash column chromatography (20:1 to 10:1 dichloromethane/MeOH) provided the desired product as a yellow solid (42 mg, 93%). MS APCI (+) m/z 459, 461 (M+, Cl pattern) detected.
Step C: Preparation of 3-chloro-7-(2,4-dichlorophenylamino)-8-fluoroimidazof 1,2-alpvridine-6-carboxvlic acid (2-hvdroxv-ethoxv)-amide. 3-Chloro-7-(2,4-dichloro-phenylamino)-8-fluoro-imidazo[1,2-a]pyridine-6-carboxylic acid (2-vinyloxy-ethoxy)-amide was converted to the desired product according to Example 3, Step B, to provide 31 mg (78%) of desired product as a light yellow solid.
MS
3o APCI (+) m/z 433, 435 (M+, Cl pattern) detected. 1H NMR (400 MHz, CD30D) 8 8.52 (s, 1 H), 7.57 (s, 1 H), 7.42 (d, 1 H), 7.16 (dd, 1 H), 6.79 (dd, 1 H), 4.07 (m, 2H), 3.80 (m, 2H). t9F NMR (376 MHz, CD30D) -140.83 (s).
Example 22 H
~,O,N O F
H
N
N I I /
~F
N
7-(4-Ethyl-2-fluorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid ethoxyamide The reaction scheme for the synthesis of this compound is shown below.
i0 O F ~O O F i0 O F
z / ~ N ~ '~ ~BFgK / ~ N ~ \ 10% Pd/C / ~ N ~ \
~~F / I PdClz(dppf)-CHzCIz \N~F / / EtOH N~F
( NEt3, iPrOH/THF
N . reflux H
~O~NHZ.HCI ~O~N O F
H
LHMDS / N \
THF N F /
~N
Step A. Preparation of 8-fluoro-7-(2-fluoro-4-vinylphenylamino)-imidazo f 1 2-a]pyridine-6-carboxylic acid methyl ester. 8-Fluoro-7-(2-fluoro-iodophenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (250 mg, 0.58 mmol), which was synthesized in a similar manner to the alternative synthesis set forth in Example 20 Step B, was suspended in isopropyl alcohol (6 mL) and tetrahydrofuran (1 mL). Potassium vinyltrifluoroborate (90 mg, 0.67 mmol) and triethylamine (0.165 mL, 1.2 mmol) were added, at which time the reaction mixture became a solution. The reaction mixture was sparged with NZ. PdClz(dppf)-CHzCIZ
(2 mol %, 9 mg) was then added and the reaction was heated to 90 °C and stirred under Nz for 16 hours. The reaction mixture was cooled to room temperature and diluted with water, followed by extraction with ethyl acetate (2x). The combined organic layers were washed with saturated aqueous NaCI, dried over Na2S04 and concentrated. Purification of the crude product by flash column chromatography (30:1 dichloromethane/methanol) provided the desired product (143 mg, 81%) as a dark yellow solid. MS ESI (+) m/z 330 (M+1) detected.
Step B. Preparation of 7-(4-ethyl-2-fluoro-phenylamino)-8-1o fluoroimidazof 1,2-a]pyridine-6-carboxylic acid methyl ester. 8-Fluoro-7-(2-fluoro-4-vinyl-phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (165 mg, 0.50 mmol) was suspended in ethanol (5 mL), added 10% Pd/C (267 mg, 0.25 mmol) and placed under an atmosphere of H2. The reaction mixture was stirred vigorously at room temperature for 16 hours. The reaction mixture was filtered through celite, washed with ethanol and tetrahydrofuran and the filtrate concentrated to a yellow oil.
Purification of the crude product by flash column chromatography (gradient of dichloromethane to 20:1 dichloromethane/methanol) provided the desired product (110 mg, 66%) as a dark yellow solid. MS ESI (+) m/z 332 (M+1) detected.
Step C: Preparation of 7-(4-ethyl-2-fluorophenylamino)-8-fluoroimidazo[1,2-2o alpyr'idine-6-carboxylic acid ethox -~. 7-(4-Ethyl-2-fluorophenylamino)-8-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (40 mg, 0.12 mmol) was converted to the desired product according to procedure of Step B of Example 21, using O-ethyl-hydroxylamine-HCl salt, to provide the desired product as a yellow colored solid (31 mg, 71%). MS ESI (+) m/z 361 (M+1) detected. 'H NMR (400 MHz, CD30D) 8 8.62 (s, 1H), 7.86 (s, 1H), 7.56 (s, 1H), 6.97 (d, 1H), 6.90 -6.80 (m, 2H), 3.88 (q, 2H), 2.60 (q, 2H), 1.23 (m, 9H). 19F (376 MHz, CD30D) -132.7 (s, 1F), -145.2 (s, 1F).
became a solution. The reaction mixture was sparged with N2. PdCl2(dppf)-(2 mol %, 9 mg) was then added and the reaction was heated to 90 °C and stirred under NZ for 16 hours. The reaction mixture was cooled to room temperature and diluted with water, followed by extraction with ethyl acetate (2x). The combined organic layers were washed with saturated aqueous NaCI, dried over Na2S04 and concentrated. Purification of the crude product by flash column chromatography (30:1 dichloromethane/methanol) provided the desired product (143 mg, 81%) as a dark yellow solid. MS ESI (+) m/z 330 (M+1) detected.
Step B. Preparation of 7-(4-ethyl-2-fluoro-phenylaminoL
1o fluoroimidazo(1,2-a]pyridine-6-carboxylic acid meth, 1~. 8-Fluoro-7-(2-fluoro-4-vinyl-phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (165 mg, 0.50 mmol) was suspended in ethanol (S mL), added 10% Pd/C (267 mg, 0.25 mmol) and placed under an atmosphere of H2. The reaction mixture was stirred vigorously at room temperature for 16 hours. The reaction mixture was filtered through celite, washed with ethanol and tetrahydrofuran and the filtrate concentrated to a yellow oil.
Purification of the crude product by flash column chromatography (gradient of dichloromethane to 20:1 dichloromethane/methanol) provided the desired product (110 mg, 66%) as a dark yellow solid. MS ESI (+) m/z 332 (M+1) detected.
Step C: Preparation of 7-(4-ethyl-2-fluorophen l~o~-8-fluoroimidazo[1,2-2o a]pyridine-6-carboxylic acid ethoxy-amide. 7-(4-Ethyl-2-fluorophenylamino)-fluoroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (40 mg, 0.12 mmol) was converted to the desired product according to procedure of Step B of Example 21, using O-ethyl-hydroxylamine-HCl salt, to provide the desired product as a yellow colored solid (31 mg, 71%). MS ESI (+) m/z 361 (M+1) detected. 1H NMR (400 MHz, CD30D) 8 8.62 (s, 1H), 7.86 (s, 1H), 7.56 (s, 1H), 6.97 (d, 1H), 6.90 -6.80 (m, 2H), 3.88 (q, 2H), 2.60 (q, 2H), 1.23 (m, 9H). 19F (376 MHz, CD30D) -132.7 (s, 1F), -145.2 (s, 1F).
Example 23 H
HO~O, N O F
H
N
N
~F Me N
3-Ethyl-8-fluoro-7-(2-fluoro-4-methylphenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide The reaction scheme for the synthesis of this compound is shown below.
PdCl2(PPh3)z O O O O Cul H F NIS ~ H F diisopropylamine N ~ ~ , N ~ + H = TMS
cN ~ I F I ~ Me ACN I N / I F I ~ Me THF
~N ~N
~O O F ~O 0 F Hz ~0 0 H F
H KpC03 H 10% Pd/C N
N w ~ N
y - ~~ I - N
TMS = \N / F ~ Me MeOH ~ \N ~ F ~ Me MeOH ~ ~ F Me N N N
H H
~O~O.NHZ ~O~O.N 0 H F HCI H0~0-N O H F
N ~ N
LHMDS ~ I F I ~ Me MeOH ~ I F I ~ Me THF ~N ~N
Step A: Preparation of 8-Fluoro-7-(2-fluoro-4-methyl-phenylamino)-3-iodo-imidazo[1,2-~pyridine-6-carboxylic acid methyl ester. N iodosuccinimide (134 mg, 0.60 mmol) was added in a single portion to a solution of 8-fluoro-7-(2-fluoro-methyl-phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (172 mg, 0.54 mmol) in acetonitrile (10 mL) resulting in a thick precipitate after ten minutes of stirnng. The suspension was diluted with ethyl acetate, washed with NaHS03, saturated NaHC03, water, brine, and dried over NaZSOa. Concentration provided the desired product as a yellow solid (241 mg, 100%). MS APCI (+) m/z 444 (M+1) detected. 1H NMR (400 MHz, CD30D) 8 8.78 (s, 1H), 7.62 (s, 1H), 6.95 (m, 3H), 4.00 (s, 3H), 2.33 (s, 3H). '9F NMR (376 MHz, CD30D) -131.11 (s, 1F), -146.71 (s, 1 F).
Step B: Preparation of 8-fluoro-7-y2-fluoro-4-meth~phenylamino~3-trimethylsilanyleth~nyl-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester.
THF
(1.0 mL), diisopropylamine (95 pL, 0.68 mmol) and trimethylsilylacetylene (38 pL, 0.27 mmol) were added to a mixture of 8-fluoro-7-(2-fluoro-4-methyl-phenylamino)-3-iodo-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (100 mg, 0.23 mmol), 1o CuI (4.0 mg, 0.023 mmol) and PdCl2(PPh3)2 (16 mg, 0.023 mmol). The solution was stirred at room temperature for 16 hours. The reaction was diluted with ethyl acetate, washed with saturated NaHC03 (3x), brine (2x), dried over NazS04 and concentrated to a dark brown solid. Flash column chromatography (40:1 dichloromethane/MeOH) provide desired product (30 mg, 32%) as a yellow liquid. MS APCI (+) m/z 414 (M+1) detected. 'H NMR (400 MHz, CDCl3) 8 8.77 (s, 1H), 8.61 (s, 1H), 7.80 (s, 1H), 6.90 (m, 3H), 4.00 (s, 3H), 2.32 (s, 3H), 0.33 (s, 9H). '9F NMR (376 MHz, CDCl3) -129.12 (s, 1F), -141.99 (s, 1F).
Step C: Preparation of 3-ethynyl-8-fluoro-7-(2-fluoro-4-meth~phenylamino~
imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester. Potassium carbonate (70 mg, 0.51 mmol) was added to a solution of 8-fluoro-7-(2-fluoro-4-methyl-phenylamino)-3-trimethylsilanylethynyl-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester in MeOH (S mL) and stirred at room temperature for two hours. The mixture was diluted with ethyl acetate, washed with brine (2x), dried over NaZS04 and concentrated to a brown residue. Flash column chromatography (dichloromethane to 80:1 dichloromethane/MeOH) provided the desired product (16 mg, 65%) as a yellow liquid. MS APCI (+) m/z 342 (M+1) detected.
Step D: Preparation of 3-ethyl-8-fluoro-7-(2-fluoro-4-meth~phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester. A mixture of 3-ethynyl-fluoro-7-(2-fluoro-4-methyl-phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid 3o methyl ester (16 mg, 0.047 mmol) and 10% Pd/C (5 mg) under an atmosphere of hydrogen (balloon) was stirred vigorously for one hour. The mixture was filtered through a plug of rinsing with dichloromethane and concentrated to provide the desired product (14 mg, 86%) as a yellow foam. MS APCI (+) m/z 346 (M+1) detected. 1H NMR (400 MHz, CDCl3) 8 8.51 (s, 1H), 8.31 (s, 1H), 7.38 (s, 1H), 6.91 (d, 1H), 6.84 (s, 2H), 3.97 (s, 3H), 2.86 (q, 2H), 2.30 (s, 3H), 1.43 (t, 3H).
Step E: Preparation of 3-ethyl-8-fluoro-7-(2-fluoro-4-methyl-phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxy-ethoxy)-amide. 3-Ethyl-8-fluoro-7-(2-fluoro-4-methyl-phenylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (14 mg, 0.041 mmol) was converted to the desired product according to 1o the Step A of example 21 and Step B of Example 3, Step B to provide the desired product (hydrochloride salt) as a tan colored solid (9 mg, 51 % over two steps). MS
APCI (+) m/z 391 (M+1) detected. 1H NMR (400 MHz, CD30D) 8 8.63 (s, 1H), 7.65 (s, 1H), 7.16 (m, 1H), 7.01 (m, 2H), 4.04 (br s, 2H), 3.79 (br s, 2H), 2.97 (q, 2H), 2.35 (2, 3H), 1.45 (t, 3H). 19F NMR (376 MHz, CD30D) -127.69 (s, 1F), -155.07 (s, 1F).
Example 24 H
~O'N ~H CI
N
~CI Br N-N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methyl-[1,2,4]-2o triazolo-[4,3-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (53a) The reaction scheme for the synthesis of compound 53a is shown in Figure 14.
Step A: Preparation of 4-(4-bromo-2-chloro~hen 1~)-5-chloro-6-hydrazinonicotinic acid ethyl ester (49): 4-(4-Bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid ethyl ester (48) was prepared by standard methods from 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid. Hydrazine monohydrate (0.59 mL, 12.16 mmol) was added to a solution of 4-(4-bromo-2-chlorophenylamino)-5,6-dichloronicotinic acid ethyl ester (48) (1.72 g, 4.05 mmol) in N,N-dimethylacetamide (20 mL). After stirnng at 90 °C for 1 hour, the reaction mixture was cooled to room temperature and diluted with EtOAc. The organic layer was washed with water and brine, dried (Na2S04) and concentrated. Purification by flash column chromatography using the Biotage system (20:1 CH2C12/EtOAc) provided the desired product (49) (307 mg, 18%).
Step B: Preparation of 7-(4-bromo-2-chlorophen lamino~8-chloro-3-meth ~~l-I1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid ether ester (51a): Acetic anhydride (22 ~,L, 0.238 mmol) was added to a solution of 4-(4-bromo-2-chlorophenylamino)-5-l0 chloro-6-hydrazinonicotinic acid ethyl ester (49) (0.100 g, 0.238 mmol) and triethylamine (66 ~.L, 0.476 mmol) in CHZC12 (2.5 mL) at 0 °C, and then the solution was warmed to room temperature to provide compound SOa (not isolated). After minutes, POC13 (87 ~,L, 0.952 mmol) was added dropwise and the reaction mixture was warmed to room temperature. After 16 hours, the reaction mixture was heated to 1 5 reflux and stirred for 3 days. The reaction mixture was cooled to room temperature and concentrated. The residue was diluted with EtOAc and saturated NaHC03 was added and the mixture stirred for 20 minutes. The layers were separated and the organic layer was washed with brine. The aqueous washings were back extracted with EtOAc. The combined organic extracts were dried (NaZS04) and concentrated.
2o Purification by flash column chromatography using the Biotage system (9:1 CHZC12/EtOAc) provided compound S l a (80 mg, 75%).
Step C: Preparation of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid (52a): Sodium hydroxide (715 ~.L of a 1 M solution) was added to a solution of 7-(4-bromo-2-chlorophenylamino)-8-25 chloro-3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid ethyl ester (51a) (79 mg, 179 mmol) in 3:1 THF:water (4.5 mL). After 16 hours, the reaction mixture was poured into a separatory funnel, diluted with brine and acidified with 1 M HCl to about pH 2. The aqueous layer was extracted with 1:1 EtOAc/THF. The combined organic extracts were dried (Na2S04) and concentrated and the residue (52a) was 30 carned forward without further purification.
Step D: Preparation of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-meth ~~-1-1,2,41triazolo f 4,3-alpyridine-6-carboxylic acid cyclopropylmethoxyamide 53a):
Compound 53a was prepared as described in Example 2 using 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methyl-[ 1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid (52a) to give 2 mg (S%) of the desired product. MS APCI (-) m/z 482, 484, (M-, Cl, Br pattern) detected.
Example 25 H
HO~O.N O H CI
N
N~ I i CI Br N-N
1o Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide (54a) The reaction scheme for the synthesis of compound 54a is shown in Figure 14.
Compound 54a was prepared as described herein starting with 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methyl-[ 1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid (52a) to give 1 mg (2% for the two steps) desired product (54a). MS APCI
(-) m/z 472, 474, 476 (M-, Cl, Br pattern) detected.
Example 26 H
~O'N OH CI
N I N I ~
~CI Br j N-N
Synthesis of 3-benzyl-7-(4-bromo-2-chlorophenylamino)-8-chloro [1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid cyclopropylmethoxyamide (53b) The reaction scheme for the synthesis of compound 53b is shown in Figure 14.
Step A: Preparation of 3-benzyl7-(,4-bromo-2-chlorophen~amino)-8-chloro-f 1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid meths ester (51b):
Phenylacetyl chloride (152 ~,L, 1.148 mmol) was added to a solution of 4-(4-bromo-2-chlorophenylamino)-5-chloro-6-hydrazinonicotinic acid methyl ester (49) (0.233 g, 0.574 mmol) and triethylamine (160 ~,L, 1.148 mmol) in CHZC12 (5.7 mL) at 0 °C.
After warming to room temperature, an additional 75 p.L phenylacetyl chloride was added. After 6 hours, the reaction mixture was concentrated and diluted with EtOAc.
The organic layer was washed with water and brine, dried (Na2S04) and concentrated.
1o The residue (50b) was diluted with dichloroethylene (2 mL) and POCl3 (465 p.L, 5.082 mmol) was added. After stirring at reflux for 12 hours, the reaction mixture was cooled to room temperature and concentrated. The residue was diluted with EtOAc and saturated NaHC03 was added and the mixture stirred for 20 minutes.
The resulting solid was collected by filtrate to give the desired product (51b) (97 mg, 30%).
Step B: Preparation of 3-benzyl-7-(4-bromo-2-chlorophenylamino)-8-chloro-j1,2,4]triazolo[4,3-alpyridine-6-carboxylic acid c~pro~ylmethoxyamide (53b):
Compound 53b was prepared as described in Step C of Example 24 and Example 2 using 3-benzyl-7-(4-bromo-2-chlorophenylamino)-8-chloro-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid methyl ester (51b) as the starting material to give 5 mg (4% for the two steps) of the desired product (53b). MS APCI (-) m/z 558, 560, (M-, Cl, Br pattern) detected. 'H NMR (400 MHz, CDC13) 8 8.22 (s, 1H), 7.30 (m, 6H), 6.50 (d, 1H), 4.53 (s, 2H), 3.49 (m, 2H), 0.94 (m, 1H), 0.51 (m, 2H), 0.19 (m, 2H).
Example 27 HO O
H CI
N
,F
p-N
Synthesis of 6-(2-chlorophenylamino)-7-fluoro-3-methylbenzo[c]isoxazole-5-carboxylic acid (56) The synthesis of compound 56 is shown in Figure 15.
Step A: Preparation of 6-(2-chlorophenylaminol-7-fluoro-3-methyl-benzo[cl-isoxazole-5-carboxylic acid methyl ester (55~ Sodium azide (128 mg, 1.95 mmol) was added to a mixture of S-acetyl-2-(2-chlorophenylamino)-3,4-difluorobenzoic acid l0 methyl ester (6) (601 mg, 1.59 mmol) in 3:1 acetone:water (16 ml) and heated to reflux. After 16 hours, the reaction mixture was cooled to room temperature, and diluted with EtOAc and water. The organic layer was washed with water, dried (MgS04) and concentrated. The resulting residue was diluted with water (8 mL) and heated to reflux. After 5 hours, the mixture was cooled to room temperature and diluted with EtOAc. The organic layer was washed with water, dried (MgS04) and concentrated. Purification by flash column chromatography using the Biotage system (20% EtOAc in hexanes) provided the desired product (55) (410 mg, 77%).
Step B: Preparation of 6-(2-chlorophenylamino)-7-fluoro-3-methylbenzolcl-isoxazole-5-carboxylic acid (56~, To a solution of 6-(2-chlorophenylamino)-7-fluoro-3-methyl-benzo[cJ-isoxazole-5-carboxylic acid methyl ester (55) (100 mg, 0.299 mmol) in 6:1 THF/water (3.5 mL) was added LiOH (0.60 ml of a 1 M solution in water). After 1 hour, the reaction was acidified to pH 1 with 1 N HCI, diluted with water and extracted with EtOAc. The combined organic extracts were washed with water, dried (MgS04) and concentrated to give the desired product (56) (87 mg, 91%).
MS APCI (-) m/z 319, 321 (M+, Cl pattern) detected. 1H NMR (400 MHz, CD30D) 8 8.45 (s, 1H), 7.38 (dd, 1H), 7.20 (m, 1H), 6.91 (m, 2H), 2.88 (s, 3H): ~9F NMR
(376 MHz, CD30D) -136.40 (s).
Example 28 H
HO~O~ N O CI
H
N
i ~ ~F
O-N
Synthesis of 6-(2-chlorophenylamino)-7-fluoro-3-methylbenzo[c]isoxazole-5-carboxylic acid (2-hydroxyethoxy)amide (57a) Compound 57a was prepared as shown in Figure 15 using 6-(2-chlorophenylamino)-7-fluoro-3-methylbenzo[c]isoxazole-5-carboxylic acid (56) to l0 give 35 mg (44%) desired product. MS APCI (-) m/z 388, 390 (M+, Cl pattern) detected; 1H NMR (400 MHz, CD30D) 8 7.73 (s, 1H), 7.36 (d, 1H), 7.17 (t, 1H), 6.89 (t, 1H), 6.81 (dd, 1H), 3.72(d, 2H), 2.87 (s, 3H), 1.15 (m, 1H), 0.54 (d, 2H), 0.26 (d, 2H); 19F NMR (376 MHz, CD30D) -135.08 (s).
Example 29 H
~O~ N O H CI
N
/ ~ ~F
O-N
Synthesis of 6-(2-chlorophenylamino)-7-fluoro-3-methylbenzo[c]isoxazole-5-carboxylic acid cyclopropylmethoxy-amide (57b) Compound 57b was prepared as shown in Figure 15 and described in Example 2 using 6-(2-chlorophenylamino)-7-fluoro-3-methylbenzo[c]isoxazole-5-carboxylic acid (56) to give 35 mg (44%) desired product. MS APCI (-) m/z 388, 390 (M+, Cl pattern) detected; 'H NMR (400 MHz, CD30D) 8 7.73 (s, 1H), 7.36 (d, 1H), 7.17 (t, 1 H), 6.89 (t, 1 H), 6.81 (dd, 1 H), 3.72(d, 2H), 2.87 (s, 3H), 1.1 S (m, 1 H), 0.54 (d, 2H), 0.26 (d, 2H); 19F NMR (376 MHz, CD30D) -135.08 (s).
Example 30 H
~O, N 0 H CI
N
N
~CI Br N
Synthesis of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methylaminomethyl imidazo(1,2-a]pyridine-6-carboxylic acid cyclopropylmethoxy-amide (63) to The synthesis of compound 63 is shown in Figure 16.
Step A: Preparation of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-formylimidazo~l,2-alpyridine-6-carboxylic acid methyl ester (58): A suspension of 6-amino-4-(4-bromo-2-chlorophenylamino)-5-chloro-nicotinic acid methyl ester (28) (1.06 g, 2.72 mmol) and 2-chloro-malonaldehyde (587 mg, 5.43 mmol) was heated to 80 °C for 45 minutes. The solution was allowed to cool to room temperature, and then washed with saturated aqueous NaHC03, and brine. The organic layer was dried over NaS04, filtered, concentrated in vacuo, and purified by column chromatography (20:1 methylene chloride/methanol) to give the desired product as a dark yellow solid.
The solid was triturated with ethyl acetate and isolated by filtration to provide the desired product as a yellow solid (0.436 g, 36%). MS (APCI+) m/z 442, 444, 446 (M+; Cl, Br pattern) detected.
Step B: Preparation of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-methylaminomethyl-imidazo[1 2-a]pyridine-6-carboxylic acid methyl ester (59):
A
suspension of 7-(4-bromo-2-chlorophenylamino)-8-chloro-3-formylimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (58) (25 mg, 0.056 mmol), acetic acid (7 p,L, 0.11 mmol), and methylamine (2.0 M solution in THF, 56 pL, 0.11 mmol) was stirred for 0.5 hours. Sodium triacetoxyborohydride (36 mg, 0.17 mmol) was added and the solution allowed to stir overnight. The reaction mixture was concentrated to dryness and purified by flash column chromatography (dichloromethane followed by 10:1 dichloromethane/methanol) to provide the desired product as a yellow solid (12 mg, 46%). MS (APCI+) m/z 455, 457, 459 (M+; Cl, Br pattern) detected.
Step C: Preparation of 7-(4-bromo-2-chlorophenylamino)-3-[(tert butoxycarbonyl-methyl-amino)-methyll-8-chloroimidazof 1,2-a]pyridine-6-carboxylic acid methyl ester (60): Di-tert-butyl dicarbonate (6 mg, 0.029 mmol) and triethylamine (4 ~L, 0.029 mmol) were added to a solution of 7-(4-bromo-2 chlorophenylamino)-8-chloro-3-methyaminomethylimidazo[1,2-a]pyridine-6 carboxylic acid methyl ester (59) (12 mg, 0.026 mmol) in dichloromethane. The solution was stirred at room temperature for 0.5 hr after which time HPLC
analysis indicated the reaction had gone to completion. The solution was rotovapped to dryness to provide the desired product as a yellow foam (15 mg, quantitative).
MS
(APCI+) m/z 557, 559, 561 (M+; Cl, Br pattern) detected.
Step D: Preparation of 7-(4-bromo-2-chlorophenylamino)-3-[(tert-butox carbonyl-methylamino)-methyl]-8-chloroimidazo[1,2-alpyridine-6-carboxylic acid 61 : Sodium hydroxide (1.0 M aqueous solution, 0.16 mL, 0.16 mmol) was added to a solution of 7-(4-bromo-2-chlorophenylamino)-3-[(tert-butoxycarbonylmethylamino)-methyl]-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester (60) (15 mg, 0.026 mmol) in 4:1 MeOH/water (5 mL). When the reaction was complete, the solution was diluted with water, acidified to pH 3 by addition of 1.0 M aqueous HCI, and extracted with ethyl acetate. The organic extracts were dried over NaS04, filtered, concentrated in vacuo to provide the desired product as a white crystalline solid (12 mg, 84%). MS (APCI-) m/z 541, 543, 545 (M-;
Cl, Br pattern) detected.
Step E: Preparation of [7-(4-bromo-2-chlorophenylamino)-8-chloro-6-cyclopropylmethoxycarbamoylimidazo[1,2-a]p~rridin-3- 1~~1-methylcarbamic acid tert-butyl ester (62): EDCI (6 mg, 0.033 mmol) and HOBt (5 mg, 0.033 mmol) were added to a solution of 7-(4-bromo-2-chlorophenylamino)-3-[(tert-butoxycarbonylmethylamino)-methyl]-8-chloro-imidazo[ 1,2-a]pyridine-6-carboxylic acid (61) in dimethylacetamide (0.4 mL). The yellow solution was allowed to stir at room temperature for 0.5 hours after which time O-cyclopropylmethyl-hydroxylamine (6 mg, 0.066 mmol) and triethylamine (6 ~L, 0.044 mmol) were added and the solution allowed to stir overnight. The reaction mixture was diluted with ethyl acetate, washed with water, saturated aqueous ammonium chloride, saturated aqueous potassium carbonate and brine. The organic phase was dried over NaS04, filtered, concentrated in vacuo to provide the desired product as a yellow residue (11.5 mg, 85%). MS (APCI+) m/z 612, 614, 616 (M+; Cl, Br pattern) detected.
Step F: Preparation of 7-(4-bromo-2-chlorophenylaminol-8-chloro-3-methylaminomethylimidazo[1,2-a]pyridine-6-carboxylic acid c~propylmethoxyamide (63): A solution of [7-(4-bromo-2-chlorophenylamino)-8-chloro-6-cyclopropylmethoxy-carbamoyl-imidazo[ 1,2-a]pyridin-3-ylmethyl]-methyl-carbamic acid tent-butyl ester (62) in 1:1 dichloromethane/trifluoroacetic acid was stirred for two hours. Solvent was removed under reduced pressure and the residue redissolved into ethyl acetate. The organic solution was washed with saturated aqueous potassium carbonate and brine. The aqueous washes were back-extracted with ethyl acetate. The combined organic extracts are dried over NaS04, filtered, and concentrated in vacuo to provide the desired product as a yellow solid (8 mg, 83%).
MS (APCI+) m/z 512, 514, 516 (M+; Cl, Br pattern) detected. 1H NMR (400 MHz, methanol-d4) b 8.72 (s, 1H), 7.58 (s, 1H), 7.54 (s, 1H), 7.25 (d, 1H), 6.55 (d, 1H), 4.23 (s, 2H), 3.67 (d, 2H), 2.51 (s, 3H), 1.13 (m, 1H), 0.50 (d, 2H), 0.24 (d, 2H).
Example 31 H
HO~O,N O CI
H
N
/ ~N Br -N
Synthesis of 6-(4-bromo-2-chlorophenylamino)-pyrazolo[1,5-aJpyridine-5-carboxylic acid (2-hydroxyethoxy)amide (73a) Compound 73a, where W = Br, Y = Cl, and X = H, can be prepared as shown in Figure 17.
s Example 32 H
HO.~O,N O CI
H
N
~N F Br ~N
Synthesis of 6-(4-bromo-2-chlorophenylamino)-7-fluoropyrazolo[1,5-a]pyridine-5-carboxylic acid (2-hydroxyethoxy)-amide (73b) to Compound 73b, where W = Br, Y = Cl, and X = F, can be prepared as shown in Figure 17.
Example 33 H
HO
HO'P~O~O~N O H CI
O N I N I W
CI ~ Br N
Synthesis of phosphoric acid mono-(2-{[7-(4-bromo-2-chlorophenylamino)-8 chloroimidazo[1,2-a]pyridine-6-carbonyl]-aminooxy}-ethyl) ester (74) The synthesis of compound 74 is shown in Figure 18. 7-(4-bromo-2-chlorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide (33a) (100 mg, 0.234 mmol), tetrazole (23 mg, 0.327 mmol) and di-tert-butyl diisopropylphosphoramidite (0.096 mL, 0.304 mmol) were dissolved/suspended in 30 mL of anhydrous DMF under an atmosphere of dry N2.
The reaction mixture was stirred for about 3 hours, after which time the reaction was cooled to -78 °C and tert-butyl hydrogen peroxide (0.100 mL of 70%
solution in water) was added. The cooling bath was then taken away and the reaction was slowly warmed up to room temperature and reacted over night. The reaction mixture was then partitioned between a solution of ethyl ether/ethyl acetate (5:1) and saturated aqueous NaHC03. The organic layer was saved and successively washed with 10%
aqueous sodium sulfite, 3 times with water and finally with brine. The resulting organic layer was dried over MgS04, filtered and concentrated under vacuum.
The residue was dissolved in 3 mL of a solution of TFA/DCM (2:1) under an atmosphere of dry NZ. The reaction was stirred at room temperature for about 2 hours after which time it was concentrated under vacuum and the resulting residue was stirred in methanol for about 1 hour. The off white solid was collected via suction filtration, washed with methanol followed by ethyl ether and then air-dried to give the desired compound (74).
. Example 34 HO O
CI
H
N
N I I ~
Br N
7-(4-Bromo-2-chlorophenylamino)-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid The compound was synthesized by the route shown below.
HO O HO O O O
NHZ CI ~ H CI
CI ~ CI LHMDS ~ N ~ TMSCHN2 \ N
THF ~~ ~ / or OxCI, DMF N 1 I /
gr followed by ~ \ gr CI gr CI MeOH CI
/O O CI ,O O CI HO O CI
1. NaN3 ~ N ~ CICH2CH0 / N ~ NaOH / N
2. Zn t~~ ~ / EtOH N~ ~ / N~ ~ /
Br ~ ~~ \ Br NHZ N N
4,6-Dichloro-5-methylnicotinic acid (J. Heterocyclic Chemistry 1999, 36, 953-957) was converted to 7-(4-bromo-2-chlorophenylamino)-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid according to the steps described in the alternate synthesis of Step D, Example 9. It was determined that addition of sodium azide to the 4-(4-bromo-2-chloro-phenylamino)-6-chloro-5-methyl-nicotinic acid methyl ester intermediate required heating to 50 °C, which results in a separable mixture of the desired methyl to ester, 6-azido-4-(4-bromo-2-chlorophenylamino)-5-methyl-nicotinic acid methyl ester, and the corresponding carboxylic acid. MS ESI (+) m/z 380, 382 (M+, Cl, Br pattern) detected. tH NMR (400 MHz, DMSO-d~) b 9.46 (s, 1H), 9.40 (br s, 1H), 8.25 (d, 1H), 8.12 (d, 1H), 7.79 (m, 1H), 7.42 (dd, 1H), 6.80 (d, 1H), 2.07 (s, 3H).
The following compound was prepared as described in the above example using 4-bromo-2-fluorophenylamine in the first step:
HO O
H
N
N I I /
Br N
7-(4-Bromo-2-fluorophenylamino)-8-methyl-imidazo[1,2-a]pyridine-6-carboxylic acid MS ESI (+) m/z 364, 366 (M+, Cl, Br pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 9.40 (s, 1H), 9.26 (br s, 1H), 8.22 (d, 1H), 8.10 (d, 1H), 7.61 (dd, 1H), 7.29 (dd, 1H), 6.87 (t, 1H), 2.14 (s, 3H). t9F (376 MHz, DMSO-d6) -125.7 (s).
Example 35 [6-(5-Amino-[1,3,4]oxadiazol-2-yl)-8-chloroimidazo[1,2-a]pyridin-7-yl]-(4-bromo-2-fluorophenyl)-amine 1o The compound was synthesized by the route shown below.
HO O
HZNNHZ _ / I I \ EDCI, HOBt HZN N
N / ~ H v ' CI Br NEt3, DMF HzN'N O H F BrCN 0 N H F
N
N I \ NaHC03 / ~ N ~ \
diox O N /
/O 0 H F HZN~ ~~CI Br ~~CI Br N N
/ ~ N I \ EtOH
N reflux ~~CI / Br N
Step A: Preparation of 7-(4-Bromo-2-fluorophenylamino)-8-chloroimidazof 1,2-alpyridine-6-carboxylic acid hydrazide. 7-(4-Bromo-2-fluoro-phenylamino)-8-chloro-imidazo[1,2-a]pyridine-6-carboxylic acid was converted to the hydrazide according to the coupling conditions described in Step A of Example 3.
Alternatively, the hydrazide can be prepared directly from 7-(4-Bromo-2-fluorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester by refluxing with hydrazine in ethanol. MS ESI (+) m/z 398, 400 (M+, Cl, Br pattern) detected.
Step B: Preparation of [6-(5-Amino-[1,3,4]oxadiazol-2-yl)-8-chloroimidazo[1,2-al>pyridin-7-~l-(4-bromo-2-fluoro-phenyl)-amine. 7-(4-Bromo-fluoro-phenylamino)-8-chloro-imidazo[1,2-a]pyridine-6-carboxylic acid hydrazide (100 mg, 0.25 mmol) was suspended in dioxane (2 mL). Cyanogen bromide (27 mg, 0.253 mmol) was added, followed by a solution of sodium bicarbonate (21 mg, 0.25 mmol) in HZO (1.2 mL). The reaction mixture was stirred at room temperature for 16 1o hours. The reaction mixture was diluted with ethyl acetate and washed with water and saturated aqueous NaCI, dried over Na2S04 and concentrated to yield the desired product (97 mg, 91%) as a white solid. MS ESI (+) m/z 423, 425 (M+, Cl, Br pattern) detected. 'H NMR (400 MHz, CD30D) 8 8.98 (s, 1H), 7.95 (s, 1H), 7.61 (s, 1H), 7.33 (d, 1H), 7.17 (d, 1H), 6.78 (t, 1H). 19F (376 MHz, CD30D) -128.6 (t).
Example 36 5-[7-(4-Bromo-2-fluorophenylamino)-8-chloro-imidazo[1,2-a]pyridin-6-yl]-[1,3,4] oxadiazole-2-thiol The compound was synthesized by the route shown below.
HS~
N
,N O O ~N
HzN H F CSz H F
/ N \ KOH / N \
C\N CI / Br EtOH ~ CI / Br ~N N
7-(4-Bromo-2-fluorophenylamino)-8-chloroimidazo[ 1,2-a]pyridine-6-carboxylic acid hydrazide (50 mg, 0.13 mmol) was suspended in ethanol (2.5 mL) and cooled to 0 °C. Carbon disulfide (22 mg, 0.29 mmol) was added, followed by powdered potassium hydroxide (7 mg, 0.13 mmol). The reaction mixture was stirred under NZ for 1 hour at 0 °C and then for 30 minutes at room temperature. The reaction mixture was then brought to reflux and stirred under N2 for 5 days.
The reaction mixture was diluted with water and acidified to pH 1-2 with aqueous 1 M
HCI. This mixture was then extracted with ethyl acetate (2x). The combined organic layers were washed with saturated aqueous NaHC03, saturated aqueous NaCI, dried over Na2S04 and concentrated. Purification of the crude product was achieved by flash column chromatography (gradient of dichloromethane to 15:1 dichloromethane/methanol) and then trituration with diethyl ether and dichloromethane to yield the desired product (17 mg, 31%) as a yellow solid.
MS ESI
(+) m/z 440, 442 (M+, Cl, Br pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 9.29 (s, 1 H), 8.16 (s, 1 H), 8.08 (br s, 1 H), 7.73 (s, 1 H), 7.49 (d, 1 H), 7.15 (d, 1 H), 6.59 (t, 1H). ~~F (376 MHz, DMSO-d6) -128.7 (s).
Example 37 ~NH
O ,N
F
H
N
N ~ ~ /
~F Br ~N
5-[7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo [1,2-a] pyridin-6-yl]-3H
[1,3,4]oxadiazol-2-one The compound was synthesized by the route shown below.
H
H N~N O F carbonyldiimidazole H DMF, RT
N or N I I
F gr phosgene / toluene, reflux N
7-(4-bromo-2-fluorophenylamino)-8-fluoroimidazo[ 1,2-a]pyridine-6-carboxylic acid hydrazide (373 mg, 0.98 mmol), which was prepared according to Step A, Example 35, was dissolved into dimethylformamide (5 mL).
Carbonyldiimidazole (166 mg, 1.02 mmol) was added as a solid. The reaction mixture was stirred for 1 hour at room temperature. It was then diluted with ethyl acetate and washed with water. The aqueous layer was back-extracted with ethyl acetate (3x). The combined organic layers were washed with saturated aqueous NaCI, 1o dried over Na2SOa and concentrated. Purification of the crude product was achieved by trituration with ethyl acetate and diethyl ether. The resulting solid was filtered, washed with diethyl ether, collected and dried under vacuum. The filtrate was concentrated and the trituration procedure was repeated. The solids were combined to yield the desired product (334 mg, 84%) as a yellow solid. MS ESI (+) m/z 408, 1s (M+, Br pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 12.69 (br s, 1H), 9.05 (s, 1 H), 8.11 (d, 1 H), 7.89 (s, 1 H), 7.67 (s, 1 H), 7.51 (dd, 1 H), 7.20 (d, 1 H), 6.77 (m, .
1H). 19F (376 MHz, DMSO-d6) -128.9 (t, 1F ), -139.5 (s, 1F).
Example 38 HzN
/~-N
O /N
F
H
N
N I I ~
~CI Br [6-(5-Aminomethyl-[1,3,4]oxadiazol-2-yl)-8-chloroimidazo[1,2-a]pyridin-7-yl]-(4-bromo-2-fluorophenyl)-amine The compound was synthesized by the route shown below.
c1 H O H ~=N
H N~N O F O CI~N~N O F O ~ N F
/ I N I \ CI' v Cl H / I N \ POCI3 / I N I \
\N~CI / Br ~ N- \N~CI I / Br 100C, 4h ~~CI / Br cH2clZ, oc N
O ~N
F
NH3 in MeOH
KI N I I /
THF ~~ SCI Br Step A: Preparation of 7-(4-bromo-2-fluorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid N'-(2-chloro-acetyl)-hydrazide.
7-(4-Bromo-2-fluorophenylamino)-8-chloro-imidazo[1,2-a]pyridine-6-carboxylic acid hydrazide (100 mg, 0.25 mmol) of Step A, Example 35 was suspended in 1o dichloromethane (2 mL) and 4-Me morpholine (0.040 mL, 0.36 mmol) was added.
The mixture was cooled to 0 °C and then chloroacetyl chloride (0.029 mL, 0.36 mmol) was added dropwise. The reaction mixture was warmed to room temperature and stirred for 1 hour under N2. Rinsed reaction mixture into a separatory funnel with a small amount of tetrahydrofuran and methanol and then diluted with ethyl acetate.
The organic layer was washed with water and saturated aqueous NaCI, dried over Na2S04 and concentrated. Purification of the crude product was achieved by flash column chromatography (20:1 dichloromethane/methanol) to yield the desired product (64 mg, 54%) as a yellow solid. MS ESI (+) m/z 474, 476 (M+, Cl, Br pattern) detected.
2o Step B: Preparation of (4-bromo-2-fluorophenyl)-[8-chloro-6-(5-chloromethyl-[1,3,4]oxadiazol-2-yl -imidazo[1,2-a]pyridin-7-yl]-amine. 7-(4-Bromo-2-fluorophenylamino)-8-chloroimidazo[1,2-a]pyridine-6-carboxylic acid N'-(2-chloro-acetyl)-hydrazide (63 mg, 0.13 mmol) was suspended in POC13 (1 mL). The reaction mixture was heated to 100 °C for 8 hours, during which time it became a bright red solution. The reaction mixture was cooled to room temperature and the solvent evaporated under reduced pressure. The residue was dissolved in ethyl acetate and washed with saturated aqueous NaHC03, saturated aqueous NaCI, dried over NazS04 and concentrated. The crude product (38 mg, 62%) was used without further purification in next step. MS ESI (+) m/z 456, 458 (M+, Cl, Br pattern) detected.
to Step C: Preparation of [6~5-aminomethyl-[1,3,41oxadiazol-2-yl)-8-chloroimidazo~l,2-a]pyridin-7-yl]-(4-bromo-2-fluoro-phenyl)-amine. (4-Bromo-2-fluoro-phenyl)-[8-chloro-6-(5-chloromethyl-[ 1,3,4]oxadiazol-2-yl)-imidazo[
1,2-a]pyridin-7-yl]-amine (38 mg, 0.083 mmol) was dissolved in tetrahydrofuran (1 mL).
Potassium iodide (14 mg, 0.083 mmol) was added and then ammonia (7 M solution in methanol, 0.30 mL, 2.08 mmol). The reaction mixture was stirred at room temperature for 16 hours. The solvent was removed under reduced pressure and the crude product was purified by flash column chromatography (gradient of 20:1 dichloromethane/methanol to 5:1 ) to yield the desired product (26 mg, 71 %) as a yellow solid. MS ESI (+) m/z 437, 439 (M+, Cl, Br pattern) detected. 1H NMR
(400 MHz, DMSO-d6) 8 9.35 (s, 1H), 8.33 (s, 1H), 8.17 (d, 1H), 7.70 (d, 1H), 7.51 (dd, 1H), 7.16 (d, 1H), 6.65 (t, 1H), 3.94 (s, 2H). 19F (376 MHz, DMSO-d6) -128.3 (t).
Example 39 HO~
NH
~N
O/ / N
H F
N
N
~F Br 2-{5-[7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo[1,2-a]pyridin-6-yl]-[1,3,4]oxadiazol-2-ylamino}-ethanol The compound was synthesized by the route shown below.
~NH OII H
O , N F HO~N~N~N O F
H OOH H H H PPhs N ~ HzN / N ~ NEt3, CCI, EtOH N ~ / CHZCI2, ref N F ~ ~ Br reflux I F Br ~N
5-[7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo[ 1,2-a]pyridin-6-yl]-3H-[1,3,4]oxadiazol-2-one of Example 37 was converted in two steps to the desired product following the procedures described in WO 04/056789. MS ESI (+) m/z 451, 453 (M+, Br pattern) detected. 'H NMR (400 MHz, DMSO-d6) 8 8.96 (s, 1H), 8.42 (s, 1 H), 8.13 (d, 1 H), 7.98 (t, 1 H), 7.64 (d, 1 H), 7.5 S (dd, 1 H), 7.26 (d, 1 H), 6.87 (m, 1H), 4.78 (t, 1H), 3.56 (q, 2H), 3.30 (m, 2H). '9F (376 MHz, DMSO-d6) -128.3 (t, 1F), -139.6 (s, 1F) Example 40 N-{5-[7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo[1,2-a]pyridin-6-yl]-[1,3,4] oxadiazol-2-yl}-N'-methyl-ethane-1,2-diamine The compound was synthesized by the route shown below.
m Boc ~ H 1. PPh3 O N
Boc /NON N~N O F NEt3, CCIQ ~ F
N
~NH2 H H / N ~ CHzCh, refluxreflux /
reOx \N F ~ / gr 2. NCI, MeOH \N~F ~ / gr 5-[7-(4-Bromo-2-fluorophenylamino)-8-fluoroimidazo[ 1,2-a]pyridin-6-yl]-3H-[1,3,4]oxadiazol-2-one of Example 37 was converted in three steps to the desired product, isolated as the HCl salt, following the procedures described in WO
04/056789. MS ESI (+) m/z 464, 466 (M+, Br pattern) detected. 1H NMR (400 MHz, DMSO-d6) 8 9.26 (s, 1H), 8.95 (br s, 1H), 8.86 (br s, 2H), 8.39 (t, 1H), 8.25 (s, 1 H), 7.93 (s, 1 H), 7.64 (dd, 1 H), 7.36 (d, 1 H), 7.13 (m, 1 H), 3.5 9 (q, 2H), 3.17 (m, io 2H), 2.59 (t, 3H).
Example 41 Preparation of Hydroxylamines Hydroxylamines useful for synthesizing compounds of the present invention may be prepared as follows:
TBSO~sy~O,NH2 TBSO~O.NH2 (i). (S)-O-[2-(tert-Butyl-dimethylsilanyloxy)-propyl]-hydroxylamine and (R)-O-[2-(tert-Butyl-dimethyl-silanyloxy)-propyl]-hydroxylamine (S)-O-[2-(tert-Butyl-dimethyl-silanyloxy)-propyl]-hydroxylamine and (R)-O-[2-(tert-Butyl-dimethyl-silanyloxy)-propyl]-hydroxylamine were prepared from (S)-(--propylene oxide and (R)-(+)-propylene oxide respectively by the following procedure:
Step A: Preparation of (S)-1-iodopropan-2-of and (R)-1-Iodo-propan-2-ol.
Acetic acid (12.8 mL, 224 mmol) and (S)-(-)- or (R)-(+)-propylene oxide (16.0 mL, 224 mmol) were added sequentially to a solution of lithium iodide (15.0 g, 112 mmol) in THF (200 mL) cooled to 0 °C. The resulting thick suspension was allowed to warm to room temperature and stir for 16 hours. The suspension was diluted with ether, washed with water (3x), saturated NaHC03 (3x), brine, dried over Na2S04, and concentrated to provide the desired product as a yellow liquid (19.5 g, 94%).
Step B: Preparation of (S)-tert-but ~~-1-(2-iodo-1-methyl-ethoxy)-dimethyl-silane and (R)-tert-Butyl-(2-iodo-1-methyl-ethoxX)-dimethyl-silane. Pyridine (9.50 1o mL, 118 mmol) was added to a solution of (S)- or (R)-1-iodo-propan-2-of (19.9 g, 107 mmol) and TBSCI (17.0 g, 113 mmol) in DMF (100 mL) cooled to 0 °C.
After stirnng for two days, the solution was diluted with hexanes, washed with water (3x) and brine. The aqueous washes were back-extracted with 1:1 hexanes/ethyl acetate.
The combined organic phases were dried over Na2S04. Concentration provided the desired product as a yellow liquid (26.7 g, 83%).
Step C: Preparation of (S)-2-[2-(tert-Butyl-dimethyl-silanyloxy)-propoxyl-isoindole-1.3-dione and (R1- 2-f2-(tert-Butyl-dimethvl-silanvloxv)-pro ox isoindole-1,3-dione. A solution of (S)- or (R)-tert-butyl-(2-iodo-1-methyl-ethoxy)-dimethyl-silane (22.7 g, 75.4 mmol), N hydroxyphthalimide (14.8 g, 90.5 mmol) and 2o diisopropylethylamine (15.8 mL, 90.5 mmol) was heated at 75 °C for 48 hours. The solution was cooled to room temperature, diluted with water and extracted with 1:1 hexanes/ethyl acetate (2x) and diethyl ether (2x). The combined organic extracts were washed with water (3x), brine (2x), dried over Na2S04 and concentrated to a red liquid. The crude product was purified by flash column chromatography (dichloromethane) to provide the desired product as a yellow liquid (12.8 g, 50%).
Step D: Preparation of (~-O-[2-(tert-Butyl-dimethyl-silanyloxy)-propyll-hvdroxvlamine or (R)-O-f2-(tert-Butyl-dimethvl-silanvloxv)-nropvll-hvdroxvlamine.
Methyl hydrazine (2.12 mL, 39.9 mmol) was added to a solution of (S)- or (R)-2-[2-(tert-butyl-dimethyl-silanyloxy)-propoxy]-isoindole-1,3-dione (12.8 g, 38.0 mmol) in 3o dichloromethane (100 mL) and the resulting suspension was stirred for 16 hours.
The suspension was filtered to remove solids and the filtrate was concentrated to a yellow liquid. Flash column chromatography (2:1 hexanes/ethyl acetate) provided the desired product as a light yellow liquid (6.37 g, 82%). MS APCI (+) m/z 206 (M+1) detected. 1H NMR (400 MHz, CDC13) 8 5.44 (br s, 2H), 4.03 (m, 1H), 3.58 (m, 1H), 3.51 (m, 1H), 1.12 (d, 3H), 0.90 (s, 9H), 0.08 (s, 6H).
(ii). The following hydroxylamines were prepared similarly starting with the appropriate terminal epoxide. The isoindol-1,3-diones intermediates and the final hydroxylamines were purified by flash column chromatography.
TBSO.~Sy~O,NH2 TBSO R O,NH2 (S)-O-[2-(tert-butyl-dimethyl-silanyloxy)-butyl]-hydroxylamine and (R)-O-[2-(tert-butyl-dimethyl-silanyloxy)-butyl]-hydroxylamine The hydroxylamines (S)-O-[2-(tert-butyl-dimethyl-silanyloxy)-butyl]-hydroxylamine and (R)-O-[2-(tent-butyl-dimethyl-silanyloxy)-butyl]-hydroxylamine were prepared from the homochiral terminal epoxides (S)- and (R)-1,2-epoxybutane respectively, which were obtained by kinetic resolution of 1,2-epoxybutane as described within J. Am. Chem. Soc., 2002, 124:1307. MS APCI (+) mlz 220 (M+1) detected. 1H NMR (400 MHz, CDC13) 8 5.41 (br s, 2H), 3.79 (m, 1H), 3.60 (m, 2H), 1.54 (m, 1H), 1.44 (m, 1H), 0.90 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H).
TBSO O,NH2 D-[2-(tert-butyl-dimethyl-silanyloxy)-3-methyl-butyl]-hydroxylamine MS APCI (+) m/z 234 (M+1) detected. 'H NMR (400 MHz, CDC13) 8 5.38 (br s, 2H), 3.64 (m, 3H), 1.75 (m, 1H), 0.90 (m, 15H), 0.08 (s, 3H), 0.05 (s, 3H).
HO O,NH2 I
(iii). 1-Aminooxy-3,3-dimethyl-butan-2-of Step A: Preparation of 2-(2-H~y-3 3-dimeth~-butoxy)-isoindole-1,3-dione. To a solution of 3,3-dimethyl-1,2-epoxybutane (5.0 mL, 41.0 mmol) in DMF
(100 mL) was added N hydroxyphthalimide (8.03 g, 49.2 mmol) and triethylamine (6.90 mL, 49.2 mmol). The solution was heated at 75 °C for two days.
The solution was cooled to room temperature, diluted with ethyl acetate and washed with water (2x), saturated potassium carbonate (3x), brine (2x), dried over NaZS04 and 1o concentrated to an orange solid. Purification using flash column chromatography (dichloromethane) provided the desired product as a white solid (1.50 g, 14%).
Step B: Preparation of 1-Aminooxy-3,3-dimethyl-butan-2-ol. To a solution of 2-(2-hydroxy-3,3-dimethyl-butoxy)-isoindole-1,3-dione (1.47 g, 5.60 mmol) in dichloromethane (20 mL) cooled to 0 °C was added methylhydrazine (0.31 mL, 5.90 mmol). The white suspension was allowed to stir for 16 hours at room temperature.
Diethyl ether (50 mL) was added and the solids were removed by filtration. The filtrate was concentrated, diluted with diethyl ether and the solids were removed by filtration. This procedure was repeated twice more and the final filtrate was concentrated to provide the desired product as a yellow liquid (0.643 g, 86%).
'H
2o NMR (400 MHz, CDCl3) 8 4.87 (br s, 2H), 3.85 (q, 1H), 3.58 (q, 2H), 0.93 (s, 9H).
O
~O~N~O,NH2 H
(iv). (2-Aminooxy-ethyl)-carbamic acid tert-butyl ester Step A: Preparation of Methanesulfonic acid 2-tert-butoxycarbonylamino-ethyl ester. Methanesulfonyl chloride (0.60 mL, 7.76 mmol) was added to a solution of (2-hydroxy-ethyl)-carbamic acid tert-butyl ester (1.04 g, 6.46 mmol) and triethylamine (1.35 mL, 9.70 mmol) in dichloromethane (35 mL) cooled to 0 °C. The solution was stirred for one hour, after which time it was diluted with ethyl acetate, washed with saturated NaHC03 (2x), brine, dried over NaZS04 and concentrated to a thick colorless liquid (1.37 g, 89%).
Step B: Preparation of [2 ~1 3-Dioxo-1 3-dih~dro-isoindol-2-yloxy)-ethyll-carbamic acid tert-but, 1~ ester. Added N hydroxyphthalimide (1.12 g, 6.87 mmol) and triethylamine (0.96 mL, 6.87 mmol) to a solution of methanesulfonic acid 2-tert-butoxycarbonylamino-ethyl ester (1.37 g, 5.73 mmol) in DMF (20 mL). The solution was heated to 50 °C for 16 hours after which time it was cooled to room temperature.
The solution was diluted with ethyl acetate, washed with water (2x), saturated KZC03, dried over Na2S04 and concentrated to an orange solid (747 mg, 43%) which was taken on without purification.
Step C: Preparation of (2-Aminooxy-ethyl)-carbamic acid tert-but l~.
The synthesis of the title compound was carned out according to STEP D of Example 41 (i) using [2-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-ethyl]-carbamic acid tert-butyl ester as the starting material to provide 255 mg (71 %) of the desired compound as a yellow liquid. 'H NMR (400 MHz, CDCl3) 8 5.50 (br s, 2H), 5.02 (br s, 1H), 3.71 (t, 2H), 3.36 (q, 2H), 1.45 (s, 9H).
The following hydroxylamine was prepared similarly using (3-hydroxypropyl)-carbamic acid tert-butyl ester as the starting material.
O
~O~N~O~NH2 H
(3-Aminooxy-propyl)-carbamic acid tert-butyl ester 1H NMR (400 MHz, CDC13) 8 5.41 (br s, 2H), 4.76 (br s, 1H), 3.73 (t, 2H), 3.21 (q, 2H), 1.78 (m, 2H), 1.44 (s, 9H).
O
~O~ N O~ N H2 H /~~
(v). (3-Aminooxy-2,2-dimethylpropyl)-carbamic acid tert-butyl ester Step A: Preparation of (3-Hydroxy-2,2-dimethyl-propyl)-carbamic acid tert-butyl ester. Boc-anhydride (13.07 g, 59.9 mmol) in THF (10 mL) was added dropwise to a solution of 3-amino-2,2-dimethyl-propan-1-of (5.15 g, 49.9 mmol) and NaOH (2.40 g, 59.9 mmol) dissolved into 1:1 THF/water (50 mL). The solution was stirred at room temperature for 72 hours. The solution was concentrated under reduced pressure to about one half of the reaction volume. The remaining solution l0 was acidified to pH 6 and was then extracted with ethyl acetate (2x). The organic extracts were washed with water, brine, dried over NazS04 and concentrated to provide the desired product ( 10.2 g, quantitative) as a white solid.
Step B: Preparation of ~3-(1,3-Dioxo-1,3-dihydro-isoindol-2-yloxy)-2 2-dimeth ~~1-propyl]-carbamic acid tert-butyl ester. Diethylazodicarboxylate (8.26 mL, 52.4 mmol) was added to a solution of (3-hydroxy-2,2-dimethyl-propyl)-carbamic acid tert-butyl ester (10.2 g, 49.9 mmol), N hydroxyphthalimide (8.15 g, 49.9 mmol) and triphenylphosphine (13.1 g, 49.9 mmol) in THF (200 mL). The solution was stirred at room temperature for 16 hours after which time it was diluted with dichloromethane and passed through a plug of silica gel, eluting with dichloromethane. The product containing fractions were concentrated to a yellow liquid, which was further purified by flash column chromatography (dichloromethane to 4:1 dichloromethane/ethyl acetate) to provide pure desired product ( 1.98 g, 11 %) as a waxy white solid.
Step C: Preparation of (3-Aminooxy-2,2-dimeth ~~1-propel)-carbamic acid tert-butyl ester. The synthesis of the title compound was carried out according to Step D
of the Example 41 using [3-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester as the starting material to provide 998 mg (80%) desired product as a pale yellow liquid. 1H NMR (400 MHz, CDCl3) 8 5.45 (br s, 2H), 4.94 (br s, 1H), 3.44 (s, 2H), 3.03 (br d, 2H), 1.45 (s, 9H), 0.88 (s, 6H).
O
~O~ N ~O, N H2 H
(vi). (3-Aminooxy-1-methylpropyl)-carbamic acid tert-butyl ester Step A: Preparation of 3-amino-butan-1-ol. Lithium aluminum hydride (1.0 M in THF, 43.8 mL, 43.8 mmol) was added dropwise over one hour to a suspension of 3-aminobutyric acid (2.26 g, 21.9 mmol) in THF (100 mL) cooled to 0 °C. The solution was then refluxed for 16 hours after which time it was cooled to 0 °C and quenched by the careful sequential addition of water (2 mL), 15% aqueous NaOH
(2 1o mL) and water (2 mL). The mixture was stirred for 15 minutes and was filtered through Celite~, washing the filter pad with THF. Concentration of the filtrated provided the desired product (1.43 g, 73%) as a clear oil.
Step B: Preparation of (3-Aminooxy-1-methyl-propyl)-carbamic acid tert-butyl ester. The synthesis of the title compound was carned out according to Steps A, B and C of Example 41(iii) above using 3-amino-butan-1-of as the starting material to provide 998 mg (80%) desired product as a pale yellow liquid. 1H NMR (400 MHz, CDC13) 8 5.39 (br s, 2H), 4.52 (br s, 1H), 3.72 (m, 3H), 1.70 (m, 2H), 1.43 (2, 9H), 1.14 (d, 3H).
(vii). The following hydroxylamines were prepared as described in WO
02/06213: O-(2-vinyloxy-ethyl)-hydroxylamine; O-(2-methoxy-ethyl)-hydroxylamine; 2-aminooxy-propan-1-ol; 3-aminooxy-propan-1-ol; 1-aminooxy-2-methyl-propan-2-ol; 1-aminooxy-3-methoxy-propan-2-ol; 3-aminooxy-1,1,1-trifluoro-propan-2-ol; 2-aminooxy-2-methyl-propan-1-ol; (2-aminooxy-ethyl)-methyl-carbamic acid tert-butyl ester; (R)-O-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-hydroxylamine;
(S)-O-2,2-dimethyl-[1,3]dioxolan-4-ylinethyl)-hydroxylamine.
(viii). The isoindole-1,3-dione intermediates of the following hydroxylamines are prepared from the appropriate alkyl halide and N hydroxyphthalimide by the procedure described within J. Heterocyclic Chemistry 2000, 37, 827-830: O-propyl-hydroxylamine; O-isopropyl-hydroxylamine; O-cyclopropylmethyl-hydroxylamine.
The isoindole-1,3-diones are deprotected by the procedure described above.
(ix). The following hydroxylamines were obtained from commercial sources:
methoxylamine hydrochloride; D-ethylhydroxylamine hydrochloride; O-(tert butyl)amine hydrochloride; O-allylamine hydrochloride.
Additional compounds of the present invention are shown in Figurses 19A-19G.
The foregoing description is considered as illustrative only of the principles of the invention. Further, since numerous modifications and changes will be readily 1o apparent to those skilled in the art, it is not desired to limit the invention to the exact construction and process shown as described above. Accordingly, all suitable modifications and equivalents may be resorted to falling within the scope of the invention as defined by the claims that follow.
The words "comprise," "comprising," "include," "including," and "includes"
when used in this specification and in the following claims are intended to specify the presence of stated features, integers, components, or steps, but they do not preclude the presence or addition of one or more other features, integers, components, steps, or groups thereof.
Claims (85)
1. A compound of the Formula (I) and pharmaceutically accepted salts, prodrugs and solvates thereof, wherein:
R1, R2, R7, R8, R9, and R10 are independently hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)R3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SR', -S(O)R"", -SO2R"", -NR'R", -NR'C(O)NR"R"", -NR'C(NCN)NR"R"', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, heteroaryl or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NRC(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R", -NR'C(O)NR"R"", -NR'C(NCN)NR"R"", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R"' independently are hydrogen, lower alkyl, lower alkenyl, aryl or arylalkyl, and R"" is lower alkyl, lower alkenyl, aryl or arylalkyl, or any two of R', R", R"' or R"" together with the atom to which they are attached form a to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl carbocyclic rings, heteroaryl rings or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently are hydrogen or C1-C6 alkyl, or R4 and R5 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein said alkyl or any of said carbocyclic, heteroaryl and heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R', -C(O)R'''', -C(O)OR, -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R6 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R', -NR'C(O)NR''R''', -NRC(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SO2)CH3 or CR3OR3, wherein any of said heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SO2)CH3 and CR3OR3 are optionally substituted with one or more groups independently selected from -NR3R4, -OR3, -R2, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, wherein any of said C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl are optionally substituted with 1 or more groups independently selected from -NR3R4 and -OR3;
m is 0, 1, 2, 3, 4 or 5; and j is 0, 1 or 2.
R1, R2, R7, R8, R9, and R10 are independently hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)R3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SR', -S(O)R"", -SO2R"", -NR'R", -NR'C(O)NR"R"", -NR'C(NCN)NR"R"', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, heteroaryl or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NRC(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R", -NR'C(O)NR"R"", -NR'C(NCN)NR"R"", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R"' independently are hydrogen, lower alkyl, lower alkenyl, aryl or arylalkyl, and R"" is lower alkyl, lower alkenyl, aryl or arylalkyl, or any two of R', R", R"' or R"" together with the atom to which they are attached form a to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl carbocyclic rings, heteroaryl rings or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently are hydrogen or C1-C6 alkyl, or R4 and R5 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein said alkyl or any of said carbocyclic, heteroaryl and heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R', -C(O)R'''', -C(O)OR, -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R6 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R', -NR'C(O)NR''R''', -NRC(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SO2)CH3 or CR3OR3, wherein any of said heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SO2)CH3 and CR3OR3 are optionally substituted with one or more groups independently selected from -NR3R4, -OR3, -R2, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, wherein any of said C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl are optionally substituted with 1 or more groups independently selected from -NR3R4 and -OR3;
m is 0, 1, 2, 3, 4 or 5; and j is 0, 1 or 2.
2. The compound of claim 1, where R1 is 2-Cl.
3. The compound of claim 1, where R7 is Me, NH2 or H.
4. The compound of claim 1, where R8 is Br or Cl.
5. The compound of claim 1, where R9 is F.
6. The compound of claim 1, where W is -C(O)OH, -C(O)NHOCH2-(cyclopropyl), -C(O)NHO(CH2)2OH, or -CONH(SO2)CH3.
7. The compound of claim 1, having the formula
8. The compound of claim 1, having the formula
9. The compound of claim 1, having the formula
10. The compound of claim 1, having the formula
11. The compound of claim 1, having the formula
12. The compound of claim 1, having the formula
13. The compound of claim 1, having the formula
14. The compound of claim 1, having the formula
15. The prodrug of claim 1, comprising the compound of Formula I covalently coupled to an amino acid residue.
16. The prodrug of claim 1, wherein the amino acid residue is valine.
17. The prodrug of claim 1, wherein said prodrug is a phosphate ester of the compound of Formula I.
18. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
19. A method of inhibiting MEK activity in a mammal comprising administrating to said mammal one or more compounds of claim 1 in an amount effective to inhibit said MEK activity.
20. A method for treatment of a hyperproliferative disorder in a mammal comprising administrating to said mammal one or more compounds of claim 1 in an amount effective to treat said hyperproliferative disorder.
21. A compound of the Formula (II) and pharmaceutically accepted salts, prodrugs and solvates thereof, wherein:
R1, R2, R7, R8, R9, R10 and R11 are independently selected from hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl and -NR4(CR4R5)m-heterocyclyl, where any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
or R7 and R11 together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated carbocyclic or heterocyclic ring, wherein any of said saturated, unsaturated, partially saturated carbocyclic or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R", -NR'C(O)NR"R'", -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is selected from hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate and an amino acid residue, where any of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R' -NR'(O)OR"", -NR'C(O)R", -C(O)NR'R", -SR', -S(O)R"", -SO2R"", -NR'R", -NR'C(O)NR"R"', -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R", -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R'' and R''' independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and arylalkyl;
R'''' is selected from lower alkyl, lower alkenyl, aryl and arylalkyl, or any two of R', R'', R''' or R'''' together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently represent hydrogen or C1-C6 alkyl;
R6 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is selected from heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), C(O)(heteroaryl), -C(O)(heterocyclyl) and -CR3OR3, wherein any of said heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl) and -C(O)(heterocyclyl), and -CR3OR3 are optionally substituted with one or more groups independently selected from -NR3R4, -OR3, -R2, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, wherein any of said alkyl, alkenyl, and alkynyl portions are optionally substituted with 1 or more groups independently selected from -NR3R4 and -OR3;
m is 0,1,2,3,4 or 5;and j is 0,1 or 2.
R1, R2, R7, R8, R9, R10 and R11 are independently selected from hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl and -NR4(CR4R5)m-heterocyclyl, where any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
or R7 and R11 together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated carbocyclic or heterocyclic ring, wherein any of said saturated, unsaturated, partially saturated carbocyclic or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R", -NR'C(O)NR"R'", -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is selected from hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate and an amino acid residue, where any of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R' -NR'(O)OR"", -NR'C(O)R", -C(O)NR'R", -SR', -S(O)R"", -SO2R"", -NR'R", -NR'C(O)NR"R"', -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R", -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R'' and R''' independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and arylalkyl;
R'''' is selected from lower alkyl, lower alkenyl, aryl and arylalkyl, or any two of R', R'', R''' or R'''' together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently represent hydrogen or C1-C6 alkyl;
R6 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is selected from heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), C(O)(heteroaryl), -C(O)(heterocyclyl) and -CR3OR3, wherein any of said heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl) and -C(O)(heterocyclyl), and -CR3OR3 are optionally substituted with one or more groups independently selected from -NR3R4, -OR3, -R2, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, wherein any of said alkyl, alkenyl, and alkynyl portions are optionally substituted with 1 or more groups independently selected from -NR3R4 and -OR3;
m is 0,1,2,3,4 or 5;and j is 0,1 or 2.
22. The compound of claim 21, where R1 is C1.
23. The compound of claim 21, where R1 is H, 1-(4-methylpiperazinyl), morpholinyl, -NMe2, or -CH2(piperidinyl).
24. The compound of claim 21, where R8 is Cl or Br.
25. The compound of claim 21, where R9 is Cl or H.
26. The compound of claim 21, where W is -COOH, -C(O)NHOCH2-(cyclopropyl) or -C(O)NHO(CH2)2OH.
27. The compound of claim 21 having the formula
28. The compound of claim 21 having the formula
29. The compound of claim 21 having the formula
30. The compound of claim 21 having the formula
31. The compound of claim 21 having the formula
32. The compound of claim 21 having the formula
33. The compound of claim 21 having the formula
34. The compound of claim 21 having the formula
35. The compound of claim 21 having the formula
36. The compound of claim 21 having the formula
37. A composition comprising a compound of claim 21 and a pharmaceutically acceptable carrier.
38. The prodrug of claim 21, comprising the compound of Formula II
covalently coupled to an amino acid residue.
covalently coupled to an amino acid residue.
39. The prodrug of claim 38, wherein the amino acid residue is valine.
40. The prodrug of claim 21, wherein said prodrug is a phosphate ester of the compound of Formula II.
41. The prodrug of claim 40, wherein said prodrug has the formula
42. A method of inhibiting MEK activity in a mammal comprising administrating to said mammal one or more compounds of claim 21 in an amount effective to inhibit said MEK activity.
43. A method for treatment of a hyperproliferative disorder in a mammal comprising administrating to said mammal one or more compounds of claim 21 in an amount effective to treat said hyperproliferative disorder.
44. A compound of the Formula III
and pharmaceutically accepted salts, prodrugs and solvates thereof, wherein:
R1, R2, R7, R8, R9, and R10 are independently selected from hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl and -NR4(CR4R5)m-heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C1-C10 alkynyl, cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SR', -S(O)R"", -SO2R"", -NR'R", -NR'C(O)NR"R"', -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R", -NR'C(O)NR"R'", -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R"' independently are hydrogen, lower alkyl, lower alkenyl, aryl or arylalkyl, R"" is lower alkyl, lower alkenyl, aryl or arylalkyl, or any two of R', R", R"' or R"" together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently are hydrogen or C1-C6 alkyl;
R6 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R', -NR'C(O)NR"R"', -NRC(NCN)NR"R"', -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), or CR3OR3, wherein any of said heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), and CR3OR3 are optionally substituted with one or more groups independently selected from -NR3R4, -OR3, -R2, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, wherein any of said C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl are optionally substituted with 1 or more groups independently selected from NR3R4 and -OR3;
m is 0, 1, 2, 3, 4 or 5; and j is 0, 1 or 2.
and pharmaceutically accepted salts, prodrugs and solvates thereof, wherein:
R1, R2, R7, R8, R9, and R10 are independently selected from hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl and -NR4(CR4R5)m-heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C1-C10 alkynyl, cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SR', -S(O)R"", -SO2R"", -NR'R", -NR'C(O)NR"R"', -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R", -NR'C(O)NR"R'", -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R"' independently are hydrogen, lower alkyl, lower alkenyl, aryl or arylalkyl, R"" is lower alkyl, lower alkenyl, aryl or arylalkyl, or any two of R', R", R"' or R"" together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently are hydrogen or C1-C6 alkyl;
R6 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R', -NR'C(O)NR"R"', -NRC(NCN)NR"R"', -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), or CR3OR3, wherein any of said heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), and CR3OR3 are optionally substituted with one or more groups independently selected from -NR3R4, -OR3, -R2, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, wherein any of said C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl are optionally substituted with 1 or more groups independently selected from NR3R4 and -OR3;
m is 0, 1, 2, 3, 4 or 5; and j is 0, 1 or 2.
45. The compound of claim 44, where R1 is Cl.
46. The compound of claim 44, where R7 is methyl or benzyl.
47. The compound of claim 44, where R8 is Br.
48. The compound of claim 44, where R9 is Cl.
49. The compound of claim 44, where W is -C(O)NHOCH2-(cyclopropyl) or -C(O)NHO(CH2)2OH.
50. The compound of claim 44, having the formula
51. The compound of claim 44, having the formula
52. The compound of claim 44, having the formula
53. A composition comprising a compound of claim 44 and a pharmaceutically acceptable carrier.
54. The prodrug of claim 44, comprising the compound of Formula III
covalently coupled to an amino acid residue.
covalently coupled to an amino acid residue.
55. The prodrug of claim 54, wherein the amino acid residue is valine.
56. The prodrug of claim 44, wherein said prodrug is a phosphate ester of the compound of Formula III.
57. A method of inhibiting MEK activity in a mammal comprising administrating to said mammal one or more compounds of claim 44 in an amount effective to inhibit said MEK activity.
58. A method for treatment of a hyperproliferative disorder in a mammal comprising administrating to said mammal one or more compounds of claim 44 in an amount effective to treat said hyperproliferative disorder.
59. A compound of the Formula IV
and pharmaceutically accepted salts, prodrugs and solvates thereof, wherein:
R1, R2, R7, R8, R9, and R10 are independently hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SR', -S(O)R"", -SO2R"", -NR'R", -NR'C(O)NR"R'", -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R", -NR'C(O)NR"R'", -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R"' independently are hydrogen, lower alkyl, lower alkenyl, aryl or arylalkyl, R"" is lower alkyl, lower alkenyl, aryl or arylalkyl, or any two of R', R", R"' or R"" together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently are hydrogen or C1-C6 alkyl;
R6 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R, -NRC(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R', -NRC(O)NR"R'", -NR'C(NCN)R"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), or CR3OR3, wherein any of said heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), and CR3OR3 are optionally substituted with one or more groups independently selected from -NR3R4, -OR3, -R2, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, wherein any of said C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl are optionally substituted with 1 or more groups independently selected from NR3R4 and -OR3;
m is 0,1,2,3,4or5;and j is 0,1 or 2.
and pharmaceutically accepted salts, prodrugs and solvates thereof, wherein:
R1, R2, R7, R8, R9, and R10 are independently hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SR', -S(O)R"", -SO2R"", -NR'R", -NR'C(O)NR"R'", -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R", -NR'C(O)NR"R'", -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R"' independently are hydrogen, lower alkyl, lower alkenyl, aryl or arylalkyl, R"" is lower alkyl, lower alkenyl, aryl or arylalkyl, or any two of R', R", R"' or R"" together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently are hydrogen or C1-C6 alkyl;
R6 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R, -NRC(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R', -NRC(O)NR"R'", -NR'C(NCN)R"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), or CR3OR3, wherein any of said heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), and CR3OR3 are optionally substituted with one or more groups independently selected from -NR3R4, -OR3, -R2, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, wherein any of said C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl are optionally substituted with 1 or more groups independently selected from NR3R4 and -OR3;
m is 0,1,2,3,4or5;and j is 0,1 or 2.
60. The compound of claim 59, where R1 is 2-C1.
61. The compound of claim 59, where R7 is methyl.
62. The compound of claim 59, where R9 is F.
63. The compound of claim 59, where W is -COOH or -C(O)NHO(CH2)2OH.
64. The compound of claim 59, having the formula
65. The compound of claim 59, having the formula
66. A composition comprising a compound of claim 59 and a pharmaceutically acceptable carrier.
67. The prodrug of claim 59, comprising the compound of Formula IV
covalently coupled to an amino acid residue.
covalently coupled to an amino acid residue.
68. The prodrug of claim 59, wherein the amino acid residue is valine.
69. The prodrug of claim 59, wherein said prodrug is a phosphate ester of the compound of Formula IV.
70. A method of inhibiting MEK activity in a mammal comprising administrating to said mammal one or more compounds of claim 59 in an amount effective to inhibit said MEK activity.
71. A method for treatment of a hyperproliferative disorder in a mammal comprising administrating to said mammal one or more compounds of claim 59 in an amount effective to treat said hyperproliferative disorder.
72. A compound of the Formula V
and pharmaceutically accepted salts, prodrugs and solvates thereof, wherein:
R1, R2, R7, R8, R9, R10 and R11 are independently selected from hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl and -NR4(CR4R5)m-heterocyclyl, where any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
or R7 and R11 together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated carbocyclic, or heterocyclic ring, wherein any of said saturated, unsaturated, or partially saturated carbocyclic, or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R'', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is selected from hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate and an amino acid residue, where any of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SR', -S(O)R'''',-SO2R'''', -NR'R'', -NR'C(O)NR"R''', -NR'C(NCN)NR''R''', -OR' , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said saturated, unsaturated, and partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R''' independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and arylalkyl;
R'''' is selected from lower alkyl, lower alkenyl, aryl and arylalkyl;
or any two of R', R", R''' or R'''' together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently represent hydrogen or C1-C6 alkyl;
R6 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NRC(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R', -NR'C(O)NR"R'", -NR'C(NCN)NR"R'", -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is selected from heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SO2)CH3 and -CR3OR3, wherein any of said heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SO2)CH3 and -CR3OR3 are optionally substituted with one or more groups independently selected from -NR3R4, -OR3, -R2, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, wherein any of said alkyl, alkenyl, and alkynyl portions are optionally substituted with 1 or more groups independently selected from -NR3R4 and -OR3;
m is 0,1,2,3,4 or 5;and j is 0, 1 or 2.
and pharmaceutically accepted salts, prodrugs and solvates thereof, wherein:
R1, R2, R7, R8, R9, R10 and R11 are independently selected from hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl and -NR4(CR4R5)m-heterocyclyl, where any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
or R7 and R11 together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated carbocyclic, or heterocyclic ring, wherein any of said saturated, unsaturated, or partially saturated carbocyclic, or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R'', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is selected from hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate and an amino acid residue, where any of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SR', -S(O)R'''',-SO2R'''', -NR'R'', -NR'C(O)NR"R''', -NR'C(NCN)NR''R''', -OR' , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said saturated, unsaturated, and partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R''' independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and arylalkyl;
R'''' is selected from lower alkyl, lower alkenyl, aryl and arylalkyl;
or any two of R', R", R''' or R'''' together with the atom to which they are attached form a 4 to 10 membered saturated, unsaturated, or partially saturated heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl saturated, unsaturated, or partially saturated heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently represent hydrogen or C1-C6 alkyl;
R6 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NRC(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R', -NR'C(O)NR"R'", -NR'C(NCN)NR"R'", -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is selected from heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SO2)CH3 and -CR3OR3, wherein any of said heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -CONH(SO2)CH3 and -CR3OR3 are optionally substituted with one or more groups independently selected from -NR3R4, -OR3, -R2, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, wherein any of said alkyl, alkenyl, and alkynyl portions are optionally substituted with 1 or more groups independently selected from -NR3R4 and -OR3;
m is 0,1,2,3,4 or 5;and j is 0, 1 or 2.
73. The compound of claim 72, where R1 is 2-Cl, 2-H, or 2-F.
74. The compound of claim 72, where R8 is Cl or Br.
75. The compound of claim 72, where R9 is H, F or Cl.
76. The compound of claim 72, where W is -C(O)OH, -C(O)NHOCH2-(cyclopropyl), -C(O)NHO(CH2)2OH, or -CONH(SO2)CH3.
77. A composition comprising a compound of claim 72 and a pharmaceutically acceptable carrier.
78. The prodrug of claim 72, comprising the compound of Formula V
covalently coupled to an amino acid residue.
covalently coupled to an amino acid residue.
79. The prodrug of claim 72, wherein the amino acid residue is valine.
80. The prodrug of claim 72, wherein said prodrug is a phosphate ester of the compound of Formula V.
81. A method of inhibiting MEK activity in a mammal comprising administrating to said mammal one or more compounds of 72 in an amount effective to inhibit said MEK activity.
82. A method for treatment of a hyperproliferative disorder in a mammal comprising administrating to said mammal one or more compounds of claim 72 in an amount effective to treat said hyperproliferative disorder.
83. A compound of the Formula (I) and pharmaceutically accepted salts, prodrugs and solvates thereof, wherein:
R1, R2, R7, R8, R9, and R10 are independently hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SR', -S(O)R"", -SO2R'''', -NR'R'', -NR'C(O)NR"R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, heteroaryl or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R"' independently are hydrogen, lower alkyl, lower alkenyl, aryl or arylalkyl, and R"" is lower alkyl, lower alkenyl, aryl or arylalkyl, or any two of R', R", R"' or R"" together with the atom to which they are attached form a to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl carbocyclic rings, heteroaryl rings or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently are hydrogen or C1-C6 alkyl, or R4 and R5 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein said alkyl or any of said carbocyclic, heteroaryl and heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R"", -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R", -NR'C(O)NR"R"', -NR'C(NCN)NR"R"', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R6 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R', -NR'C(O)NR"R"', -NR'C(NCN)NR"R"', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl) or CR3OR3, wherein any of said heteroaryl, heterocyclyl, -C(O)OR5, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C,-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl) and CR3OR3 are optionally substituted with one or more groups independently selected from -NR3R4, -OR3, -R2, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, wherein any of said C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl are optionally substituted with 1 or more groups independently selected from -NR3R4 and -OR3;
m is 0,1,2,3,4 or 5;
j is 0, 1 or 2; and Y is a linker.
R1, R2, R7, R8, R9, and R10 are independently hydrogen, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SR', -S(O)R"", -SO2R'''', -NR'R'', -NR'C(O)NR"R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or R3 and R4 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, heteroaryl or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R"' independently are hydrogen, lower alkyl, lower alkenyl, aryl or arylalkyl, and R"" is lower alkyl, lower alkenyl, aryl or arylalkyl, or any two of R', R", R"' or R"" together with the atom to which they are attached form a to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein any of said alkyl, alkenyl, aryl, arylalkyl carbocyclic rings, heteroaryl rings or heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently are hydrogen or C1-C6 alkyl, or R4 and R5 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, wherein said alkyl or any of said carbocyclic, heteroaryl and heterocyclic rings are optionally substituted with one or more groups independently selected from halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R"", -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R", -NR'C(O)NR"R"', -NR'C(NCN)NR"R"', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R6 is trifluoromethyl, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein any of said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted with one or more groups independently selected from oxo, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R"", -SO2NR'R", -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NR'R', -NR'C(O)NR"R"', -NR'C(NCN)NR"R"', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl) or CR3OR3, wherein any of said heteroaryl, heterocyclyl, -C(O)OR5, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C,-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl) and CR3OR3 are optionally substituted with one or more groups independently selected from -NR3R4, -OR3, -R2, C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, wherein any of said C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl are optionally substituted with 1 or more groups independently selected from -NR3R4 and -OR3;
m is 0,1,2,3,4 or 5;
j is 0, 1 or 2; and Y is a linker.
84. A compound according to claims 1, 21, 44, 56, 59, or 72 for use as a medicament.
85. The use of a compound according to claims 1, 21, 44, 56, 59, or 72 in the manufacture of a medicament for the treatment of a hyperproliferative disorder.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/654,580 US7144907B2 (en) | 2003-09-03 | 2003-09-03 | Heterocyclic inhibitors of MEK and methods of use thereof |
US10/654,580 | 2003-09-03 | ||
US10/929,295 US7230099B2 (en) | 2003-09-03 | 2004-08-30 | Heterocyclic inhibitors of MEK and methods of use thereof |
US10/929,295 | 2004-08-30 | ||
PCT/US2004/028649 WO2005023759A2 (en) | 2003-09-03 | 2004-09-01 | Heterocyclic inhibitors of mek and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2537321A1 true CA2537321A1 (en) | 2005-03-17 |
Family
ID=34218110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002537321A Abandoned CA2537321A1 (en) | 2003-09-03 | 2004-09-01 | Heterocyclic inhibitors of mek and methods of use thereof |
Country Status (18)
Country | Link |
---|---|
US (5) | US7144907B2 (en) |
EP (1) | EP1673339B1 (en) |
JP (1) | JP4131741B2 (en) |
KR (1) | KR20060070558A (en) |
CN (1) | CN1874769A (en) |
AR (1) | AR046081A1 (en) |
AU (1) | AU2004270699B2 (en) |
BR (1) | BRPI0414111A (en) |
CA (1) | CA2537321A1 (en) |
IL (4) | IL173936A (en) |
IS (1) | IS8392A (en) |
MX (1) | MXPA06002466A (en) |
NO (1) | NO20061506L (en) |
PT (1) | PT1673339E (en) |
RU (1) | RU2006109599A (en) |
TW (1) | TW200526607A (en) |
WO (1) | WO2005023759A2 (en) |
ZA (1) | ZA200602581B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7488823B2 (en) * | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
JP4931419B2 (en) * | 2003-09-19 | 2012-05-16 | 中外製薬株式会社 | Novel 4-phenylamino-benzaldoxime derivatives and their use as MEK inhibitors |
US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
AU2004293018B2 (en) * | 2003-11-19 | 2010-02-18 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
TWI361066B (en) | 2004-07-26 | 2012-04-01 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
AU2005311451A1 (en) * | 2004-12-01 | 2006-06-08 | Merck Serono Sa | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
US7666880B2 (en) * | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
ES2470766T3 (en) * | 2005-03-21 | 2014-06-24 | Mei Pharma, Inc. | [1,2-a] pyridine derivatives: preparation and pharmaceutical applications |
PT2361905E (en) * | 2005-05-18 | 2013-03-18 | Array Biopharma Inc | Heterocyclic inhibitors of mek and methods of use thereof |
US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
JP5463034B2 (en) * | 2005-05-20 | 2014-04-09 | アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
US7579360B2 (en) * | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US7572807B2 (en) * | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
WO2007025090A2 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
AU2012261703B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
EP1934174B1 (en) * | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
AU2013203939B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
GB0616214D0 (en) * | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
MX2009001875A (en) * | 2006-08-21 | 2009-03-02 | Genentech Inc | Aza-benzothiophenyl compounds and methods of use. |
EP2069354B1 (en) * | 2006-08-21 | 2011-11-02 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
RU2444524C2 (en) * | 2006-08-21 | 2012-03-10 | Дженентек, Инк. | Azabenzothiophenyl compounds and methods of use |
WO2008027812A2 (en) | 2006-08-28 | 2008-03-06 | Forest Laboratories Holdings Limited | Imidazopyridine and imidazopyrimidine derivatives |
EP2070927A4 (en) * | 2006-09-13 | 2010-10-13 | Kyowa Hakko Kirin Co Ltd | Fused heterocyclic derivative |
EP2096923B1 (en) * | 2006-11-27 | 2014-01-22 | H. Lundbeck A/S | Heteroaryl amide derivatives |
CA2671982C (en) * | 2006-12-14 | 2016-01-26 | Exelixis, Inc. | Methods of using mek inhibitors |
MY148461A (en) * | 2007-04-10 | 2013-04-30 | Lundbeck & Co As H | Heteroaryl amide analogues as p2x7 antagonists |
KR101238479B1 (en) | 2007-06-25 | 2013-03-04 | 노파르티스 아게 | N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8022057B2 (en) * | 2007-11-12 | 2011-09-20 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
JP5710268B2 (en) * | 2007-12-19 | 2015-04-30 | ジェネンテック, インコーポレイテッド | 8-Anilinoimidazopyridine and its use as an anti-cancer and / or anti-inflammatory agent |
PE20131210A1 (en) | 2007-12-19 | 2013-10-31 | Genentech Inc | 5-ANILINOIMIDAZOPYRIDINE DERIVATIVES AS MEK INHIBITORS |
WO2009093008A1 (en) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
CA2727250A1 (en) * | 2008-07-01 | 2010-01-07 | Genentech, Inc. | Bicyclic heterocycles as mek kinase inhibitors |
RU2495028C2 (en) * | 2008-07-01 | 2013-10-10 | Дженентек, Инк. | Isoindolones and methods for using them |
AU2009325133B2 (en) | 2008-12-08 | 2016-02-04 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
MX345155B (en) * | 2009-10-12 | 2017-01-18 | F Hoffmann-La Roche Ag * | Combinations of a pi3k inhibitor and a mek inhibitor. |
AU2011226689B2 (en) * | 2010-03-11 | 2016-09-01 | Kronos Bio, Inc. | Imidazopyridines Syk inhibitors |
US9173887B2 (en) | 2010-12-22 | 2015-11-03 | Abbvie Inc. | Hepatitis C inhibitors and uses thereof |
UY34305A (en) | 2011-09-01 | 2013-04-30 | Novartis Ag | DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
CN103204827B (en) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | Benzothiadiazole compounds as protein kinase inhibitors, and preparation method and application thereof |
CA2867760C (en) | 2012-04-04 | 2021-10-05 | Rigel Pharmaceuticals, Inc. | Indolizinyl derivatives as protein kinase c inhibitors and uses thereof |
EA201401353A1 (en) | 2012-05-31 | 2015-05-29 | Байер Фарма Акциенгезельшафт | BIOMARKERS TO DETERMINE AN EFFECTIVE RESPONSE RESPONSE TO THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) |
PT2884979T (en) | 2012-08-17 | 2019-09-04 | Hoffmann La Roche | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
GEP201706690B (en) | 2012-10-12 | 2017-06-26 | Exelixis Inc | Novel process for making compounds for use in treatment of cancer |
UA111925C2 (en) | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
WO2014151900A1 (en) | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
CN105209073A (en) | 2013-03-21 | 2015-12-30 | 诺华股份有限公司 | Combination therapy comprising a B-Raf inhibitor and a second inhibitor |
EP3094736A4 (en) | 2014-01-14 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
CN103980217B (en) * | 2014-05-26 | 2015-12-30 | 南京林业大学 | One class pinane isoxazole compounds and synthetic method thereof and application |
CA2963091A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
MA41866A (en) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | SELF-ASSEMBLING MOLECULES FOR TARGETED DRUG DELIVERY |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
RU2638155C1 (en) * | 2016-02-29 | 2017-12-12 | Общество С Ограниченной Ответственностью "Сай Фарма" | Benzo[d]isoxazole derivatives and their application |
CN107759532B (en) * | 2017-11-23 | 2021-02-12 | 苏州大学 | Benzoxazole-2-ethyl oxime derivative, and preparation method and application thereof |
MX2021009863A (en) | 2019-03-21 | 2021-11-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer. |
TWI817018B (en) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | Compounds for the treatment of braf-associated diseases and disorders |
KR20220098759A (en) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | A method of treating cancer that has acquired resistance to a kinase inhibitor |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CA3186343A1 (en) | 2020-06-09 | 2021-12-16 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
CA2116117A1 (en) | 1991-08-22 | 1993-03-04 | Hiroyuki Sueoka | Benzisoxazole compound and use thereof |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
EP0710654A4 (en) | 1993-07-23 | 1996-08-28 | Green Cross Corp | Triazole derivative and pharmaceutical use thereof |
US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
DE19517448A1 (en) | 1995-05-12 | 1996-11-14 | Thomae Gmbh Dr K | Novel benzothiazoles and benzoxazoles, medicaments containing them and their use, and processes for their preparation |
JP3195756B2 (en) | 1996-07-04 | 2001-08-06 | 公子 吉水 | Lubrication auxiliary |
CN1225639A (en) | 1996-07-18 | 1999-08-11 | 美国辉瑞有限公司 | Phosphinate based inhibitors of matrix metalloproteases |
PL331895A1 (en) | 1996-08-23 | 1999-08-16 | Pfizer | Arylosulphonylamino derivatives of hydroxamic acid |
US6077864A (en) | 1997-01-06 | 2000-06-20 | Pfizer Inc. | Cyclic sulfone derivatives |
ID22799A (en) | 1997-02-03 | 1999-12-09 | Pfizer Prod Inc | ARILSULFONILAMINO HYDROCSAMATE ACID DRIVINGS |
CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
EP0960098A1 (en) | 1997-02-11 | 1999-12-01 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
UA73073C2 (en) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Substituted 3-cyan chinolines |
DE69826662T2 (en) | 1997-07-01 | 2005-02-17 | Warner-Lambert Co. Llc | 4-BROM OR 4-IOD-PHENYLAMINO-BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS |
US6506798B1 (en) | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
US6821963B2 (en) * | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
NZ501277A (en) | 1997-07-01 | 2002-12-20 | Warner Lambert Co | -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469501A1 (en) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO |
PA8469401A1 (en) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | BICYCLE DERIVATIVES OF HYDROXAMIC ACID |
EP1140067A1 (en) | 1999-01-07 | 2001-10-10 | Warner-Lambert Company | Antiviral method using mek inhibitors |
US6696440B1 (en) | 1999-01-07 | 2004-02-24 | Warner-Lambert Company | Treatment of asthma with MEK inhibitors |
SK9832001A3 (en) | 1999-01-13 | 2003-02-04 | Warner Lambert Co | Benzoheterocycles and their use as MEK inhibitors |
CA2349467A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
CA2349832A1 (en) * | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
WO2000041505A2 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Anthranilic acid derivatives |
JP2000204079A (en) * | 1999-01-13 | 2000-07-25 | Warner Lambert Co | Diarylamine |
CN1149204C (en) | 1999-01-13 | 2004-05-12 | 沃尼尔·朗伯公司 | 1-heterocycle substd. diarylamines |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
TR200200204T2 (en) | 1999-07-16 | 2002-11-21 | Warner-Lambert Company | Treating chronic pain using MEK inhibitors. |
US7030119B1 (en) | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
CN1358094A (en) | 1999-07-16 | 2002-07-10 | 沃尼尔·朗伯公司 | Method for treating chronic pain using MEK inhibitors |
EP1202726A2 (en) | 1999-07-16 | 2002-05-08 | Warner-Lambert Company Llc | Method for treating chronic pain using mek inhibitors |
PT1202724E (en) | 1999-07-16 | 2004-02-27 | Warner Lambert Co | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS |
JP2003527379A (en) | 2000-03-15 | 2003-09-16 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 5-Amido-substituted diarylamines as MEX inhibitors |
OA12333A (en) | 2000-07-19 | 2004-04-06 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids. |
PL360699A1 (en) | 2000-08-25 | 2004-09-20 | Warner-Lambert Company Llc. | Process for making n-aryl-anthranilic acids and their derivatives |
US20020052373A1 (en) * | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
EP1337524A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
US6748692B2 (en) * | 2001-10-23 | 2004-06-15 | Travis Sprouse | Spinner bait |
EP2275102B1 (en) | 2002-03-13 | 2015-07-29 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US20030216460A1 (en) | 2002-03-13 | 2003-11-20 | Wallace Eli M. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
-
2003
- 2003-09-03 US US10/654,580 patent/US7144907B2/en not_active Expired - Fee Related
-
2004
- 2004-08-30 US US10/929,295 patent/US7230099B2/en not_active Expired - Fee Related
- 2004-09-01 RU RU2006109599/04A patent/RU2006109599A/en not_active Application Discontinuation
- 2004-09-01 MX MXPA06002466A patent/MXPA06002466A/en not_active Application Discontinuation
- 2004-09-01 ZA ZA200602581A patent/ZA200602581B/en unknown
- 2004-09-01 BR BRPI0414111-3A patent/BRPI0414111A/en not_active IP Right Cessation
- 2004-09-01 WO PCT/US2004/028649 patent/WO2005023759A2/en active Application Filing
- 2004-09-01 EP EP04783028.6A patent/EP1673339B1/en active Active
- 2004-09-01 CN CNA2004800326551A patent/CN1874769A/en active Pending
- 2004-09-01 PT PT47830286T patent/PT1673339E/en unknown
- 2004-09-01 CA CA002537321A patent/CA2537321A1/en not_active Abandoned
- 2004-09-01 KR KR1020067004505A patent/KR20060070558A/en not_active Application Discontinuation
- 2004-09-01 AU AU2004270699A patent/AU2004270699B2/en not_active Ceased
- 2004-09-01 JP JP2006525449A patent/JP4131741B2/en not_active Expired - Fee Related
- 2004-09-02 AR ARP040103151A patent/AR046081A1/en not_active Application Discontinuation
- 2004-09-02 TW TW093126520A patent/TW200526607A/en unknown
-
2006
- 2006-02-26 IL IL173936A patent/IL173936A/en not_active IP Right Cessation
- 2006-03-31 IS IS8392A patent/IS8392A/en unknown
- 2006-04-03 NO NO20061506A patent/NO20061506L/en not_active Application Discontinuation
- 2006-04-24 US US11/410,343 patent/US7271178B2/en not_active Expired - Fee Related
- 2006-04-24 US US11/410,344 patent/US20060189668A1/en not_active Abandoned
- 2006-04-24 US US11/410,336 patent/US7511058B2/en not_active Expired - Fee Related
-
2012
- 2012-05-08 IL IL219669A patent/IL219669A0/en unknown
- 2012-05-08 IL IL219671A patent/IL219671A0/en unknown
- 2012-05-08 IL IL219670A patent/IL219670A/en not_active IP Right Cessation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
US8637246B2 (en) | 2010-02-25 | 2014-01-28 | Dana-Farber Cancer Institute, Inc. | BRAF mutations conferring resistance to BRAF inhibitors |
US9279144B2 (en) | 2010-02-25 | 2016-03-08 | Dana-Farber Cancer Institute, Inc. | Screening method for BRAF inhibitors |
EP3028699A1 (en) | 2010-02-25 | 2016-06-08 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1673339B1 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
US7538120B2 (en) | Method of treating inflammatory diseases | |
US7576072B2 (en) | Heterocyclic inhibitors of MEK and methods of use thereof | |
US7517994B2 (en) | Heterocyclic inhibitors of MEK and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |